other	In the present study , we tested whether the highly specific metabotropic glutamate receptor 5 antagonist , <e1> DRUG1 </e1> , reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of <e2> DRUG2 </e2> . 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
other	Weekly intramuscular <e1> DRUG1 </e1> injections (0.2-0.5 mg/kg body weight) , in combination with daily administration of <e2> DRUG2 </e2> or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine / 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine /vehicle) . 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine
other	Weekly intramuscular <e1> DRUG1 </e1> injections (0.2-0.5 mg/kg body weight) , in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine / <e2> DRUG2 </e2> versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine /vehicle) . 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine
other	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight) , in combination with daily administration of <e1> DRUG1 </e1> or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( <e2> DRUG2 </e2> / 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine /vehicle) . 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
other	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight) , in combination with daily administration of <e1> DRUG1 </e1> or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine / 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus <e2> DRUG2 </e2> /vehicle) . 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
other	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight) , in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( <e1> DRUG1 </e1> / <e2> DRUG2 </e2> versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine /vehicle) . 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine
other	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight) , in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine / <e1> DRUG1 </e1> versus <e2> DRUG2 </e2> /vehicle) . 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
other	After 21 weeks of <e1> DRUG1 </e1> treatment , all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine /vehicle-treated animals displayed parkinsonian symptoms , whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine / <e2> DRUG2 </e2> -treated monkeys were significantly affected . 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine
other	After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment , all <e1> DRUG1 </e1> /vehicle-treated animals displayed parkinsonian symptoms , whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine / <e2> DRUG2 </e2> -treated monkeys were significantly affected . 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine
effect	After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment , all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine /vehicle-treated animals displayed parkinsonian symptoms , whereas none of the <e1> DRUG1 </e1> / <e2> DRUG2 </e2> -treated monkeys were significantly affected . 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine
effect	These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data , and with post-mortem stereological counts of midbrain dopaminergic neurons , as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity , which were all significantly higher in <e1> DRUG1 </e1> / <e2> DRUG2 </e2> -treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine /vehicle-treated monkeys . 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine
other	These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data , and with post-mortem stereological counts of midbrain dopaminergic neurons , as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity , which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine / <e1> DRUG1 </e1> -treated animals than in <e2> DRUG2 </e2> /vehicle-treated monkeys . 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
effect	The <e1> DRUG1 </e1> treatment also had a significant effect on the <e2> DRUG2 </e2> -induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups . 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
other	In <e1> DRUG1 </e1> /vehicle-treated animals , almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups , whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine / <e2> DRUG2 </e2> -treated monkeys . 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine
effect	In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine /vehicle-treated animals , almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups , whereas the extent of neuronal loss was lower than 15% of control values in <e1> DRUG1 </e1> / <e2> DRUG2 </e2> -treated monkeys . 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine
effect	Our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist , <e1> DRUG1 </e1> , significantly reduces <e2> DRUG2 </e2> toxicity towards dopaminergic and noradrenergic cell groups in non-human primates . 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
other	Effect of <e1> DRUG1 </e1> -mediated CYP3A4 inhibition on clinical pharmacokinetics of <e2> DRUG2 </e2> ( LBH589 ) , an orally active histone deacetylase inhibitor . 	ketoconazole	panobinostat
other	Effect of <e1> DRUG1 </e1> -mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat ( <e2> DRUG2 </e2> ) , an orally active histone deacetylase inhibitor . 	ketoconazole	LBH589
other	Effect of <e1> DRUG1 </e1> -mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat ( LBH589 ) , an orally active <e2> DRUG2 </e2> . 	ketoconazole	histone deacetylase inhibitor
other	Effect of ketoconazole -mediated CYP3A4 inhibition on clinical pharmacokinetics of <e1> DRUG1 </e1> ( LBH589 ) , an orally active <e2> DRUG2 </e2> . 	panobinostat	histone deacetylase inhibitor
other	Effect of ketoconazole -mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat ( <e1> DRUG1 </e1> ) , an orally active <e2> DRUG2 </e2> . 	LBH589	histone deacetylase inhibitor
other	This study evaluated the effect of a potent CYP3A inhibitor , <e1> DRUG1 </e1> , on the pharmacokinetics and safety of <e2> DRUG2 </e2> . 	ketoconazole	panobinostat
other	On day 8 , a single <e1> DRUG1 </e1> dose was co-administered with <e2> DRUG2 </e2> . 	panobinostat	ketoconazole
mechanism	In the presence of <e1> DRUG1 </e1> , there was 1.6- and 1.8-fold increase in C (max) and AUC of <e2> DRUG2 </e2> , respectively . 	ketoconazole	panobinostat
other	Interaction study of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> with co-administered drugs . 	moxifloxacin	lomefloxacin
other	<e1> DRUG1 </e1> and <e2> DRUG2 </e2> are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections . 	Moxifloxacin	lomefloxacin
other	<e1> DRUG1 </e1> and lomefloxacin are <e2> DRUG2 </e2> used in treating urinary and respiratory tract infections . 	Moxifloxacin	fluoroquinolone antibiotics
other	Moxifloxacin and <e1> DRUG1 </e1> are <e2> DRUG2 </e2> used in treating urinary and respiratory tract infections . 	lomefloxacin	fluoroquinolone antibiotics
other	Being <e1> DRUG1 </e1> and lomefloxacin <e2> DRUG2 </e2> the interaction study of was carried out with sucralfate , gelusil , erythromycin and multi minerals . 	moxifloxacin	fluoroquinolones
other	Being <e1> DRUG1 </e1> and lomefloxacin fluoroquinolones the interaction study of was carried out with <e2> DRUG2 </e2> , gelusil , erythromycin and multi minerals . 	moxifloxacin	sucralfate
other	Being <e1> DRUG1 </e1> and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate , <e2> DRUG2 </e2> , erythromycin and multi minerals . 	moxifloxacin	gelusil
other	Being <e1> DRUG1 </e1> and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate , gelusil , <e2> DRUG2 </e2> and multi minerals . 	moxifloxacin	erythromycin
other	Being <e1> DRUG1 </e1> and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate , gelusil , erythromycin and <e2> DRUG2 </e2> . 	moxifloxacin	multi minerals
other	Being moxifloxacin and lomefloxacin <e1> DRUG1 </e1> the interaction study of was carried out with <e2> DRUG2 </e2> , gelusil , erythromycin and multi minerals . 	fluoroquinolones	sucralfate
other	Being moxifloxacin and lomefloxacin <e1> DRUG1 </e1> the interaction study of was carried out with sucralfate , <e2> DRUG2 </e2> , erythromycin and multi minerals . 	fluoroquinolones	gelusil
other	Being moxifloxacin and lomefloxacin <e1> DRUG1 </e1> the interaction study of was carried out with sucralfate , gelusil , <e2> DRUG2 </e2> and multi minerals . 	fluoroquinolones	erythromycin
other	Being moxifloxacin and lomefloxacin <e1> DRUG1 </e1> the interaction study of was carried out with sucralfate , gelusil , erythromycin and <e2> DRUG2 </e2> . 	fluoroquinolones	multi minerals
other	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with <e1> DRUG1 </e1> , gelusil , <e2> DRUG2 </e2> and multi minerals . 	sucralfate	erythromycin
other	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with <e1> DRUG1 </e1> , gelusil , erythromycin and <e2> DRUG2 </e2> . 	sucralfate	multi minerals
other	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate , <e1> DRUG1 </e1> , erythromycin and <e2> DRUG2 </e2> . 	gelusil	multi minerals
other	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate , gelusil , <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	erythromycin	multi minerals
other	The response of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector . 	moxifloxacin	lomefloxacin
other	<e1> DRUG1 </e1> and <e2> DRUG2 </e2> reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media . 	Moxifloxacin	Lomefloxacin
mechanism	<e1> DRUG1 </e1> and Lomefloxacin reacts faster with <e2> DRUG2 </e2> and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media . 	Moxifloxacin	sucralfate
mechanism	<e1> DRUG1 </e1> and Lomefloxacin reacts faster with sucralfate and <e2> DRUG2 </e2> in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media . 	Moxifloxacin	gelusil
mechanism	<e1> DRUG1 </e1> and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with <e2> DRUG2 </e2> in basic media and multi-minerals in neutral media . 	Moxifloxacin	erythromycin
mechanism	<e1> DRUG1 </e1> and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and <e2> DRUG2 </e2> in neutral media . 	Moxifloxacin	multi-minerals
mechanism	Moxifloxacin and <e1> DRUG1 </e1> reacts faster with <e2> DRUG2 </e2> and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media . 	Lomefloxacin	sucralfate
mechanism	Moxifloxacin and <e1> DRUG1 </e1> reacts faster with sucralfate and <e2> DRUG2 </e2> in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media . 	Lomefloxacin	gelusil
mechanism	Moxifloxacin and <e1> DRUG1 </e1> reacts faster with sucralfate and gelusil in acidic media whereas with <e2> DRUG2 </e2> in basic media and multi-minerals in neutral media . 	Lomefloxacin	erythromycin
mechanism	Moxifloxacin and <e1> DRUG1 </e1> reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and <e2> DRUG2 </e2> in neutral media . 	Lomefloxacin	multi-minerals
other	Moxifloxacin and Lomefloxacin reacts faster with <e1> DRUG1 </e1> and <e2> DRUG2 </e2> in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media . 	sucralfate	gelusil
other	Moxifloxacin and Lomefloxacin reacts faster with <e1> DRUG1 </e1> and gelusil in acidic media whereas with <e2> DRUG2 </e2> in basic media and multi-minerals in neutral media . 	sucralfate	erythromycin
other	Moxifloxacin and Lomefloxacin reacts faster with <e1> DRUG1 </e1> and gelusil in acidic media whereas with erythromycin in basic media and <e2> DRUG2 </e2> in neutral media . 	sucralfate	multi-minerals
other	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and <e1> DRUG1 </e1> in acidic media whereas with <e2> DRUG2 </e2> in basic media and multi-minerals in neutral media . 	gelusil	erythromycin
other	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and <e1> DRUG1 </e1> in acidic media whereas with erythromycin in basic media and <e2> DRUG2 </e2> in neutral media . 	gelusil	multi-minerals
other	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with <e1> DRUG1 </e1> in basic media and <e2> DRUG2 </e2> in neutral media . 	erythromycin	multi-minerals
other	Exposure to oral <e1> DRUG1 </e1> is unaffected by <e2> DRUG2 </e2> but greatly increased by ticlopidine . 	S-ketamine	itraconazole
effect	Exposure to oral <e1> DRUG1 </e1> is unaffected by itraconazole but greatly increased by <e2> DRUG2 </e2> . 	S-ketamine	ticlopidine
other	Exposure to oral S-ketamine is unaffected by <e1> DRUG1 </e1> but greatly increased by <e2> DRUG2 </e2> . 	itraconazole	ticlopidine
other	This study examined drug-drug interactions of oral <e1> DRUG1 </e1> with the cytochrome P450 (CYP) 2B6 inhibitor <e2> DRUG2 </e2> and the CYP3A inhibitor itraconazole . 	S-ketamine	ticlopidine
other	This study examined drug-drug interactions of oral <e1> DRUG1 </e1> with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor <e2> DRUG2 </e2> . 	S-ketamine	itraconazole
other	This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor <e1> DRUG1 </e1> and the CYP3A inhibitor <e2> DRUG2 </e2> . 	ticlopidine	itraconazole
other	In this randomized , blinded , crossover study , 11 healthy volunteers ingested 0.2 mg/kg <e1> DRUG1 </e1> after pretreatments with oral <e2> DRUG2 </e2> (250 mg twice daily) , itraconazole (200 mg once daily) , or placebo in 6-day treatment periods at intervals of 4 weeks . 	S-ketamine	ticlopidine
other	In this randomized , blinded , crossover study , 11 healthy volunteers ingested 0.2 mg/kg <e1> DRUG1 </e1> after pretreatments with oral ticlopidine (250 mg twice daily) , <e2> DRUG2 </e2> (200 mg once daily) , or placebo in 6-day treatment periods at intervals of 4 weeks . 	S-ketamine	itraconazole
other	In this randomized , blinded , crossover study , 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral <e1> DRUG1 </e1> (250 mg twice daily) , <e2> DRUG2 </e2> (200 mg once daily) , or placebo in 6-day treatment periods at intervals of 4 weeks . 	ticlopidine	itraconazole
mechanism	<e1> DRUG1 </e1> treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral <e2> DRUG2 </e2> by 2.4-fold , whereas itraconazole treatment did not increase the exposure to S-ketamine . 	Ticlopidine	ketamine
other	<e1> DRUG1 </e1> treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold , whereas <e2> DRUG2 </e2> treatment did not increase the exposure to S-ketamine . 	Ticlopidine	itraconazole
other	<e1> DRUG1 </e1> treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold , whereas itraconazole treatment did not increase the exposure to <e2> DRUG2 </e2> . 	Ticlopidine	S-ketamine
other	Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral <e1> DRUG1 </e1> by 2.4-fold , whereas <e2> DRUG2 </e2> treatment did not increase the exposure to S-ketamine . 	ketamine	itraconazole
other	Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral <e1> DRUG1 </e1> by 2.4-fold , whereas itraconazole treatment did not increase the exposure to <e2> DRUG2 </e2> . 	ketamine	S-ketamine
other	Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold , whereas <e1> DRUG1 </e1> treatment did not increase the exposure to <e2> DRUG2 </e2> . 	itraconazole	S-ketamine
other	The ratio of <e1> DRUG1 </e1> AUC(0-   ) to <e2> DRUG2 </e2> AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo . 	norketamine	ketamine
other	The ratio of <e1> DRUG1 </e1> AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the <e2> DRUG2 </e2> (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo . 	norketamine	ticlopidine
other	The ratio of <e1> DRUG1 </e1> AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and <e2> DRUG2 </e2> phases (P = 0.006) as compared to placebo . 	norketamine	itraconazole
other	The ratio of norketamine AUC(0-   ) to <e1> DRUG1 </e1> AUC(0-   ) was significantly decreased in the <e2> DRUG2 </e2> (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo . 	ketamine	ticlopidine
other	The ratio of norketamine AUC(0-   ) to <e1> DRUG1 </e1> AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and <e2> DRUG2 </e2> phases (P = 0.006) as compared to placebo . 	ketamine	itraconazole
other	The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the <e1> DRUG1 </e1> (P &lt; 0.001) and <e2> DRUG2 </e2> phases (P = 0.006) as compared to placebo . 	ticlopidine	itraconazole
other	In the <e1> DRUG1 </e1> and <e2> DRUG2 </e2> phases , the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < 0.05) . 	ticlopidine	itraconazole
advise	The findings suggest that the dosage of <e1> DRUG1 </e1> should be reduced in patients receiving <e2> DRUG2 </e2> . 	S-ketamine	ticlopidine
other	We also found that Bcl-2 was overexpressed in <e1> DRUG1 </e1> insensitive cells , and cotreatment with DZNep and <e2> DRUG2 </e2> , a Bcl-2 family inhibitor , synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells . 	DZNep	ABT-737
effect	We also found that Bcl-2 was overexpressed in DZNep insensitive cells , and cotreatment with <e1> DRUG1 </e1> and <e2> DRUG2 </e2> , a Bcl-2 family inhibitor , synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells . 	DZNep	ABT-737
other	We also found that Bcl-2 was overexpressed in DZNep insensitive cells , and cotreatment with DZNep and <e1> DRUG1 </e1> , a Bcl-2 family inhibitor , synergistically inhibited growth and induced apoptosis of <e2> DRUG2 </e2> insensitive MM cells . 	ABT-737	DZNep
other	In addition , <e1> DRUG1 </e1> insensitivity might be associated with overexpression of Bcl-2 , and the combination of <e2> DRUG2 </e2> and DZNep could synergistically induced apoptosis . 	DZNep	ABT-737
effect	In addition , DZNep insensitivity might be associated with overexpression of Bcl-2 , and the combination of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> could synergistically induced apoptosis . 	ABT-737	DZNep
effect	<e1> DRUG1 </e1> failure in an HIV-positive woman on <e2> DRUG2 </e2> therapy resulting in two ectopic pregnancies . 	Implanon	antiretroviral
effect	We present an interesting case of an HIV-positive woman on <e1> DRUG1 </e1> therapy having tubal pregnancies on two separate occasions with <e2> DRUG2 </e2> in place . 	antiretroviral	Implanon
other	We sought to evaluate whether initiation of an <e1> DRUG1 </e1> increases the risk of hospitalization for gastrointestinal bleeding in <e2> DRUG2 </e2> users . 	antidepressant	warfarin
effect	<e1> DRUG1 </e1> users had an increased odds ratio of gastrointestinal bleeding upon initiation of <e2> DRUG2 </e2> (OR   =   1.73 [95% CI , 1.25-2.38]) , fluoxetine (OR   =   1.63 [95% CI , 1.11-2.38]) , paroxetine (OR   =   1.64 [95% CI , 1.27-2.12]) , amitriptyline (OR   =   1.47 [95% CI , 1.02-2.11]) . 	Warfarin	citalopram
effect	<e1> DRUG1 </e1> users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI , 1.25-2.38]) , <e2> DRUG2 </e2> (OR   =   1.63 [95% CI , 1.11-2.38]) , paroxetine (OR   =   1.64 [95% CI , 1.27-2.12]) , amitriptyline (OR   =   1.47 [95% CI , 1.02-2.11]) . 	Warfarin	fluoxetine
effect	<e1> DRUG1 </e1> users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI , 1.25-2.38]) , fluoxetine (OR   =   1.63 [95% CI , 1.11-2.38]) , <e2> DRUG2 </e2> (OR   =   1.64 [95% CI , 1.27-2.12]) , amitriptyline (OR   =   1.47 [95% CI , 1.02-2.11]) . 	Warfarin	paroxetine
effect	<e1> DRUG1 </e1> users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI , 1.25-2.38]) , fluoxetine (OR   =   1.63 [95% CI , 1.11-2.38]) , paroxetine (OR   =   1.64 [95% CI , 1.27-2.12]) , <e2> DRUG2 </e2> (OR   =   1.47 [95% CI , 1.02-2.11]) . 	Warfarin	amitriptyline
other	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of <e1> DRUG1 </e1> (OR   =   1.73 [95% CI , 1.25-2.38]) , <e2> DRUG2 </e2> (OR   =   1.63 [95% CI , 1.11-2.38]) , paroxetine (OR   =   1.64 [95% CI , 1.27-2.12]) , amitriptyline (OR   =   1.47 [95% CI , 1.02-2.11]) . 	citalopram	fluoxetine
other	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of <e1> DRUG1 </e1> (OR   =   1.73 [95% CI , 1.25-2.38]) , fluoxetine (OR   =   1.63 [95% CI , 1.11-2.38]) , <e2> DRUG2 </e2> (OR   =   1.64 [95% CI , 1.27-2.12]) , amitriptyline (OR   =   1.47 [95% CI , 1.02-2.11]) . 	citalopram	paroxetine
other	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of <e1> DRUG1 </e1> (OR   =   1.73 [95% CI , 1.25-2.38]) , fluoxetine (OR   =   1.63 [95% CI , 1.11-2.38]) , paroxetine (OR   =   1.64 [95% CI , 1.27-2.12]) , <e2> DRUG2 </e2> (OR   =   1.47 [95% CI , 1.02-2.11]) . 	citalopram	amitriptyline
other	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI , 1.25-2.38]) , <e1> DRUG1 </e1> (OR   =   1.63 [95% CI , 1.11-2.38]) , <e2> DRUG2 </e2> (OR   =   1.64 [95% CI , 1.27-2.12]) , amitriptyline (OR   =   1.47 [95% CI , 1.02-2.11]) . 	fluoxetine	paroxetine
other	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI , 1.25-2.38]) , <e1> DRUG1 </e1> (OR   =   1.63 [95% CI , 1.11-2.38]) , paroxetine (OR   =   1.64 [95% CI , 1.27-2.12]) , <e2> DRUG2 </e2> (OR   =   1.47 [95% CI , 1.02-2.11]) . 	fluoxetine	amitriptyline
other	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI , 1.25-2.38]) , fluoxetine (OR   =   1.63 [95% CI , 1.11-2.38]) , <e1> DRUG1 </e1> (OR   =   1.64 [95% CI , 1.27-2.12]) , <e2> DRUG2 </e2> (OR   =   1.47 [95% CI , 1.02-2.11]) . 	paroxetine	amitriptyline
effect	Also <e1> DRUG1 </e1> , which is not believed to interact with <e2> DRUG2 </e2> , increased the risk of GI bleeding (OR   =   1.75 [95% CI , 1.30-2.35]) . 	mirtazapine	warfarin
effect	<e1> DRUG1 </e1> users who initiated <e2> DRUG2 </e2> , fluoxetine , paroxetine , amitriptyline , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding . 	Warfarin	citalopram
effect	<e1> DRUG1 </e1> users who initiated citalopram , <e2> DRUG2 </e2> , paroxetine , amitriptyline , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding . 	Warfarin	fluoxetine
effect	<e1> DRUG1 </e1> users who initiated citalopram , fluoxetine , <e2> DRUG2 </e2> , amitriptyline , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding . 	Warfarin	paroxetine
effect	<e1> DRUG1 </e1> users who initiated citalopram , fluoxetine , paroxetine , <e2> DRUG2 </e2> , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding . 	Warfarin	amitriptyline
effect	<e1> DRUG1 </e1> users who initiated citalopram , fluoxetine , paroxetine , amitriptyline , or <e2> DRUG2 </e2> had an increased risk of hospitalization for gastrointestinal bleeding . 	Warfarin	mirtazapine
other	Warfarin users who initiated <e1> DRUG1 </e1> , fluoxetine , <e2> DRUG2 </e2> , amitriptyline , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding . 	citalopram	paroxetine
other	Warfarin users who initiated <e1> DRUG1 </e1> , fluoxetine , paroxetine , <e2> DRUG2 </e2> , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding . 	citalopram	amitriptyline
other	Warfarin users who initiated <e1> DRUG1 </e1> , fluoxetine , paroxetine , amitriptyline , or <e2> DRUG2 </e2> had an increased risk of hospitalization for gastrointestinal bleeding . 	citalopram	mirtazapine
other	Warfarin users who initiated citalopram , <e1> DRUG1 </e1> , paroxetine , <e2> DRUG2 </e2> , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding . 	fluoxetine	amitriptyline
other	Warfarin users who initiated citalopram , <e1> DRUG1 </e1> , paroxetine , amitriptyline , or <e2> DRUG2 </e2> had an increased risk of hospitalization for gastrointestinal bleeding . 	fluoxetine	mirtazapine
other	Warfarin users who initiated citalopram , fluoxetine , <e1> DRUG1 </e1> , amitriptyline , or <e2> DRUG2 </e2> had an increased risk of hospitalization for gastrointestinal bleeding . 	paroxetine	mirtazapine
effect	<e1> DRUG1 </e1> decreased the toxicity of <e2> DRUG2 </e2> , increased exposure to parent compound , and decreased metabolite levels in a dose-dependent manner . 	ABT	precocene I
other	Of the isoform-specific CYP inhibitors tested for an effect on the <e1> DRUG1 </e1> metabolite profile , only <e2> DRUG2 </e2> was noticeably effective , indicating a role of CYPs 2A6 , 2C9 , 2Cl9 , and 2E1 . 	precocene I	tranylcypromine
other	With respect to toxicity , the order of CYP inhibitor effectiveness was <e1> DRUG1 </e1> > <e2> DRUG2 </e2> ~ tranylcypromine > ketoconazole . 	ABT	diethyldithiocarbamate
other	With respect to toxicity , the order of CYP inhibitor effectiveness was <e1> DRUG1 </e1> > diethyldithiocarbamate ~ <e2> DRUG2 </e2> > ketoconazole . 	ABT	tranylcypromine
other	With respect to toxicity , the order of CYP inhibitor effectiveness was <e1> DRUG1 </e1> > diethyldithiocarbamate ~ tranylcypromine > <e2> DRUG2 </e2> . 	ABT	ketoconazole
other	With respect to toxicity , the order of CYP inhibitor effectiveness was ABT > <e1> DRUG1 </e1> ~ <e2> DRUG2 </e2> > ketoconazole . 	diethyldithiocarbamate	tranylcypromine
other	With respect to toxicity , the order of CYP inhibitor effectiveness was ABT > <e1> DRUG1 </e1> ~ tranylcypromine > <e2> DRUG2 </e2> . 	diethyldithiocarbamate	ketoconazole
other	With respect to toxicity , the order of CYP inhibitor effectiveness was ABT > diethyldithiocarbamate ~ <e1> DRUG1 </e1> > <e2> DRUG2 </e2> . 	tranylcypromine	ketoconazole
other	<e1> DRUG1 </e1> and <e2> DRUG2 </e2> had no effect , while quinidine appeared to augment precocene I toxicity . 	Furafylline	sulfaphenazole
other	<e1> DRUG1 </e1> and sulfaphenazole had no effect , while <e2> DRUG2 </e2> appeared to augment precocene I toxicity . 	Furafylline	quinidine
other	<e1> DRUG1 </e1> and sulfaphenazole had no effect , while quinidine appeared to augment <e2> DRUG2 </e2> toxicity . 	Furafylline	precocene I
other	Furafylline and <e1> DRUG1 </e1> had no effect , while <e2> DRUG2 </e2> appeared to augment precocene I toxicity . 	sulfaphenazole	quinidine
other	Furafylline and <e1> DRUG1 </e1> had no effect , while quinidine appeared to augment <e2> DRUG2 </e2> toxicity . 	sulfaphenazole	precocene I
effect	Furafylline and sulfaphenazole had no effect , while <e1> DRUG1 </e1> appeared to augment <e2> DRUG2 </e2> toxicity . 	quinidine	precocene I
other	<e1> DRUG1 </e1> containing cDNA encoding enhanced green fluorescent protein (GFP) , under the control of a chicken   -actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including <e2> DRUG2 </e2> , hyaluronan lyase , heparinase III , or chondroitin ABC lyase . 	AAV2	collagenase
other	<e1> DRUG1 </e1> containing cDNA encoding enhanced green fluorescent protein (GFP) , under the control of a chicken   -actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase , <e2> DRUG2 </e2> , heparinase III , or chondroitin ABC lyase . 	AAV2	hyaluronan lyase
other	<e1> DRUG1 </e1> containing cDNA encoding enhanced green fluorescent protein (GFP) , under the control of a chicken   -actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase , hyaluronan lyase , <e2> DRUG2 </e2> , or chondroitin ABC lyase . 	AAV2	heparinase III
other	<e1> DRUG1 </e1> containing cDNA encoding enhanced green fluorescent protein (GFP) , under the control of a chicken   -actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase , hyaluronan lyase , heparinase III , or <e2> DRUG2 </e2> . 	AAV2	chondroitin ABC lyase
other	AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP) , under the control of a chicken   -actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including <e1> DRUG1 </e1> , hyaluronan lyase , <e2> DRUG2 </e2> , or chondroitin ABC lyase . 	collagenase	heparinase III
other	AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP) , under the control of a chicken   -actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including <e1> DRUG1 </e1> , hyaluronan lyase , heparinase III , or <e2> DRUG2 </e2> . 	collagenase	chondroitin ABC lyase
other	AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP) , under the control of a chicken   -actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase , <e1> DRUG1 </e1> , heparinase III , or <e2> DRUG2 </e2> . 	hyaluronan lyase	chondroitin ABC lyase
other	<e1> DRUG1 </e1> had a limited effect and <e2> DRUG2 </e2> was ineffective . 	Hyaluronan lyase	collagenase
other	Electroretinograms survived with higher concentrations of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> than were required for optimal retinal transduction . 	heparinase III	chondroitin ABC lyase
effect	<e1> DRUG1 </e1> -mediated retinal transduction is improved by co-injection of <e2> DRUG2 </e2> or chondroitin ABC lyase . 	AAV2	heparinase III
effect	<e1> DRUG1 </e1> -mediated retinal transduction is improved by co-injection of heparinase III or <e2> DRUG2 </e2> . 	AAV2	chondroitin ABC lyase
other	Prevention of emergence agitation in seven children receiving low-dose <e1> DRUG1 </e1> and <e2> DRUG2 </e2> total intravenous anesthesia . 	ketamine	propofol
other	We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose <e1> DRUG1 </e1> in conjunction with <e2> DRUG2 </e2> for total intravenous anesthesia (TIVA) repeatedly for radiation therapy . 	ketamine	propofol
other	EA signs were observed in all 7 patients in association with <e1> DRUG1 </e1> TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose <e2> DRUG2 </e2> was added to propofol . 	propofol	ketamine
other	EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose <e1> DRUG1 </e1> was added to <e2> DRUG2 </e2> . 	ketamine	propofol
effect	Based on this experience , we suggest that low-dose <e1> DRUG1 </e1> added to <e2> DRUG2 </e2> may be associated with prevention of EA in children with a history of EA with propofol TIVA . 	ketamine	propofol
other	Based on this experience , we suggest that low-dose <e1> DRUG1 </e1> added to propofol may be associated with prevention of EA in children with a history of EA with <e2> DRUG2 </e2> TIVA . 	ketamine	propofol
other	<e1> DRUG1 </e1> , an <e2> DRUG2 </e2> , is the standard hormone treatment for breast cancer . 	Tamoxifen	estrogen antagonist
other	<e1> DRUG1 </e1> and <e2> DRUG2 </e2> reduce the plasma concentration of endoxifen by about 50% . 	Paroxetine	fluoxetine
mechanism	<e1> DRUG1 </e1> and fluoxetine reduce the plasma concentration of <e2> DRUG2 </e2> by about 50% . 	Paroxetine	endoxifen
mechanism	Paroxetine and <e1> DRUG1 </e1> reduce the plasma concentration of <e2> DRUG2 </e2> by about 50% . 	fluoxetine	endoxifen
advise	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with <e1> DRUG1 </e1> for breast cancer , especially <e2> DRUG2 </e2> such as paroxetine and fluoxetine . 	tamoxifen	SSRI antidepressants
advise	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with <e1> DRUG1 </e1> for breast cancer , especially SSRI antidepressants such as <e2> DRUG2 </e2> and fluoxetine . 	tamoxifen	paroxetine
advise	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with <e1> DRUG1 </e1> for breast cancer , especially SSRI antidepressants such as paroxetine and <e2> DRUG2 </e2> . 	tamoxifen	fluoxetine
other	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer , especially <e1> DRUG1 </e1> such as paroxetine and <e2> DRUG2 </e2> . 	SSRI antidepressants	fluoxetine
other	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer , especially SSRI antidepressants such as <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	paroxetine	fluoxetine
other	Depression does not always require <e1> DRUG1 </e1> therapy , and <e2> DRUG2 </e2> have no proven preventive impact on hot flushes linked to the menopause . 	antidepressant drug	antidepressants
advise	If in certain cases , an <e1> DRUG1 </e1> is considered necessary , it may be advisable to replace <e2> DRUG2 </e2> with anastrozole . 	antidepressant	tamoxifen
other	If in certain cases , an <e1> DRUG1 </e1> is considered necessary , it may be advisable to replace tamoxifen with <e2> DRUG2 </e2> . 	antidepressant	anastrozole
other	If in certain cases , an antidepressant is considered necessary , it may be advisable to replace <e1> DRUG1 </e1> with <e2> DRUG2 </e2> . 	tamoxifen	anastrozole
other	<e1> DRUG1 </e1> locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with <e2> DRUG2 </e2> . 	Amphetamine	quinpirole
other	The objective was to analyze the effects of neonatal <e1> DRUG1 </e1> treatment on effects of <e2> DRUG2 </e2> in adolescent rats using locomotor sensitization and conditioned place preference procedures . 	quinpirole	amphetamine
effect	In female rats , neonatal <e1> DRUG1 </e1> treatment enhanced <e2> DRUG2 </e2> locomotor sensitization compared with quinpirole -free controls sensitized to amphetamine . 	quinpirole	amphetamine
other	In female rats , neonatal <e1> DRUG1 </e1> treatment enhanced amphetamine locomotor sensitization compared with quinpirole -free controls sensitized to <e2> DRUG2 </e2> . 	quinpirole	amphetamine
other	In female rats , neonatal quinpirole treatment enhanced <e1> DRUG1 </e1> locomotor sensitization compared with <e2> DRUG2 </e2> -free controls sensitized to amphetamine . 	amphetamine	quinpirole
other	In female rats , neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with <e1> DRUG1 </e1> -free controls sensitized to <e2> DRUG2 </e2> . 	quinpirole	amphetamine
other	Male rats demonstrated sensitization to <e1> DRUG1 </e1> , although this was muted compared with female rats , and were unaffected by neonatal <e2> DRUG2 </e2> . 	amphetamine	quinpirole
other	Rats treated with neonatal <e1> DRUG1 </e1> enhanced time spent in the <e2> DRUG2 </e2> -paired context compared with quinpirole -free controls conditioned with amphetamine , but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls . 	quinpirole	amphetamine
other	Rats treated with neonatal <e1> DRUG1 </e1> enhanced time spent in the amphetamine -paired context compared with quinpirole -free controls conditioned with <e2> DRUG2 </e2> , but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls . 	quinpirole	amphetamine
other	Rats treated with neonatal <e1> DRUG1 </e1> enhanced time spent in the amphetamine -paired context compared with quinpirole -free controls conditioned with amphetamine , but only female controls conditioned with <e2> DRUG2 </e2> spent more time in the drug-paired context compared with saline-treated controls . 	quinpirole	amphetamine
other	Rats treated with neonatal quinpirole enhanced time spent in the <e1> DRUG1 </e1> -paired context compared with <e2> DRUG2 </e2> -free controls conditioned with amphetamine , but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls . 	amphetamine	quinpirole
other	Rats treated with neonatal quinpirole enhanced time spent in the amphetamine -paired context compared with <e1> DRUG1 </e1> -free controls conditioned with <e2> DRUG2 </e2> , but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls . 	quinpirole	amphetamine
other	Rats treated with neonatal quinpirole enhanced time spent in the amphetamine -paired context compared with <e1> DRUG1 </e1> -free controls conditioned with amphetamine , but only female controls conditioned with <e2> DRUG2 </e2> spent more time in the drug-paired context compared with saline-treated controls . 	quinpirole	amphetamine
other	In vivo CYP3A activity is significantly lower in <e1> DRUG1 </e1> -treated as compared with <e2> DRUG2 </e2> -treated renal allograft recipients . 	cyclosporine	tacrolimus
other	In vitro studies have identified <e1> DRUG1 </e1> and <e2> DRUG2 </e2> as CYP3A inhibitors . 	cyclosporine	tacrolimus
other	Systemic and apparent oral midazolam clearance were 24% (269    73 vs . 354    102  ml/min , P = 0.022) and 31% (479    190 vs . 688    265  ml/min , P = 0.013) , respectively , lower in <e1> DRUG1 </e1> -treated patients (n = 20) than in matched <e2> DRUG2 </e2> -treated patients (n = 20) . 	cyclosporine	tacrolimus
other	The latter displayed <e1> DRUG1 </e1> clearances similar to those in two larger cohorts of nonmatched <e2> DRUG2 </e2> -treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor -free regimen (n = 6) . 	midazolam	tacrolimus
other	The latter displayed <e1> DRUG1 </e1> clearances similar to those in two larger cohorts of nonmatched tacrolimus -treated patients (n = 58 and n = 80) and to those receiving a <e2> DRUG2 </e2> -free regimen (n = 6) . 	midazolam	calcineurin inhibitor
other	The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched <e1> DRUG1 </e1> -treated patients (n = 58 and n = 80) and to those receiving a <e2> DRUG2 </e2> -free regimen (n = 6) . 	tacrolimus	calcineurin inhibitor
other	This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving <e1> DRUG1 </e1> than in those receiving <e2> DRUG2 </e2> , indicating that , at the doses generally used in clinical practice , cyclosporine is the stronger of the two with respect to CYP3A inhibition . 	cyclosporine	tacrolimus
other	This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving <e1> DRUG1 </e1> , indicating that , at the doses generally used in clinical practice , <e2> DRUG2 </e2> is the stronger of the two with respect to CYP3A inhibition . 	tacrolimus	cyclosporine
other	Improved parathyroid hormone control by <e1> DRUG1 </e1> is associated with reduction in <e2> DRUG2 </e2> requirement in patients with end-stage renal disease . 	cinacalcet	darbepoetin
other	Medical treatment with <e1> DRUG1 </e1> is effective in reducing plasma parathyroid hormone (PTH) levels , but its effect on <e2> DRUG2 </e2> dosing is unknown . 	cinacalcet	darbepoetin
other	The primary objective of the study was to ascertain the difference in <e1> DRUG1 </e1> responsiveness before and after 12 months of <e2> DRUG2 </e2> therapy . 	darbepoetin	cinacalcet
effect	Reduction of PTH by <e1> DRUG1 </e1> is associated with a decrease in <e2> DRUG2 </e2> requirement . 	cinacalcet	darbepoetin
effect	Interaction of <e1> DRUG1 </e1> with different <e2> DRUG2 </e2> is antagonistic in breast but not in other cancer cells . 	celecoxib	anti-cancer drugs
other	This study investigates the ability of <e1> DRUG1 </e1> to sensitize cells from different origins to several <e2> DRUG2 </e2> . 	cyclooxygenase-2 inhibitors	chemotherapeutic agents
other	The sensitivity , cell cycle , apoptosis and DNA damage of five different cancer cell lines (HeLa , HCT116 , HepG2 , MCF7 and U251) to <e1> DRUG1 </e1> , cisplatin , <e2> DRUG2 </e2> and etoposide celecoxib following different incubation schedules were analyzed . 	5-FU	doxorubicin
other	The sensitivity , cell cycle , apoptosis and DNA damage of five different cancer cell lines (HeLa , HCT116 , HepG2 , MCF7 and U251) to <e1> DRUG1 </e1> , cisplatin , doxorubicin and <e2> DRUG2 </e2> celecoxib following different incubation schedules were analyzed . 	5-FU	etoposide
other	The sensitivity , cell cycle , apoptosis and DNA damage of five different cancer cell lines (HeLa , HCT116 , HepG2 , MCF7 and U251) to <e1> DRUG1 </e1> , cisplatin , doxorubicin and etoposide <e2> DRUG2 </e2> following different incubation schedules were analyzed . 	5-FU	celecoxib
other	The sensitivity , cell cycle , apoptosis and DNA damage of five different cancer cell lines (HeLa , HCT116 , HepG2 , MCF7 and U251) to 5-FU , <e1> DRUG1 </e1> , doxorubicin and <e2> DRUG2 </e2> celecoxib following different incubation schedules were analyzed . 	cisplatin	etoposide
other	The sensitivity , cell cycle , apoptosis and DNA damage of five different cancer cell lines (HeLa , HCT116 , HepG2 , MCF7 and U251) to 5-FU , <e1> DRUG1 </e1> , doxorubicin and etoposide <e2> DRUG2 </e2> following different incubation schedules were analyzed . 	cisplatin	celecoxib
other	The sensitivity , cell cycle , apoptosis and DNA damage of five different cancer cell lines (HeLa , HCT116 , HepG2 , MCF7 and U251) to 5-FU , cisplatin , <e1> DRUG1 </e1> and <e2> DRUG2 </e2> celecoxib following different incubation schedules were analyzed . 	doxorubicin	etoposide
other	The sensitivity , cell cycle , apoptosis and DNA damage of five different cancer cell lines (HeLa , HCT116 , HepG2 , MCF7 and U251) to 5-FU , cisplatin , <e1> DRUG1 </e1> and etoposide <e2> DRUG2 </e2> following different incubation schedules were analyzed . 	doxorubicin	celecoxib
other	We found antagonism between <e1> DRUG1 </e1> and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and <e2> DRUG2 </e2> in all cell lines except for two combinations in HCT116 cells . 	celecoxib	doxorubicin
effect	We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between <e1> DRUG1 </e1> and <e2> DRUG2 </e2> in all cell lines except for two combinations in HCT116 cells . 	celecoxib	doxorubicin
other	These results , if confirmed in-vivo , indicate that <e1> DRUG1 </e1> is not a suitable chemosensitizer for breast cancer or with <e2> DRUG2 </e2> for other cancers . 	celecoxib	doxorubicin
other	[Interaction between <e1> DRUG1 </e1> and <e2> DRUG2 </e2> ] . 	clopidogrel	proton pump inhibitors
other	The drug interaction between <e1> DRUG1 </e1> and <e2> DRUG2 </e2> has been the subject of much study in recent years . 	proton pump inhibitors	clopidogrel
other	Contradictory results regarding the effect of <e1> DRUG1 </e1> on platelet reactivity and on clinical outcome in <e2> DRUG2 </e2> -treated patients have been reported in literature . 	proton pump inhibitors	clopidogrel
mechanism	Concomitant use of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity , as a result of inhibition by omeprazole of CYP2C19 , a cytochrome P450 (CYP) enzyme . 	omeprazole	clopidogrel
other	Concomitant use of omeprazole and <e1> DRUG1 </e1> was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity , as a result of inhibition by <e2> DRUG2 </e2> of CYP2C19 , a cytochrome P450 (CYP) enzyme . 	clopidogrel	omeprazole
mechanism	<e1> DRUG1 </e1> has a much weaker effect on <e2> DRUG2 </e2> 's pharmacokinetics and on platelet reactivity during concomitant use . 	Pantoprazole	clopidogrel
other	The influence of the other <e1> DRUG1 </e1> when used simultaneously with <e2> DRUG2 </e2> has not yet been investigated in adequately randomized studies . 	proton pump inhibitors	clopidogrel
advise	Regulatory agencies state that the combination of <e1> DRUG1 </e1> and the CYP2C19 inhibitors <e2> DRUG2 </e2> and esomeprazole should be avoided . 	clopidogrel	omeprazole
advise	Regulatory agencies state that the combination of <e1> DRUG1 </e1> and the CYP2C19 inhibitors omeprazole and <e2> DRUG2 </e2> should be avoided . 	clopidogrel	esomeprazole
other	Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors <e1> DRUG1 </e1> and <e2> DRUG2 </e2> should be avoided . 	omeprazole	esomeprazole
other	To date , there is no conclusive evidence of a clinically-relevant interaction between any of the <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	proton pump inhibitors	clopidogrel
other	In vitro activity of <e1> DRUG1 </e1> combined with <e2> DRUG2 </e2> against clinical isolates of methicillin -resistant Staphylococcus aureus . 	minocycline	fosfomycin
other	In vitro activity of <e1> DRUG1 </e1> combined with fosfomycin against clinical isolates of <e2> DRUG2 </e2> -resistant Staphylococcus aureus . 	minocycline	methicillin
other	In vitro activity of minocycline combined with <e1> DRUG1 </e1> against clinical isolates of <e2> DRUG2 </e2> -resistant Staphylococcus aureus . 	fosfomycin	methicillin
other	This study aimed to evaluate the in vitro activity of <e1> DRUG1 </e1> combined with <e2> DRUG2 </e2> against isolates of methicillin -resistant Staphylococcus aureus (MRSA) . 	minocycline	fosfomycin
other	This study aimed to evaluate the in vitro activity of <e1> DRUG1 </e1> combined with fosfomycin against isolates of <e2> DRUG2 </e2> -resistant Staphylococcus aureus (MRSA) . 	minocycline	methicillin
other	This study aimed to evaluate the in vitro activity of minocycline combined with <e1> DRUG1 </e1> against isolates of <e2> DRUG2 </e2> -resistant Staphylococcus aureus (MRSA) . 	fosfomycin	methicillin
other	The susceptibility results for <e1> DRUG1 </e1> and <e2> DRUG2 </e2> were interpreted according to the most relevant criteria . 	minocycline	fosfomycin
effect	The combination of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> can be synergistic against MRSA . 	minocycline	fosfomycin
int	The authors report the case of an infant with confirmed congenital hypothyroidism on <e1> DRUG1 </e1> who experienced a possible drug interaction with <e2> DRUG2 </e2> . 	levothyroxine	simeticone
other	Questioning revealed the child was taking <e1> DRUG1 </e1> drops before feeds while on <e2> DRUG2 </e2> . 	Infacol	levothyroxine
other	Drug interaction of <e1> DRUG1 </e1> with <e2> DRUG2 </e2> has not been reported previously and is not listed in the British National Formulary for Children . 	thyroxine	simeticone
other	<e1> DRUG1 </e1> does not inhibit the absorption of 5 milligrams of nonheme iron or <e2> DRUG2 </e2> at doses less than 800 milligrams in nonpregnant women . 	Calcium	heme iron
mechanism	<e1> DRUG1 </e1> is the only known component in the diet that may affect absorption of both nonheme iron and <e2> DRUG2 </e2> . 	Calcium	heme iron
mechanism	However , the evidence for a <e1> DRUG1 </e1> effect on <e2> DRUG2 </e2> absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components , because it was detected in single-meal studies . 	calcium	iron
other	However , the evidence for a calcium effect on <e1> DRUG1 </e1> absorption mainly comes from studies that did not isolate the effect of <e2> DRUG2 </e2> from that of other dietary components , because it was detected in single-meal studies . 	iron	calcium
other	Our objective was to establish potential effects of <e1> DRUG1 </e1> on absorption of nonheme iron and <e2> DRUG2 </e2> and the dose response for this effect in the absence of a meal . 	calcium	heme iron
other	We evaluated the effects of <e1> DRUG1 </e1> doses between 200 and 1500 mg on absorption of 5 mg <e2> DRUG2 </e2> (as ferrous sulfate ) . 	calcium	nonheme iron
other	We evaluated the effects of <e1> DRUG1 </e1> doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as <e2> DRUG2 </e2> ) . 	calcium	ferrous sulfate
other	We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg <e1> DRUG1 </e1> (as <e2> DRUG2 </e2> ) . 	nonheme iron	ferrous sulfate
other	We also evaluated the effects of <e1> DRUG1 </e1> doses between 200 and 800 mg on absorption of 5 mg <e2> DRUG2 </e2> [as concentrated RBC (CRBC)] . 	calcium	heme iron
other	<e1> DRUG1 </e1> was administered as <e2> DRUG2 </e2> in all studies and minerals were ingested on an empty stomach . 	Calcium	calcium chloride
other	<e1> DRUG1 </e1> was administered as calcium chloride in all studies and <e2> DRUG2 </e2> were ingested on an empty stomach . 	Calcium	minerals
other	Calcium was administered as <e1> DRUG1 </e1> in all studies and <e2> DRUG2 </e2> were ingested on an empty stomach . 	calcium chloride	minerals
mechanism	<e1> DRUG1 </e1> doses   1000 mg diminished <e2> DRUG2 </e2> absorption by an average of 49.6% . 	Calcium	nonheme iron
mechanism	A <e1> DRUG1 </e1> dose of 800 mg diminished absorption of 5 mg <e2> DRUG2 </e2> by 37.7% . 	calcium	heme iron
int	Synergistic interaction between <e1> DRUG1 </e1> and <e2> DRUG2 </e2> is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation . 	sunitinib	docetaxel
other	This study was aimed to investigate the efficacy of single use of <e1> DRUG1 </e1> and that of concurrent or sequential administration of sunitinib and <e2> DRUG2 </e2> in NSCLC cell lines that are resistant to EGFR TKIs . 	sunitinib	docetaxel
other	This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> in NSCLC cell lines that are resistant to EGFR TKIs . 	sunitinib	docetaxel
other	<e1> DRUG1 </e1> exhibited dose-dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase , whereas <e2> DRUG2 </e2> arrested at S phase . 	Sunitinib	docetaxel
effect	Although single or concurrent use of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> has some anti-proliferative effects , the sequential administrations of both drugs remarkably enhanced anti-tumor activity . 	sunitinib	docetaxel
effect	When cells were exposed to <e1> DRUG1 </e1> followed by <e2> DRUG2 </e2> , synergism was observed . 	docetaxel	sunitinib
effect	The molecular basis of this synergism is that the signaling pathways that were initially activated by <e1> DRUG1 </e1> exposure were efficiently suppressed by the subsequent exposure to <e2> DRUG2 </e2> . 	docetaxel	sunitinib
other	<e1> DRUG1 </e1> as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of <e2> DRUG2 </e2> followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration . 	Sunitinib	docetaxel
other	<e1> DRUG1 </e1> as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by <e2> DRUG2 </e2> and concurrent administration . 	Sunitinib	docetaxel
effect	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of <e1> DRUG1 </e1> followed by <e2> DRUG2 </e2> is superior to sunitinib followed by docetaxel and concurrent administration . 	docetaxel	sunitinib
other	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of <e1> DRUG1 </e1> followed by sunitinib is superior to <e2> DRUG2 </e2> followed by docetaxel and concurrent administration . 	docetaxel	sunitinib
other	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by <e1> DRUG1 </e1> is superior to sunitinib followed by <e2> DRUG2 </e2> and concurrent administration . 	sunitinib	docetaxel
other	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to <e1> DRUG1 </e1> followed by <e2> DRUG2 </e2> and concurrent administration . 	sunitinib	docetaxel
other	Distinct synergistic action of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> against Pseudomonas aeruginosa . 	piperacillin	methylglyoxal
other	Results revealed that the strains were resistant to many drugs at high levels , only <e1> DRUG1 </e1> , carbenicillin , <e2> DRUG2 </e2> and ciprofloxacin showed resistances at comparatively lower levels . 	piperacillin	amikacin
other	Results revealed that the strains were resistant to many drugs at high levels , only <e1> DRUG1 </e1> , carbenicillin , amikacin and <e2> DRUG2 </e2> showed resistances at comparatively lower levels . 	piperacillin	ciprofloxacin
other	Results revealed that the strains were resistant to many drugs at high levels , only piperacillin , <e1> DRUG1 </e1> , amikacin and <e2> DRUG2 </e2> showed resistances at comparatively lower levels . 	carbenicillin	ciprofloxacin
other	Results revealed that the strains were resistant to many drugs at high levels , only piperacillin , carbenicillin , <e1> DRUG1 </e1> and <e2> DRUG2 </e2> showed resistances at comparatively lower levels . 	amikacin	ciprofloxacin
effect	Distinct and statistically significant synergism was observed between <e1> DRUG1 </e1> and <e2> DRUG2 </e2> by disc diffusion tests when compared with their individual effects . 	methylglyoxal	piperacillin
effect	Synergism was also noted when <e1> DRUG1 </e1> was combined with <e2> DRUG2 </e2> and amikacin . 	methylglyoxal	carbenicillin
effect	Synergism was also noted when <e1> DRUG1 </e1> was combined with carbenicillin and <e2> DRUG2 </e2> . 	methylglyoxal	amikacin
other	Synergism was also noted when methylglyoxal was combined with <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	carbenicillin	amikacin
other	Protective effect of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> against the acute toxicity of diepoxybutane to human lymphocytes . 	acetyl-l-carnitine	alpha lipoic acid
effect	(ii) <e1> DRUG1 </e1> elicits a significant protective effect on DEB induced toxicity , which was potentiated by <e2> DRUG2 </e2> . 	acetyl-l-carnitine	alpha-lipoic acid
other	[Influence of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> on MPTP-evoked behavior violations in C57BL/6 mice] . 	hemantane	doxycycline
other	The effects of <e1> DRUG1 </e1> hemantane [ <e2> DRUG2 </e2> ] (10 mg/kg , p . o.) 	anti-parkinsonian drug	(2-adamantyl)hexamethylenimine
other	The effects of anti-parkinsonian drug <e1> DRUG1 </e1> [ <e2> DRUG2 </e2> ] (10 mg/kg , p . o.) 	hemantane	(2-adamantyl)hexamethylenimine
other	and/or <e1> DRUG1 </e1> doxycycline (100 mg/kg , p . o.) , as well as that of neurotoxin <e2> DRUG2 </e2> ( MPTP ) (4 x 20 mg/kg , i . p.) 	antibiotic drug	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine
other	and/or <e1> DRUG1 </e1> doxycycline (100 mg/kg , p . o.) , as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine ( <e2> DRUG2 </e2> ) (4 x 20 mg/kg , i . p.) 	antibiotic drug	MPTP
other	and/or antibiotic drug <e1> DRUG1 </e1> (100 mg/kg , p . o.) , as well as that of neurotoxin <e2> DRUG2 </e2> ( MPTP ) (4 x 20 mg/kg , i . p.) 	doxycycline	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine
other	and/or antibiotic drug <e1> DRUG1 </e1> (100 mg/kg , p . o.) , as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine ( <e2> DRUG2 </e2> ) (4 x 20 mg/kg , i . p.) 	doxycycline	MPTP
effect	The role of p27(Kip1) in <e1> DRUG1 </e1> -enhanced <e2> DRUG2 </e2> cytotoxicity in human ovarian cancer cells . 	dasatinib	paclitaxel
other	The effect of <e1> DRUG1 </e1> , an inhibitor of Src and Abl kinases , on <e2> DRUG2 </e2> sensitivity was measured in ovarian cancer cells and HEY xenografts . 	dasatinib	paclitaxel
other	The roles of p27(Kip1) , Bcl-2 , and Cdk1 in apoptosis induced by <e1> DRUG1 </e1> and <e2> DRUG2 </e2> were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay , siRNA knockdown of gene expression , transfection with Bcl-2 and Cdk1 expression vectors , and flow cytometry . 	dasatinib	paclitaxel
effect	HEY cells treated with <e1> DRUG1 </e1> plus <e2> DRUG2 </e2> formed fewer colonies than did cells treated with either agent alone . 	dasatinib	paclitaxel
effect	Treatment of HEY xenograft-bearing mice with <e1> DRUG1 </e1> plus <e2> DRUG2 </e2> inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse , dasatinib + paclitaxel vs paclitaxel : 0.28 vs . 0.81 cm3 , difference = 0.53 cm3 , 95% confidence interval [CI] = 0.44 to 0.62 cm3 , P = .014); 	dasatinib	paclitaxel
other	Treatment of HEY xenograft-bearing mice with <e1> DRUG1 </e1> plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse , dasatinib + <e2> DRUG2 </e2> vs paclitaxel : 0.28 vs . 0.81 cm3 , difference = 0.53 cm3 , 95% confidence interval [CI] = 0.44 to 0.62 cm3 , P = .014); 	dasatinib	paclitaxel
other	Treatment of HEY xenograft-bearing mice with <e1> DRUG1 </e1> plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse , dasatinib + paclitaxel vs <e2> DRUG2 </e2> : 0.28 vs . 0.81 cm3 , difference = 0.53 cm3 , 95% confidence interval [CI] = 0.44 to 0.62 cm3 , P = .014); 	dasatinib	paclitaxel
other	Treatment of HEY xenograft-bearing mice with dasatinib plus <e1> DRUG1 </e1> inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse , <e2> DRUG2 </e2> + paclitaxel vs paclitaxel : 0.28 vs . 0.81 cm3 , difference = 0.53 cm3 , 95% confidence interval [CI] = 0.44 to 0.62 cm3 , P = .014); 	paclitaxel	dasatinib
other	Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse , <e1> DRUG1 </e1> + <e2> DRUG2 </e2> vs paclitaxel : 0.28 vs . 0.81 cm3 , difference = 0.53 cm3 , 95% confidence interval [CI] = 0.44 to 0.62 cm3 , P = .014); 	dasatinib	paclitaxel
other	Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse , <e1> DRUG1 </e1> + paclitaxel vs <e2> DRUG2 </e2> : 0.28 vs . 0.81 cm3 , difference = 0.53 cm3 , 95% confidence interval [CI] = 0.44 to 0.62 cm3 , P = .014); 	dasatinib	paclitaxel
other	<e1> DRUG1 </e1> + <e2> DRUG2 </e2> vs . 	dasatinib	paclitaxel
other	The siRNA knockdown of p27(Kip1) decreased <e1> DRUG1 </e1> - and <e2> DRUG2 </e2> -induced apoptosis compared with a negative control siRNA (sub-G1 fraction , control siRNA vs . p27(Kip1) siRNA : 42.5% vs . 20.1% , difference = 22.4% , 95% CI = 20.1% to 24.7% , P = .017) . 	dasatinib	paclitaxel
effect	Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that <e1> DRUG1 </e1> -mediated induction of p27(Kip1) enhanced <e2> DRUG2 </e2> -induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression . 	dasatinib	paclitaxel
effect	Inhibition of Src family and Abl kinases with either siRNAs or <e1> DRUG1 </e1> enhances <e2> DRUG2 </e2> sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression . 	dasatinib	paclitaxel
other	Phase I trial of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> in patients with relapsed multiple myeloma : evidence for lenalidomide - CCI-779 interaction via P-glycoprotein . 	lenalidomide	CCI-779
other	Phase I trial of <e1> DRUG1 </e1> and CCI-779 in patients with relapsed multiple myeloma : evidence for lenalidomide - <e2> DRUG2 </e2> interaction via P-glycoprotein . 	lenalidomide	CCI-779
other	Phase I trial of lenalidomide and <e1> DRUG1 </e1> in patients with relapsed multiple myeloma : evidence for <e2> DRUG2 </e2> - CCI-779 interaction via P-glycoprotein . 	CCI-779	lenalidomide
effect	The preclinical combination of <e1> DRUG1 </e1> with the mTOR inhibitor <e2> DRUG2 </e2> has displayed synergy in vitro and represents a novel combination in MM . 	lenalidomide	CCI-779
other	Enhancement of humoral immune responses to inactivated Newcastle disease and <e1> DRUG1 </e1> by oral administration of <e2> DRUG2 </e2> in chickens . 	avian influenza vaccines	ginseng stem-and-leaf saponins
other	In experiment 1 , oral administration of <e1> DRUG1 </e1> at a dose of 5 mg/kg of BW for 7 d on the immune response in chickens intramuscularly injected with <e2> DRUG2 </e2> was evaluated . 	GSLS	inactivated ND vaccine
effect	In experiment 2 , the same regimen of <e1> DRUG1 </e1> was administered to chickens inoculated with <e2> DRUG2 </e2> , and an enhanced serum antibody response to AI vaccination was also observed . 	GSLS	inactivated AI vaccines
other	Interaction of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> , in vitro and in vivo , in human A375 melanoma cells . 	dacarbazine	imexon
other	We evaluated mechanisms of interaction between the alkyating agent <e1> DRUG1 </e1> ( DTIC ) and the pro-oxidant , <e2> DRUG2 </e2> , in the human A375 melanoma cell line . 	dacarbazine	imexon
other	We evaluated mechanisms of interaction between the alkyating agent dacarbazine ( <e1> DRUG1 </e1> ) and the pro-oxidant , <e2> DRUG2 </e2> , in the human A375 melanoma cell line . 	DTIC	imexon
other	The effect of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> , alone and in combination , was evaluated for growth inhibition (MTT) , radiolabeled drug uptake , cellular thiol content (HPLC) , and DNA strand breaks (Comet assay) . 	DTIC	imexon
other	There was a >75% reduction in cellular glutathione and cysteine with <e1> DRUG1 </e1> but not <e2> DRUG2 </e2> . 	imexon	DTIC
effect	<e1> DRUG1 </e1> and <e2> DRUG2 </e2> show additive effects in vitro but not in vivo in human A375 melanoma cells . 	Imexon	dacarbazine
effect	<e1> DRUG1 </e1> enhances <e2> DRUG2 </e2> -mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression . 	Lapatinib	herceptin
effect	Although it was previously reported that <e1> DRUG1 </e1> combined with <e2> DRUG2 </e2> improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin -refractory HER2-positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents . 	lapatinib	Herceptin
other	Although it was previously reported that <e1> DRUG1 </e1> combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with <e2> DRUG2 </e2> -refractory HER2-positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents . 	lapatinib	Herceptin
other	Although it was previously reported that lapatinib combined with <e1> DRUG1 </e1> improved the progression-free survival rate compared with <e2> DRUG2 </e2> alone for patients with Herceptin -refractory HER2-positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents . 	Herceptin	lapatinib
other	Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with <e1> DRUG1 </e1> alone for patients with <e2> DRUG2 </e2> -refractory HER2-positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents . 	lapatinib	Herceptin
other	We evaluated how <e1> DRUG1 </e1> interacts with <e2> DRUG2 </e2> in HER2-positive breast cancer , with a particular focus on Herceptin -mediated antibody-dependent cellular cytotoxicity (ADCC) . 	lapatinib	Herceptin
other	We evaluated how <e1> DRUG1 </e1> interacts with Herceptin in HER2-positive breast cancer , with a particular focus on <e2> DRUG2 </e2> -mediated antibody-dependent cellular cytotoxicity (ADCC) . 	lapatinib	Herceptin
effect	In an in vitro assay , <e1> DRUG1 </e1> induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines , leading to the enhancement of <e2> DRUG2 </e2> -mediated ADCC . 	lapatinib	Herceptin
effect	Furthermore , we present a case report in which a second <e1> DRUG1 </e1> treatment following <e2> DRUG2 </e2> resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer . 	Herceptin	lapatinib
other	<e1> DRUG1 </e1> may have the potential to convert <e2> DRUG2 </e2> -refractory to Herceptin -sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2 . 	Lapatinib	Herceptin
other	<e1> DRUG1 </e1> may have the potential to convert Herceptin -refractory to <e2> DRUG2 </e2> -sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2 . 	Lapatinib	Herceptin
other	We elucidated the expression of HB-EGF in T-ALL cell lines , and evaluated the effect of <e1> DRUG1 </e1> on these cells alone or in combination with <e2> DRUG2 </e2> . 	CRM197	anticancer agent
other	<e1> DRUG1 </e1> induced apoptosis , and furthermore , the combination of CRM197 plus <e2> DRUG2 </e2> enhanced cytotoxicity in a T-ALL cell line . 	CRM197	doxorubicin
effect	CRM197 induced apoptosis , and furthermore , the combination of <e1> DRUG1 </e1> plus <e2> DRUG2 </e2> enhanced cytotoxicity in a T-ALL cell line . 	CRM197	doxorubicin
effect	<e1> DRUG1 </e1> enhances the antinociceptive effect of <e2> DRUG2 </e2> in mice . 	Ephedrine	dexmedetomidine
other	The purpose of this study was to evaluate whether the psychostimulant drug <e1> DRUG1 </e1> has any effect on <e2> DRUG2 </e2> -induced antinociception and locomotor inhibitor activity in mice in acute application . 	ephedrine	dexmedetomidine
other	saline + saline , <e1> DRUG1 </e1> (10   mg/kg) + saline , saline + <e2> DRUG2 </e2> (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg) , intraperitoneally , 30 min before hot plate or holed open field tests . 	ephedrine	dexmedetomidine
other	saline + saline , <e1> DRUG1 </e1> (10   mg/kg) + saline , saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + <e2> DRUG2 </e2> (15     g/kg) , intraperitoneally , 30 min before hot plate or holed open field tests . 	ephedrine	dexmedetomidine
other	saline + saline , ephedrine (10   mg/kg) + saline , saline + <e1> DRUG1 </e1> (15     g/kg) and <e2> DRUG2 </e2> (10   mg/kg) + dexmedetomidine (15     g/kg) , intraperitoneally , 30 min before hot plate or holed open field tests . 	dexmedetomidine	ephedrine
other	saline + saline , ephedrine (10   mg/kg) + saline , saline + dexmedetomidine (15     g/kg) and <e1> DRUG1 </e1> (10   mg/kg) + <e2> DRUG2 </e2> (15     g/kg) , intraperitoneally , 30 min before hot plate or holed open field tests . 	ephedrine	dexmedetomidine
effect	In the hot plate test in mice , co-administration of 15     g/kg <e1> DRUG1 </e1> with 10   mg/kg <e2> DRUG2 </e2> intraperitoneally not only enhanced , but also prolonged the duration of antinociception induced by dexmedetomidine . 	dexmedetomidine	ephedrine
other	In the hot plate test in mice , co-administration of 15     g/kg dexmedetomidine with 10   mg/kg <e1> DRUG1 </e1> intraperitoneally not only enhanced , but also prolonged the duration of antinociception induced by <e2> DRUG2 </e2> . 	ephedrine	dexmedetomidine
effect	At the same time , the locomotor inhibitory effect of <e1> DRUG1 </e1> was counteracted by <e2> DRUG2 </e2> . 	dexmedetomidine	ephedrine
effect	We concluded that the combined administration of <e1> DRUG1 </e1> with <e2> DRUG2 </e2> may have beneficial effects in the treatment of pain without causing sedation , which limits the use of dexmedetomidine as an analgesic in humans . 	dexmedetomidine	ephedrine
other	We concluded that the combined administration of <e1> DRUG1 </e1> with ephedrine may have beneficial effects in the treatment of pain without causing sedation , which limits the use of dexmedetomidine as an <e2> DRUG2 </e2> in humans . 	dexmedetomidine	analgesic
other	We concluded that the combined administration of dexmedetomidine with <e1> DRUG1 </e1> may have beneficial effects in the treatment of pain without causing sedation , which limits the use of <e2> DRUG2 </e2> as an analgesic in humans . 	ephedrine	dexmedetomidine
other	We concluded that the combined administration of dexmedetomidine with <e1> DRUG1 </e1> may have beneficial effects in the treatment of pain without causing sedation , which limits the use of dexmedetomidine as an <e2> DRUG2 </e2> in humans . 	ephedrine	analgesic
other	We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation , which limits the use of <e1> DRUG1 </e1> as an <e2> DRUG2 </e2> in humans . 	dexmedetomidine	analgesic
other	[Efficacy of fixed combination <e1> DRUG1 </e1> / <e2> DRUG2 </e2> in hospitalized patients with hypertensive disease] 	amlodipine	valsartan
other	Efficacy and tolerability of fixed <e1> DRUG1 </e1> / <e2> DRUG2 </e2> combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology . 	amlodipine	valsartan
other	All patients had indications for antihypertensive therapy and were randomized either to fixed combination <e1> DRUG1 </e1> / <e2> DRUG2 </e2> (n=43) or to therapy which corresponded to the hospital formulary (n=43) . 	amlodipine	valsartan
other	Rate of achievement of target BP with fixed combination <e1> DRUG1 </e1> / <e2> DRUG2 </e2> (93%) was comparable with that on traditional therapy (90%) . 	amlodipine	valsartan
effect	But the use of fixed combination <e1> DRUG1 </e1> / <e2> DRUG2 </e2> compared with traditional therapy was associated with lower clinical and self measured BP , quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days , respectively , 0.05) , lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days , respectively) , lower rate of concealed inefficacy of treatment (12 and 31% , respectively , 0.05) . 	amlodipine	valsartan
other	But the use of fixed combination <e1> DRUG1 </e1> / valsartan compared with traditional therapy was associated with lower clinical and self measured BP , quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days , respectively , 0.05) , lesser number of <e2> DRUG2 </e2> (2.5+/-0.6 and 3.0+/-0.9 days , respectively) , lower rate of concealed inefficacy of treatment (12 and 31% , respectively , 0.05) . 	amlodipine	antihypertensive drugs
other	But the use of fixed combination amlodipine / <e1> DRUG1 </e1> compared with traditional therapy was associated with lower clinical and self measured BP , quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days , respectively , 0.05) , lesser number of <e2> DRUG2 </e2> (2.5+/-0.6 and 3.0+/-0.9 days , respectively) , lower rate of concealed inefficacy of treatment (12 and 31% , respectively , 0.05) . 	valsartan	antihypertensive drugs
effect	We have demonstrated appropriateness of inhospital administration of fixed <e1> DRUG1 </e1> / <e2> DRUG2 </e2> combination as an approach allowing to achieve target BP in shorter time , with the use of fewer antihypertensive drugs , and diminishing concealed inefficacy of treatment . 	amlodipine	valsartan
other	We have demonstrated appropriateness of inhospital administration of fixed <e1> DRUG1 </e1> / valsartan combination as an approach allowing to achieve target BP in shorter time , with the use of fewer <e2> DRUG2 </e2> , and diminishing concealed inefficacy of treatment . 	amlodipine	antihypertensive drugs
other	We have demonstrated appropriateness of inhospital administration of fixed amlodipine / <e1> DRUG1 </e1> combination as an approach allowing to achieve target BP in shorter time , with the use of fewer <e2> DRUG2 </e2> , and diminishing concealed inefficacy of treatment . 	valsartan	antihypertensive drugs
other	<e1> DRUG1 </e1> ( Brilinta )--better than <e2> DRUG2 </e2> ( Plavix ) 	Ticagrelor	clopidogrel
other	<e1> DRUG1 </e1> ( Brilinta )--better than clopidogrel ( <e2> DRUG2 </e2> ) 	Ticagrelor	Plavix
other	Ticagrelor ( <e1> DRUG1 </e1> )--better than <e2> DRUG2 </e2> ( Plavix ) 	Brilinta	clopidogrel
other	Ticagrelor ( <e1> DRUG1 </e1> )--better than clopidogrel ( <e2> DRUG2 </e2> ) 	Brilinta	Plavix
other	The FDA has approved <e1> DRUG1 </e1> ( Brilinta -AstraZeneca) , an oral <e2> DRUG2 </e2> , for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) . 	ticagrelor	antiplatelet drug
effect	The FDA has approved <e1> DRUG1 </e1> ( Brilinta -AstraZeneca) , an oral antiplatelet drug , for use with low-dose <e2> DRUG2 </e2> to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) . 	ticagrelor	aspirin
other	The FDA has approved ticagrelor ( <e1> DRUG1 </e1> -AstraZeneca) , an oral <e2> DRUG2 </e2> , for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) . 	Brilinta	antiplatelet drug
effect	The FDA has approved ticagrelor ( <e1> DRUG1 </e1> -AstraZeneca) , an oral antiplatelet drug , for use with low-dose <e2> DRUG2 </e2> to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) . 	Brilinta	aspirin
other	The FDA has approved ticagrelor ( Brilinta -AstraZeneca) , an oral <e1> DRUG1 </e1> , for use with low-dose <e2> DRUG2 </e2> to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) . 	antiplatelet drug	aspirin
other	It will compete with <e1> DRUG1 </e1> ( Plavix ) and <e2> DRUG2 </e2> ( Effient ) for such use . 	clopidogrel	prasugrel
other	It will compete with <e1> DRUG1 </e1> ( Plavix ) and prasugrel ( <e2> DRUG2 </e2> ) for such use . 	clopidogrel	Effient
other	It will compete with clopidogrel ( <e1> DRUG1 </e1> ) and <e2> DRUG2 </e2> ( Effient ) for such use . 	Plavix	prasugrel
other	It will compete with clopidogrel ( <e1> DRUG1 </e1> ) and prasugrel ( <e2> DRUG2 </e2> ) for such use . 	Plavix	Effient
other	Influence of <e1> DRUG1 </e1> on <e2> DRUG2 </e2> induced antinociception and its pharmacokinetics . 	piperine	ibuprofen
effect	In the present study <e1> DRUG1 </e1> (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of <e2> DRUG2 </e2> evaluated by both acetic acid writhing and formalin test , when it was administered with ibuprofen . 	piperine	ibuprofen
other	In the present study <e1> DRUG1 </e1> (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both <e2> DRUG2 </e2> writhing and formalin test , when it was administered with ibuprofen . 	piperine	acetic acid
other	In the present study <e1> DRUG1 </e1> (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test , when it was administered with <e2> DRUG2 </e2> . 	piperine	ibuprofen
other	In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of <e1> DRUG1 </e1> evaluated by both <e2> DRUG2 </e2> writhing and formalin test , when it was administered with ibuprofen . 	ibuprofen	acetic acid
other	In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both <e1> DRUG1 </e1> writhing and formalin test , when it was administered with <e2> DRUG2 </e2> . 	acetic acid	ibuprofen
mechanism	<e1> DRUG1 </e1> plasma concentration was also increased when it was administered with <e2> DRUG2 </e2> . 	Ibuprofen	piperine
mechanism	The synergistic antinociception activity of <e1> DRUG1 </e1> when administered with <e2> DRUG2 </e2> can be attributed to increased plasma concentration of ibuprofen . 	ibuprofen	piperine
other	The synergistic antinociception activity of ibuprofen when administered with <e1> DRUG1 </e1> can be attributed to increased plasma concentration of <e2> DRUG2 </e2> . 	piperine	ibuprofen
effect	From this study it can be concluded that <e1> DRUG1 </e1> can be used as a bioenhancer along with <e2> DRUG2 </e2> . 	piperine	ibuprofen
other	Pharmacokinetic properties of <e1> DRUG1 </e1> were not altered by the addition of either <e2> DRUG2 </e2> or zidovudine or the combination of lamivudine and zidovudine . 	abacavir	lamivudine
other	Pharmacokinetic properties of <e1> DRUG1 </e1> were not altered by the addition of either lamivudine or <e2> DRUG2 </e2> or the combination of lamivudine and zidovudine . 	abacavir	zidovudine
other	Pharmacokinetic properties of <e1> DRUG1 </e1> were not altered by the addition of either lamivudine or zidovudine or the combination of <e2> DRUG2 </e2> and zidovudine . 	abacavir	lamivudine
other	Pharmacokinetic properties of <e1> DRUG1 </e1> were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and <e2> DRUG2 </e2> . 	abacavir	zidovudine
other	Pharmacokinetic properties of abacavir were not altered by the addition of either <e1> DRUG1 </e1> or zidovudine or the combination of lamivudine and <e2> DRUG2 </e2> . 	lamivudine	zidovudine
other	Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or <e1> DRUG1 </e1> or the combination of <e2> DRUG2 </e2> and zidovudine . 	zidovudine	lamivudine
other	Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	lamivudine	zidovudine
other	No clinically significant changes to <e1> DRUG1 </e1> or zidovudine pharmacokinetics were observed following concomitant administration of <e2> DRUG2 </e2> . 	lamivudine	abacavir
other	No clinically significant changes to lamivudine or <e1> DRUG1 </e1> pharmacokinetics were observed following concomitant administration of <e2> DRUG2 </e2> . 	zidovudine	abacavir
other	<e1> DRUG1 </e1> has no effect on the pharmacokinetic properties of <e2> DRUG2 </e2> . 	Abacavir	ethanol
mechanism	<e1> DRUG1 </e1> decreases the elimination of <e2> DRUG2 </e2> causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir . 	Ethanol	abacavir
other	Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of <e1> DRUG1 </e1> has no clinically significant effect on the pharmacokinetic properties of <e2> DRUG2 </e2> . 	methadone	abacavir
mechanism	In a study of 11 HIV-infected patients receiving <e1> DRUG1 </e1> -maintenance therapy (40 mg and 90 mg daily) with 600 mg of <e2> DRUG2 </e2> twice daily (twice the currently recommended dose) , oral methadone clearance increased 22% (90% CI 6% to 42%) . 	methadone	ZIAGEN
other	In a study of 11 HIV-infected patients receiving methadone -maintenance therapy (40 mg and 90 mg daily) with 600 mg of <e1> DRUG1 </e1> twice daily (twice the currently recommended dose) , oral <e2> DRUG2 </e2> clearance increased 22% (90% CI 6% to 42%) . 	ZIAGEN	methadone
other	<e1> DRUG1 </e1> : Concomitant cholestyramine administration decreased the mean AUC of total <e2> DRUG2 </e2> approximately 55% . 	Cholestyramine	ezetimibe
mechanism	Cholestyramine : Concomitant <e1> DRUG1 </e1> administration decreased the mean AUC of total <e2> DRUG2 </e2> approximately 55% . 	cholestyramine	ezetimibe
effect	The incremental LDL-C reduction due to adding <e1> DRUG1 </e1> to <e2> DRUG2 </e2> may be reduced by this interaction . 	ezetimibe	cholestyramine
other	<e1> DRUG1 </e1> : The safety and effectiveness of <e2> DRUG2 </e2> administered with fibrates have not been established . 	Fibrates	ezetimibe
other	Fibrates : The safety and effectiveness of <e1> DRUG1 </e1> administered with <e2> DRUG2 </e2> have not been established . 	ezetimibe	fibrates
advise	Co-administration of <e1> DRUG1 </e1> with <e2> DRUG2 </e2> is not recommended until use in patients is studied . 	ZETIA	fibrates
other	<e1> DRUG1 </e1> : In a pharmacokinetic study , concomitant fenofibrate administration increased total <e2> DRUG2 </e2> concentrations approximately 1.5-fold . 	Fenofibrate	ezetimibe
mechanism	Fenofibrate : In a pharmacokinetic study , concomitant <e1> DRUG1 </e1> administration increased total <e2> DRUG2 </e2> concentrations approximately 1.5-fold . 	fenofibrate	ezetimibe
other	<e1> DRUG1 </e1> : In a pharmacokinetic study , concomitant gemfibrozil administration increased total <e2> DRUG2 </e2> concentrations approximately 1.7-fold . 	Gemfibrozil	ezetimibe
other	Gemfibrozil : In a pharmacokinetic study , concomitant <e1> DRUG1 </e1> administration increased total <e2> DRUG2 </e2> concentrations approximately 1.7-fold . 	gemfibrozil	ezetimibe
other	<e1> DRUG1 </e1> : No clinically significant pharmacokinetic interactions were seen when <e2> DRUG2 </e2> was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 	HMG-CoA reductase inhibitors	ezetimibe
other	<e1> DRUG1 </e1> : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with <e2> DRUG2 </e2> , simvastatin , pravastatin , lovastatin , or fluvastatin . 	HMG-CoA reductase inhibitors	atorvastatin
other	<e1> DRUG1 </e1> : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , <e2> DRUG2 </e2> , pravastatin , lovastatin , or fluvastatin . 	HMG-CoA reductase inhibitors	simvastatin
other	<e1> DRUG1 </e1> : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , <e2> DRUG2 </e2> , lovastatin , or fluvastatin . 	HMG-CoA reductase inhibitors	pravastatin
other	<e1> DRUG1 </e1> : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , <e2> DRUG2 </e2> , or fluvastatin . 	HMG-CoA reductase inhibitors	lovastatin
other	<e1> DRUG1 </e1> : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or <e2> DRUG2 </e2> . 	HMG-CoA reductase inhibitors	fluvastatin
other	HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when <e1> DRUG1 </e1> was co-administered with <e2> DRUG2 </e2> , simvastatin , pravastatin , lovastatin , or fluvastatin . 	ezetimibe	atorvastatin
other	HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when <e1> DRUG1 </e1> was co-administered with atorvastatin , <e2> DRUG2 </e2> , pravastatin , lovastatin , or fluvastatin . 	ezetimibe	simvastatin
other	HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when <e1> DRUG1 </e1> was co-administered with atorvastatin , simvastatin , <e2> DRUG2 </e2> , lovastatin , or fluvastatin . 	ezetimibe	pravastatin
other	HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when <e1> DRUG1 </e1> was co-administered with atorvastatin , simvastatin , pravastatin , <e2> DRUG2 </e2> , or fluvastatin . 	ezetimibe	lovastatin
other	HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when <e1> DRUG1 </e1> was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or <e2> DRUG2 </e2> . 	ezetimibe	fluvastatin
other	HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with <e1> DRUG1 </e1> , simvastatin , <e2> DRUG2 </e2> , lovastatin , or fluvastatin . 	atorvastatin	pravastatin
other	HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with <e1> DRUG1 </e1> , simvastatin , pravastatin , <e2> DRUG2 </e2> , or fluvastatin . 	atorvastatin	lovastatin
other	HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with <e1> DRUG1 </e1> , simvastatin , pravastatin , lovastatin , or <e2> DRUG2 </e2> . 	atorvastatin	fluvastatin
other	HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , <e1> DRUG1 </e1> , pravastatin , <e2> DRUG2 </e2> , or fluvastatin . 	simvastatin	lovastatin
other	HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , <e1> DRUG1 </e1> , pravastatin , lovastatin , or <e2> DRUG2 </e2> . 	simvastatin	fluvastatin
other	HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , <e1> DRUG1 </e1> , lovastatin , or <e2> DRUG2 </e2> . 	pravastatin	fluvastatin
other	<e1> DRUG1 </e1> : The total <e2> DRUG2 </e2> level increased 12-fold in one renal transplant patient receiving multiple medications , including cyclosporine . 	Cyclosporine	ezetimibe
mechanism	Cyclosporine : The total <e1> DRUG1 </e1> level increased 12-fold in one renal transplant patient receiving multiple medications , including <e2> DRUG2 </e2> . 	ezetimibe	cyclosporine
advise	Patients who take both <e1> DRUG1 </e1> and <e2> DRUG2 </e2> should be carefully monitored . 	ezetimibe	cyclosporine
other	Multiple dose studies of <e1> DRUG1 </e1> given in combination with <e2> DRUG2 </e2> ( statins ) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures . 	ezetimibe	HMG-CoA reductase inhibitors
other	Multiple dose studies of <e1> DRUG1 </e1> given in combination with HMG-CoA reductase inhibitors ( <e2> DRUG2 </e2> ) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures . 	ezetimibe	statins
other	Multiple dose studies of ezetimibe given in combination with <e1> DRUG1 </e1> ( statins ) in rats and rabbits during organogenesis result in higher <e2> DRUG2 </e2> and statin exposures . 	HMG-CoA reductase inhibitors	ezetimibe
other	Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors ( <e1> DRUG1 </e1> ) in rats and rabbits during organogenesis result in higher <e2> DRUG2 </e2> and statin exposures . 	statins	ezetimibe
other	When <e1> DRUG1 </e1> is administered with an <e2> DRUG2 </e2> in a woman of childbearing potential , refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor . 	ZETIA	HMG-CoA reductase inhibitor
other	When <e1> DRUG1 </e1> is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential , refer to the pregnancy category and package labeling for the <e2> DRUG2 </e2> . 	ZETIA	HMG-CoA reductase inhibitor
other	These are described in greater detail below :  Oral <e1> DRUG1 </e1> , Coumarin-type anticoagulants , <e2> DRUG2 </e2> , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	hypoglycemics	Phenytoin
other	These are described in greater detail below :  Oral <e1> DRUG1 </e1> , Coumarin-type anticoagulants , Phenytoin , <e2> DRUG2 </e2> , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	hypoglycemics	Cyclosporine
other	These are described in greater detail below :  Oral <e1> DRUG1 </e1> , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , <e2> DRUG2 </e2> , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	hypoglycemics	Rifampin
other	These are described in greater detail below :  Oral <e1> DRUG1 </e1> , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , <e2> DRUG2 </e2> , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	hypoglycemics	Theophylline
other	These are described in greater detail below :  Oral <e1> DRUG1 </e1> , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , <e2> DRUG2 </e2> , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	hypoglycemics	Terfenadine
other	These are described in greater detail below :  Oral <e1> DRUG1 </e1> , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , <e2> DRUG2 </e2> , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	hypoglycemics	Cisapride
other	These are described in greater detail below :  Oral <e1> DRUG1 </e1> , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , <e2> DRUG2 </e2> , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	hypoglycemics	Astemizole
other	These are described in greater detail below :  Oral <e1> DRUG1 </e1> , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , <e2> DRUG2 </e2> , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	hypoglycemics	Rifabutin
other	These are described in greater detail below :  Oral <e1> DRUG1 </e1> , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , <e2> DRUG2 </e2> , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	hypoglycemics	Tacrolimus
other	These are described in greater detail below :  Oral <e1> DRUG1 </e1> , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , <e2> DRUG2 </e2> ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	hypoglycemics	Short-acting benzodiazepines
other	These are described in greater detail below :  Oral <e1> DRUG1 </e1> , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of <e2> DRUG2 </e2> with oral hypoglycemic agents ; 	hypoglycemics	DIFLUCAN
other	These are described in greater detail below :  Oral <e1> DRUG1 </e1> , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> DRUG2 </e2> ; 	hypoglycemics	hypoglycemic agents
other	These are described in greater detail below :  Oral hypoglycemics , <e1> DRUG1 </e1> , Phenytoin , <e2> DRUG2 </e2> , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Coumarin-type anticoagulants	Cyclosporine
other	These are described in greater detail below :  Oral hypoglycemics , <e1> DRUG1 </e1> , Phenytoin , Cyclosporine , <e2> DRUG2 </e2> , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Coumarin-type anticoagulants	Rifampin
other	These are described in greater detail below :  Oral hypoglycemics , <e1> DRUG1 </e1> , Phenytoin , Cyclosporine , Rifampin , <e2> DRUG2 </e2> , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Coumarin-type anticoagulants	Theophylline
other	These are described in greater detail below :  Oral hypoglycemics , <e1> DRUG1 </e1> , Phenytoin , Cyclosporine , Rifampin , Theophylline , <e2> DRUG2 </e2> , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Coumarin-type anticoagulants	Terfenadine
other	These are described in greater detail below :  Oral hypoglycemics , <e1> DRUG1 </e1> , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , <e2> DRUG2 </e2> , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Coumarin-type anticoagulants	Cisapride
other	These are described in greater detail below :  Oral hypoglycemics , <e1> DRUG1 </e1> , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , <e2> DRUG2 </e2> , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Coumarin-type anticoagulants	Astemizole
other	These are described in greater detail below :  Oral hypoglycemics , <e1> DRUG1 </e1> , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , <e2> DRUG2 </e2> , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Coumarin-type anticoagulants	Rifabutin
other	These are described in greater detail below :  Oral hypoglycemics , <e1> DRUG1 </e1> , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , <e2> DRUG2 </e2> , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Coumarin-type anticoagulants	Tacrolimus
other	These are described in greater detail below :  Oral hypoglycemics , <e1> DRUG1 </e1> , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , <e2> DRUG2 </e2> ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Coumarin-type anticoagulants	Short-acting benzodiazepines
other	These are described in greater detail below :  Oral hypoglycemics , <e1> DRUG1 </e1> , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral <e2> DRUG2 </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Coumarin-type anticoagulants	hypoglycemics
other	These are described in greater detail below :  Oral hypoglycemics , <e1> DRUG1 </e1> , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of <e2> DRUG2 </e2> with oral hypoglycemic agents ; 	Coumarin-type anticoagulants	DIFLUCAN
other	These are described in greater detail below :  Oral hypoglycemics , <e1> DRUG1 </e1> , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> DRUG2 </e2> ; 	Coumarin-type anticoagulants	hypoglycemic agents
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , <e1> DRUG1 </e1> , Cyclosporine , <e2> DRUG2 </e2> , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Phenytoin	Rifampin
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , <e1> DRUG1 </e1> , Cyclosporine , Rifampin , <e2> DRUG2 </e2> , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Phenytoin	Theophylline
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , <e1> DRUG1 </e1> , Cyclosporine , Rifampin , Theophylline , <e2> DRUG2 </e2> , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Phenytoin	Terfenadine
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , <e1> DRUG1 </e1> , Cyclosporine , Rifampin , Theophylline , Terfenadine , <e2> DRUG2 </e2> , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Phenytoin	Cisapride
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , <e1> DRUG1 </e1> , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , <e2> DRUG2 </e2> , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Phenytoin	Astemizole
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , <e1> DRUG1 </e1> , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , <e2> DRUG2 </e2> , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Phenytoin	Rifabutin
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , <e1> DRUG1 </e1> , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , <e2> DRUG2 </e2> , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Phenytoin	Tacrolimus
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , <e1> DRUG1 </e1> , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , <e2> DRUG2 </e2> ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Phenytoin	Short-acting benzodiazepines
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , <e1> DRUG1 </e1> , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral <e2> DRUG2 </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Phenytoin	hypoglycemics
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , <e1> DRUG1 </e1> , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of <e2> DRUG2 </e2> with oral hypoglycemic agents ; 	Phenytoin	DIFLUCAN
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , <e1> DRUG1 </e1> , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> DRUG2 </e2> ; 	Phenytoin	hypoglycemic agents
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , <e1> DRUG1 </e1> , Rifampin , <e2> DRUG2 </e2> , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Cyclosporine	Theophylline
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , <e1> DRUG1 </e1> , Rifampin , Theophylline , <e2> DRUG2 </e2> , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Cyclosporine	Terfenadine
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , <e1> DRUG1 </e1> , Rifampin , Theophylline , Terfenadine , <e2> DRUG2 </e2> , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Cyclosporine	Cisapride
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , <e1> DRUG1 </e1> , Rifampin , Theophylline , Terfenadine , Cisapride , <e2> DRUG2 </e2> , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Cyclosporine	Astemizole
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , <e1> DRUG1 </e1> , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , <e2> DRUG2 </e2> , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Cyclosporine	Rifabutin
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , <e1> DRUG1 </e1> , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , <e2> DRUG2 </e2> , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Cyclosporine	Tacrolimus
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , <e1> DRUG1 </e1> , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , <e2> DRUG2 </e2> ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Cyclosporine	Short-acting benzodiazepines
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , <e1> DRUG1 </e1> , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral <e2> DRUG2 </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Cyclosporine	hypoglycemics
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , <e1> DRUG1 </e1> , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of <e2> DRUG2 </e2> with oral hypoglycemic agents ; 	Cyclosporine	DIFLUCAN
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , <e1> DRUG1 </e1> , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> DRUG2 </e2> ; 	Cyclosporine	hypoglycemic agents
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , <e1> DRUG1 </e1> , Theophylline , <e2> DRUG2 </e2> , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Rifampin	Terfenadine
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , <e1> DRUG1 </e1> , Theophylline , Terfenadine , <e2> DRUG2 </e2> , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Rifampin	Cisapride
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , <e1> DRUG1 </e1> , Theophylline , Terfenadine , Cisapride , <e2> DRUG2 </e2> , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Rifampin	Astemizole
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , <e1> DRUG1 </e1> , Theophylline , Terfenadine , Cisapride , Astemizole , <e2> DRUG2 </e2> , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Rifampin	Rifabutin
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , <e1> DRUG1 </e1> , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , <e2> DRUG2 </e2> , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Rifampin	Tacrolimus
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , <e1> DRUG1 </e1> , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , <e2> DRUG2 </e2> ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Rifampin	Short-acting benzodiazepines
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , <e1> DRUG1 </e1> , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral <e2> DRUG2 </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Rifampin	hypoglycemics
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , <e1> DRUG1 </e1> , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of <e2> DRUG2 </e2> with oral hypoglycemic agents ; 	Rifampin	DIFLUCAN
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , <e1> DRUG1 </e1> , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> DRUG2 </e2> ; 	Rifampin	hypoglycemic agents
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , <e1> DRUG1 </e1> , Terfenadine , <e2> DRUG2 </e2> , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Theophylline	Cisapride
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , <e1> DRUG1 </e1> , Terfenadine , Cisapride , <e2> DRUG2 </e2> , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Theophylline	Astemizole
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , <e1> DRUG1 </e1> , Terfenadine , Cisapride , Astemizole , <e2> DRUG2 </e2> , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Theophylline	Rifabutin
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , <e1> DRUG1 </e1> , Terfenadine , Cisapride , Astemizole , Rifabutin , <e2> DRUG2 </e2> , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Theophylline	Tacrolimus
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , <e1> DRUG1 </e1> , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , <e2> DRUG2 </e2> ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Theophylline	Short-acting benzodiazepines
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , <e1> DRUG1 </e1> , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral <e2> DRUG2 </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Theophylline	hypoglycemics
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , <e1> DRUG1 </e1> , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of <e2> DRUG2 </e2> with oral hypoglycemic agents ; 	Theophylline	DIFLUCAN
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , <e1> DRUG1 </e1> , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> DRUG2 </e2> ; 	Theophylline	hypoglycemic agents
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , <e1> DRUG1 </e1> , Cisapride , <e2> DRUG2 </e2> , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Terfenadine	Astemizole
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , <e1> DRUG1 </e1> , Cisapride , Astemizole , <e2> DRUG2 </e2> , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Terfenadine	Rifabutin
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , <e1> DRUG1 </e1> , Cisapride , Astemizole , Rifabutin , <e2> DRUG2 </e2> , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Terfenadine	Tacrolimus
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , <e1> DRUG1 </e1> , Cisapride , Astemizole , Rifabutin , Tacrolimus , <e2> DRUG2 </e2> ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Terfenadine	Short-acting benzodiazepines
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , <e1> DRUG1 </e1> , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral <e2> DRUG2 </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Terfenadine	hypoglycemics
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , <e1> DRUG1 </e1> , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of <e2> DRUG2 </e2> with oral hypoglycemic agents ; 	Terfenadine	DIFLUCAN
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , <e1> DRUG1 </e1> , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> DRUG2 </e2> ; 	Terfenadine	hypoglycemic agents
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , <e1> DRUG1 </e1> , Astemizole , <e2> DRUG2 </e2> , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Cisapride	Rifabutin
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , <e1> DRUG1 </e1> , Astemizole , Rifabutin , <e2> DRUG2 </e2> , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Cisapride	Tacrolimus
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , <e1> DRUG1 </e1> , Astemizole , Rifabutin , Tacrolimus , <e2> DRUG2 </e2> ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Cisapride	Short-acting benzodiazepines
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , <e1> DRUG1 </e1> , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral <e2> DRUG2 </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Cisapride	hypoglycemics
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , <e1> DRUG1 </e1> , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of <e2> DRUG2 </e2> with oral hypoglycemic agents ; 	Cisapride	DIFLUCAN
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , <e1> DRUG1 </e1> , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> DRUG2 </e2> ; 	Cisapride	hypoglycemic agents
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , <e1> DRUG1 </e1> , Rifabutin , <e2> DRUG2 </e2> , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Astemizole	Tacrolimus
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , <e1> DRUG1 </e1> , Rifabutin , Tacrolimus , <e2> DRUG2 </e2> ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Astemizole	Short-acting benzodiazepines
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , <e1> DRUG1 </e1> , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral <e2> DRUG2 </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Astemizole	hypoglycemics
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , <e1> DRUG1 </e1> , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of <e2> DRUG2 </e2> with oral hypoglycemic agents ; 	Astemizole	DIFLUCAN
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , <e1> DRUG1 </e1> , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> DRUG2 </e2> ; 	Astemizole	hypoglycemic agents
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , <e1> DRUG1 </e1> , Tacrolimus , <e2> DRUG2 </e2> ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Rifabutin	Short-acting benzodiazepines
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , <e1> DRUG1 </e1> , Tacrolimus , Short-acting benzodiazepines ,  Oral <e2> DRUG2 </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Rifabutin	hypoglycemics
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , <e1> DRUG1 </e1> , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of <e2> DRUG2 </e2> with oral hypoglycemic agents ; 	Rifabutin	DIFLUCAN
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , <e1> DRUG1 </e1> , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> DRUG2 </e2> ; 	Rifabutin	hypoglycemic agents
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , <e1> DRUG1 </e1> , Short-acting benzodiazepines ,  Oral <e2> DRUG2 </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Tacrolimus	hypoglycemics
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , <e1> DRUG1 </e1> , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of <e2> DRUG2 </e2> with oral hypoglycemic agents ; 	Tacrolimus	DIFLUCAN
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , <e1> DRUG1 </e1> , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> DRUG2 </e2> ; 	Tacrolimus	hypoglycemic agents
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , <e1> DRUG1 </e1> ,  Oral <e2> DRUG2 </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 	Short-acting benzodiazepines	hypoglycemics
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , <e1> DRUG1 </e1> ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of <e2> DRUG2 </e2> with oral hypoglycemic agents ; 	Short-acting benzodiazepines	DIFLUCAN
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , <e1> DRUG1 </e1> ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> DRUG2 </e2> ; 	Short-acting benzodiazepines	hypoglycemic agents
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral <e1> DRUG1 </e1> : Clinically significant hypoglycemia may be precipitated by the use of <e2> DRUG2 </e2> with oral hypoglycemic agents ; 	hypoglycemics	DIFLUCAN
other	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral <e1> DRUG1 </e1> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> DRUG2 </e2> ; 	hypoglycemics	hypoglycemic agents
effect	These are described in greater detail below :  Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines ,  Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of <e1> DRUG1 </e1> with oral <e2> DRUG2 </e2> ; 	DIFLUCAN	hypoglycemic agents
effect	one fatality has been reported from hypoglycemia in association with combined <e1> DRUG1 </e1> and <e2> DRUG2 </e2> use . 	DIFLUCAN	glyburide
mechanism	<e1> DRUG1 </e1> reduces the metabolism of <e2> DRUG2 </e2> , glyburide , and glipizide and increases the plasma concentration of these agents . 	DIFLUCAN	tolbutamide
mechanism	<e1> DRUG1 </e1> reduces the metabolism of tolbutamide , <e2> DRUG2 </e2> , and glipizide and increases the plasma concentration of these agents . 	DIFLUCAN	glyburide
mechanism	<e1> DRUG1 </e1> reduces the metabolism of tolbutamide , glyburide , and <e2> DRUG2 </e2> and increases the plasma concentration of these agents . 	DIFLUCAN	glipizide
other	DIFLUCAN reduces the metabolism of <e1> DRUG1 </e1> , glyburide , and <e2> DRUG2 </e2> and increases the plasma concentration of these agents . 	tolbutamide	glipizide
other	DIFLUCAN reduces the metabolism of tolbutamide , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> and increases the plasma concentration of these agents . 	glyburide	glipizide
advise	When <e1> DRUG1 </e1> is used concomitantly with these or other <e2> DRUG2 </e2> , blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary . 	DIFLUCAN	sulfonylurea oral hypoglycemic agents
other	When <e1> DRUG1 </e1> is used concomitantly with these or other sulfonylurea oral hypoglycemic agents , blood glucose concentrations should be carefully monitored and the dose of the <e2> DRUG2 </e2> should be adjusted as necessary . 	DIFLUCAN	sulfonylurea
other	When DIFLUCAN is used concomitantly with these or other <e1> DRUG1 </e1> , blood glucose concentrations should be carefully monitored and the dose of the <e2> DRUG2 </e2> should be adjusted as necessary . 	sulfonylurea oral hypoglycemic agents	sulfonylurea
other	<e1> DRUG1 </e1> : Prothrombin time may be increased in patients receiving concomitant <e2> DRUG2 </e2> and coumarin-type anticoagulants . 	Coumarin-type anticoagulants	DIFLUCAN
effect	Coumarin-type anticoagulants : Prothrombin time may be increased in patients receiving concomitant <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	DIFLUCAN	coumarin-type anticoagulants
other	In post-marketing experience , as with other <e1> DRUG1 </e1> , bleeding events (bruising , epistaxis , gastrointestinal bleeding , hematuria , and melena) have been reported in association with increases in prothrombin time in patients receiving <e2> DRUG2 </e2> concurrently with warfarin . 	azole antifungals	fluconazole
other	In post-marketing experience , as with other <e1> DRUG1 </e1> , bleeding events (bruising , epistaxis , gastrointestinal bleeding , hematuria , and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with <e2> DRUG2 </e2> . 	azole antifungals	warfarin
effect	In post-marketing experience , as with other azole antifungals , bleeding events (bruising , epistaxis , gastrointestinal bleeding , hematuria , and melena) have been reported in association with increases in prothrombin time in patients receiving <e1> DRUG1 </e1> concurrently with <e2> DRUG2 </e2> . 	fluconazole	warfarin
advise	Careful monitoring of prothrombin time in patients receiving <e1> DRUG1 </e1> and <e2> DRUG2 </e2> is recommended . 	DIFLUCAN	coumarin-type anticoagulants
other	<e1> DRUG1 </e1> : <e2> DRUG2 </e2> increases the plasma concentrations of phenytoin . 	Phenytoin	DIFLUCAN
mechanism	Phenytoin : <e1> DRUG1 </e1> increases the plasma concentrations of <e2> DRUG2 </e2> . 	DIFLUCAN	phenytoin
other	Careful monitoring of <e1> DRUG1 </e1> concentrations in patients receiving <e2> DRUG2 </e2> and phenytoin is recommended . 	phenytoin	DIFLUCAN
advise	Careful monitoring of phenytoin concentrations in patients receiving <e1> DRUG1 </e1> and <e2> DRUG2 </e2> is recommended . 	DIFLUCAN	phenytoin
other	<e1> DRUG1 </e1> : <e2> DRUG2 </e2> may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment . 	Cyclosporine	DIFLUCAN
mechanism	Cyclosporine : <e1> DRUG1 </e1> may significantly increase <e2> DRUG2 </e2> levels in renal transplant patients with or without renal impairment . 	DIFLUCAN	cyclosporine
other	Careful monitoring of <e1> DRUG1 </e1> concentrations and serum creatinine is recommended in patients receiving <e2> DRUG2 </e2> and cyclosporine . 	cyclosporine	DIFLUCAN
advise	Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	DIFLUCAN	cyclosporine
other	<e1> DRUG1 </e1> : Rifampin enhances the metabolism of concurrently administered <e2> DRUG2 </e2> . 	Rifampin	DIFLUCAN
mechanism	Rifampin : <e1> DRUG1 </e1> enhances the metabolism of concurrently administered <e2> DRUG2 </e2> . 	Rifampin	DIFLUCAN
advise	Depending on clinical circumstances , consideration should be given to increasing the dose of <e1> DRUG1 </e1> when it is administered with <e2> DRUG2 </e2> . 	DIFLUCAN	rifampin
other	<e1> DRUG1 </e1> : <e2> DRUG2 </e2> increases the serum concentrations of theophylline . 	Theophylline	DIFLUCAN
mechanism	Theophylline : <e1> DRUG1 </e1> increases the serum concentrations of <e2> DRUG2 </e2> . 	DIFLUCAN	theophylline
other	Careful monitoring of serum <e1> DRUG1 </e1> concentrations in patients receiving <e2> DRUG2 </e2> and theophylline is recommended . 	theophylline	DIFLUCAN
advise	Careful monitoring of serum theophylline concentrations in patients receiving <e1> DRUG1 </e1> and <e2> DRUG2 </e2> is recommended . 	DIFLUCAN	theophylline
other	<e1> DRUG1 </e1> : Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving <e2> DRUG2 </e2> in conjunction with terfenadine , interaction studies have been performed . 	Terfenadine	azole antifungals
effect	Terfenadine : Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving <e1> DRUG1 </e1> in conjunction with <e2> DRUG2 </e2> , interaction studies have been performed . 	azole antifungals	terfenadine
other	Another study at a 400-mg and 800-mg daily dose of <e1> DRUG1 </e1> demonstrated that <e2> DRUG2 </e2> taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly . 	fluconazole	DIFLUCAN
other	Another study at a 400-mg and 800-mg daily dose of <e1> DRUG1 </e1> demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of <e2> DRUG2 </e2> when taken concomitantly . 	fluconazole	terfenadine
mechanism	Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that <e1> DRUG1 </e1> taken in doses of 400 mg per day or greater significantly increases plasma levels of <e2> DRUG2 </e2> when taken concomitantly . 	DIFLUCAN	terfenadine
advise	The combined use of <e1> DRUG1 </e1> at doses of 400 mg or greater with <e2> DRUG2 </e2> is contraindicated . 	fluconazole	terfenadine
advise	The coadministration of <e1> DRUG1 </e1> at doses lower than 400 mg/day with <e2> DRUG2 </e2> should be carefully monitored . 	fluconazole	terfenadine
other	<e1> DRUG1 </e1> : There have been reports of cardiac events , including torsade de pointes in patients to whom <e2> DRUG2 </e2> and cisapride were coadministered . 	Cisapride	fluconazole
effect	Cisapride : There have been reports of cardiac events , including torsade de pointes in patients to whom <e1> DRUG1 </e1> and <e2> DRUG2 </e2> were coadministered . 	fluconazole	cisapride
mechanism	A controlled study found that concomitant <e1> DRUG1 </e1> 200 mg once daily and <e2> DRUG2 </e2> 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval . 	fluconazole	cisapride
other	A controlled study found that concomitant <e1> DRUG1 </e1> 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in <e2> DRUG2 </e2> plasma levels and prolongation of QTc interval . 	fluconazole	cisapride
advise	The combined use of <e1> DRUG1 </e1> with <e2> DRUG2 </e2> is contraindicated . 	fluconazole	cisapride
other	<e1> DRUG1 </e1> : The use of <e2> DRUG2 </e2> in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs . 	Astemizole	fluconazole
mechanism	Astemizole : The use of <e1> DRUG1 </e1> in patients concurrently taking <e2> DRUG2 </e2> or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs . 	fluconazole	astemizole
other	<e1> DRUG1 </e1> : There have been reports of uveitis in patients to whom <e2> DRUG2 </e2> and rifabutin were coadministered . 	Rifabutin	fluconazole
effect	Rifabutin : There have been reports of uveitis in patients to whom <e1> DRUG1 </e1> and <e2> DRUG2 </e2> were coadministered . 	fluconazole	rifabutin
advise	Patients receiving <e1> DRUG1 </e1> and <e2> DRUG2 </e2> concomitantly should be carefully monitored . 	rifabutin	fluconazole
other	<e1> DRUG1 </e1> : There have been reports of nephrotoxicity in patients to whom <e2> DRUG2 </e2> and tacrolimus were coadministered . 	Tacrolimus	fluconazole
effect	Tacrolimus : There have been reports of nephrotoxicity in patients to whom <e1> DRUG1 </e1> and <e2> DRUG2 </e2> were coadministered . 	fluconazole	tacrolimus
advise	Patients receiving <e1> DRUG1 </e1> and <e2> DRUG2 </e2> concomitantly should be carefully monitored . 	tacrolimus	fluconazole
other	<e1> DRUG1 </e1> : Following oral administration of <e2> DRUG2 </e2> , fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects . 	Short-acting Benzodiazepines	midazolam
other	<e1> DRUG1 </e1> : Following oral administration of midazolam , <e2> DRUG2 </e2> resulted in substantial increases in midazolam concentrations and psychomotor effects . 	Short-acting Benzodiazepines	fluconazole
other	<e1> DRUG1 </e1> : Following oral administration of midazolam , fluconazole resulted in substantial increases in <e2> DRUG2 </e2> concentrations and psychomotor effects . 	Short-acting Benzodiazepines	midazolam
other	Short-acting Benzodiazepines : Following oral administration of midazolam , <e1> DRUG1 </e1> resulted in substantial increases in <e2> DRUG2 </e2> concentrations and psychomotor effects . 	fluconazole	midazolam
effect	This effect on <e1> DRUG1 </e1> appears to be more pronounced following oral administration of <e2> DRUG2 </e2> than with fluconazole administered intravenously . 	midazolam	fluconazole
other	This effect on <e1> DRUG1 </e1> appears to be more pronounced following oral administration of fluconazole than with <e2> DRUG2 </e2> administered intravenously . 	midazolam	fluconazole
advise	If <e1> DRUG1 </e1> , which are metabolized by the cytochrome P450 system , are concomitantly administered with <e2> DRUG2 </e2> , consideration should be given to decreasing the benzodiazepine dosage , and the patients should be appropriately monitored . 	short-acting benzodiazepines	fluconazole
other	If <e1> DRUG1 </e1> , which are metabolized by the cytochrome P450 system , are concomitantly administered with fluconazole , consideration should be given to decreasing the <e2> DRUG2 </e2> dosage , and the patients should be appropriately monitored . 	short-acting benzodiazepines	benzodiazepine
other	If short-acting benzodiazepines , which are metabolized by the cytochrome P450 system , are concomitantly administered with <e1> DRUG1 </e1> , consideration should be given to decreasing the <e2> DRUG2 </e2> dosage , and the patients should be appropriately monitored . 	fluconazole	benzodiazepine
mechanism	<e1> DRUG1 </e1> tablets coadministered with <e2> DRUG2 </e2> - and levonorgestrel -containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 	Fluconazole	ethinyl estradiol
mechanism	<e1> DRUG1 </e1> tablets coadministered with ethinyl estradiol - and <e2> DRUG2 </e2> -containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 	Fluconazole	levonorgestrel
other	<e1> DRUG1 </e1> tablets coadministered with ethinyl estradiol - and levonorgestrel -containing oral <e2> DRUG2 </e2> produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 	Fluconazole	contraceptives
other	<e1> DRUG1 </e1> tablets coadministered with ethinyl estradiol - and levonorgestrel -containing oral contraceptives produced an overall mean increase in <e2> DRUG2 </e2> and levonorgestrel levels; 	Fluconazole	ethinyl estradiol
other	<e1> DRUG1 </e1> tablets coadministered with ethinyl estradiol - and levonorgestrel -containing oral contraceptives produced an overall mean increase in ethinyl estradiol and <e2> DRUG2 </e2> levels; 	Fluconazole	levonorgestrel
other	Fluconazole tablets coadministered with <e1> DRUG1 </e1> - and <e2> DRUG2 </e2> -containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 	ethinyl estradiol	levonorgestrel
other	Fluconazole tablets coadministered with <e1> DRUG1 </e1> - and levonorgestrel -containing oral <e2> DRUG2 </e2> produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 	ethinyl estradiol	contraceptives
other	Fluconazole tablets coadministered with <e1> DRUG1 </e1> - and levonorgestrel -containing oral contraceptives produced an overall mean increase in ethinyl estradiol and <e2> DRUG2 </e2> levels; 	ethinyl estradiol	levonorgestrel
other	Fluconazole tablets coadministered with ethinyl estradiol - and <e1> DRUG1 </e1> -containing oral <e2> DRUG2 </e2> produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 	levonorgestrel	contraceptives
other	Fluconazole tablets coadministered with ethinyl estradiol - and <e1> DRUG1 </e1> -containing oral contraceptives produced an overall mean increase in <e2> DRUG2 </e2> and levonorgestrel levels; 	levonorgestrel	ethinyl estradiol
other	Fluconazole tablets coadministered with ethinyl estradiol - and levonorgestrel -containing oral <e1> DRUG1 </e1> produced an overall mean increase in <e2> DRUG2 </e2> and levonorgestrel levels; 	contraceptives	ethinyl estradiol
other	Fluconazole tablets coadministered with ethinyl estradiol - and levonorgestrel -containing oral <e1> DRUG1 </e1> produced an overall mean increase in ethinyl estradiol and <e2> DRUG2 </e2> levels; 	contraceptives	levonorgestrel
other	Fluconazole tablets coadministered with ethinyl estradiol - and levonorgestrel -containing oral contraceptives produced an overall mean increase in <e1> DRUG1 </e1> and <e2> DRUG2 </e2> levels; 	ethinyl estradiol	levonorgestrel
other	however , in some patients there were decreases up to 47% and 33% of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> levels . 	ethinyl estradiol	levonorgestrel
other	The data presently available indicate that the decreases in some individual <e1> DRUG1 </e1> and <e2> DRUG2 </e2> AUC values with fluconazole treatment are likely the result of random variation . 	ethinyl estradiol	levonorgestrel
other	The data presently available indicate that the decreases in some individual <e1> DRUG1 </e1> and levonorgestrel AUC values with <e2> DRUG2 </e2> treatment are likely the result of random variation . 	ethinyl estradiol	fluconazole
other	The data presently available indicate that the decreases in some individual ethinyl estradiol and <e1> DRUG1 </e1> AUC values with <e2> DRUG2 </e2> treatment are likely the result of random variation . 	levonorgestrel	fluconazole
mechanism	While there is evidence that <e1> DRUG1 </e1> can inhibit the metabolism of <e2> DRUG2 </e2> and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 	fluconazole	ethinyl estradiol
mechanism	While there is evidence that <e1> DRUG1 </e1> can inhibit the metabolism of ethinyl estradiol and <e2> DRUG2 </e2> , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 	fluconazole	levonorgestrel
other	While there is evidence that <e1> DRUG1 </e1> can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of <e2> DRUG2 </e2> or levonorgestrel metabolism . 	fluconazole	ethinyl estradiol
other	While there is evidence that <e1> DRUG1 </e1> can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or <e2> DRUG2 </e2> metabolism . 	fluconazole	levonorgestrel
other	While there is evidence that fluconazole can inhibit the metabolism of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 	ethinyl estradiol	levonorgestrel
other	While there is evidence that fluconazole can inhibit the metabolism of <e1> DRUG1 </e1> and levonorgestrel , there is no evidence that <e2> DRUG2 </e2> is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 	ethinyl estradiol	fluconazole
other	While there is evidence that fluconazole can inhibit the metabolism of <e1> DRUG1 </e1> and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or <e2> DRUG2 </e2> metabolism . 	ethinyl estradiol	levonorgestrel
other	While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and <e1> DRUG1 </e1> , there is no evidence that <e2> DRUG2 </e2> is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 	levonorgestrel	fluconazole
other	While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and <e1> DRUG1 </e1> , there is no evidence that fluconazole is a net inducer of <e2> DRUG2 </e2> or levonorgestrel metabolism . 	levonorgestrel	ethinyl estradiol
other	While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that <e1> DRUG1 </e1> is a net inducer of <e2> DRUG2 </e2> or levonorgestrel metabolism . 	fluconazole	ethinyl estradiol
other	While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that <e1> DRUG1 </e1> is a net inducer of ethinyl estradiol or <e2> DRUG2 </e2> metabolism . 	fluconazole	levonorgestrel
advise	You cannot take <e1> DRUG1 </e1> if you have taken a <e2> DRUG2 </e2> ( MAOI ) such as isocarboxazid ( Marplan ) , tranylcypromine ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 	mazindol	monoamine oxidase inhibitor
advise	You cannot take <e1> DRUG1 </e1> if you have taken a monoamine oxidase inhibitor ( <e2> DRUG2 </e2> ) such as isocarboxazid ( Marplan ) , tranylcypromine ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 	mazindol	MAOI
advise	You cannot take <e1> DRUG1 </e1> if you have taken a monoamine oxidase inhibitor ( MAOI ) such as <e2> DRUG2 </e2> ( Marplan ) , tranylcypromine ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 	mazindol	isocarboxazid
advise	You cannot take <e1> DRUG1 </e1> if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( <e2> DRUG2 </e2> ) , tranylcypromine ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 	mazindol	Marplan
advise	You cannot take <e1> DRUG1 </e1> if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( Marplan ) , <e2> DRUG2 </e2> ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 	mazindol	tranylcypromine
advise	You cannot take <e1> DRUG1 </e1> if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( Marplan ) , tranylcypromine ( <e2> DRUG2 </e2> ) , or phenelzine ( Nardil ) in the last 14 days . 	mazindol	Parnate
advise	You cannot take <e1> DRUG1 </e1> if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( Marplan ) , tranylcypromine ( Parnate ) , or <e2> DRUG2 </e2> ( Nardil ) in the last 14 days . 	mazindol	phenelzine
advise	You cannot take <e1> DRUG1 </e1> if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( Marplan ) , tranylcypromine ( Parnate ) , or phenelzine ( <e2> DRUG2 </e2> ) in the last 14 days . 	mazindol	Nardil
other	You cannot take mazindol if you have taken a <e1> DRUG1 </e1> ( MAOI ) such as <e2> DRUG2 </e2> ( Marplan ) , tranylcypromine ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 	monoamine oxidase inhibitor	isocarboxazid
other	You cannot take mazindol if you have taken a <e1> DRUG1 </e1> ( MAOI ) such as isocarboxazid ( <e2> DRUG2 </e2> ) , tranylcypromine ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 	monoamine oxidase inhibitor	Marplan
other	You cannot take mazindol if you have taken a <e1> DRUG1 </e1> ( MAOI ) such as isocarboxazid ( Marplan ) , <e2> DRUG2 </e2> ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 	monoamine oxidase inhibitor	tranylcypromine
other	You cannot take mazindol if you have taken a <e1> DRUG1 </e1> ( MAOI ) such as isocarboxazid ( Marplan ) , tranylcypromine ( <e2> DRUG2 </e2> ) , or phenelzine ( Nardil ) in the last 14 days . 	monoamine oxidase inhibitor	Parnate
other	You cannot take mazindol if you have taken a <e1> DRUG1 </e1> ( MAOI ) such as isocarboxazid ( Marplan ) , tranylcypromine ( Parnate ) , or <e2> DRUG2 </e2> ( Nardil ) in the last 14 days . 	monoamine oxidase inhibitor	phenelzine
other	You cannot take mazindol if you have taken a <e1> DRUG1 </e1> ( MAOI ) such as isocarboxazid ( Marplan ) , tranylcypromine ( Parnate ) , or phenelzine ( <e2> DRUG2 </e2> ) in the last 14 days . 	monoamine oxidase inhibitor	Nardil
other	You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( <e1> DRUG1 </e1> ) such as <e2> DRUG2 </e2> ( Marplan ) , tranylcypromine ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 	MAOI	isocarboxazid
other	You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( <e1> DRUG1 </e1> ) such as isocarboxazid ( <e2> DRUG2 </e2> ) , tranylcypromine ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 	MAOI	Marplan
other	You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( <e1> DRUG1 </e1> ) such as isocarboxazid ( Marplan ) , <e2> DRUG2 </e2> ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 	MAOI	tranylcypromine
other	You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( <e1> DRUG1 </e1> ) such as isocarboxazid ( Marplan ) , tranylcypromine ( <e2> DRUG2 </e2> ) , or phenelzine ( Nardil ) in the last 14 days . 	MAOI	Parnate
other	You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( <e1> DRUG1 </e1> ) such as isocarboxazid ( Marplan ) , tranylcypromine ( Parnate ) , or <e2> DRUG2 </e2> ( Nardil ) in the last 14 days . 	MAOI	phenelzine
other	You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( <e1> DRUG1 </e1> ) such as isocarboxazid ( Marplan ) , tranylcypromine ( Parnate ) , or phenelzine ( <e2> DRUG2 </e2> ) in the last 14 days . 	MAOI	Nardil
other	You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as <e1> DRUG1 </e1> ( Marplan ) , <e2> DRUG2 </e2> ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 	isocarboxazid	tranylcypromine
other	You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as <e1> DRUG1 </e1> ( Marplan ) , tranylcypromine ( <e2> DRUG2 </e2> ) , or phenelzine ( Nardil ) in the last 14 days . 	isocarboxazid	Parnate
other	You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as <e1> DRUG1 </e1> ( Marplan ) , tranylcypromine ( Parnate ) , or <e2> DRUG2 </e2> ( Nardil ) in the last 14 days . 	isocarboxazid	phenelzine
other	You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as <e1> DRUG1 </e1> ( Marplan ) , tranylcypromine ( Parnate ) , or phenelzine ( <e2> DRUG2 </e2> ) in the last 14 days . 	isocarboxazid	Nardil
other	You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( <e1> DRUG1 </e1> ) , <e2> DRUG2 </e2> ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 	Marplan	tranylcypromine
other	You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( <e1> DRUG1 </e1> ) , tranylcypromine ( <e2> DRUG2 </e2> ) , or phenelzine ( Nardil ) in the last 14 days . 	Marplan	Parnate
other	You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( <e1> DRUG1 </e1> ) , tranylcypromine ( Parnate ) , or <e2> DRUG2 </e2> ( Nardil ) in the last 14 days . 	Marplan	phenelzine
other	You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( <e1> DRUG1 </e1> ) , tranylcypromine ( Parnate ) , or phenelzine ( <e2> DRUG2 </e2> ) in the last 14 days . 	Marplan	Nardil
other	You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( Marplan ) , <e1> DRUG1 </e1> ( Parnate ) , or <e2> DRUG2 </e2> ( Nardil ) in the last 14 days . 	tranylcypromine	phenelzine
other	You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( Marplan ) , <e1> DRUG1 </e1> ( Parnate ) , or phenelzine ( <e2> DRUG2 </e2> ) in the last 14 days . 	tranylcypromine	Nardil
other	You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( Marplan ) , tranylcypromine ( <e1> DRUG1 </e1> ) , or <e2> DRUG2 </e2> ( Nardil ) in the last 14 days . 	Parnate	phenelzine
other	You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( Marplan ) , tranylcypromine ( <e1> DRUG1 </e1> ) , or phenelzine ( <e2> DRUG2 </e2> ) in the last 14 days . 	Parnate	Nardil
advise	Changes in <e1> DRUG1 </e1> and other diabetes drug therapies may be necessary during treatment with <e2> DRUG2 </e2> . 	insulin	mazindol
effect	<e1> DRUG1 </e1> may reduce the effects of <e2> DRUG2 </e2> ( Ismelin ) . 	Mazindol	guanethidine
effect	<e1> DRUG1 </e1> may reduce the effects of guanethidine ( <e2> DRUG2 </e2> ) . 	Mazindol	Ismelin
other	Before taking this medication , tell your doctor if you are taking a <e1> DRUG1 </e1> such as amitriptyline ( <e2> DRUG2 </e2> ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	tricyclic antidepressant	Elavil
other	Before taking this medication , tell your doctor if you are taking a <e1> DRUG1 </e1> such as amitriptyline ( Elavil ) , <e2> DRUG2 </e2> ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	tricyclic antidepressant	amoxapine
other	Before taking this medication , tell your doctor if you are taking a <e1> DRUG1 </e1> such as amitriptyline ( Elavil ) , amoxapine ( <e2> DRUG2 </e2> ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	tricyclic antidepressant	Asendin
other	Before taking this medication , tell your doctor if you are taking a <e1> DRUG1 </e1> such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , <e2> DRUG2 </e2> ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	tricyclic antidepressant	doxepin
other	Before taking this medication , tell your doctor if you are taking a <e1> DRUG1 </e1> such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( <e2> DRUG2 </e2> ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	tricyclic antidepressant	Sinequan
other	Before taking this medication , tell your doctor if you are taking a <e1> DRUG1 </e1> such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , <e2> DRUG2 </e2> ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	tricyclic antidepressant	nortriptyline
other	Before taking this medication , tell your doctor if you are taking a <e1> DRUG1 </e1> such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( <e2> DRUG2 </e2> ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	tricyclic antidepressant	Pamelor
other	Before taking this medication , tell your doctor if you are taking a <e1> DRUG1 </e1> such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , <e2> DRUG2 </e2> ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	tricyclic antidepressant	imipramine
other	Before taking this medication , tell your doctor if you are taking a <e1> DRUG1 </e1> such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( <e2> DRUG2 </e2> ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	tricyclic antidepressant	Tofranil
other	Before taking this medication , tell your doctor if you are taking a <e1> DRUG1 </e1> such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , <e2> DRUG2 </e2> ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	tricyclic antidepressant	clomipramine
other	Before taking this medication , tell your doctor if you are taking a <e1> DRUG1 </e1> such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( <e2> DRUG2 </e2> ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	tricyclic antidepressant	Anafranil
other	Before taking this medication , tell your doctor if you are taking a <e1> DRUG1 </e1> such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , <e2> DRUG2 </e2> ( Vivactil ) , or desipramine ( Norpramin ) . 	tricyclic antidepressant	protriptyline
other	Before taking this medication , tell your doctor if you are taking a <e1> DRUG1 </e1> such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( <e2> DRUG2 </e2> ) , or desipramine ( Norpramin ) . 	tricyclic antidepressant	Vivactil
other	Before taking this medication , tell your doctor if you are taking a <e1> DRUG1 </e1> such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or <e2> DRUG2 </e2> ( Norpramin ) . 	tricyclic antidepressant	desipramine
other	Before taking this medication , tell your doctor if you are taking a <e1> DRUG1 </e1> such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( <e2> DRUG2 </e2> ) . 	tricyclic antidepressant	Norpramin
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as <e1> DRUG1 </e1> ( Elavil ) , <e2> DRUG2 </e2> ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	amitriptyline	amoxapine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as <e1> DRUG1 </e1> ( Elavil ) , amoxapine ( <e2> DRUG2 </e2> ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	amitriptyline	Asendin
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as <e1> DRUG1 </e1> ( Elavil ) , amoxapine ( Asendin ) , <e2> DRUG2 </e2> ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	amitriptyline	doxepin
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as <e1> DRUG1 </e1> ( Elavil ) , amoxapine ( Asendin ) , doxepin ( <e2> DRUG2 </e2> ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	amitriptyline	Sinequan
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as <e1> DRUG1 </e1> ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , <e2> DRUG2 </e2> ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	amitriptyline	nortriptyline
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as <e1> DRUG1 </e1> ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( <e2> DRUG2 </e2> ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	amitriptyline	Pamelor
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as <e1> DRUG1 </e1> ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , <e2> DRUG2 </e2> ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	amitriptyline	imipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as <e1> DRUG1 </e1> ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( <e2> DRUG2 </e2> ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	amitriptyline	Tofranil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as <e1> DRUG1 </e1> ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , <e2> DRUG2 </e2> ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	amitriptyline	clomipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as <e1> DRUG1 </e1> ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( <e2> DRUG2 </e2> ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	amitriptyline	Anafranil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as <e1> DRUG1 </e1> ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , <e2> DRUG2 </e2> ( Vivactil ) , or desipramine ( Norpramin ) . 	amitriptyline	protriptyline
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as <e1> DRUG1 </e1> ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( <e2> DRUG2 </e2> ) , or desipramine ( Norpramin ) . 	amitriptyline	Vivactil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as <e1> DRUG1 </e1> ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or <e2> DRUG2 </e2> ( Norpramin ) . 	amitriptyline	desipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as <e1> DRUG1 </e1> ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( <e2> DRUG2 </e2> ) . 	amitriptyline	Norpramin
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> DRUG1 </e1> ) , <e2> DRUG2 </e2> ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Elavil	amoxapine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> DRUG1 </e1> ) , amoxapine ( <e2> DRUG2 </e2> ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Elavil	Asendin
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> DRUG1 </e1> ) , amoxapine ( Asendin ) , <e2> DRUG2 </e2> ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Elavil	doxepin
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> DRUG1 </e1> ) , amoxapine ( Asendin ) , doxepin ( <e2> DRUG2 </e2> ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Elavil	Sinequan
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> DRUG1 </e1> ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , <e2> DRUG2 </e2> ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Elavil	nortriptyline
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> DRUG1 </e1> ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( <e2> DRUG2 </e2> ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Elavil	Pamelor
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> DRUG1 </e1> ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , <e2> DRUG2 </e2> ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Elavil	imipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> DRUG1 </e1> ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( <e2> DRUG2 </e2> ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Elavil	Tofranil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> DRUG1 </e1> ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , <e2> DRUG2 </e2> ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Elavil	clomipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> DRUG1 </e1> ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( <e2> DRUG2 </e2> ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Elavil	Anafranil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> DRUG1 </e1> ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , <e2> DRUG2 </e2> ( Vivactil ) , or desipramine ( Norpramin ) . 	Elavil	protriptyline
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> DRUG1 </e1> ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( <e2> DRUG2 </e2> ) , or desipramine ( Norpramin ) . 	Elavil	Vivactil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> DRUG1 </e1> ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or <e2> DRUG2 </e2> ( Norpramin ) . 	Elavil	desipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> DRUG1 </e1> ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( <e2> DRUG2 </e2> ) . 	Elavil	Norpramin
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , <e1> DRUG1 </e1> ( Asendin ) , <e2> DRUG2 </e2> ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	amoxapine	doxepin
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , <e1> DRUG1 </e1> ( Asendin ) , doxepin ( <e2> DRUG2 </e2> ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	amoxapine	Sinequan
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , <e1> DRUG1 </e1> ( Asendin ) , doxepin ( Sinequan ) , <e2> DRUG2 </e2> ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	amoxapine	nortriptyline
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , <e1> DRUG1 </e1> ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( <e2> DRUG2 </e2> ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	amoxapine	Pamelor
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , <e1> DRUG1 </e1> ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , <e2> DRUG2 </e2> ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	amoxapine	imipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , <e1> DRUG1 </e1> ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( <e2> DRUG2 </e2> ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	amoxapine	Tofranil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , <e1> DRUG1 </e1> ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , <e2> DRUG2 </e2> ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	amoxapine	clomipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , <e1> DRUG1 </e1> ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( <e2> DRUG2 </e2> ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	amoxapine	Anafranil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , <e1> DRUG1 </e1> ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , <e2> DRUG2 </e2> ( Vivactil ) , or desipramine ( Norpramin ) . 	amoxapine	protriptyline
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , <e1> DRUG1 </e1> ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( <e2> DRUG2 </e2> ) , or desipramine ( Norpramin ) . 	amoxapine	Vivactil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , <e1> DRUG1 </e1> ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or <e2> DRUG2 </e2> ( Norpramin ) . 	amoxapine	desipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , <e1> DRUG1 </e1> ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( <e2> DRUG2 </e2> ) . 	amoxapine	Norpramin
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( <e1> DRUG1 </e1> ) , <e2> DRUG2 </e2> ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Asendin	doxepin
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( <e1> DRUG1 </e1> ) , doxepin ( <e2> DRUG2 </e2> ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Asendin	Sinequan
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( <e1> DRUG1 </e1> ) , doxepin ( Sinequan ) , <e2> DRUG2 </e2> ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Asendin	nortriptyline
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( <e1> DRUG1 </e1> ) , doxepin ( Sinequan ) , nortriptyline ( <e2> DRUG2 </e2> ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Asendin	Pamelor
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( <e1> DRUG1 </e1> ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , <e2> DRUG2 </e2> ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Asendin	imipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( <e1> DRUG1 </e1> ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( <e2> DRUG2 </e2> ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Asendin	Tofranil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( <e1> DRUG1 </e1> ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , <e2> DRUG2 </e2> ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Asendin	clomipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( <e1> DRUG1 </e1> ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( <e2> DRUG2 </e2> ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Asendin	Anafranil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( <e1> DRUG1 </e1> ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , <e2> DRUG2 </e2> ( Vivactil ) , or desipramine ( Norpramin ) . 	Asendin	protriptyline
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( <e1> DRUG1 </e1> ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( <e2> DRUG2 </e2> ) , or desipramine ( Norpramin ) . 	Asendin	Vivactil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( <e1> DRUG1 </e1> ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or <e2> DRUG2 </e2> ( Norpramin ) . 	Asendin	desipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( <e1> DRUG1 </e1> ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( <e2> DRUG2 </e2> ) . 	Asendin	Norpramin
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , <e1> DRUG1 </e1> ( Sinequan ) , <e2> DRUG2 </e2> ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	doxepin	nortriptyline
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , <e1> DRUG1 </e1> ( Sinequan ) , nortriptyline ( <e2> DRUG2 </e2> ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	doxepin	Pamelor
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , <e1> DRUG1 </e1> ( Sinequan ) , nortriptyline ( Pamelor ) , <e2> DRUG2 </e2> ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	doxepin	imipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , <e1> DRUG1 </e1> ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( <e2> DRUG2 </e2> ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	doxepin	Tofranil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , <e1> DRUG1 </e1> ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , <e2> DRUG2 </e2> ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	doxepin	clomipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , <e1> DRUG1 </e1> ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( <e2> DRUG2 </e2> ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	doxepin	Anafranil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , <e1> DRUG1 </e1> ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , <e2> DRUG2 </e2> ( Vivactil ) , or desipramine ( Norpramin ) . 	doxepin	protriptyline
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , <e1> DRUG1 </e1> ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( <e2> DRUG2 </e2> ) , or desipramine ( Norpramin ) . 	doxepin	Vivactil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , <e1> DRUG1 </e1> ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or <e2> DRUG2 </e2> ( Norpramin ) . 	doxepin	desipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , <e1> DRUG1 </e1> ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( <e2> DRUG2 </e2> ) . 	doxepin	Norpramin
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( <e1> DRUG1 </e1> ) , <e2> DRUG2 </e2> ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Sinequan	nortriptyline
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( <e1> DRUG1 </e1> ) , nortriptyline ( <e2> DRUG2 </e2> ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Sinequan	Pamelor
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( <e1> DRUG1 </e1> ) , nortriptyline ( Pamelor ) , <e2> DRUG2 </e2> ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Sinequan	imipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( <e1> DRUG1 </e1> ) , nortriptyline ( Pamelor ) , imipramine ( <e2> DRUG2 </e2> ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Sinequan	Tofranil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( <e1> DRUG1 </e1> ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , <e2> DRUG2 </e2> ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Sinequan	clomipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( <e1> DRUG1 </e1> ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( <e2> DRUG2 </e2> ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Sinequan	Anafranil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( <e1> DRUG1 </e1> ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , <e2> DRUG2 </e2> ( Vivactil ) , or desipramine ( Norpramin ) . 	Sinequan	protriptyline
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( <e1> DRUG1 </e1> ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( <e2> DRUG2 </e2> ) , or desipramine ( Norpramin ) . 	Sinequan	Vivactil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( <e1> DRUG1 </e1> ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or <e2> DRUG2 </e2> ( Norpramin ) . 	Sinequan	desipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( <e1> DRUG1 </e1> ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( <e2> DRUG2 </e2> ) . 	Sinequan	Norpramin
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , <e1> DRUG1 </e1> ( Pamelor ) , <e2> DRUG2 </e2> ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	nortriptyline	imipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , <e1> DRUG1 </e1> ( Pamelor ) , imipramine ( <e2> DRUG2 </e2> ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	nortriptyline	Tofranil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , <e1> DRUG1 </e1> ( Pamelor ) , imipramine ( Tofranil ) , <e2> DRUG2 </e2> ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	nortriptyline	clomipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , <e1> DRUG1 </e1> ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( <e2> DRUG2 </e2> ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	nortriptyline	Anafranil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , <e1> DRUG1 </e1> ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , <e2> DRUG2 </e2> ( Vivactil ) , or desipramine ( Norpramin ) . 	nortriptyline	protriptyline
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , <e1> DRUG1 </e1> ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( <e2> DRUG2 </e2> ) , or desipramine ( Norpramin ) . 	nortriptyline	Vivactil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , <e1> DRUG1 </e1> ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or <e2> DRUG2 </e2> ( Norpramin ) . 	nortriptyline	desipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , <e1> DRUG1 </e1> ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( <e2> DRUG2 </e2> ) . 	nortriptyline	Norpramin
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( <e1> DRUG1 </e1> ) , <e2> DRUG2 </e2> ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Pamelor	imipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( <e1> DRUG1 </e1> ) , imipramine ( <e2> DRUG2 </e2> ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Pamelor	Tofranil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( <e1> DRUG1 </e1> ) , imipramine ( Tofranil ) , <e2> DRUG2 </e2> ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Pamelor	clomipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( <e1> DRUG1 </e1> ) , imipramine ( Tofranil ) , clomipramine ( <e2> DRUG2 </e2> ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Pamelor	Anafranil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( <e1> DRUG1 </e1> ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , <e2> DRUG2 </e2> ( Vivactil ) , or desipramine ( Norpramin ) . 	Pamelor	protriptyline
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( <e1> DRUG1 </e1> ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( <e2> DRUG2 </e2> ) , or desipramine ( Norpramin ) . 	Pamelor	Vivactil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( <e1> DRUG1 </e1> ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or <e2> DRUG2 </e2> ( Norpramin ) . 	Pamelor	desipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( <e1> DRUG1 </e1> ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( <e2> DRUG2 </e2> ) . 	Pamelor	Norpramin
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , <e1> DRUG1 </e1> ( Tofranil ) , <e2> DRUG2 </e2> ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	imipramine	clomipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , <e1> DRUG1 </e1> ( Tofranil ) , clomipramine ( <e2> DRUG2 </e2> ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	imipramine	Anafranil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , <e1> DRUG1 </e1> ( Tofranil ) , clomipramine ( Anafranil ) , <e2> DRUG2 </e2> ( Vivactil ) , or desipramine ( Norpramin ) . 	imipramine	protriptyline
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , <e1> DRUG1 </e1> ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( <e2> DRUG2 </e2> ) , or desipramine ( Norpramin ) . 	imipramine	Vivactil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , <e1> DRUG1 </e1> ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or <e2> DRUG2 </e2> ( Norpramin ) . 	imipramine	desipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , <e1> DRUG1 </e1> ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( <e2> DRUG2 </e2> ) . 	imipramine	Norpramin
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( <e1> DRUG1 </e1> ) , <e2> DRUG2 </e2> ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Tofranil	clomipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( <e1> DRUG1 </e1> ) , clomipramine ( <e2> DRUG2 </e2> ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 	Tofranil	Anafranil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( <e1> DRUG1 </e1> ) , clomipramine ( Anafranil ) , <e2> DRUG2 </e2> ( Vivactil ) , or desipramine ( Norpramin ) . 	Tofranil	protriptyline
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( <e1> DRUG1 </e1> ) , clomipramine ( Anafranil ) , protriptyline ( <e2> DRUG2 </e2> ) , or desipramine ( Norpramin ) . 	Tofranil	Vivactil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( <e1> DRUG1 </e1> ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or <e2> DRUG2 </e2> ( Norpramin ) . 	Tofranil	desipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( <e1> DRUG1 </e1> ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( <e2> DRUG2 </e2> ) . 	Tofranil	Norpramin
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , <e1> DRUG1 </e1> ( Anafranil ) , <e2> DRUG2 </e2> ( Vivactil ) , or desipramine ( Norpramin ) . 	clomipramine	protriptyline
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , <e1> DRUG1 </e1> ( Anafranil ) , protriptyline ( <e2> DRUG2 </e2> ) , or desipramine ( Norpramin ) . 	clomipramine	Vivactil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , <e1> DRUG1 </e1> ( Anafranil ) , protriptyline ( Vivactil ) , or <e2> DRUG2 </e2> ( Norpramin ) . 	clomipramine	desipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , <e1> DRUG1 </e1> ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( <e2> DRUG2 </e2> ) . 	clomipramine	Norpramin
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( <e1> DRUG1 </e1> ) , <e2> DRUG2 </e2> ( Vivactil ) , or desipramine ( Norpramin ) . 	Anafranil	protriptyline
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( <e1> DRUG1 </e1> ) , protriptyline ( <e2> DRUG2 </e2> ) , or desipramine ( Norpramin ) . 	Anafranil	Vivactil
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( <e1> DRUG1 </e1> ) , protriptyline ( Vivactil ) , or <e2> DRUG2 </e2> ( Norpramin ) . 	Anafranil	desipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( <e1> DRUG1 </e1> ) , protriptyline ( Vivactil ) , or desipramine ( <e2> DRUG2 </e2> ) . 	Anafranil	Norpramin
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , <e1> DRUG1 </e1> ( Vivactil ) , or <e2> DRUG2 </e2> ( Norpramin ) . 	protriptyline	desipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , <e1> DRUG1 </e1> ( Vivactil ) , or desipramine ( <e2> DRUG2 </e2> ) . 	protriptyline	Norpramin
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( <e1> DRUG1 </e1> ) , or <e2> DRUG2 </e2> ( Norpramin ) . 	Vivactil	desipramine
other	Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( <e1> DRUG1 </e1> ) , or desipramine ( <e2> DRUG2 </e2> ) . 	Vivactil	Norpramin
mechanism	Preliminary evidence suggests that <e1> DRUG1 </e1> inhibits <e2> DRUG2 </e2> metabolism and may result in an increase in plasma concentrations of mebendazole . 	cimetidine	mebendazole
other	Preliminary evidence suggests that <e1> DRUG1 </e1> inhibits mebendazole metabolism and may result in an increase in plasma concentrations of <e2> DRUG2 </e2> . 	cimetidine	mebendazole
other	Patients receiving <e1> DRUG1 </e1> and <e2> DRUG2 </e2> generally should not be treated with ganglion blockers . 	antibiotics	sulfonamides
advise	Patients receiving <e1> DRUG1 </e1> and sulfonamides generally should not be treated with <e2> DRUG2 </e2> . 	antibiotics	ganglion blockers
advise	Patients receiving antibiotics and <e1> DRUG1 </e1> generally should not be treated with <e2> DRUG2 </e2> . 	sulfonamides	ganglion blockers
effect	The action of <e1> DRUG1 </e1> may be potentiated by anesthesia , other <e2> DRUG2 </e2> and alcohol . 	Mecamylamine	antihypertensive drugs
effect	The action of <e1> DRUG1 </e1> may be potentiated by anesthesia , other antihypertensive drugs and <e2> DRUG2 </e2> . 	Mecamylamine	alcohol
other	The action of Mecamylamine may be potentiated by anesthesia , other <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	antihypertensive drugs	alcohol
mechanism	<e1> DRUG1 </e1> administered concomitantly with <e2> DRUG2 </e2> may significantly decrease the serum concentrations of MPA . 	Aminoglutethimide	depo-subQ provera 104
other	<e1> DRUG1 </e1> administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of <e2> DRUG2 </e2> . 	Aminoglutethimide	MPA
other	Aminoglutethimide administered concomitantly with <e1> DRUG1 </e1> may significantly decrease the serum concentrations of <e2> DRUG2 </e2> . 	depo-subQ provera 104	MPA
other	Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of <e1> DRUG1 </e1> or rifabutin to warrant dosage adjustment when <e2> DRUG2 </e2> is administered with these drugs . 	zidovudine	megestrol acetate
other	Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or <e1> DRUG1 </e1> to warrant dosage adjustment when <e2> DRUG2 </e2> is administered with these drugs . 	rifabutin	megestrol acetate
mechanism	A pharmacokinetic study demonstrated that coadministration of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir . 	megestrol acetate	indinavir
other	A pharmacokinetic study demonstrated that coadministration of <e1> DRUG1 </e1> and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of <e2> DRUG2 </e2> . 	megestrol acetate	indinavir
advise	Administration of a higher dose of <e1> DRUG1 </e1> should be considered when coadministering with <e2> DRUG2 </e2> . 	indinavir	megestrol acetate
other	The effects of <e1> DRUG1 </e1> , zidovudine or <e2> DRUG2 </e2> on the pharmacokinetics of megestrol acetate were not studied . 	indinavir	rifabutin
other	The effects of <e1> DRUG1 </e1> , zidovudine or rifabutin on the pharmacokinetics of <e2> DRUG2 </e2> were not studied . 	indinavir	megestrol acetate
other	The effects of indinavir , <e1> DRUG1 </e1> or rifabutin on the pharmacokinetics of <e2> DRUG2 </e2> were not studied . 	zidovudine	megestrol acetate
other	The effects of indinavir , zidovudine or <e1> DRUG1 </e1> on the pharmacokinetics of <e2> DRUG2 </e2> were not studied . 	rifabutin	megestrol acetate
int	<e1> DRUG1 </e1> may interact with the following drugs : <e2> DRUG2 </e2> and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	Melatonin	aspirin
int	<e1> DRUG1 </e1> may interact with the following drugs : aspirin and other <e2> DRUG2 </e2> (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	Melatonin	NSAIDs
int	<e1> DRUG1 </e1> may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , <e2> DRUG2 </e2> (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	Melatonin	fluvoxamine
int	<e1> DRUG1 </e1> may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , <e2> DRUG2 </e2> (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	Melatonin	beta blockers
int	<e1> DRUG1 </e1> may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , <e2> DRUG2 </e2> (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	Melatonin	fluoxetine
int	<e1> DRUG1 </e1> may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , <e2> DRUG2 </e2> (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	Melatonin	progestin
other	<e1> DRUG1 </e1> may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with <e2> DRUG2 </e2> can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	Melatonin	progestin
int	<e1> DRUG1 </e1> may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , <e2> DRUG2 </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	Melatonin	benzodiazepenes
int	<e1> DRUG1 </e1> may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and <e2> DRUG2 </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	Melatonin	corticosteroids
other	<e1> DRUG1 </e1> may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and <e2> DRUG2 </e2> may interfere with the efficacy of the corticosteroids ) . 	Melatonin	corticosteroids
other	<e1> DRUG1 </e1> may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> DRUG2 </e2> ) . 	Melatonin	corticosteroids
other	Melatonin may interact with the following drugs : <e1> DRUG1 </e1> and other <e2> DRUG2 </e2> (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	aspirin	NSAIDs
other	Melatonin may interact with the following drugs : <e1> DRUG1 </e1> and other NSAIDs (may lower <e2> DRUG2 </e2> levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	aspirin	melatonin
other	Melatonin may interact with the following drugs : <e1> DRUG1 </e1> and other NSAIDs (may lower melatonin levels) , <e2> DRUG2 </e2> (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	aspirin	fluvoxamine
other	Melatonin may interact with the following drugs : <e1> DRUG1 </e1> and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral <e2> DRUG2 </e2> is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	aspirin	melatonin
other	Melatonin may interact with the following drugs : <e1> DRUG1 </e1> and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , <e2> DRUG2 </e2> (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	aspirin	beta blockers
other	Melatonin may interact with the following drugs : <e1> DRUG1 </e1> and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease <e2> DRUG2 </e2> levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	aspirin	melatonin
other	Melatonin may interact with the following drugs : <e1> DRUG1 </e1> and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , <e2> DRUG2 </e2> (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	aspirin	fluoxetine
other	Melatonin may interact with the following drugs : <e1> DRUG1 </e1> and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , <e2> DRUG2 </e2> (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	aspirin	progestin
other	Melatonin may interact with the following drugs : <e1> DRUG1 </e1> and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of <e2> DRUG2 </e2> with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	aspirin	melatonin
other	Melatonin may interact with the following drugs : <e1> DRUG1 </e1> and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with <e2> DRUG2 </e2> can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	aspirin	progestin
other	Melatonin may interact with the following drugs : <e1> DRUG1 </e1> and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , <e2> DRUG2 </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	aspirin	benzodiazepenes
other	Melatonin may interact with the following drugs : <e1> DRUG1 </e1> and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and <e2> DRUG2 </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	aspirin	corticosteroids
other	Melatonin may interact with the following drugs : <e1> DRUG1 </e1> and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of <e2> DRUG2 </e2> and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	aspirin	melatonin
other	Melatonin may interact with the following drugs : <e1> DRUG1 </e1> and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and <e2> DRUG2 </e2> may interfere with the efficacy of the corticosteroids ) . 	aspirin	corticosteroids
other	Melatonin may interact with the following drugs : <e1> DRUG1 </e1> and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> DRUG2 </e2> ) . 	aspirin	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other <e1> DRUG1 </e1> (may lower <e2> DRUG2 </e2> levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	NSAIDs	melatonin
other	Melatonin may interact with the following drugs : aspirin and other <e1> DRUG1 </e1> (may lower melatonin levels) , <e2> DRUG2 </e2> (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	NSAIDs	fluvoxamine
other	Melatonin may interact with the following drugs : aspirin and other <e1> DRUG1 </e1> (may lower melatonin levels) , fluvoxamine (bioavailability of oral <e2> DRUG2 </e2> is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	NSAIDs	melatonin
other	Melatonin may interact with the following drugs : aspirin and other <e1> DRUG1 </e1> (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , <e2> DRUG2 </e2> (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	NSAIDs	beta blockers
other	Melatonin may interact with the following drugs : aspirin and other <e1> DRUG1 </e1> (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease <e2> DRUG2 </e2> levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	NSAIDs	melatonin
other	Melatonin may interact with the following drugs : aspirin and other <e1> DRUG1 </e1> (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , <e2> DRUG2 </e2> (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	NSAIDs	fluoxetine
other	Melatonin may interact with the following drugs : aspirin and other <e1> DRUG1 </e1> (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , <e2> DRUG2 </e2> (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	NSAIDs	progestin
other	Melatonin may interact with the following drugs : aspirin and other <e1> DRUG1 </e1> (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of <e2> DRUG2 </e2> with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	NSAIDs	melatonin
other	Melatonin may interact with the following drugs : aspirin and other <e1> DRUG1 </e1> (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with <e2> DRUG2 </e2> can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	NSAIDs	progestin
other	Melatonin may interact with the following drugs : aspirin and other <e1> DRUG1 </e1> (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , <e2> DRUG2 </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	NSAIDs	benzodiazepenes
other	Melatonin may interact with the following drugs : aspirin and other <e1> DRUG1 </e1> (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and <e2> DRUG2 </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	NSAIDs	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other <e1> DRUG1 </e1> (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of <e2> DRUG2 </e2> and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	NSAIDs	melatonin
other	Melatonin may interact with the following drugs : aspirin and other <e1> DRUG1 </e1> (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and <e2> DRUG2 </e2> may interfere with the efficacy of the corticosteroids ) . 	NSAIDs	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other <e1> DRUG1 </e1> (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> DRUG2 </e2> ) . 	NSAIDs	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower <e1> DRUG1 </e1> levels) , <e2> DRUG2 </e2> (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	melatonin	fluvoxamine
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower <e1> DRUG1 </e1> levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , <e2> DRUG2 </e2> (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	melatonin	beta blockers
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower <e1> DRUG1 </e1> levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , <e2> DRUG2 </e2> (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	melatonin	fluoxetine
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower <e1> DRUG1 </e1> levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , <e2> DRUG2 </e2> (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	melatonin	progestin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower <e1> DRUG1 </e1> levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with <e2> DRUG2 </e2> can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	melatonin	progestin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower <e1> DRUG1 </e1> levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , <e2> DRUG2 </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	melatonin	benzodiazepenes
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower <e1> DRUG1 </e1> levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and <e2> DRUG2 </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	melatonin	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower <e1> DRUG1 </e1> levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and <e2> DRUG2 </e2> may interfere with the efficacy of the corticosteroids ) . 	melatonin	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower <e1> DRUG1 </e1> levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> DRUG2 </e2> ) . 	melatonin	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , <e1> DRUG1 </e1> (bioavailability of oral <e2> DRUG2 </e2> is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	fluvoxamine	melatonin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , <e1> DRUG1 </e1> (bioavailability of oral melatonin is increased with coadministration) , <e2> DRUG2 </e2> (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	fluvoxamine	beta blockers
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , <e1> DRUG1 </e1> (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease <e2> DRUG2 </e2> levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	fluvoxamine	melatonin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , <e1> DRUG1 </e1> (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , <e2> DRUG2 </e2> (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	fluvoxamine	fluoxetine
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , <e1> DRUG1 </e1> (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , <e2> DRUG2 </e2> (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	fluvoxamine	progestin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , <e1> DRUG1 </e1> (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of <e2> DRUG2 </e2> with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	fluvoxamine	melatonin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , <e1> DRUG1 </e1> (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with <e2> DRUG2 </e2> can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	fluvoxamine	progestin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , <e1> DRUG1 </e1> (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , <e2> DRUG2 </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	fluvoxamine	benzodiazepenes
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , <e1> DRUG1 </e1> (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and <e2> DRUG2 </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	fluvoxamine	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , <e1> DRUG1 </e1> (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of <e2> DRUG2 </e2> and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	fluvoxamine	melatonin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , <e1> DRUG1 </e1> (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and <e2> DRUG2 </e2> may interfere with the efficacy of the corticosteroids ) . 	fluvoxamine	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , <e1> DRUG1 </e1> (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> DRUG2 </e2> ) . 	fluvoxamine	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral <e1> DRUG1 </e1> is increased with coadministration) , <e2> DRUG2 </e2> (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	melatonin	beta blockers
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral <e1> DRUG1 </e1> is increased with coadministration) , beta blockers (may decrease melatonin levels) , <e2> DRUG2 </e2> (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	melatonin	fluoxetine
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral <e1> DRUG1 </e1> is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , <e2> DRUG2 </e2> (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	melatonin	progestin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral <e1> DRUG1 </e1> is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with <e2> DRUG2 </e2> can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	melatonin	progestin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral <e1> DRUG1 </e1> is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , <e2> DRUG2 </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	melatonin	benzodiazepenes
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral <e1> DRUG1 </e1> is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and <e2> DRUG2 </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	melatonin	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral <e1> DRUG1 </e1> is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and <e2> DRUG2 </e2> may interfere with the efficacy of the corticosteroids ) . 	melatonin	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral <e1> DRUG1 </e1> is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> DRUG2 </e2> ) . 	melatonin	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , <e1> DRUG1 </e1> (may decrease <e2> DRUG2 </e2> levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	beta blockers	melatonin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , <e1> DRUG1 </e1> (may decrease melatonin levels) , <e2> DRUG2 </e2> (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	beta blockers	fluoxetine
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , <e1> DRUG1 </e1> (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , <e2> DRUG2 </e2> (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	beta blockers	progestin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , <e1> DRUG1 </e1> (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of <e2> DRUG2 </e2> with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	beta blockers	melatonin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , <e1> DRUG1 </e1> (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with <e2> DRUG2 </e2> can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	beta blockers	progestin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , <e1> DRUG1 </e1> (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , <e2> DRUG2 </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	beta blockers	benzodiazepenes
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , <e1> DRUG1 </e1> (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and <e2> DRUG2 </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	beta blockers	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , <e1> DRUG1 </e1> (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of <e2> DRUG2 </e2> and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	beta blockers	melatonin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , <e1> DRUG1 </e1> (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and <e2> DRUG2 </e2> may interfere with the efficacy of the corticosteroids ) . 	beta blockers	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , <e1> DRUG1 </e1> (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> DRUG2 </e2> ) . 	beta blockers	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease <e1> DRUG1 </e1> levels) , <e2> DRUG2 </e2> (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	melatonin	fluoxetine
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease <e1> DRUG1 </e1> levels) , fluoxetine (reports of psychotic episodes when coadministered) , <e2> DRUG2 </e2> (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	melatonin	progestin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease <e1> DRUG1 </e1> levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with <e2> DRUG2 </e2> can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	melatonin	progestin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease <e1> DRUG1 </e1> levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , <e2> DRUG2 </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	melatonin	benzodiazepenes
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease <e1> DRUG1 </e1> levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and <e2> DRUG2 </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	melatonin	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease <e1> DRUG1 </e1> levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and <e2> DRUG2 </e2> may interfere with the efficacy of the corticosteroids ) . 	melatonin	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease <e1> DRUG1 </e1> levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> DRUG2 </e2> ) . 	melatonin	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , <e1> DRUG1 </e1> (reports of psychotic episodes when coadministered) , <e2> DRUG2 </e2> (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	fluoxetine	progestin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , <e1> DRUG1 </e1> (reports of psychotic episodes when coadministered) , progestin (coadministration of <e2> DRUG2 </e2> with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	fluoxetine	melatonin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , <e1> DRUG1 </e1> (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with <e2> DRUG2 </e2> can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	fluoxetine	progestin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , <e1> DRUG1 </e1> (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , <e2> DRUG2 </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	fluoxetine	benzodiazepenes
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , <e1> DRUG1 </e1> (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and <e2> DRUG2 </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	fluoxetine	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , <e1> DRUG1 </e1> (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of <e2> DRUG2 </e2> and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	fluoxetine	melatonin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , <e1> DRUG1 </e1> (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and <e2> DRUG2 </e2> may interfere with the efficacy of the corticosteroids ) . 	fluoxetine	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , <e1> DRUG1 </e1> (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> DRUG2 </e2> ) . 	fluoxetine	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , <e1> DRUG1 </e1> (coadministration of <e2> DRUG2 </e2> with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	progestin	melatonin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , <e1> DRUG1 </e1> (coadministration of melatonin with progestin can inhibit ovarian function in women) , <e2> DRUG2 </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	progestin	benzodiazepenes
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , <e1> DRUG1 </e1> (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and <e2> DRUG2 </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	progestin	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , <e1> DRUG1 </e1> (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of <e2> DRUG2 </e2> and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	progestin	melatonin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , <e1> DRUG1 </e1> (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and <e2> DRUG2 </e2> may interfere with the efficacy of the corticosteroids ) . 	progestin	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , <e1> DRUG1 </e1> (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> DRUG2 </e2> ) . 	progestin	corticosteroids
effect	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of <e1> DRUG1 </e1> with <e2> DRUG2 </e2> can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	melatonin	progestin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of <e1> DRUG1 </e1> with progestin can inhibit ovarian function in women) , <e2> DRUG2 </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	melatonin	benzodiazepenes
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of <e1> DRUG1 </e1> with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and <e2> DRUG2 </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	melatonin	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of <e1> DRUG1 </e1> with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and <e2> DRUG2 </e2> may interfere with the efficacy of the corticosteroids ) . 	melatonin	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of <e1> DRUG1 </e1> with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> DRUG2 </e2> ) . 	melatonin	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with <e1> DRUG1 </e1> can inhibit ovarian function in women) , <e2> DRUG2 </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	progestin	benzodiazepenes
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with <e1> DRUG1 </e1> can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and <e2> DRUG2 </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	progestin	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with <e1> DRUG1 </e1> can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of <e2> DRUG2 </e2> and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	progestin	melatonin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with <e1> DRUG1 </e1> can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and <e2> DRUG2 </e2> may interfere with the efficacy of the corticosteroids ) . 	progestin	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with <e1> DRUG1 </e1> can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> DRUG2 </e2> ) . 	progestin	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , <e1> DRUG1 </e1> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and <e2> DRUG2 </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	benzodiazepenes	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , <e1> DRUG1 </e1> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of <e2> DRUG2 </e2> and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	benzodiazepenes	melatonin
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , <e1> DRUG1 </e1> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and <e2> DRUG2 </e2> may interfere with the efficacy of the corticosteroids ) . 	benzodiazepenes	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , <e1> DRUG1 </e1> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> DRUG2 </e2> ) . 	benzodiazepenes	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and <e1> DRUG1 </e1> (coadministration of <e2> DRUG2 </e2> and corticosteroids may interfere with the efficacy of the corticosteroids ) . 	corticosteroids	melatonin
effect	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> may interfere with the efficacy of the corticosteroids ) . 	melatonin	corticosteroids
other	Melatonin may interact with the following drugs : aspirin and other NSAIDs (may lower melatonin levels) , fluvoxamine (bioavailability of oral melatonin is increased with coadministration) , beta blockers (may decrease melatonin levels) , fluoxetine (reports of psychotic episodes when coadministered) , progestin (coadministration of melatonin with progestin can inhibit ovarian function in women) , benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects) , and corticosteroids (coadministration of <e1> DRUG1 </e1> and corticosteroids may interfere with the efficacy of the <e2> DRUG2 </e2> ) . 	melatonin	corticosteroids
effect	ACE inhibitors Reports suggest that <e1> DRUG1 </e1> may diminish the antihypertensive effect of <e2> DRUG2 </e2> . 	NSAIDs	angiotensin-converting enzyme (ACE) inhibitors
advise	This interaction should be given consideration in patients taking <e1> DRUG1 </e1> concomitantly with <e2> DRUG2 </e2> . 	NSAIDs	ACE inhibitors
other	<e1> DRUG1 </e1> : Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of <e2> DRUG2 </e2> . 	Aspirin	meloxicam
mechanism	Aspirin : Concomitant administration of <e1> DRUG1 </e1> (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of <e2> DRUG2 </e2> . 	aspirin	meloxicam
other	however , as with other <e1> DRUG1 </e1> , concomitant administration of <e2> DRUG2 </e2> and aspirin is not generally recommended because of the potential for increased adverse effects . 	NSAIDs	meloxicam
advise	however , as with other <e1> DRUG1 </e1> , concomitant administration of meloxicam and <e2> DRUG2 </e2> is not generally recommended because of the potential for increased adverse effects . 	NSAIDs	aspirin
advise	however , as with other NSAIDs , concomitant administration of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> is not generally recommended because of the potential for increased adverse effects . 	meloxicam	aspirin
effect	Concomitant administration of low-dose <e1> DRUG1 </e1> with <e2> DRUG2 </e2> may result in an increased rate of GI ulceration or other complications , compared to use of MOBIC alone . 	aspirin	MOBIC
other	Concomitant administration of low-dose <e1> DRUG1 </e1> with MOBIC may result in an increased rate of GI ulceration or other complications , compared to use of <e2> DRUG2 </e2> alone . 	aspirin	MOBIC
other	<e1> DRUG1 </e1> is not a substitute for <e2> DRUG2 </e2> for cardiovascular prophylaxis . 	MOBIC	aspirin
other	<e1> DRUG1 </e1> : Pretreatment for four days with cholestyramine significantly increased the clearance of <e2> DRUG2 </e2> by 50% . 	Cholestyramine	meloxicam
mechanism	Cholestyramine : Pretreatment for four days with <e1> DRUG1 </e1> significantly increased the clearance of <e2> DRUG2 </e2> by 50% . 	cholestyramine	meloxicam
other	<e1> DRUG1 </e1> : Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg <e2> DRUG2 </e2> . 	Cimetidine	meloxicam
other	Cimetidine : Concomitant administration of 200 mg <e1> DRUG1 </e1> QID did not alter the single-dose pharmacokinetics of 30 mg <e2> DRUG2 </e2> . 	cimetidine	meloxicam
other	<e1> DRUG1 </e1> : <e2> DRUG2 </e2> 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses . 	Digoxin	Meloxicam
other	Digoxin : <e1> DRUG1 </e1> 15 mg once daily for 7 days did not alter the plasma concentration profile of <e2> DRUG2 </e2> after b-acetyldigoxin administration for 7 days at clinical doses . 	Meloxicam	digoxin
other	In vitro testing found no protein binding drug interaction between <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	digoxin	meloxicam
other	<e1> DRUG1 </e1> : Clinical studies , as well as post-marketing observations , have shown that <e2> DRUG2 </e2> can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients . 	Furosemide	NSAIDs
other	<e1> DRUG1 </e1> : Clinical studies , as well as post-marketing observations , have shown that NSAIDs can reduce the natriuretic effect of furosemide and <e2> DRUG2 </e2> in some patients . 	Furosemide	thiazide diuretics
effect	Furosemide : Clinical studies , as well as post-marketing observations , have shown that <e1> DRUG1 </e1> can reduce the natriuretic effect of <e2> DRUG2 </e2> and thiazide diuretics in some patients . 	NSAIDs	furosemide
effect	Furosemide : Clinical studies , as well as post-marketing observations , have shown that <e1> DRUG1 </e1> can reduce the natriuretic effect of furosemide and <e2> DRUG2 </e2> in some patients . 	NSAIDs	thiazide diuretics
other	Furosemide : Clinical studies , as well as post-marketing observations , have shown that NSAIDs can reduce the natriuretic effect of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> in some patients . 	furosemide	thiazide diuretics
other	Studies with <e1> DRUG1 </e1> agents and <e2> DRUG2 </e2> have not demonstrated a reduction in natriuretic effect . 	furosemide	meloxicam
other	<e1> DRUG1 </e1> : single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of <e2> DRUG2 </e2> . 	Furosemide	meloxicam
advise	Nevertheless , during concomitant therapy with <e1> DRUG1 </e1> and <e2> DRUG2 </e2> , patients should be observed closely for signs of declining renal function , as well as to assure diuretic efficacy . 	furosemide	MOBIC
other	<e1> DRUG1 </e1> : In clinical trials , <e2> DRUG2 </e2> have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance . 	Lithium	NSAIDs
mechanism	Lithium : In clinical trials , <e1> DRUG1 </e1> have produced an elevation of plasma <e2> DRUG2 </e2> levels and a reduction in renal lithium clearance . 	NSAIDs	lithium
other	Lithium : In clinical trials , <e1> DRUG1 </e1> have produced an elevation of plasma lithium levels and a reduction in renal <e2> DRUG2 </e2> clearance . 	NSAIDs	lithium
other	In a study conducted in healthy subjects , mean pre-dose <e1> DRUG1 </e1> concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with <e2> DRUG2 </e2> 15 mg QD as compared to subjects receiving lithium alone . 	lithium	meloxicam
mechanism	In a study conducted in healthy subjects , mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving <e1> DRUG1 </e1> doses ranging from 804 to 1072 mg BID with <e2> DRUG2 </e2> 15 mg QD as compared to subjects receiving lithium alone . 	lithium	meloxicam
other	In a study conducted in healthy subjects , mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with <e1> DRUG1 </e1> 15 mg QD as compared to subjects receiving <e2> DRUG2 </e2> alone . 	meloxicam	lithium
advise	Patients on <e1> DRUG1 </e1> treatment should be closely monitored when <e2> DRUG2 </e2> is introduced or withdrawn . 	lithium	MOBIC
other	<e1> DRUG1 </e1> : A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of <e2> DRUG2 </e2> on the pharmacokinetics of methotrexate taken once weekly . 	Methotrexate	meloxicam
other	Methotrexate : A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of <e1> DRUG1 </e1> on the pharmacokinetics of <e2> DRUG2 </e2> taken once weekly . 	meloxicam	methotrexate
other	<e1> DRUG1 </e1> did not have a significant effect on the pharmacokinetics of single doses of <e2> DRUG2 </e2> . 	Meloxicam	methotrexate
other	In vitro , <e1> DRUG1 </e1> did not displace <e2> DRUG2 </e2> from its human serum binding sites . 	methotrexate	meloxicam
other	<e1> DRUG1 </e1> : Anticoagulant activity should be monitored , particularly in the first few days after initiating or changing <e2> DRUG2 </e2> therapy in patients receiving warfarin or similar agents , since these patients are at an increased risk of bleeding . 	Warfarin	MOBIC
advise	Warfarin : Anticoagulant activity should be monitored , particularly in the first few days after initiating or changing <e1> DRUG1 </e1> therapy in patients receiving <e2> DRUG2 </e2> or similar agents , since these patients are at an increased risk of bleeding . 	MOBIC	warfarin
other	The effect of <e1> DRUG1 </e1> on the anticoagulant effect of <e2> DRUG2 </e2> was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8 . 	meloxicam	warfarin
other	The effect of <e1> DRUG1 </e1> on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of <e2> DRUG2 </e2> that produced an INR (International Normalized Ratio) between 1.2 and 1.8 . 	meloxicam	warfarin
other	In these subjects , <e1> DRUG1 </e1> did not alter <e2> DRUG2 </e2> pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time . 	meloxicam	warfarin
other	In these subjects , <e1> DRUG1 </e1> did not alter warfarin pharmacokinetics and the average anticoagulant effect of <e2> DRUG2 </e2> as determined by prothrombin time . 	meloxicam	warfarin
advise	Caution should be used when administering <e1> DRUG1 </e1> with <e2> DRUG2 </e2> since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced . 	MOBIC	warfarin
other	Caution should be used when administering <e1> DRUG1 </e1> with warfarin since patients on <e2> DRUG2 </e2> may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced . 	MOBIC	warfarin
other	DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN Vaccinations with <e1> DRUG1 </e1> are not recommended in immunocompromised individuals <e2> DRUG2 </e2> together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis . 	live organism vaccines	Nalidixic acid
effect	DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN Vaccinations with live organism vaccines are not recommended in immunocompromised individuals <e1> DRUG1 </e1> together with high-dose intravenous <e2> DRUG2 </e2> has caused deaths in children due to haemorrhagic enterocolitis . 	Nalidixic acid	melphalan
effect	Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous <e1> DRUG1 </e1> and who subsequently received <e2> DRUG2 </e2> to prevent graft-versus-host disease 	melphalan	cyclosporin
effect	The following agents may increase certain actions or side effects of <e1> DRUG1 </e1> : <e2> DRUG2 </e2> , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	anticholinergic drugs	amantadine
effect	The following agents may increase certain actions or side effects of <e1> DRUG1 </e1> : amantadine , <e2> DRUG2 </e2> (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	anticholinergic drugs	antiarrhythmic agents of class I
effect	The following agents may increase certain actions or side effects of <e1> DRUG1 </e1> : amantadine , antiarrhythmic agents of class I (e.g. , <e2> DRUG2 </e2> ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	anticholinergic drugs	quinidine
effect	The following agents may increase certain actions or side effects of <e1> DRUG1 </e1> : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , <e2> DRUG2 </e2> , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	anticholinergic drugs	antihistamines
effect	The following agents may increase certain actions or side effects of <e1> DRUG1 </e1> : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , <e2> DRUG2 </e2> (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	anticholinergic drugs	antipsychotic agents
effect	The following agents may increase certain actions or side effects of <e1> DRUG1 </e1> : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , <e2> DRUG2 </e2> ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	anticholinergic drugs	phenothiazines
effect	The following agents may increase certain actions or side effects of <e1> DRUG1 </e1> : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , <e2> DRUG2 </e2> , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	anticholinergic drugs	benzodiazepines
effect	The following agents may increase certain actions or side effects of <e1> DRUG1 </e1> : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , <e2> DRUG2 </e2> , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	anticholinergic drugs	MAO inhibitors
effect	The following agents may increase certain actions or side effects of <e1> DRUG1 </e1> : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , <e2> DRUG2 </e2> (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	anticholinergic drugs	narcotic analgesics
effect	The following agents may increase certain actions or side effects of <e1> DRUG1 </e1> : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , <e2> DRUG2 </e2> ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	anticholinergic drugs	meperidine
effect	The following agents may increase certain actions or side effects of <e1> DRUG1 </e1> : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , <e2> DRUG2 </e2> and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	anticholinergic drugs	nitrates
effect	The following agents may increase certain actions or side effects of <e1> DRUG1 </e1> : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and <e2> DRUG2 </e2> , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	anticholinergic drugs	nitrites
effect	The following agents may increase certain actions or side effects of <e1> DRUG1 </e1> : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , <e2> DRUG2 </e2> , tricyclic antidepressants , and other drugs having anticholinergic activity . 	anticholinergic drugs	sympathomimetic agents
effect	The following agents may increase certain actions or side effects of <e1> DRUG1 </e1> : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , <e2> DRUG2 </e2> , and other drugs having anticholinergic activity . 	anticholinergic drugs	tricyclic antidepressants
other	The following agents may increase certain actions or side effects of anticholinergic drugs : <e1> DRUG1 </e1> , antiarrhythmic agents of class I (e.g. , <e2> DRUG2 </e2> ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	amantadine	quinidine
other	The following agents may increase certain actions or side effects of anticholinergic drugs : <e1> DRUG1 </e1> , antiarrhythmic agents of class I (e.g. , quinidine ) , <e2> DRUG2 </e2> , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	amantadine	antihistamines
other	The following agents may increase certain actions or side effects of anticholinergic drugs : <e1> DRUG1 </e1> , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , <e2> DRUG2 </e2> (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	amantadine	antipsychotic agents
other	The following agents may increase certain actions or side effects of anticholinergic drugs : <e1> DRUG1 </e1> , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , <e2> DRUG2 </e2> ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	amantadine	phenothiazines
other	The following agents may increase certain actions or side effects of anticholinergic drugs : <e1> DRUG1 </e1> , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , <e2> DRUG2 </e2> , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	amantadine	benzodiazepines
other	The following agents may increase certain actions or side effects of anticholinergic drugs : <e1> DRUG1 </e1> , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , <e2> DRUG2 </e2> , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	amantadine	MAO inhibitors
other	The following agents may increase certain actions or side effects of anticholinergic drugs : <e1> DRUG1 </e1> , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , <e2> DRUG2 </e2> (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	amantadine	narcotic analgesics
other	The following agents may increase certain actions or side effects of anticholinergic drugs : <e1> DRUG1 </e1> , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , <e2> DRUG2 </e2> ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	amantadine	meperidine
other	The following agents may increase certain actions or side effects of anticholinergic drugs : <e1> DRUG1 </e1> , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , <e2> DRUG2 </e2> and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	amantadine	nitrates
other	The following agents may increase certain actions or side effects of anticholinergic drugs : <e1> DRUG1 </e1> , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and <e2> DRUG2 </e2> , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	amantadine	nitrites
other	The following agents may increase certain actions or side effects of anticholinergic drugs : <e1> DRUG1 </e1> , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , <e2> DRUG2 </e2> , tricyclic antidepressants , and other drugs having anticholinergic activity . 	amantadine	sympathomimetic agents
other	The following agents may increase certain actions or side effects of anticholinergic drugs : <e1> DRUG1 </e1> , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , <e2> DRUG2 </e2> , and other drugs having anticholinergic activity . 	amantadine	tricyclic antidepressants
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , <e1> DRUG1 </e1> (e.g. , <e2> DRUG2 </e2> ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antiarrhythmic agents of class I	quinidine
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , <e1> DRUG1 </e1> (e.g. , quinidine ) , <e2> DRUG2 </e2> , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antiarrhythmic agents of class I	antihistamines
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , <e1> DRUG1 </e1> (e.g. , quinidine ) , antihistamines , <e2> DRUG2 </e2> (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antiarrhythmic agents of class I	antipsychotic agents
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , <e1> DRUG1 </e1> (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , <e2> DRUG2 </e2> ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antiarrhythmic agents of class I	phenothiazines
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , <e1> DRUG1 </e1> (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , <e2> DRUG2 </e2> , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antiarrhythmic agents of class I	benzodiazepines
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , <e1> DRUG1 </e1> (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , <e2> DRUG2 </e2> , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antiarrhythmic agents of class I	MAO inhibitors
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , <e1> DRUG1 </e1> (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , <e2> DRUG2 </e2> (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antiarrhythmic agents of class I	narcotic analgesics
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , <e1> DRUG1 </e1> (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , <e2> DRUG2 </e2> ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antiarrhythmic agents of class I	meperidine
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , <e1> DRUG1 </e1> (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , <e2> DRUG2 </e2> and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antiarrhythmic agents of class I	nitrates
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , <e1> DRUG1 </e1> (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and <e2> DRUG2 </e2> , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antiarrhythmic agents of class I	nitrites
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , <e1> DRUG1 </e1> (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , <e2> DRUG2 </e2> , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antiarrhythmic agents of class I	sympathomimetic agents
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , <e1> DRUG1 </e1> (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , <e2> DRUG2 </e2> , and other drugs having anticholinergic activity . 	antiarrhythmic agents of class I	tricyclic antidepressants
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , <e1> DRUG1 </e1> ) , <e2> DRUG2 </e2> , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	quinidine	antihistamines
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , <e1> DRUG1 </e1> ) , antihistamines , <e2> DRUG2 </e2> (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	quinidine	antipsychotic agents
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , <e1> DRUG1 </e1> ) , antihistamines , antipsychotic agents (e.g. , <e2> DRUG2 </e2> ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	quinidine	phenothiazines
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , <e1> DRUG1 </e1> ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , <e2> DRUG2 </e2> , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	quinidine	benzodiazepines
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , <e1> DRUG1 </e1> ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , <e2> DRUG2 </e2> , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	quinidine	MAO inhibitors
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , <e1> DRUG1 </e1> ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , <e2> DRUG2 </e2> (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	quinidine	narcotic analgesics
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , <e1> DRUG1 </e1> ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , <e2> DRUG2 </e2> ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	quinidine	meperidine
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , <e1> DRUG1 </e1> ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , <e2> DRUG2 </e2> and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	quinidine	nitrates
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , <e1> DRUG1 </e1> ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and <e2> DRUG2 </e2> , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	quinidine	nitrites
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , <e1> DRUG1 </e1> ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , <e2> DRUG2 </e2> , tricyclic antidepressants , and other drugs having anticholinergic activity . 	quinidine	sympathomimetic agents
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , <e1> DRUG1 </e1> ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , <e2> DRUG2 </e2> , and other drugs having anticholinergic activity . 	quinidine	tricyclic antidepressants
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , <e1> DRUG1 </e1> , antipsychotic agents (e.g. , <e2> DRUG2 </e2> ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antihistamines	phenothiazines
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , <e1> DRUG1 </e1> , antipsychotic agents (e.g. , phenothiazines ) , <e2> DRUG2 </e2> , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antihistamines	benzodiazepines
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , <e1> DRUG1 </e1> , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , <e2> DRUG2 </e2> , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antihistamines	MAO inhibitors
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , <e1> DRUG1 </e1> , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , <e2> DRUG2 </e2> (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antihistamines	narcotic analgesics
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , <e1> DRUG1 </e1> , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , <e2> DRUG2 </e2> ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antihistamines	meperidine
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , <e1> DRUG1 </e1> , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , <e2> DRUG2 </e2> and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antihistamines	nitrates
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , <e1> DRUG1 </e1> , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and <e2> DRUG2 </e2> , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antihistamines	nitrites
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , <e1> DRUG1 </e1> , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , <e2> DRUG2 </e2> , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antihistamines	sympathomimetic agents
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , <e1> DRUG1 </e1> , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , <e2> DRUG2 </e2> , and other drugs having anticholinergic activity . 	antihistamines	tricyclic antidepressants
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , <e1> DRUG1 </e1> (e.g. , <e2> DRUG2 </e2> ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antipsychotic agents	phenothiazines
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , <e1> DRUG1 </e1> (e.g. , phenothiazines ) , <e2> DRUG2 </e2> , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antipsychotic agents	benzodiazepines
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , <e1> DRUG1 </e1> (e.g. , phenothiazines ) , benzodiazepines , <e2> DRUG2 </e2> , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antipsychotic agents	MAO inhibitors
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , <e1> DRUG1 </e1> (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , <e2> DRUG2 </e2> (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antipsychotic agents	narcotic analgesics
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , <e1> DRUG1 </e1> (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , <e2> DRUG2 </e2> ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antipsychotic agents	meperidine
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , <e1> DRUG1 </e1> (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , <e2> DRUG2 </e2> and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antipsychotic agents	nitrates
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , <e1> DRUG1 </e1> (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and <e2> DRUG2 </e2> , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antipsychotic agents	nitrites
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , <e1> DRUG1 </e1> (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , <e2> DRUG2 </e2> , tricyclic antidepressants , and other drugs having anticholinergic activity . 	antipsychotic agents	sympathomimetic agents
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , <e1> DRUG1 </e1> (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , <e2> DRUG2 </e2> , and other drugs having anticholinergic activity . 	antipsychotic agents	tricyclic antidepressants
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , <e1> DRUG1 </e1> ) , <e2> DRUG2 </e2> , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	phenothiazines	benzodiazepines
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , <e1> DRUG1 </e1> ) , benzodiazepines , <e2> DRUG2 </e2> , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	phenothiazines	MAO inhibitors
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , <e1> DRUG1 </e1> ) , benzodiazepines , MAO inhibitors , <e2> DRUG2 </e2> (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	phenothiazines	narcotic analgesics
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , <e1> DRUG1 </e1> ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , <e2> DRUG2 </e2> ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	phenothiazines	meperidine
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , <e1> DRUG1 </e1> ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , <e2> DRUG2 </e2> and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	phenothiazines	nitrates
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , <e1> DRUG1 </e1> ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and <e2> DRUG2 </e2> , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	phenothiazines	nitrites
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , <e1> DRUG1 </e1> ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , <e2> DRUG2 </e2> , tricyclic antidepressants , and other drugs having anticholinergic activity . 	phenothiazines	sympathomimetic agents
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , <e1> DRUG1 </e1> ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , <e2> DRUG2 </e2> , and other drugs having anticholinergic activity . 	phenothiazines	tricyclic antidepressants
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , <e1> DRUG1 </e1> , MAO inhibitors , <e2> DRUG2 </e2> (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	benzodiazepines	narcotic analgesics
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , <e1> DRUG1 </e1> , MAO inhibitors , narcotic analgesics (e.g. , <e2> DRUG2 </e2> ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	benzodiazepines	meperidine
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , <e1> DRUG1 </e1> , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , <e2> DRUG2 </e2> and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	benzodiazepines	nitrates
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , <e1> DRUG1 </e1> , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and <e2> DRUG2 </e2> , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	benzodiazepines	nitrites
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , <e1> DRUG1 </e1> , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , <e2> DRUG2 </e2> , tricyclic antidepressants , and other drugs having anticholinergic activity . 	benzodiazepines	sympathomimetic agents
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , <e1> DRUG1 </e1> , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , <e2> DRUG2 </e2> , and other drugs having anticholinergic activity . 	benzodiazepines	tricyclic antidepressants
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , <e1> DRUG1 </e1> , narcotic analgesics (e.g. , <e2> DRUG2 </e2> ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	MAO inhibitors	meperidine
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , <e1> DRUG1 </e1> , narcotic analgesics (e.g. , meperidine ) , <e2> DRUG2 </e2> and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	MAO inhibitors	nitrates
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , <e1> DRUG1 </e1> , narcotic analgesics (e.g. , meperidine ) , nitrates and <e2> DRUG2 </e2> , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	MAO inhibitors	nitrites
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , <e1> DRUG1 </e1> , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , <e2> DRUG2 </e2> , tricyclic antidepressants , and other drugs having anticholinergic activity . 	MAO inhibitors	sympathomimetic agents
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , <e1> DRUG1 </e1> , narcotic analgesics (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , <e2> DRUG2 </e2> , and other drugs having anticholinergic activity . 	MAO inhibitors	tricyclic antidepressants
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , <e1> DRUG1 </e1> (e.g. , <e2> DRUG2 </e2> ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	narcotic analgesics	meperidine
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , <e1> DRUG1 </e1> (e.g. , meperidine ) , <e2> DRUG2 </e2> and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	narcotic analgesics	nitrates
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , <e1> DRUG1 </e1> (e.g. , meperidine ) , nitrates and <e2> DRUG2 </e2> , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	narcotic analgesics	nitrites
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , <e1> DRUG1 </e1> (e.g. , meperidine ) , nitrates and nitrites , <e2> DRUG2 </e2> , tricyclic antidepressants , and other drugs having anticholinergic activity . 	narcotic analgesics	sympathomimetic agents
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , <e1> DRUG1 </e1> (e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , <e2> DRUG2 </e2> , and other drugs having anticholinergic activity . 	narcotic analgesics	tricyclic antidepressants
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , <e1> DRUG1 </e1> ) , <e2> DRUG2 </e2> and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	meperidine	nitrates
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , <e1> DRUG1 </e1> ) , nitrates and <e2> DRUG2 </e2> , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	meperidine	nitrites
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , <e1> DRUG1 </e1> ) , nitrates and nitrites , <e2> DRUG2 </e2> , tricyclic antidepressants , and other drugs having anticholinergic activity . 	meperidine	sympathomimetic agents
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , <e1> DRUG1 </e1> ) , nitrates and nitrites , sympathomimetic agents , <e2> DRUG2 </e2> , and other drugs having anticholinergic activity . 	meperidine	tricyclic antidepressants
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , <e1> DRUG1 </e1> and <e2> DRUG2 </e2> , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 	nitrates	nitrites
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , <e1> DRUG1 </e1> and nitrites , <e2> DRUG2 </e2> , tricyclic antidepressants , and other drugs having anticholinergic activity . 	nitrates	sympathomimetic agents
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , <e1> DRUG1 </e1> and nitrites , sympathomimetic agents , <e2> DRUG2 </e2> , and other drugs having anticholinergic activity . 	nitrates	tricyclic antidepressants
other	The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I (e.g. , quinidine ) , antihistamines , antipsychotic agents (e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics (e.g. , meperidine ) , nitrates and <e1> DRUG1 </e1> , sympathomimetic agents , <e2> DRUG2 </e2> , and other drugs having anticholinergic activity . 	nitrites	tricyclic antidepressants
effect	<e1> DRUG1 </e1> antagonize the effects of <e2> DRUG2 </e2> . 	Anticholinergics	antiglaucoma agents
effect	<e1> DRUG1 </e1> in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as <e2> DRUG2 </e2> . 	Anticholinergic drugs	corticosteroids
mechanism	<e1> DRUG1 </e1> may affect gastrointestinal absorption of various drugs , such as slowly dissolving dosage forms of <e2> DRUG2 </e2> ; 	Anticholinergic agents	digoxin
effect	<e1> DRUG1 </e1> may antagonize the effects of drugs that alter gastrointestinal motility , such as <e2> DRUG2 </e2> . 	Anticholinergic drugs	metoclopramide
mechanism	Because <e1> DRUG1 </e1> may interfere with the absorption of <e2> DRUG2 </e2> , simultaneous use of these drugs should be avoided . 	antacids	anticholinergic agents
other	Interaction with Other <e1> DRUG1 </e1> : <e2> DRUG2 </e2> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	Central Nervous System Depressants	MEPERIDINE
other	Interaction with Other <e1> DRUG1 </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e2> DRUG2 </e2> , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	Central Nervous System Depressants	NARCOTIC ANALGESICS
other	Interaction with Other <e1> DRUG1 </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL <e2> DRUG2 </e2> , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	Central Nervous System Depressants	ANESTHETICS
other	Interaction with Other <e1> DRUG1 </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , <e2> DRUG2 </e2> , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	Central Nervous System Depressants	PHENOTHIAZINES
other	Interaction with Other <e1> DRUG1 </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER <e2> DRUG2 </e2> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	Central Nervous System Depressants	TRANQUILIZERS
other	Interaction with Other <e1> DRUG1 </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , <e2> DRUG2 </e2> (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	Central Nervous System Depressants	SEDATIVE-HYPNOTICS
other	Interaction with Other <e1> DRUG1 </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING <e2> DRUG2 </e2> ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	Central Nervous System Depressants	BARBITURATES
other	Interaction with Other <e1> DRUG1 </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , <e2> DRUG2 </e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	Central Nervous System Depressants	TRICYCLIC ANTIDEPRESSANTS
other	Interaction with Other <e1> DRUG1 </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2> DRUG2 </e2> (INCLUDING ALCOHOL ) . 	Central Nervous System Depressants	CNS DEPRESSANTS
other	Interaction with Other <e1> DRUG1 </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2> DRUG2 </e2> ) . 	Central Nervous System Depressants	ALCOHOL
advise	Interaction with Other Central Nervous System Depressants : <e1> DRUG1 </e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e2> DRUG2 </e2> , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	MEPERIDINE	NARCOTIC ANALGESICS
advise	Interaction with Other Central Nervous System Depressants : <e1> DRUG1 </e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL <e2> DRUG2 </e2> , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	MEPERIDINE	ANESTHETICS
advise	Interaction with Other Central Nervous System Depressants : <e1> DRUG1 </e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , <e2> DRUG2 </e2> , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	MEPERIDINE	PHENOTHIAZINES
advise	Interaction with Other Central Nervous System Depressants : <e1> DRUG1 </e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER <e2> DRUG2 </e2> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	MEPERIDINE	TRANQUILIZERS
advise	Interaction with Other Central Nervous System Depressants : <e1> DRUG1 </e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , <e2> DRUG2 </e2> (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	MEPERIDINE	SEDATIVE-HYPNOTICS
advise	Interaction with Other Central Nervous System Depressants : <e1> DRUG1 </e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING <e2> DRUG2 </e2> ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	MEPERIDINE	BARBITURATES
advise	Interaction with Other Central Nervous System Depressants : <e1> DRUG1 </e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , <e2> DRUG2 </e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	MEPERIDINE	TRICYCLIC ANTIDEPRESSANTS
advise	Interaction with Other Central Nervous System Depressants : <e1> DRUG1 </e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2> DRUG2 </e2> (INCLUDING ALCOHOL ) . 	MEPERIDINE	CNS DEPRESSANTS
advise	Interaction with Other Central Nervous System Depressants : <e1> DRUG1 </e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2> DRUG2 </e2> ) . 	MEPERIDINE	ALCOHOL
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1> DRUG1 </e1> , GENERAL <e2> DRUG2 </e2> , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	NARCOTIC ANALGESICS	ANESTHETICS
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1> DRUG1 </e1> , GENERAL ANESTHETICS , <e2> DRUG2 </e2> , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	NARCOTIC ANALGESICS	PHENOTHIAZINES
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1> DRUG1 </e1> , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER <e2> DRUG2 </e2> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	NARCOTIC ANALGESICS	TRANQUILIZERS
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1> DRUG1 </e1> , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , <e2> DRUG2 </e2> (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	NARCOTIC ANALGESICS	SEDATIVE-HYPNOTICS
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1> DRUG1 </e1> , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING <e2> DRUG2 </e2> ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	NARCOTIC ANALGESICS	BARBITURATES
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1> DRUG1 </e1> , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , <e2> DRUG2 </e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	NARCOTIC ANALGESICS	TRICYCLIC ANTIDEPRESSANTS
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1> DRUG1 </e1> , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2> DRUG2 </e2> (INCLUDING ALCOHOL ) . 	NARCOTIC ANALGESICS	CNS DEPRESSANTS
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1> DRUG1 </e1> , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2> DRUG2 </e2> ) . 	NARCOTIC ANALGESICS	ALCOHOL
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL <e1> DRUG1 </e1> , PHENOTHIAZINES , OTHER <e2> DRUG2 </e2> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	ANESTHETICS	TRANQUILIZERS
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL <e1> DRUG1 </e1> , PHENOTHIAZINES , OTHER TRANQUILIZERS , <e2> DRUG2 </e2> (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	ANESTHETICS	SEDATIVE-HYPNOTICS
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL <e1> DRUG1 </e1> , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING <e2> DRUG2 </e2> ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	ANESTHETICS	BARBITURATES
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL <e1> DRUG1 </e1> , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , <e2> DRUG2 </e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	ANESTHETICS	TRICYCLIC ANTIDEPRESSANTS
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL <e1> DRUG1 </e1> , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2> DRUG2 </e2> (INCLUDING ALCOHOL ) . 	ANESTHETICS	CNS DEPRESSANTS
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL <e1> DRUG1 </e1> , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2> DRUG2 </e2> ) . 	ANESTHETICS	ALCOHOL
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , <e1> DRUG1 </e1> , OTHER <e2> DRUG2 </e2> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	PHENOTHIAZINES	TRANQUILIZERS
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , <e1> DRUG1 </e1> , OTHER TRANQUILIZERS , <e2> DRUG2 </e2> (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	PHENOTHIAZINES	SEDATIVE-HYPNOTICS
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , <e1> DRUG1 </e1> , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING <e2> DRUG2 </e2> ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	PHENOTHIAZINES	BARBITURATES
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , <e1> DRUG1 </e1> , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , <e2> DRUG2 </e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	PHENOTHIAZINES	TRICYCLIC ANTIDEPRESSANTS
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , <e1> DRUG1 </e1> , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2> DRUG2 </e2> (INCLUDING ALCOHOL ) . 	PHENOTHIAZINES	CNS DEPRESSANTS
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , <e1> DRUG1 </e1> , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2> DRUG2 </e2> ) . 	PHENOTHIAZINES	ALCOHOL
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER <e1> DRUG1 </e1> , SEDATIVE-HYPNOTICS (INCLUDING <e2> DRUG2 </e2> ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	TRANQUILIZERS	BARBITURATES
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER <e1> DRUG1 </e1> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , <e2> DRUG2 </e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	TRANQUILIZERS	TRICYCLIC ANTIDEPRESSANTS
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER <e1> DRUG1 </e1> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2> DRUG2 </e2> (INCLUDING ALCOHOL ) . 	TRANQUILIZERS	CNS DEPRESSANTS
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER <e1> DRUG1 </e1> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2> DRUG2 </e2> ) . 	TRANQUILIZERS	ALCOHOL
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , <e1> DRUG1 </e1> (INCLUDING <e2> DRUG2 </e2> ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	SEDATIVE-HYPNOTICS	BARBITURATES
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , <e1> DRUG1 </e1> (INCLUDING BARBITURATES ) , <e2> DRUG2 </e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	SEDATIVE-HYPNOTICS	TRICYCLIC ANTIDEPRESSANTS
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , <e1> DRUG1 </e1> (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2> DRUG2 </e2> (INCLUDING ALCOHOL ) . 	SEDATIVE-HYPNOTICS	CNS DEPRESSANTS
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , <e1> DRUG1 </e1> (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2> DRUG2 </e2> ) . 	SEDATIVE-HYPNOTICS	ALCOHOL
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING <e1> DRUG1 </e1> ) , <e2> DRUG2 </e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL ) . 	BARBITURATES	TRICYCLIC ANTIDEPRESSANTS
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING <e1> DRUG1 </e1> ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2> DRUG2 </e2> (INCLUDING ALCOHOL ) . 	BARBITURATES	CNS DEPRESSANTS
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING <e1> DRUG1 </e1> ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2> DRUG2 </e2> ) . 	BARBITURATES	ALCOHOL
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , <e1> DRUG1 </e1> AND OTHER <e2> DRUG2 </e2> (INCLUDING ALCOHOL ) . 	TRICYCLIC ANTIDEPRESSANTS	CNS DEPRESSANTS
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , <e1> DRUG1 </e1> AND OTHER CNS DEPRESSANTS (INCLUDING <e2> DRUG2 </e2> ) . 	TRICYCLIC ANTIDEPRESSANTS	ALCOHOL
other	Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER <e1> DRUG1 </e1> (INCLUDING <e2> DRUG2 </e2> ) . 	CNS DEPRESSANTS	ALCOHOL
int	Some <e1> DRUG1 </e1> may interact with <e2> DRUG2 </e2> . 	anticonvulsants	Mephenytoin
other	Those <e1> DRUG1 </e1> include <e2> DRUG2 </e2> , valproic acid , and phenobarbital . 	anticonvulsants	divalproex sodium
other	Those <e1> DRUG1 </e1> include divalproex sodium , <e2> DRUG2 </e2> , and phenobarbital . 	anticonvulsants	valproic acid
other	Those <e1> DRUG1 </e1> include divalproex sodium , valproic acid , and <e2> DRUG2 </e2> . 	anticonvulsants	phenobarbital
other	Those anticonvulsants include <e1> DRUG1 </e1> , valproic acid , and <e2> DRUG2 </e2> . 	divalproex sodium	phenobarbital
other	Those anticonvulsants include divalproex sodium , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> . 	valproic acid	phenobarbital
effect	<e1> DRUG1 </e1> may also affect the effects of other drugs , which include some <e2> DRUG2 </e2> , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 	Mephenytoin	steroid medications
effect	<e1> DRUG1 </e1> may also affect the effects of other drugs , which include some steroid medications , <e2> DRUG2 </e2> , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 	Mephenytoin	warfarin
effect	<e1> DRUG1 </e1> may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , <e2> DRUG2 </e2> , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 	Mephenytoin	anti-infective medicines
effect	<e1> DRUG1 </e1> may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , <e2> DRUG2 </e2> and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 	Mephenytoin	furosemide
effect	<e1> DRUG1 </e1> may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and <e2> DRUG2 </e2> Please note that Mephenytoin may interact with other drugs that are not listed here . 	Mephenytoin	theophylline
other	Mephenytoin may also affect the effects of other drugs , which include some <e1> DRUG1 </e1> , warfarin , certain heart medicines , birth control pills , <e2> DRUG2 </e2> , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 	steroid medications	anti-infective medicines
other	Mephenytoin may also affect the effects of other drugs , which include some <e1> DRUG1 </e1> , warfarin , certain heart medicines , birth control pills , anti-infective medicines , <e2> DRUG2 </e2> and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 	steroid medications	furosemide
other	Mephenytoin may also affect the effects of other drugs , which include some <e1> DRUG1 </e1> , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and <e2> DRUG2 </e2> Please note that Mephenytoin may interact with other drugs that are not listed here . 	steroid medications	theophylline
other	Mephenytoin may also affect the effects of other drugs , which include some <e1> DRUG1 </e1> , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that <e2> DRUG2 </e2> may interact with other drugs that are not listed here . 	steroid medications	Mephenytoin
other	Mephenytoin may also affect the effects of other drugs , which include some steroid medications , <e1> DRUG1 </e1> , certain heart medicines , birth control pills , <e2> DRUG2 </e2> , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 	warfarin	anti-infective medicines
other	Mephenytoin may also affect the effects of other drugs , which include some steroid medications , <e1> DRUG1 </e1> , certain heart medicines , birth control pills , anti-infective medicines , <e2> DRUG2 </e2> and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 	warfarin	furosemide
other	Mephenytoin may also affect the effects of other drugs , which include some steroid medications , <e1> DRUG1 </e1> , certain heart medicines , birth control pills , anti-infective medicines , furosemide and <e2> DRUG2 </e2> Please note that Mephenytoin may interact with other drugs that are not listed here . 	warfarin	theophylline
other	Mephenytoin may also affect the effects of other drugs , which include some steroid medications , <e1> DRUG1 </e1> , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that <e2> DRUG2 </e2> may interact with other drugs that are not listed here . 	warfarin	Mephenytoin
other	Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , <e1> DRUG1 </e1> , furosemide and <e2> DRUG2 </e2> Please note that Mephenytoin may interact with other drugs that are not listed here . 	anti-infective medicines	theophylline
other	Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , <e1> DRUG1 </e1> , furosemide and theophylline Please note that <e2> DRUG2 </e2> may interact with other drugs that are not listed here . 	anti-infective medicines	Mephenytoin
other	Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , <e1> DRUG1 </e1> and <e2> DRUG2 </e2> Please note that Mephenytoin may interact with other drugs that are not listed here . 	furosemide	theophylline
other	Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , <e1> DRUG1 </e1> and theophylline Please note that <e2> DRUG2 </e2> may interact with other drugs that are not listed here . 	furosemide	Mephenytoin
int	<e1> DRUG1 </e1> can interact with <e2> DRUG2 </e2> , antichlolinergic , TCA , MAOIs , and alcohol . 	Mequitazine	CNS depressant
int	<e1> DRUG1 </e1> can interact with CNS depressant , <e2> DRUG2 </e2> , TCA , MAOIs , and alcohol . 	Mequitazine	antichlolinergic
int	<e1> DRUG1 </e1> can interact with CNS depressant , antichlolinergic , <e2> DRUG2 </e2> , MAOIs , and alcohol . 	Mequitazine	TCA
int	<e1> DRUG1 </e1> can interact with CNS depressant , antichlolinergic , TCA , <e2> DRUG2 </e2> , and alcohol . 	Mequitazine	MAOIs
int	<e1> DRUG1 </e1> can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and <e2> DRUG2 </e2> . 	Mequitazine	alcohol
other	Mequitazine can interact with <e1> DRUG1 </e1> , antichlolinergic , <e2> DRUG2 </e2> , MAOIs , and alcohol . 	CNS depressant	TCA
other	Mequitazine can interact with <e1> DRUG1 </e1> , antichlolinergic , TCA , <e2> DRUG2 </e2> , and alcohol . 	CNS depressant	MAOIs
other	Mequitazine can interact with <e1> DRUG1 </e1> , antichlolinergic , TCA , MAOIs , and <e2> DRUG2 </e2> . 	CNS depressant	alcohol
other	Mequitazine can interact with CNS depressant , <e1> DRUG1 </e1> , TCA , <e2> DRUG2 </e2> , and alcohol . 	antichlolinergic	MAOIs
other	Mequitazine can interact with CNS depressant , <e1> DRUG1 </e1> , TCA , MAOIs , and <e2> DRUG2 </e2> . 	antichlolinergic	alcohol
other	Mequitazine can interact with CNS depressant , antichlolinergic , <e1> DRUG1 </e1> , MAOIs , and <e2> DRUG2 </e2> . 	TCA	alcohol
other	Mequitazine can interact with CNS depressant , antichlolinergic , TCA , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> . 	MAOIs	alcohol
mechanism	<e1> DRUG1 </e1> competes with <e2> DRUG2 </e2> for active tubular secretion and thus inhibits the renal excretion of meropenem . 	Probenecid	meropenem
other	<e1> DRUG1 </e1> competes with meropenem for active tubular secretion and thus inhibits the renal excretion of <e2> DRUG2 </e2> . 	Probenecid	meropenem
advise	Therefore , the coadministration of <e1> DRUG1 </e1> with <e2> DRUG2 </e2> is not recommended . 	probenecid	meropenem
mechanism	There is evidence that <e1> DRUG1 </e1> may reduce serum levels of <e2> DRUG2 </e2> to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate ) . 	meropenem	valproic acid
other	There is evidence that <e1> DRUG1 </e1> may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total <e2> DRUG2 </e2> ) . 	meropenem	valproate
other	There is evidence that meropenem may reduce serum levels of <e1> DRUG1 </e1> to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total <e2> DRUG2 </e2> ) . 	valproic acid	valproate
other	<e1> DRUG1 </e1> should be used with caution in digitalized patients , since the combination of <e2> DRUG2 </e2> and sympathomimetic amines may cause ectopic arrhythmias . 	ARAMINE	digitalis
other	<e1> DRUG1 </e1> should be used with caution in digitalized patients , since the combination of digitalis and <e2> DRUG2 </e2> may cause ectopic arrhythmias . 	ARAMINE	sympathomimetic amines
effect	ARAMINE should be used with caution in digitalized patients , since the combination of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> may cause ectopic arrhythmias . 	digitalis	sympathomimetic amines
effect	<e1> DRUG1 </e1> or tricyclic antidepressants may potentiate the action of <e2> DRUG2 </e2> . 	Monoamine oxidase inhibitors	sympathomimetic amines
effect	Monoamine oxidase inhibitors or <e1> DRUG1 </e1> may potentiate the action of <e2> DRUG2 </e2> . 	tricyclic antidepressants	sympathomimetic amines
effect	<e1> DRUG1 </e1> may enhance the effects of <e2> DRUG2 </e2> , barbiturates and other CNS depressants . 	SKELAXIN	alcohol
effect	<e1> DRUG1 </e1> may enhance the effects of alcohol , <e2> DRUG2 </e2> and other CNS depressants . 	SKELAXIN	barbiturates
effect	<e1> DRUG1 </e1> may enhance the effects of alcohol , barbiturates and other <e2> DRUG2 </e2> . 	SKELAXIN	CNS depressants
other	SKELAXIN may enhance the effects of <e1> DRUG1 </e1> , barbiturates and other <e2> DRUG2 </e2> . 	alcohol	CNS depressants
other	SKELAXIN may enhance the effects of alcohol , <e1> DRUG1 </e1> and other <e2> DRUG2 </e2> . 	barbiturates	CNS depressants
advise	Caution is advised for patients receiving high-dose <e1> DRUG1 </e1> and <e2> DRUG2 </e2> concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors . 	aspirin	methazolamide
other	Caution is advised for patients receiving high-dose <e1> DRUG1 </e1> and methazolamide concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose aspirin and <e2> DRUG2 </e2> . 	aspirin	carbonic anhydrase inhibitors
other	Caution is advised for patients receiving high-dose aspirin and <e1> DRUG1 </e1> concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose <e2> DRUG2 </e2> and carbonic anhydrase inhibitors . 	methazolamide	aspirin
other	Caution is advised for patients receiving high-dose aspirin and <e1> DRUG1 </e1> concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose aspirin and <e2> DRUG2 </e2> . 	methazolamide	carbonic anhydrase inhibitors
effect	Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	aspirin	carbonic anhydrase inhibitors
effect	Anticoagulants (oral) : The activity of oral <e1> DRUG1 </e1> may be potentiated by anti-vitamin-K activity attributed to <e2> DRUG2 </e2> . 	anticoagulants	methimazole
other	<e1> DRUG1 </e1> : Serum digitalis levels may be increased when hyperthyroid patients on a stable <e2> DRUG2 </e2> regimen become euthyroid; 	Digitalis glycosides	digitalis glycoside
effect	Dosages of concomitantly administered <e1> DRUG1 </e1> should be reduced by approximately half , because <e2> DRUG2 </e2> amplifies the therapeutic actions and side-effects of opioids . 	opioids	levomepromazine
effect	Dosages of concomitantly administered opioids should be reduced by approximately half , because <e1> DRUG1 </e1> amplifies the therapeutic actions and side-effects of <e2> DRUG2 </e2> . 	levomepromazine	opioids
effect	Additive sedative effects and confusional states may emerge if <e1> DRUG1 </e1> is given with <e2> DRUG2 </e2> or barbiturates . 	levomepromazine	benzodiazepines
effect	Additive sedative effects and confusional states may emerge if <e1> DRUG1 </e1> is given with benzodiazepines or <e2> DRUG2 </e2> . 	levomepromazine	barbiturates
advise	Exert particular caution in combining <e1> DRUG1 </e1> with other <e2> DRUG2 </e2> ( tricyclic antidepressants and antiparkinsonian-agents ) : Particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma . 	levomepromazine	anticholinergic drugs
advise	Exert particular caution in combining <e1> DRUG1 </e1> with other anticholinergic drugs ( <e2> DRUG2 </e2> and antiparkinsonian-agents ) : Particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma . 	levomepromazine	tricyclic antidepressants
advise	Exert particular caution in combining <e1> DRUG1 </e1> with other anticholinergic drugs ( tricyclic antidepressants and <e2> DRUG2 </e2> ) : Particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma . 	levomepromazine	antiparkinsonian-agents
other	Exert particular caution in combining levomepromazine with other <e1> DRUG1 </e1> ( tricyclic antidepressants and <e2> DRUG2 </e2> ) : Particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma . 	anticholinergic drugs	antiparkinsonian-agents
other	Exert particular caution in combining levomepromazine with other anticholinergic drugs ( <e1> DRUG1 </e1> and <e2> DRUG2 </e2> ) : Particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma . 	tricyclic antidepressants	antiparkinsonian-agents
other	<e1> DRUG1 </e1> and/or stimulantes of the <e2> DRUG2 </e2> / amphetamine type may counteract the specific actions of levomepromazine . 	Caffeine	ephedrine
other	<e1> DRUG1 </e1> and/or stimulantes of the ephedrine / <e2> DRUG2 </e2> type may counteract the specific actions of levomepromazine . 	Caffeine	amphetamine
effect	<e1> DRUG1 </e1> and/or stimulantes of the ephedrine / amphetamine type may counteract the specific actions of <e2> DRUG2 </e2> . 	Caffeine	levomepromazine
other	Caffeine and/or stimulantes of the <e1> DRUG1 </e1> / <e2> DRUG2 </e2> type may counteract the specific actions of levomepromazine . 	ephedrine	amphetamine
effect	Caffeine and/or stimulantes of the <e1> DRUG1 </e1> / amphetamine type may counteract the specific actions of <e2> DRUG2 </e2> . 	ephedrine	levomepromazine
effect	Caffeine and/or stimulantes of the ephedrine / <e1> DRUG1 </e1> type may counteract the specific actions of <e2> DRUG2 </e2> . 	amphetamine	levomepromazine
advise	Since <e1> DRUG1 </e1> ( methsuximide ) may interact with concurrently administered <e2> DRUG2 </e2> , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) . 	Celontin	antiepileptic drugs
other	Since <e1> DRUG1 </e1> ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary (eg <e2> DRUG2 </e2> may increase the plasma concentrations of phenytoin and phenobarbital ) . 	Celontin	methsuximide
other	Since <e1> DRUG1 </e1> ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of <e2> DRUG2 </e2> and phenobarbital ) . 	Celontin	phenytoin
other	Since <e1> DRUG1 </e1> ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and <e2> DRUG2 </e2> ) . 	Celontin	phenobarbital
advise	Since Celontin ( <e1> DRUG1 </e1> ) may interact with concurrently administered <e2> DRUG2 </e2> , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) . 	methsuximide	antiepileptic drugs
other	Since Celontin ( <e1> DRUG1 </e1> ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of <e2> DRUG2 </e2> and phenobarbital ) . 	methsuximide	phenytoin
other	Since Celontin ( <e1> DRUG1 </e1> ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and <e2> DRUG2 </e2> ) . 	methsuximide	phenobarbital
other	Since Celontin ( methsuximide ) may interact with concurrently administered <e1> DRUG1 </e1> , periodic serum level determinations of these drugs may be necessary (eg <e2> DRUG2 </e2> may increase the plasma concentrations of phenytoin and phenobarbital ) . 	antiepileptic drugs	methsuximide
other	Since Celontin ( methsuximide ) may interact with concurrently administered <e1> DRUG1 </e1> , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of <e2> DRUG2 </e2> and phenobarbital ) . 	antiepileptic drugs	phenytoin
other	Since Celontin ( methsuximide ) may interact with concurrently administered <e1> DRUG1 </e1> , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and <e2> DRUG2 </e2> ) . 	antiepileptic drugs	phenobarbital
mechanism	Since Celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary (eg <e1> DRUG1 </e1> may increase the plasma concentrations of <e2> DRUG2 </e2> and phenobarbital ) . 	methsuximide	phenytoin
mechanism	Since Celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary (eg <e1> DRUG1 </e1> may increase the plasma concentrations of phenytoin and <e2> DRUG2 </e2> ) . 	methsuximide	phenobarbital
other	Since Celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> ) . 	phenytoin	phenobarbital
effect	<e1> DRUG1 </e1> may decrease arterial responsiveness to <e2> DRUG2 </e2> . 	Thiazides	norepinephrine
effect	<e1> DRUG1 </e1> may increase the responsiveness of <e2> DRUG2 </e2> . 	Thiazide drugs	tubocurarine
mechanism	<e1> DRUG1 </e1> renal clearance is reduced by <e2> DRUG2 </e2> , increasing the risk of lithium toxicity . 	Lithium	thiazides
other	Lithium renal clearance is reduced by <e1> DRUG1 </e1> , increasing the risk of <e2> DRUG2 </e2> toxicity . 	thiazides	lithium
effect	<e1> DRUG1 </e1> may add to or potentiate the action of other <e2> DRUG2 </e2> . 	Thiazides	antihypertensive drugs
effect	When <e1> DRUG1 </e1> is used with other <e2> DRUG2 </e2> , potentiation of antihypertensive effect may occur . 	methyldopa	antihypertensive drugs
advise	Patients may require reduced doses of <e1> DRUG1 </e1> when on <e2> DRUG2 </e2> . 	anesthetics	methyldopa
advise	When <e1> DRUG1 </e1> and <e2> DRUG2 </e2> are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity . 	methyldopa	lithium
other	When <e1> DRUG1 </e1> and lithium are given concomitantly the patient should be carefully monitored for symptoms of <e2> DRUG2 </e2> toxicity . 	methyldopa	lithium
mechanism	Several studies demonstrate a decrease in the bioavailability of <e1> DRUG1 </e1> when it is ingested with <e2> DRUG2 </e2> or ferrous gluconate . 	methyldopa	ferrous sulfate
mechanism	Several studies demonstrate a decrease in the bioavailability of <e1> DRUG1 </e1> when it is ingested with ferrous sulfate or <e2> DRUG2 </e2> . 	methyldopa	ferrous gluconate
advise	Coadministration of <e1> DRUG1 </e1> with <e2> DRUG2 </e2> or ferrous gluconate is not recommended . 	methyldopa	ferrous sulfate
advise	Coadministration of <e1> DRUG1 </e1> with ferrous sulfate or <e2> DRUG2 </e2> is not recommended . 	methyldopa	ferrous gluconate
other	<e1> DRUG1 </e1> does not interfere with measurement of <e2> DRUG2 </e2> ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert VMA to vanillin . 	Methyldopa	VMA
other	<e1> DRUG1 </e1> does not interfere with measurement of VMA ( <e2> DRUG2 </e2> ) , a test for pheochromocytoma , by those methods which convert VMA to vanillin . 	Methyldopa	vanillylmandelic acid
other	<e1> DRUG1 </e1> does not interfere with measurement of VMA ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert <e2> DRUG2 </e2> to vanillin . 	Methyldopa	VMA
other	<e1> DRUG1 </e1> does not interfere with measurement of VMA ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert VMA to <e2> DRUG2 </e2> . 	Methyldopa	vanillin
other	Methyldopa does not interfere with measurement of <e1> DRUG1 </e1> ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert VMA to <e2> DRUG2 </e2> . 	VMA	vanillin
other	Methyldopa does not interfere with measurement of VMA ( <e1> DRUG1 </e1> ) , a test for pheochromocytoma , by those methods which convert <e2> DRUG2 </e2> to vanillin . 	vanillylmandelic acid	VMA
other	Methyldopa does not interfere with measurement of VMA ( <e1> DRUG1 </e1> ) , a test for pheochromocytoma , by those methods which convert VMA to <e2> DRUG2 </e2> . 	vanillylmandelic acid	vanillin
other	Methyldopa does not interfere with measurement of VMA ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert <e1> DRUG1 </e1> to <e2> DRUG2 </e2> . 	VMA	vanillin
other	CYP 3A4 Inhibitors (e.g . <e1> DRUG1 </e1> and <e2> DRUG2 </e2> ) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g . dihydroergotamine and ergotamine ) and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities . 	Macrolide Antibiotics	Protease Inhibitors
other	CYP 3A4 Inhibitors (e.g . Macrolide Antibiotics and Protease Inhibitors ) There have been rare reports of serious adverse events in connection with the coadministration of certain <e1> DRUG1 </e1> (e.g . <e2> DRUG2 </e2> and ergotamine ) and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities . 	ergot alkaloid drugs	dihydroergotamine
other	CYP 3A4 Inhibitors (e.g . Macrolide Antibiotics and Protease Inhibitors ) There have been rare reports of serious adverse events in connection with the coadministration of certain <e1> DRUG1 </e1> (e.g . dihydroergotamine and <e2> DRUG2 </e2> ) and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities . 	ergot alkaloid drugs	ergotamine
other	CYP 3A4 Inhibitors (e.g . Macrolide Antibiotics and Protease Inhibitors ) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g . <e1> DRUG1 </e1> and <e2> DRUG2 </e2> ) and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities . 	dihydroergotamine	ergotamine
other	Examples of some of the more potent CYP 3A4 inhibitors include <e1> DRUG1 </e1> (e.g. , <e2> DRUG2 </e2> , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	macrolide antibiotics	erythromycin
other	Examples of some of the more potent CYP 3A4 inhibitors include <e1> DRUG1 </e1> (e.g. , erythromycin , <e2> DRUG2 </e2> , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	macrolide antibiotics	troleandomycin
other	Examples of some of the more potent CYP 3A4 inhibitors include <e1> DRUG1 </e1> (e.g. , erythromycin , troleandomycin , <e2> DRUG2 </e2> ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	macrolide antibiotics	clarithromycin
other	Examples of some of the more potent CYP 3A4 inhibitors include <e1> DRUG1 </e1> (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors <e2> DRUG2 </e2> , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	macrolide antibiotics	reverse transcriptase inhibitors
other	Examples of some of the more potent CYP 3A4 inhibitors include <e1> DRUG1 </e1> (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir <e2> DRUG2 </e2> indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	macrolide antibiotics	ritonavir
other	Examples of some of the more potent CYP 3A4 inhibitors include <e1> DRUG1 </e1> (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir <e2> DRUG2 </e2> nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	macrolide antibiotics	indinavir
other	Examples of some of the more potent CYP 3A4 inhibitors include <e1> DRUG1 </e1> (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir <e2> DRUG2 </e2> delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	macrolide antibiotics	nelfinavir
other	Examples of some of the more potent CYP 3A4 inhibitors include <e1> DRUG1 </e1> (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine <e2> DRUG2 </e2> or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	macrolide antibiotics	delavirdine
other	Examples of some of the more potent CYP 3A4 inhibitors include <e1> DRUG1 </e1> (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals <e2> DRUG2 </e2> , ketoconazole , itraconazole , voriconazole ) . 	macrolide antibiotics	azole antifungals
other	Examples of some of the more potent CYP 3A4 inhibitors include <e1> DRUG1 </e1> (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole <e2> DRUG2 </e2> itraconazole , voriconazole ) . 	macrolide antibiotics	ketoconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include <e1> DRUG1 </e1> (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole <e2> DRUG2 </e2> voriconazole ) . 	macrolide antibiotics	itraconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include <e1> DRUG1 </e1> (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole <e2> DRUG2 </e2> . 	macrolide antibiotics	voriconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , <e1> DRUG1 </e1> , troleandomycin , <e2> DRUG2 </e2> ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	erythromycin	clarithromycin
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , <e1> DRUG1 </e1> , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors <e2> DRUG2 </e2> , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	erythromycin	reverse transcriptase inhibitors
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , <e1> DRUG1 </e1> , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir <e2> DRUG2 </e2> indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	erythromycin	ritonavir
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , <e1> DRUG1 </e1> , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir <e2> DRUG2 </e2> nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	erythromycin	indinavir
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , <e1> DRUG1 </e1> , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir <e2> DRUG2 </e2> delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	erythromycin	nelfinavir
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , <e1> DRUG1 </e1> , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine <e2> DRUG2 </e2> or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	erythromycin	delavirdine
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , <e1> DRUG1 </e1> , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals <e2> DRUG2 </e2> , ketoconazole , itraconazole , voriconazole ) . 	erythromycin	azole antifungals
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , <e1> DRUG1 </e1> , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole <e2> DRUG2 </e2> itraconazole , voriconazole ) . 	erythromycin	ketoconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , <e1> DRUG1 </e1> , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole <e2> DRUG2 </e2> voriconazole ) . 	erythromycin	itraconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , <e1> DRUG1 </e1> , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole <e2> DRUG2 </e2> . 	erythromycin	voriconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , <e1> DRUG1 </e1> , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors <e2> DRUG2 </e2> , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	troleandomycin	reverse transcriptase inhibitors
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , <e1> DRUG1 </e1> , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir <e2> DRUG2 </e2> indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	troleandomycin	ritonavir
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , <e1> DRUG1 </e1> , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir <e2> DRUG2 </e2> nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	troleandomycin	indinavir
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , <e1> DRUG1 </e1> , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir <e2> DRUG2 </e2> delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	troleandomycin	nelfinavir
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , <e1> DRUG1 </e1> , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine <e2> DRUG2 </e2> or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	troleandomycin	delavirdine
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , <e1> DRUG1 </e1> , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals <e2> DRUG2 </e2> , ketoconazole , itraconazole , voriconazole ) . 	troleandomycin	azole antifungals
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , <e1> DRUG1 </e1> , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole <e2> DRUG2 </e2> itraconazole , voriconazole ) . 	troleandomycin	ketoconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , <e1> DRUG1 </e1> , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole <e2> DRUG2 </e2> voriconazole ) . 	troleandomycin	itraconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , <e1> DRUG1 </e1> , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole <e2> DRUG2 </e2> . 	troleandomycin	voriconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , <e1> DRUG1 </e1> ) , HIV protease inhibitors or reverse transcriptase inhibitors <e2> DRUG2 </e2> , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	clarithromycin	reverse transcriptase inhibitors
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , <e1> DRUG1 </e1> ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir <e2> DRUG2 </e2> indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	clarithromycin	ritonavir
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , <e1> DRUG1 </e1> ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir <e2> DRUG2 </e2> nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	clarithromycin	indinavir
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , <e1> DRUG1 </e1> ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir <e2> DRUG2 </e2> delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	clarithromycin	nelfinavir
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , <e1> DRUG1 </e1> ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine <e2> DRUG2 </e2> or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	clarithromycin	delavirdine
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , <e1> DRUG1 </e1> ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals <e2> DRUG2 </e2> , ketoconazole , itraconazole , voriconazole ) . 	clarithromycin	azole antifungals
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , <e1> DRUG1 </e1> ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole <e2> DRUG2 </e2> itraconazole , voriconazole ) . 	clarithromycin	ketoconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , <e1> DRUG1 </e1> ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole <e2> DRUG2 </e2> voriconazole ) . 	clarithromycin	itraconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , <e1> DRUG1 </e1> ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole <e2> DRUG2 </e2> . 	clarithromycin	voriconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors <e1> DRUG1 </e1> , ritonavir <e2> DRUG2 </e2> indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	reverse transcriptase inhibitors	ritonavir
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors <e1> DRUG1 </e1> , ritonavir , indinavir <e2> DRUG2 </e2> nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	reverse transcriptase inhibitors	indinavir
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors <e1> DRUG1 </e1> , ritonavir , indinavir , nelfinavir <e2> DRUG2 </e2> delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	reverse transcriptase inhibitors	nelfinavir
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors <e1> DRUG1 </e1> , ritonavir , indinavir , nelfinavir , delavirdine <e2> DRUG2 </e2> or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	reverse transcriptase inhibitors	delavirdine
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors <e1> DRUG1 </e1> , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals <e2> DRUG2 </e2> , ketoconazole , itraconazole , voriconazole ) . 	reverse transcriptase inhibitors	azole antifungals
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors <e1> DRUG1 </e1> , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole <e2> DRUG2 </e2> itraconazole , voriconazole ) . 	reverse transcriptase inhibitors	ketoconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors <e1> DRUG1 </e1> , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole <e2> DRUG2 </e2> voriconazole ) . 	reverse transcriptase inhibitors	itraconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors <e1> DRUG1 </e1> , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole <e2> DRUG2 </e2> . 	reverse transcriptase inhibitors	voriconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir <e1> DRUG1 </e1> indinavir <e2> DRUG2 </e2> nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	ritonavir	indinavir
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir <e1> DRUG1 </e1> indinavir , nelfinavir <e2> DRUG2 </e2> delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	ritonavir	nelfinavir
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir <e1> DRUG1 </e1> indinavir , nelfinavir , delavirdine <e2> DRUG2 </e2> or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	ritonavir	delavirdine
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir <e1> DRUG1 </e1> indinavir , nelfinavir , delavirdine ) or azole antifungals <e2> DRUG2 </e2> , ketoconazole , itraconazole , voriconazole ) . 	ritonavir	azole antifungals
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir <e1> DRUG1 </e1> indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole <e2> DRUG2 </e2> itraconazole , voriconazole ) . 	ritonavir	ketoconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir <e1> DRUG1 </e1> indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole <e2> DRUG2 </e2> voriconazole ) . 	ritonavir	itraconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir <e1> DRUG1 </e1> indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole <e2> DRUG2 </e2> . 	ritonavir	voriconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir <e1> DRUG1 </e1> nelfinavir <e2> DRUG2 </e2> delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	indinavir	nelfinavir
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir <e1> DRUG1 </e1> nelfinavir , delavirdine <e2> DRUG2 </e2> or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	indinavir	delavirdine
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir <e1> DRUG1 </e1> nelfinavir , delavirdine ) or azole antifungals <e2> DRUG2 </e2> , ketoconazole , itraconazole , voriconazole ) . 	indinavir	azole antifungals
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir <e1> DRUG1 </e1> nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole <e2> DRUG2 </e2> itraconazole , voriconazole ) . 	indinavir	ketoconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir <e1> DRUG1 </e1> nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole <e2> DRUG2 </e2> voriconazole ) . 	indinavir	itraconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir <e1> DRUG1 </e1> nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole <e2> DRUG2 </e2> . 	indinavir	voriconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir <e1> DRUG1 </e1> delavirdine <e2> DRUG2 </e2> or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole ) . 	nelfinavir	delavirdine
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir <e1> DRUG1 </e1> delavirdine ) or azole antifungals <e2> DRUG2 </e2> , ketoconazole , itraconazole , voriconazole ) . 	nelfinavir	azole antifungals
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir <e1> DRUG1 </e1> delavirdine ) or azole antifungals (e.g. , ketoconazole <e2> DRUG2 </e2> itraconazole , voriconazole ) . 	nelfinavir	ketoconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir <e1> DRUG1 </e1> delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole <e2> DRUG2 </e2> voriconazole ) . 	nelfinavir	itraconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir <e1> DRUG1 </e1> delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole <e2> DRUG2 </e2> . 	nelfinavir	voriconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine <e1> DRUG1 </e1> or azole antifungals <e2> DRUG2 </e2> , ketoconazole , itraconazole , voriconazole ) . 	delavirdine	azole antifungals
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine <e1> DRUG1 </e1> or azole antifungals (e.g. , ketoconazole <e2> DRUG2 </e2> itraconazole , voriconazole ) . 	delavirdine	ketoconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine <e1> DRUG1 </e1> or azole antifungals (e.g. , ketoconazole , itraconazole <e2> DRUG2 </e2> voriconazole ) . 	delavirdine	itraconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine <e1> DRUG1 </e1> or azole antifungals (e.g. , ketoconazole , itraconazole , voriconazole <e2> DRUG2 </e2> . 	delavirdine	voriconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals <e1> DRUG1 </e1> , ketoconazole <e2> DRUG2 </e2> itraconazole , voriconazole ) . 	azole antifungals	ketoconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals <e1> DRUG1 </e1> , ketoconazole , itraconazole <e2> DRUG2 </e2> voriconazole ) . 	azole antifungals	itraconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals <e1> DRUG1 </e1> , ketoconazole , itraconazole , voriconazole <e2> DRUG2 </e2> . 	azole antifungals	voriconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole <e1> DRUG1 </e1> itraconazole <e2> DRUG2 </e2> voriconazole ) . 	ketoconazole	itraconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole <e1> DRUG1 </e1> itraconazole , voriconazole <e2> DRUG2 </e2> . 	ketoconazole	voriconazole
other	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease inhibitors or reverse transcriptase inhibitors (e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals (e.g. , ketoconazole , itraconazole <e1> DRUG1 </e1> voriconazole <e2> DRUG2 </e2> . 	itraconazole	voriconazole
other	Less potent inhibitors include <e1> DRUG1 </e1> , nefazodone , <e2> DRUG2 </e2> , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 	saquinavir	fluconazole
other	Less potent inhibitors include <e1> DRUG1 </e1> , nefazodone , fluconazole , grapefruit juice , <e2> DRUG2 </e2> , fluvoxamine , zileuton , and clotrimazole . 	saquinavir	fluoxetine
other	Less potent inhibitors include <e1> DRUG1 </e1> , nefazodone , fluconazole , grapefruit juice , fluoxetine , <e2> DRUG2 </e2> , zileuton , and clotrimazole . 	saquinavir	fluvoxamine
other	Less potent inhibitors include <e1> DRUG1 </e1> , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , <e2> DRUG2 </e2> , and clotrimazole . 	saquinavir	zileuton
other	Less potent inhibitors include <e1> DRUG1 </e1> , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and <e2> DRUG2 </e2> . 	saquinavir	clotrimazole
other	Less potent inhibitors include saquinavir , <e1> DRUG1 </e1> , fluconazole , grapefruit juice , <e2> DRUG2 </e2> , fluvoxamine , zileuton , and clotrimazole . 	nefazodone	fluoxetine
other	Less potent inhibitors include saquinavir , <e1> DRUG1 </e1> , fluconazole , grapefruit juice , fluoxetine , <e2> DRUG2 </e2> , zileuton , and clotrimazole . 	nefazodone	fluvoxamine
other	Less potent inhibitors include saquinavir , <e1> DRUG1 </e1> , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , <e2> DRUG2 </e2> , and clotrimazole . 	nefazodone	zileuton
other	Less potent inhibitors include saquinavir , <e1> DRUG1 </e1> , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and <e2> DRUG2 </e2> . 	nefazodone	clotrimazole
other	Less potent inhibitors include saquinavir , nefazodone , <e1> DRUG1 </e1> , grapefruit juice , <e2> DRUG2 </e2> , fluvoxamine , zileuton , and clotrimazole . 	fluconazole	fluoxetine
other	Less potent inhibitors include saquinavir , nefazodone , <e1> DRUG1 </e1> , grapefruit juice , fluoxetine , <e2> DRUG2 </e2> , zileuton , and clotrimazole . 	fluconazole	fluvoxamine
other	Less potent inhibitors include saquinavir , nefazodone , <e1> DRUG1 </e1> , grapefruit juice , fluoxetine , fluvoxamine , <e2> DRUG2 </e2> , and clotrimazole . 	fluconazole	zileuton
other	Less potent inhibitors include saquinavir , nefazodone , <e1> DRUG1 </e1> , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and <e2> DRUG2 </e2> . 	fluconazole	clotrimazole
other	Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , <e1> DRUG1 </e1> , fluvoxamine , <e2> DRUG2 </e2> , and clotrimazole . 	fluoxetine	zileuton
other	Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , <e1> DRUG1 </e1> , fluvoxamine , zileuton , and <e2> DRUG2 </e2> . 	fluoxetine	clotrimazole
other	Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , <e1> DRUG1 </e1> , zileuton , and <e2> DRUG2 </e2> . 	fluvoxamine	clotrimazole
other	Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> . 	zileuton	clotrimazole
advise	Caution should be exercised when <e1> DRUG1 </e1> ( methylergonovine maleate ) is used concurrently with other <e2> DRUG2 </e2> or ergot alkaloids . 	Methergine	vasoconstrictors
advise	Caution should be exercised when <e1> DRUG1 </e1> ( methylergonovine maleate ) is used concurrently with other vasoconstrictors or <e2> DRUG2 </e2> . 	Methergine	ergot alkaloids
advise	Caution should be exercised when Methergine ( <e1> DRUG1 </e1> ) is used concurrently with other <e2> DRUG2 </e2> or ergot alkaloids . 	methylergonovine maleate	vasoconstrictors
other	Caution should be exercised when Methergine ( <e1> DRUG1 </e1> ) is used concurrently with other vasoconstrictors or <e2> DRUG2 </e2> . 	methylergonovine maleate	ergot alkaloids
effect	<e1> DRUG1 </e1> may decrease the hypotensive effect of <e2> DRUG2 </e2> . 	Ritalin	guanethidine
mechanism	Human pharmacologic studies have shown that <e1> DRUG1 </e1> may inhibit the metabolism of <e2> DRUG2 </e2> , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 	Ritalin	coumarin anticoagulants
mechanism	Human pharmacologic studies have shown that <e1> DRUG1 </e1> may inhibit the metabolism of coumarin anticoagulants , <e2> DRUG2 </e2> ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 	Ritalin	anticonvulsants
mechanism	Human pharmacologic studies have shown that <e1> DRUG1 </e1> may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( <e2> DRUG2 </e2> , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 	Ritalin	phenobarbital
mechanism	Human pharmacologic studies have shown that <e1> DRUG1 </e1> may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , <e2> DRUG2 </e2> , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 	Ritalin	diphenylhydantoin
mechanism	Human pharmacologic studies have shown that <e1> DRUG1 </e1> may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , <e2> DRUG2 </e2> ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 	Ritalin	primidone
mechanism	Human pharmacologic studies have shown that <e1> DRUG1 </e1> may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , <e2> DRUG2 </e2> , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 	Ritalin	phenylbutazone
mechanism	Human pharmacologic studies have shown that <e1> DRUG1 </e1> may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and <e2> DRUG2 </e2> ( imipramine , clomipramine , desipramine ) . 	Ritalin	tricyclic drugs
mechanism	Human pharmacologic studies have shown that <e1> DRUG1 </e1> may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( <e2> DRUG2 </e2> , clomipramine , desipramine ) . 	Ritalin	imipramine
mechanism	Human pharmacologic studies have shown that <e1> DRUG1 </e1> may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , <e2> DRUG2 </e2> , desipramine ) . 	Ritalin	clomipramine
mechanism	Human pharmacologic studies have shown that <e1> DRUG1 </e1> may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , <e2> DRUG2 </e2> ) . 	Ritalin	desipramine
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1> DRUG1 </e1> , anticonvulsants ( <e2> DRUG2 </e2> , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 	coumarin anticoagulants	phenobarbital
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1> DRUG1 </e1> , anticonvulsants ( phenobarbital , <e2> DRUG2 </e2> , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 	coumarin anticoagulants	diphenylhydantoin
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1> DRUG1 </e1> , anticonvulsants ( phenobarbital , diphenylhydantoin , <e2> DRUG2 </e2> ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 	coumarin anticoagulants	primidone
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1> DRUG1 </e1> , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , <e2> DRUG2 </e2> , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 	coumarin anticoagulants	phenylbutazone
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1> DRUG1 </e1> , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and <e2> DRUG2 </e2> ( imipramine , clomipramine , desipramine ) . 	coumarin anticoagulants	tricyclic drugs
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1> DRUG1 </e1> , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( <e2> DRUG2 </e2> , clomipramine , desipramine ) . 	coumarin anticoagulants	imipramine
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1> DRUG1 </e1> , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , <e2> DRUG2 </e2> , desipramine ) . 	coumarin anticoagulants	clomipramine
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1> DRUG1 </e1> , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , <e2> DRUG2 </e2> ) . 	coumarin anticoagulants	desipramine
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , <e1> DRUG1 </e1> ( phenobarbital , <e2> DRUG2 </e2> , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 	anticonvulsants	diphenylhydantoin
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , <e1> DRUG1 </e1> ( phenobarbital , diphenylhydantoin , <e2> DRUG2 </e2> ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 	anticonvulsants	primidone
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , <e1> DRUG1 </e1> ( phenobarbital , diphenylhydantoin , primidone ) , <e2> DRUG2 </e2> , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 	anticonvulsants	phenylbutazone
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , <e1> DRUG1 </e1> ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and <e2> DRUG2 </e2> ( imipramine , clomipramine , desipramine ) . 	anticonvulsants	tricyclic drugs
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , <e1> DRUG1 </e1> ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( <e2> DRUG2 </e2> , clomipramine , desipramine ) . 	anticonvulsants	imipramine
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , <e1> DRUG1 </e1> ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , <e2> DRUG2 </e2> , desipramine ) . 	anticonvulsants	clomipramine
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , <e1> DRUG1 </e1> ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , <e2> DRUG2 </e2> ) . 	anticonvulsants	desipramine
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( <e1> DRUG1 </e1> , diphenylhydantoin , <e2> DRUG2 </e2> ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 	phenobarbital	primidone
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( <e1> DRUG1 </e1> , diphenylhydantoin , primidone ) , <e2> DRUG2 </e2> , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 	phenobarbital	phenylbutazone
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( <e1> DRUG1 </e1> , diphenylhydantoin , primidone ) , phenylbutazone , and <e2> DRUG2 </e2> ( imipramine , clomipramine , desipramine ) . 	phenobarbital	tricyclic drugs
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( <e1> DRUG1 </e1> , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( <e2> DRUG2 </e2> , clomipramine , desipramine ) . 	phenobarbital	imipramine
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( <e1> DRUG1 </e1> , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , <e2> DRUG2 </e2> , desipramine ) . 	phenobarbital	clomipramine
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( <e1> DRUG1 </e1> , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , <e2> DRUG2 </e2> ) . 	phenobarbital	desipramine
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , <e1> DRUG1 </e1> , primidone ) , <e2> DRUG2 </e2> , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 	diphenylhydantoin	phenylbutazone
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , <e1> DRUG1 </e1> , primidone ) , phenylbutazone , and <e2> DRUG2 </e2> ( imipramine , clomipramine , desipramine ) . 	diphenylhydantoin	tricyclic drugs
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , <e1> DRUG1 </e1> , primidone ) , phenylbutazone , and tricyclic drugs ( <e2> DRUG2 </e2> , clomipramine , desipramine ) . 	diphenylhydantoin	imipramine
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , <e1> DRUG1 </e1> , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , <e2> DRUG2 </e2> , desipramine ) . 	diphenylhydantoin	clomipramine
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , <e1> DRUG1 </e1> , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , <e2> DRUG2 </e2> ) . 	diphenylhydantoin	desipramine
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , <e1> DRUG1 </e1> ) , <e2> DRUG2 </e2> , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 	primidone	phenylbutazone
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , <e1> DRUG1 </e1> ) , phenylbutazone , and <e2> DRUG2 </e2> ( imipramine , clomipramine , desipramine ) . 	primidone	tricyclic drugs
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , <e1> DRUG1 </e1> ) , phenylbutazone , and tricyclic drugs ( <e2> DRUG2 </e2> , clomipramine , desipramine ) . 	primidone	imipramine
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , <e1> DRUG1 </e1> ) , phenylbutazone , and tricyclic drugs ( imipramine , <e2> DRUG2 </e2> , desipramine ) . 	primidone	clomipramine
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , <e1> DRUG1 </e1> ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , <e2> DRUG2 </e2> ) . 	primidone	desipramine
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> ( imipramine , clomipramine , desipramine ) . 	phenylbutazone	tricyclic drugs
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , <e1> DRUG1 </e1> , and tricyclic drugs ( <e2> DRUG2 </e2> , clomipramine , desipramine ) . 	phenylbutazone	imipramine
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , <e1> DRUG1 </e1> , and tricyclic drugs ( imipramine , <e2> DRUG2 </e2> , desipramine ) . 	phenylbutazone	clomipramine
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , <e1> DRUG1 </e1> , and tricyclic drugs ( imipramine , clomipramine , <e2> DRUG2 </e2> ) . 	phenylbutazone	desipramine
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and <e1> DRUG1 </e1> ( imipramine , <e2> DRUG2 </e2> , desipramine ) . 	tricyclic drugs	clomipramine
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and <e1> DRUG1 </e1> ( imipramine , clomipramine , <e2> DRUG2 </e2> ) . 	tricyclic drugs	desipramine
other	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( <e1> DRUG1 </e1> , clomipramine , <e2> DRUG2 </e2> ) . 	imipramine	desipramine
other	The safety of using <e1> DRUG1 </e1> in combination with <e2> DRUG2 </e2> or other centrally acting alpha-2 agonists has not been systemically evaluated . 	methylphenidate	clonidine
other	The safety of using <e1> DRUG1 </e1> in combination with clonidine or other centrally acting <e2> DRUG2 </e2> has not been systemically evaluated . 	methylphenidate	alpha-2 agonists
other	The safety of using methylphenidate in combination with <e1> DRUG1 </e1> or other centrally acting <e2> DRUG2 </e2> has not been systemically evaluated . 	clonidine	alpha-2 agonists
mechanism	Mutual inhibition of metabolism occurs with concurrent use of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> ; 	cyclosporin	methylprednisolone
effect	convulsions have been reported with concurrent use of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	methylprednisolone	cyclosporin
other	Drugs that induce hepatic enzymes such as <e1> DRUG1 </e1> , phenytoin , and <e2> DRUG2 </e2> may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 	phenobarbital	rifampin
mechanism	Drugs that induce hepatic enzymes such as <e1> DRUG1 </e1> , phenytoin , and rifampin may increase the clearance of <e2> DRUG2 </e2> and may require increased in methylprednisolone dose to achieve the desired response . 	phenobarbital	methylprednisolone
advise	Drugs that induce hepatic enzymes such as <e1> DRUG1 </e1> , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in <e2> DRUG2 </e2> dose to achieve the desired response . 	phenobarbital	methylprednisolone
other	Drugs that induce hepatic enzymes such as phenobarbital , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 	phenytoin	rifampin
mechanism	Drugs that induce hepatic enzymes such as phenobarbital , <e1> DRUG1 </e1> , and rifampin may increase the clearance of <e2> DRUG2 </e2> and may require increased in methylprednisolone dose to achieve the desired response . 	phenytoin	methylprednisolone
advise	Drugs that induce hepatic enzymes such as phenobarbital , <e1> DRUG1 </e1> , and rifampin may increase the clearance of methylprednisolone and may require increased in <e2> DRUG2 </e2> dose to achieve the desired response . 	phenytoin	methylprednisolone
mechanism	Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and <e1> DRUG1 </e1> may increase the clearance of <e2> DRUG2 </e2> and may require increased in methylprednisolone dose to achieve the desired response . 	rifampin	methylprednisolone
advise	Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and <e1> DRUG1 </e1> may increase the clearance of methylprednisolone and may require increased in <e2> DRUG2 </e2> dose to achieve the desired response . 	rifampin	methylprednisolone
other	Drugs such as <e1> DRUG1 </e1> and <e2> DRUG2 </e2> may inhibit the metabolism of methylprednisolone and thus decrease its clearance . 	troleandomycin	ketoconazole
mechanism	Drugs such as <e1> DRUG1 </e1> and ketoconazole may inhibit the metabolism of <e2> DRUG2 </e2> and thus decrease its clearance . 	troleandomycin	methylprednisolone
mechanism	Drugs such as troleandomycin and <e1> DRUG1 </e1> may inhibit the metabolism of <e2> DRUG2 </e2> and thus decrease its clearance . 	ketoconazole	methylprednisolone
mechanism	<e1> DRUG1 </e1> may increase the clearance of chronic high dose <e2> DRUG2 </e2> . 	Methylprednisolone	aspirin
other	This could lead to decreased <e1> DRUG1 </e1> serum levels or increase the risk of salicylate toxicity when <e2> DRUG2 </e2> is withdrawn . 	salicylate	methylprednisolone
effect	This could lead to decreased salicylate serum levels or increase the risk of <e1> DRUG1 </e1> toxicity when <e2> DRUG2 </e2> is withdrawn . 	salicylate	methylprednisolone
advise	<e1> DRUG1 </e1> should be used cautiously in conjunction with <e2> DRUG2 </e2> in patients suffering from hypoprothrombinemia . 	Aspirin	corticosteroids
other	The effect of <e1> DRUG1 </e1> on oral <e2> DRUG2 </e2> is variable . 	methylprednisolone	anticoagulants
effect	There are reports of enhanced as well as diminished effects of <e1> DRUG1 </e1> when given concurrently with <e2> DRUG2 </e2> . 	anticoagulant	corticosteroids
other	<e1> DRUG1 </e1> may interact with <e2> DRUG2 </e2> ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	Methscopolamine	antidepressants
int	<e1> DRUG1 </e1> may interact with antidepressants ( <e2> DRUG2 </e2> type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	Methscopolamine	tricyclic
int	<e1> DRUG1 </e1> may interact with antidepressants ( tricyclic type) , <e2> DRUG2 </e2> (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	Methscopolamine	MAO inhibitors
int	<e1> DRUG1 </e1> may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , <e2> DRUG2 </e2> , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	Methscopolamine	phenelzine
int	<e1> DRUG1 </e1> may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , <e2> DRUG2 </e2> , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	Methscopolamine	linezolid
int	<e1> DRUG1 </e1> may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , <e2> DRUG2 </e2> , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	Methscopolamine	tranylcypromine
int	<e1> DRUG1 </e1> may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , <e2> DRUG2 </e2> , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	Methscopolamine	isocarboxazid
int	<e1> DRUG1 </e1> may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , <e2> DRUG2 </e2> , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	Methscopolamine	selegiline
int	<e1> DRUG1 </e1> may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , <e2> DRUG2 </e2> ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	Methscopolamine	furazolidone
int	<e1> DRUG1 </e1> may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , <e2> DRUG2 </e2> , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	Methscopolamine	quinidine
int	<e1> DRUG1 </e1> may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , <e2> DRUG2 </e2> , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	Methscopolamine	amantadine
int	<e1> DRUG1 </e1> may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , <e2> DRUG2 </e2> (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	Methscopolamine	antihistamines
int	<e1> DRUG1 </e1> may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , <e2> DRUG2 </e2> ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	Methscopolamine	diphenhydramine
int	<e1> DRUG1 </e1> may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other <e2> DRUG2 </e2> , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	Methscopolamine	anticholinergics
int	<e1> DRUG1 </e1> may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , <e2> DRUG2 </e2> supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	Methscopolamine	potassium chloride
int	<e1> DRUG1 </e1> may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , <e2> DRUG2 </e2> , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	Methscopolamine	antacids
int	<e1> DRUG1 </e1> may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , <e2> DRUG2 </e2> (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	Methscopolamine	absorbent-type anti-diarrhea medicines
int	<e1> DRUG1 </e1> may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , <e2> DRUG2 </e2> - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	Methscopolamine	kaolin
int	<e1> DRUG1 </e1> may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - <e2> DRUG2 </e2> ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	Methscopolamine	pectin
int	<e1> DRUG1 </e1> may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , <e2> DRUG2 </e2> (e.g. , chlorpromazine , promethazine ) . 	Methscopolamine	phenothiazines
int	<e1> DRUG1 </e1> may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , <e2> DRUG2 </e2> , promethazine ) . 	Methscopolamine	chlorpromazine
int	<e1> DRUG1 </e1> may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , <e2> DRUG2 </e2> ) . 	Methscopolamine	promethazine
other	Methscopolamine may interact with <e1> DRUG1 </e1> ( tricyclic type) , <e2> DRUG2 </e2> (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antidepressants	MAO inhibitors
other	Methscopolamine may interact with <e1> DRUG1 </e1> ( tricyclic type) , MAO inhibitors (e.g. , <e2> DRUG2 </e2> , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antidepressants	phenelzine
other	Methscopolamine may interact with <e1> DRUG1 </e1> ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , <e2> DRUG2 </e2> , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antidepressants	linezolid
other	Methscopolamine may interact with <e1> DRUG1 </e1> ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , <e2> DRUG2 </e2> , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antidepressants	tranylcypromine
other	Methscopolamine may interact with <e1> DRUG1 </e1> ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , <e2> DRUG2 </e2> , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antidepressants	isocarboxazid
other	Methscopolamine may interact with <e1> DRUG1 </e1> ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , <e2> DRUG2 </e2> , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antidepressants	selegiline
other	Methscopolamine may interact with <e1> DRUG1 </e1> ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , <e2> DRUG2 </e2> ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antidepressants	furazolidone
other	Methscopolamine may interact with <e1> DRUG1 </e1> ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , <e2> DRUG2 </e2> , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antidepressants	quinidine
other	Methscopolamine may interact with <e1> DRUG1 </e1> ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , <e2> DRUG2 </e2> , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antidepressants	amantadine
other	Methscopolamine may interact with <e1> DRUG1 </e1> ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , <e2> DRUG2 </e2> (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antidepressants	antihistamines
other	Methscopolamine may interact with <e1> DRUG1 </e1> ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , <e2> DRUG2 </e2> ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antidepressants	diphenhydramine
other	Methscopolamine may interact with <e1> DRUG1 </e1> ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other <e2> DRUG2 </e2> , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antidepressants	anticholinergics
other	Methscopolamine may interact with <e1> DRUG1 </e1> ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , <e2> DRUG2 </e2> supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antidepressants	potassium chloride
other	Methscopolamine may interact with <e1> DRUG1 </e1> ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , <e2> DRUG2 </e2> , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antidepressants	antacids
other	Methscopolamine may interact with <e1> DRUG1 </e1> ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , <e2> DRUG2 </e2> (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antidepressants	absorbent-type anti-diarrhea medicines
other	Methscopolamine may interact with <e1> DRUG1 </e1> ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , <e2> DRUG2 </e2> - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antidepressants	kaolin
other	Methscopolamine may interact with <e1> DRUG1 </e1> ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - <e2> DRUG2 </e2> ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antidepressants	pectin
other	Methscopolamine may interact with <e1> DRUG1 </e1> ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , <e2> DRUG2 </e2> (e.g. , chlorpromazine , promethazine ) . 	antidepressants	phenothiazines
other	Methscopolamine may interact with <e1> DRUG1 </e1> ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , <e2> DRUG2 </e2> , promethazine ) . 	antidepressants	chlorpromazine
other	Methscopolamine may interact with <e1> DRUG1 </e1> ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , <e2> DRUG2 </e2> ) . 	antidepressants	promethazine
other	Methscopolamine may interact with antidepressants ( <e1> DRUG1 </e1> type) , <e2> DRUG2 </e2> (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tricyclic	MAO inhibitors
other	Methscopolamine may interact with antidepressants ( <e1> DRUG1 </e1> type) , MAO inhibitors (e.g. , <e2> DRUG2 </e2> , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tricyclic	phenelzine
other	Methscopolamine may interact with antidepressants ( <e1> DRUG1 </e1> type) , MAO inhibitors (e.g. , phenelzine , <e2> DRUG2 </e2> , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tricyclic	linezolid
other	Methscopolamine may interact with antidepressants ( <e1> DRUG1 </e1> type) , MAO inhibitors (e.g. , phenelzine , linezolid , <e2> DRUG2 </e2> , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tricyclic	tranylcypromine
other	Methscopolamine may interact with antidepressants ( <e1> DRUG1 </e1> type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , <e2> DRUG2 </e2> , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tricyclic	isocarboxazid
other	Methscopolamine may interact with antidepressants ( <e1> DRUG1 </e1> type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , <e2> DRUG2 </e2> , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tricyclic	selegiline
other	Methscopolamine may interact with antidepressants ( <e1> DRUG1 </e1> type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , <e2> DRUG2 </e2> ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tricyclic	furazolidone
other	Methscopolamine may interact with antidepressants ( <e1> DRUG1 </e1> type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , <e2> DRUG2 </e2> , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tricyclic	quinidine
other	Methscopolamine may interact with antidepressants ( <e1> DRUG1 </e1> type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , <e2> DRUG2 </e2> , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tricyclic	amantadine
other	Methscopolamine may interact with antidepressants ( <e1> DRUG1 </e1> type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , <e2> DRUG2 </e2> (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tricyclic	antihistamines
other	Methscopolamine may interact with antidepressants ( <e1> DRUG1 </e1> type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , <e2> DRUG2 </e2> ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tricyclic	diphenhydramine
other	Methscopolamine may interact with antidepressants ( <e1> DRUG1 </e1> type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other <e2> DRUG2 </e2> , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tricyclic	anticholinergics
other	Methscopolamine may interact with antidepressants ( <e1> DRUG1 </e1> type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , <e2> DRUG2 </e2> supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tricyclic	potassium chloride
other	Methscopolamine may interact with antidepressants ( <e1> DRUG1 </e1> type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , <e2> DRUG2 </e2> , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tricyclic	antacids
other	Methscopolamine may interact with antidepressants ( <e1> DRUG1 </e1> type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , <e2> DRUG2 </e2> (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tricyclic	absorbent-type anti-diarrhea medicines
other	Methscopolamine may interact with antidepressants ( <e1> DRUG1 </e1> type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , <e2> DRUG2 </e2> - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tricyclic	kaolin
other	Methscopolamine may interact with antidepressants ( <e1> DRUG1 </e1> type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - <e2> DRUG2 </e2> ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tricyclic	pectin
other	Methscopolamine may interact with antidepressants ( <e1> DRUG1 </e1> type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , <e2> DRUG2 </e2> (e.g. , chlorpromazine , promethazine ) . 	tricyclic	phenothiazines
other	Methscopolamine may interact with antidepressants ( <e1> DRUG1 </e1> type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , <e2> DRUG2 </e2> , promethazine ) . 	tricyclic	chlorpromazine
other	Methscopolamine may interact with antidepressants ( <e1> DRUG1 </e1> type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , <e2> DRUG2 </e2> ) . 	tricyclic	promethazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , <e1> DRUG1 </e1> (e.g. , <e2> DRUG2 </e2> , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	MAO inhibitors	phenelzine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , <e1> DRUG1 </e1> (e.g. , phenelzine , <e2> DRUG2 </e2> , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	MAO inhibitors	linezolid
other	Methscopolamine may interact with antidepressants ( tricyclic type) , <e1> DRUG1 </e1> (e.g. , phenelzine , linezolid , <e2> DRUG2 </e2> , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	MAO inhibitors	tranylcypromine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , <e1> DRUG1 </e1> (e.g. , phenelzine , linezolid , tranylcypromine , <e2> DRUG2 </e2> , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	MAO inhibitors	isocarboxazid
other	Methscopolamine may interact with antidepressants ( tricyclic type) , <e1> DRUG1 </e1> (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , <e2> DRUG2 </e2> , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	MAO inhibitors	selegiline
other	Methscopolamine may interact with antidepressants ( tricyclic type) , <e1> DRUG1 </e1> (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , <e2> DRUG2 </e2> ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	MAO inhibitors	furazolidone
other	Methscopolamine may interact with antidepressants ( tricyclic type) , <e1> DRUG1 </e1> (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , <e2> DRUG2 </e2> , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	MAO inhibitors	quinidine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , <e1> DRUG1 </e1> (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , <e2> DRUG2 </e2> , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	MAO inhibitors	amantadine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , <e1> DRUG1 </e1> (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , <e2> DRUG2 </e2> (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	MAO inhibitors	antihistamines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , <e1> DRUG1 </e1> (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , <e2> DRUG2 </e2> ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	MAO inhibitors	diphenhydramine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , <e1> DRUG1 </e1> (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other <e2> DRUG2 </e2> , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	MAO inhibitors	anticholinergics
other	Methscopolamine may interact with antidepressants ( tricyclic type) , <e1> DRUG1 </e1> (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , <e2> DRUG2 </e2> supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	MAO inhibitors	potassium chloride
other	Methscopolamine may interact with antidepressants ( tricyclic type) , <e1> DRUG1 </e1> (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , <e2> DRUG2 </e2> , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	MAO inhibitors	antacids
other	Methscopolamine may interact with antidepressants ( tricyclic type) , <e1> DRUG1 </e1> (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , <e2> DRUG2 </e2> (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	MAO inhibitors	absorbent-type anti-diarrhea medicines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , <e1> DRUG1 </e1> (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , <e2> DRUG2 </e2> - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	MAO inhibitors	kaolin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , <e1> DRUG1 </e1> (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - <e2> DRUG2 </e2> ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	MAO inhibitors	pectin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , <e1> DRUG1 </e1> (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , <e2> DRUG2 </e2> (e.g. , chlorpromazine , promethazine ) . 	MAO inhibitors	phenothiazines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , <e1> DRUG1 </e1> (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , <e2> DRUG2 </e2> , promethazine ) . 	MAO inhibitors	chlorpromazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , <e1> DRUG1 </e1> (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , <e2> DRUG2 </e2> ) . 	MAO inhibitors	promethazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , <e1> DRUG1 </e1> , linezolid , <e2> DRUG2 </e2> , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	phenelzine	tranylcypromine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , <e1> DRUG1 </e1> , linezolid , tranylcypromine , <e2> DRUG2 </e2> , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	phenelzine	isocarboxazid
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , <e1> DRUG1 </e1> , linezolid , tranylcypromine , isocarboxazid , <e2> DRUG2 </e2> , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	phenelzine	selegiline
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , <e1> DRUG1 </e1> , linezolid , tranylcypromine , isocarboxazid , selegiline , <e2> DRUG2 </e2> ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	phenelzine	furazolidone
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , <e1> DRUG1 </e1> , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , <e2> DRUG2 </e2> , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	phenelzine	quinidine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , <e1> DRUG1 </e1> , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , <e2> DRUG2 </e2> , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	phenelzine	amantadine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , <e1> DRUG1 </e1> , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , <e2> DRUG2 </e2> (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	phenelzine	antihistamines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , <e1> DRUG1 </e1> , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , <e2> DRUG2 </e2> ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	phenelzine	diphenhydramine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , <e1> DRUG1 </e1> , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other <e2> DRUG2 </e2> , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	phenelzine	anticholinergics
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , <e1> DRUG1 </e1> , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , <e2> DRUG2 </e2> supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	phenelzine	potassium chloride
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , <e1> DRUG1 </e1> , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , <e2> DRUG2 </e2> , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	phenelzine	antacids
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , <e1> DRUG1 </e1> , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , <e2> DRUG2 </e2> (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	phenelzine	absorbent-type anti-diarrhea medicines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , <e1> DRUG1 </e1> , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , <e2> DRUG2 </e2> - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	phenelzine	kaolin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , <e1> DRUG1 </e1> , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - <e2> DRUG2 </e2> ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	phenelzine	pectin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , <e1> DRUG1 </e1> , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , <e2> DRUG2 </e2> (e.g. , chlorpromazine , promethazine ) . 	phenelzine	phenothiazines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , <e1> DRUG1 </e1> , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , <e2> DRUG2 </e2> , promethazine ) . 	phenelzine	chlorpromazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , <e1> DRUG1 </e1> , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , <e2> DRUG2 </e2> ) . 	phenelzine	promethazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , <e1> DRUG1 </e1> , tranylcypromine , <e2> DRUG2 </e2> , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	linezolid	isocarboxazid
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , <e1> DRUG1 </e1> , tranylcypromine , isocarboxazid , <e2> DRUG2 </e2> , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	linezolid	selegiline
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , <e1> DRUG1 </e1> , tranylcypromine , isocarboxazid , selegiline , <e2> DRUG2 </e2> ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	linezolid	furazolidone
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , <e1> DRUG1 </e1> , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , <e2> DRUG2 </e2> , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	linezolid	quinidine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , <e1> DRUG1 </e1> , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , <e2> DRUG2 </e2> , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	linezolid	amantadine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , <e1> DRUG1 </e1> , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , <e2> DRUG2 </e2> (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	linezolid	antihistamines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , <e1> DRUG1 </e1> , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , <e2> DRUG2 </e2> ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	linezolid	diphenhydramine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , <e1> DRUG1 </e1> , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other <e2> DRUG2 </e2> , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	linezolid	anticholinergics
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , <e1> DRUG1 </e1> , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , <e2> DRUG2 </e2> supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	linezolid	potassium chloride
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , <e1> DRUG1 </e1> , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , <e2> DRUG2 </e2> , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	linezolid	antacids
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , <e1> DRUG1 </e1> , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , <e2> DRUG2 </e2> (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	linezolid	absorbent-type anti-diarrhea medicines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , <e1> DRUG1 </e1> , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , <e2> DRUG2 </e2> - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	linezolid	kaolin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , <e1> DRUG1 </e1> , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - <e2> DRUG2 </e2> ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	linezolid	pectin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , <e1> DRUG1 </e1> , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , <e2> DRUG2 </e2> (e.g. , chlorpromazine , promethazine ) . 	linezolid	phenothiazines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , <e1> DRUG1 </e1> , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , <e2> DRUG2 </e2> , promethazine ) . 	linezolid	chlorpromazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , <e1> DRUG1 </e1> , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , <e2> DRUG2 </e2> ) . 	linezolid	promethazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , <e1> DRUG1 </e1> , isocarboxazid , <e2> DRUG2 </e2> , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tranylcypromine	selegiline
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , <e1> DRUG1 </e1> , isocarboxazid , selegiline , <e2> DRUG2 </e2> ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tranylcypromine	furazolidone
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , <e1> DRUG1 </e1> , isocarboxazid , selegiline , furazolidone ) , <e2> DRUG2 </e2> , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tranylcypromine	quinidine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , <e1> DRUG1 </e1> , isocarboxazid , selegiline , furazolidone ) , quinidine , <e2> DRUG2 </e2> , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tranylcypromine	amantadine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , <e1> DRUG1 </e1> , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , <e2> DRUG2 </e2> (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tranylcypromine	antihistamines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , <e1> DRUG1 </e1> , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , <e2> DRUG2 </e2> ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tranylcypromine	diphenhydramine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , <e1> DRUG1 </e1> , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other <e2> DRUG2 </e2> , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tranylcypromine	anticholinergics
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , <e1> DRUG1 </e1> , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , <e2> DRUG2 </e2> supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tranylcypromine	potassium chloride
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , <e1> DRUG1 </e1> , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , <e2> DRUG2 </e2> , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tranylcypromine	antacids
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , <e1> DRUG1 </e1> , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , <e2> DRUG2 </e2> (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tranylcypromine	absorbent-type anti-diarrhea medicines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , <e1> DRUG1 </e1> , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , <e2> DRUG2 </e2> - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tranylcypromine	kaolin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , <e1> DRUG1 </e1> , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - <e2> DRUG2 </e2> ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	tranylcypromine	pectin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , <e1> DRUG1 </e1> , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , <e2> DRUG2 </e2> (e.g. , chlorpromazine , promethazine ) . 	tranylcypromine	phenothiazines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , <e1> DRUG1 </e1> , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , <e2> DRUG2 </e2> , promethazine ) . 	tranylcypromine	chlorpromazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , <e1> DRUG1 </e1> , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , <e2> DRUG2 </e2> ) . 	tranylcypromine	promethazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , <e1> DRUG1 </e1> , selegiline , <e2> DRUG2 </e2> ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	isocarboxazid	furazolidone
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , <e1> DRUG1 </e1> , selegiline , furazolidone ) , <e2> DRUG2 </e2> , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	isocarboxazid	quinidine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , <e1> DRUG1 </e1> , selegiline , furazolidone ) , quinidine , <e2> DRUG2 </e2> , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	isocarboxazid	amantadine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , <e1> DRUG1 </e1> , selegiline , furazolidone ) , quinidine , amantadine , <e2> DRUG2 </e2> (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	isocarboxazid	antihistamines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , <e1> DRUG1 </e1> , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , <e2> DRUG2 </e2> ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	isocarboxazid	diphenhydramine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , <e1> DRUG1 </e1> , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other <e2> DRUG2 </e2> , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	isocarboxazid	anticholinergics
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , <e1> DRUG1 </e1> , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , <e2> DRUG2 </e2> supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	isocarboxazid	potassium chloride
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , <e1> DRUG1 </e1> , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , <e2> DRUG2 </e2> , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	isocarboxazid	antacids
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , <e1> DRUG1 </e1> , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , <e2> DRUG2 </e2> (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	isocarboxazid	absorbent-type anti-diarrhea medicines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , <e1> DRUG1 </e1> , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , <e2> DRUG2 </e2> - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	isocarboxazid	kaolin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , <e1> DRUG1 </e1> , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - <e2> DRUG2 </e2> ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	isocarboxazid	pectin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , <e1> DRUG1 </e1> , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , <e2> DRUG2 </e2> (e.g. , chlorpromazine , promethazine ) . 	isocarboxazid	phenothiazines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , <e1> DRUG1 </e1> , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , <e2> DRUG2 </e2> , promethazine ) . 	isocarboxazid	chlorpromazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , <e1> DRUG1 </e1> , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , <e2> DRUG2 </e2> ) . 	isocarboxazid	promethazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , <e1> DRUG1 </e1> , furazolidone ) , <e2> DRUG2 </e2> , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	selegiline	quinidine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , <e1> DRUG1 </e1> , furazolidone ) , quinidine , <e2> DRUG2 </e2> , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	selegiline	amantadine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , <e1> DRUG1 </e1> , furazolidone ) , quinidine , amantadine , <e2> DRUG2 </e2> (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	selegiline	antihistamines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , <e1> DRUG1 </e1> , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , <e2> DRUG2 </e2> ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	selegiline	diphenhydramine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , <e1> DRUG1 </e1> , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other <e2> DRUG2 </e2> , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	selegiline	anticholinergics
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , <e1> DRUG1 </e1> , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , <e2> DRUG2 </e2> supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	selegiline	potassium chloride
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , <e1> DRUG1 </e1> , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , <e2> DRUG2 </e2> , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	selegiline	antacids
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , <e1> DRUG1 </e1> , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , <e2> DRUG2 </e2> (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	selegiline	absorbent-type anti-diarrhea medicines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , <e1> DRUG1 </e1> , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , <e2> DRUG2 </e2> - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	selegiline	kaolin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , <e1> DRUG1 </e1> , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - <e2> DRUG2 </e2> ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	selegiline	pectin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , <e1> DRUG1 </e1> , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , <e2> DRUG2 </e2> (e.g. , chlorpromazine , promethazine ) . 	selegiline	phenothiazines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , <e1> DRUG1 </e1> , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , <e2> DRUG2 </e2> , promethazine ) . 	selegiline	chlorpromazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , <e1> DRUG1 </e1> , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , <e2> DRUG2 </e2> ) . 	selegiline	promethazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , <e1> DRUG1 </e1> ) , <e2> DRUG2 </e2> , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	furazolidone	quinidine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , <e1> DRUG1 </e1> ) , quinidine , <e2> DRUG2 </e2> , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	furazolidone	amantadine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , <e1> DRUG1 </e1> ) , quinidine , amantadine , <e2> DRUG2 </e2> (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	furazolidone	antihistamines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , <e1> DRUG1 </e1> ) , quinidine , amantadine , antihistamines (e.g. , <e2> DRUG2 </e2> ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	furazolidone	diphenhydramine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , <e1> DRUG1 </e1> ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other <e2> DRUG2 </e2> , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	furazolidone	anticholinergics
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , <e1> DRUG1 </e1> ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , <e2> DRUG2 </e2> supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	furazolidone	potassium chloride
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , <e1> DRUG1 </e1> ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , <e2> DRUG2 </e2> , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	furazolidone	antacids
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , <e1> DRUG1 </e1> ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , <e2> DRUG2 </e2> (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	furazolidone	absorbent-type anti-diarrhea medicines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , <e1> DRUG1 </e1> ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , <e2> DRUG2 </e2> - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	furazolidone	kaolin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , <e1> DRUG1 </e1> ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - <e2> DRUG2 </e2> ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	furazolidone	pectin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , <e1> DRUG1 </e1> ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , <e2> DRUG2 </e2> (e.g. , chlorpromazine , promethazine ) . 	furazolidone	phenothiazines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , <e1> DRUG1 </e1> ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , <e2> DRUG2 </e2> , promethazine ) . 	furazolidone	chlorpromazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , <e1> DRUG1 </e1> ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , <e2> DRUG2 </e2> ) . 	furazolidone	promethazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , <e1> DRUG1 </e1> , amantadine , <e2> DRUG2 </e2> (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	quinidine	antihistamines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , <e1> DRUG1 </e1> , amantadine , antihistamines (e.g. , <e2> DRUG2 </e2> ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	quinidine	diphenhydramine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , <e1> DRUG1 </e1> , amantadine , antihistamines (e.g. , diphenhydramine ) , other <e2> DRUG2 </e2> , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	quinidine	anticholinergics
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , <e1> DRUG1 </e1> , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , <e2> DRUG2 </e2> supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	quinidine	potassium chloride
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , <e1> DRUG1 </e1> , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , <e2> DRUG2 </e2> , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	quinidine	antacids
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , <e1> DRUG1 </e1> , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , <e2> DRUG2 </e2> (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	quinidine	absorbent-type anti-diarrhea medicines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , <e1> DRUG1 </e1> , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , <e2> DRUG2 </e2> - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	quinidine	kaolin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , <e1> DRUG1 </e1> , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - <e2> DRUG2 </e2> ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	quinidine	pectin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , <e1> DRUG1 </e1> , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , <e2> DRUG2 </e2> (e.g. , chlorpromazine , promethazine ) . 	quinidine	phenothiazines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , <e1> DRUG1 </e1> , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , <e2> DRUG2 </e2> , promethazine ) . 	quinidine	chlorpromazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , <e1> DRUG1 </e1> , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , <e2> DRUG2 </e2> ) . 	quinidine	promethazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , <e1> DRUG1 </e1> , antihistamines (e.g. , <e2> DRUG2 </e2> ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	amantadine	diphenhydramine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , <e1> DRUG1 </e1> , antihistamines (e.g. , diphenhydramine ) , other <e2> DRUG2 </e2> , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	amantadine	anticholinergics
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , <e1> DRUG1 </e1> , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , <e2> DRUG2 </e2> supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	amantadine	potassium chloride
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , <e1> DRUG1 </e1> , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , <e2> DRUG2 </e2> , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	amantadine	antacids
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , <e1> DRUG1 </e1> , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , <e2> DRUG2 </e2> (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	amantadine	absorbent-type anti-diarrhea medicines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , <e1> DRUG1 </e1> , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , <e2> DRUG2 </e2> - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	amantadine	kaolin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , <e1> DRUG1 </e1> , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - <e2> DRUG2 </e2> ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	amantadine	pectin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , <e1> DRUG1 </e1> , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , <e2> DRUG2 </e2> (e.g. , chlorpromazine , promethazine ) . 	amantadine	phenothiazines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , <e1> DRUG1 </e1> , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , <e2> DRUG2 </e2> , promethazine ) . 	amantadine	chlorpromazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , <e1> DRUG1 </e1> , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , <e2> DRUG2 </e2> ) . 	amantadine	promethazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , <e1> DRUG1 </e1> (e.g. , <e2> DRUG2 </e2> ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antihistamines	diphenhydramine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , <e1> DRUG1 </e1> (e.g. , diphenhydramine ) , other <e2> DRUG2 </e2> , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antihistamines	anticholinergics
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , <e1> DRUG1 </e1> (e.g. , diphenhydramine ) , other anticholinergics , <e2> DRUG2 </e2> supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antihistamines	potassium chloride
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , <e1> DRUG1 </e1> (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , <e2> DRUG2 </e2> , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antihistamines	antacids
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , <e1> DRUG1 </e1> (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , <e2> DRUG2 </e2> (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antihistamines	absorbent-type anti-diarrhea medicines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , <e1> DRUG1 </e1> (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , <e2> DRUG2 </e2> - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antihistamines	kaolin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , <e1> DRUG1 </e1> (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - <e2> DRUG2 </e2> ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antihistamines	pectin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , <e1> DRUG1 </e1> (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , <e2> DRUG2 </e2> (e.g. , chlorpromazine , promethazine ) . 	antihistamines	phenothiazines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , <e1> DRUG1 </e1> (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , <e2> DRUG2 </e2> , promethazine ) . 	antihistamines	chlorpromazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , <e1> DRUG1 </e1> (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , <e2> DRUG2 </e2> ) . 	antihistamines	promethazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , <e1> DRUG1 </e1> ) , other <e2> DRUG2 </e2> , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	diphenhydramine	anticholinergics
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , <e1> DRUG1 </e1> ) , other anticholinergics , <e2> DRUG2 </e2> supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	diphenhydramine	potassium chloride
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , <e1> DRUG1 </e1> ) , other anticholinergics , potassium chloride supplements , <e2> DRUG2 </e2> , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	diphenhydramine	antacids
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , <e1> DRUG1 </e1> ) , other anticholinergics , potassium chloride supplements , antacids , <e2> DRUG2 </e2> (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	diphenhydramine	absorbent-type anti-diarrhea medicines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , <e1> DRUG1 </e1> ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , <e2> DRUG2 </e2> - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	diphenhydramine	kaolin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , <e1> DRUG1 </e1> ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - <e2> DRUG2 </e2> ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	diphenhydramine	pectin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , <e1> DRUG1 </e1> ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , <e2> DRUG2 </e2> (e.g. , chlorpromazine , promethazine ) . 	diphenhydramine	phenothiazines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , <e1> DRUG1 </e1> ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , <e2> DRUG2 </e2> , promethazine ) . 	diphenhydramine	chlorpromazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , <e1> DRUG1 </e1> ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , <e2> DRUG2 </e2> ) . 	diphenhydramine	promethazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other <e1> DRUG1 </e1> , potassium chloride supplements , <e2> DRUG2 </e2> , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	anticholinergics	antacids
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other <e1> DRUG1 </e1> , potassium chloride supplements , antacids , <e2> DRUG2 </e2> (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	anticholinergics	absorbent-type anti-diarrhea medicines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other <e1> DRUG1 </e1> , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , <e2> DRUG2 </e2> - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	anticholinergics	kaolin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other <e1> DRUG1 </e1> , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - <e2> DRUG2 </e2> ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	anticholinergics	pectin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other <e1> DRUG1 </e1> , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , <e2> DRUG2 </e2> (e.g. , chlorpromazine , promethazine ) . 	anticholinergics	phenothiazines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other <e1> DRUG1 </e1> , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , <e2> DRUG2 </e2> , promethazine ) . 	anticholinergics	chlorpromazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other <e1> DRUG1 </e1> , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , <e2> DRUG2 </e2> ) . 	anticholinergics	promethazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , <e1> DRUG1 </e1> supplements , <e2> DRUG2 </e2> , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	potassium chloride	antacids
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , <e1> DRUG1 </e1> supplements , antacids , <e2> DRUG2 </e2> (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	potassium chloride	absorbent-type anti-diarrhea medicines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , <e1> DRUG1 </e1> supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , <e2> DRUG2 </e2> - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	potassium chloride	kaolin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , <e1> DRUG1 </e1> supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - <e2> DRUG2 </e2> ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	potassium chloride	pectin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , <e1> DRUG1 </e1> supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , <e2> DRUG2 </e2> (e.g. , chlorpromazine , promethazine ) . 	potassium chloride	phenothiazines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , <e1> DRUG1 </e1> supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , <e2> DRUG2 </e2> , promethazine ) . 	potassium chloride	chlorpromazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , <e1> DRUG1 </e1> supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , <e2> DRUG2 </e2> ) . 	potassium chloride	promethazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , <e1> DRUG1 </e1> , absorbent-type anti-diarrhea medicines (e.g. , <e2> DRUG2 </e2> - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antacids	kaolin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , <e1> DRUG1 </e1> , absorbent-type anti-diarrhea medicines (e.g. , kaolin - <e2> DRUG2 </e2> ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	antacids	pectin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , <e1> DRUG1 </e1> , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , <e2> DRUG2 </e2> (e.g. , chlorpromazine , promethazine ) . 	antacids	phenothiazines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , <e1> DRUG1 </e1> , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , <e2> DRUG2 </e2> , promethazine ) . 	antacids	chlorpromazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , <e1> DRUG1 </e1> , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , <e2> DRUG2 </e2> ) . 	antacids	promethazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , <e1> DRUG1 </e1> (e.g. , <e2> DRUG2 </e2> - pectin ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	absorbent-type anti-diarrhea medicines	kaolin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , <e1> DRUG1 </e1> (e.g. , kaolin - <e2> DRUG2 </e2> ) , phenothiazines (e.g. , chlorpromazine , promethazine ) . 	absorbent-type anti-diarrhea medicines	pectin
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , <e1> DRUG1 </e1> (e.g. , kaolin - pectin ) , <e2> DRUG2 </e2> (e.g. , chlorpromazine , promethazine ) . 	absorbent-type anti-diarrhea medicines	phenothiazines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , <e1> DRUG1 </e1> (e.g. , kaolin - pectin ) , phenothiazines (e.g. , <e2> DRUG2 </e2> , promethazine ) . 	absorbent-type anti-diarrhea medicines	chlorpromazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , <e1> DRUG1 </e1> (e.g. , kaolin - pectin ) , phenothiazines (e.g. , chlorpromazine , <e2> DRUG2 </e2> ) . 	absorbent-type anti-diarrhea medicines	promethazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , <e1> DRUG1 </e1> - pectin ) , <e2> DRUG2 </e2> (e.g. , chlorpromazine , promethazine ) . 	kaolin	phenothiazines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , <e1> DRUG1 </e1> - pectin ) , phenothiazines (e.g. , <e2> DRUG2 </e2> , promethazine ) . 	kaolin	chlorpromazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , <e1> DRUG1 </e1> - pectin ) , phenothiazines (e.g. , chlorpromazine , <e2> DRUG2 </e2> ) . 	kaolin	promethazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - <e1> DRUG1 </e1> ) , <e2> DRUG2 </e2> (e.g. , chlorpromazine , promethazine ) . 	pectin	phenothiazines
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - <e1> DRUG1 </e1> ) , phenothiazines (e.g. , <e2> DRUG2 </e2> , promethazine ) . 	pectin	chlorpromazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - <e1> DRUG1 </e1> ) , phenothiazines (e.g. , chlorpromazine , <e2> DRUG2 </e2> ) . 	pectin	promethazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , <e1> DRUG1 </e1> (e.g. , <e2> DRUG2 </e2> , promethazine ) . 	phenothiazines	chlorpromazine
other	Methscopolamine may interact with antidepressants ( tricyclic type) , MAO inhibitors (e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines (e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines (e.g. , kaolin - pectin ) , <e1> DRUG1 </e1> (e.g. , chlorpromazine , <e2> DRUG2 </e2> ) . 	phenothiazines	promethazine
other	Concurrent use of <e1> DRUG1 </e1> and other <e2> DRUG2 </e2> may increase the CNS depressant effects of methyprylon or these other medications . 	alcohol	CNS depression-producing drugs
effect	Concurrent use of <e1> DRUG1 </e1> and other CNS depression-producing drugs may increase the CNS depressant effects of <e2> DRUG2 </e2> or these other medications . 	alcohol	methyprylon
effect	Concurrent use of alcohol and other <e1> DRUG1 </e1> may increase the CNS depressant effects of <e2> DRUG2 </e2> or these other medications . 	CNS depression-producing drugs	methyprylon
effect	<e1> DRUG1 </e1> may reverse the analgesic activity of <e2> DRUG2 </e2> . 	Methysergide	narcotic analgesics
other	Concurrent use with <e1> DRUG1 </e1> including <e2> DRUG2 </e2> , sumatriptan , and nicotine (e.g . smoking) may result in enhanced vasoconstriction . 	vasoconstrictor agents	ergot alkaloids
other	Concurrent use with <e1> DRUG1 </e1> including ergot alkaloids , <e2> DRUG2 </e2> , and nicotine (e.g . smoking) may result in enhanced vasoconstriction . 	vasoconstrictor agents	sumatriptan
other	Concurrent use with <e1> DRUG1 </e1> including ergot alkaloids , sumatriptan , and <e2> DRUG2 </e2> (e.g . smoking) may result in enhanced vasoconstriction . 	vasoconstrictor agents	nicotine
other	Concurrent use with vasoconstrictor agents including <e1> DRUG1 </e1> , sumatriptan , and <e2> DRUG2 </e2> (e.g . smoking) may result in enhanced vasoconstriction . 	ergot alkaloids	nicotine
other	Concurrent use with vasoconstrictor agents including ergot alkaloids , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> (e.g . smoking) may result in enhanced vasoconstriction . 	sumatriptan	nicotine
effect	The effects of <e1> DRUG1 </e1> on gastrointestinal motility are antagonized by <e2> DRUG2 </e2> and narcotic analgesics . 	metoclopramide	anticholinergic drugs
effect	The effects of <e1> DRUG1 </e1> on gastrointestinal motility are antagonized by anticholinergic drugs and <e2> DRUG2 </e2> . 	metoclopramide	narcotic analgesics
other	The effects of metoclopramide on gastrointestinal motility are antagonized by <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	anticholinergic drugs	narcotic analgesics
effect	Additive sedative effects can occur when <e1> DRUG1 </e1> is given with <e2> DRUG2 </e2> , sedatives , hypnotics , narcotics , or tranquilizers . 	metoclopramide	alcohol
effect	Additive sedative effects can occur when <e1> DRUG1 </e1> is given with alcohol , <e2> DRUG2 </e2> , hypnotics , narcotics , or tranquilizers . 	metoclopramide	sedatives
effect	Additive sedative effects can occur when <e1> DRUG1 </e1> is given with alcohol , sedatives , <e2> DRUG2 </e2> , narcotics , or tranquilizers . 	metoclopramide	hypnotics
effect	Additive sedative effects can occur when <e1> DRUG1 </e1> is given with alcohol , sedatives , hypnotics , <e2> DRUG2 </e2> , or tranquilizers . 	metoclopramide	narcotics
effect	Additive sedative effects can occur when <e1> DRUG1 </e1> is given with alcohol , sedatives , hypnotics , narcotics , or <e2> DRUG2 </e2> . 	metoclopramide	tranquilizers
other	Additive sedative effects can occur when metoclopramide is given with <e1> DRUG1 </e1> , sedatives , <e2> DRUG2 </e2> , narcotics , or tranquilizers . 	alcohol	hypnotics
other	Additive sedative effects can occur when metoclopramide is given with <e1> DRUG1 </e1> , sedatives , hypnotics , <e2> DRUG2 </e2> , or tranquilizers . 	alcohol	narcotics
other	Additive sedative effects can occur when metoclopramide is given with <e1> DRUG1 </e1> , sedatives , hypnotics , narcotics , or <e2> DRUG2 </e2> . 	alcohol	tranquilizers
other	Additive sedative effects can occur when metoclopramide is given with alcohol , <e1> DRUG1 </e1> , hypnotics , <e2> DRUG2 </e2> , or tranquilizers . 	sedatives	narcotics
other	Additive sedative effects can occur when metoclopramide is given with alcohol , <e1> DRUG1 </e1> , hypnotics , narcotics , or <e2> DRUG2 </e2> . 	sedatives	tranquilizers
other	Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , <e1> DRUG1 </e1> , narcotics , or <e2> DRUG2 </e2> . 	hypnotics	tranquilizers
advise	The finding that <e1> DRUG1 </e1> releases catecholamines in patients with essential hypertension suggests that it should be used cautiously , if at all , in patients receiving <e2> DRUG2 </e2> . 	metoclopramide	monoamine oxi-dase inhibitors
mechanism	Absorption of drugs from the stomach may be diminished (e.g. , <e1> DRUG1 </e1> ) by <e2> DRUG2 </e2> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) . 	digoxin	metoclopramide
other	Absorption of drugs from the stomach may be diminished (e.g. , <e1> DRUG1 </e1> ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g. , <e2> DRUG2 </e2> , tetracycline , levodopa , ethanol , cyclosporine ) . 	digoxin	acetaminophen
other	Absorption of drugs from the stomach may be diminished (e.g. , <e1> DRUG1 </e1> ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g. , acetaminophen , <e2> DRUG2 </e2> , levodopa , ethanol , cyclosporine ) . 	digoxin	tetracycline
other	Absorption of drugs from the stomach may be diminished (e.g. , <e1> DRUG1 </e1> ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g. , acetaminophen , tetracycline , <e2> DRUG2 </e2> , ethanol , cyclosporine ) . 	digoxin	levodopa
other	Absorption of drugs from the stomach may be diminished (e.g. , <e1> DRUG1 </e1> ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g. , acetaminophen , tetracycline , levodopa , <e2> DRUG2 </e2> , cyclosporine ) . 	digoxin	ethanol
other	Absorption of drugs from the stomach may be diminished (e.g. , <e1> DRUG1 </e1> ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g. , acetaminophen , tetracycline , levodopa , ethanol , <e2> DRUG2 </e2> ) . 	digoxin	cyclosporine
mechanism	Absorption of drugs from the stomach may be diminished (e.g. , digoxin ) by <e1> DRUG1 </e1> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g. , <e2> DRUG2 </e2> , tetracycline , levodopa , ethanol , cyclosporine ) . 	metoclopramide	acetaminophen
other	Absorption of drugs from the stomach may be diminished (e.g. , digoxin ) by <e1> DRUG1 </e1> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g. , acetaminophen , <e2> DRUG2 </e2> , levodopa , ethanol , cyclosporine ) . 	metoclopramide	tetracycline
other	Absorption of drugs from the stomach may be diminished (e.g. , digoxin ) by <e1> DRUG1 </e1> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g. , acetaminophen , tetracycline , <e2> DRUG2 </e2> , ethanol , cyclosporine ) . 	metoclopramide	levodopa
other	Absorption of drugs from the stomach may be diminished (e.g. , digoxin ) by <e1> DRUG1 </e1> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g. , acetaminophen , tetracycline , levodopa , <e2> DRUG2 </e2> , cyclosporine ) . 	metoclopramide	ethanol
other	Absorption of drugs from the stomach may be diminished (e.g. , digoxin ) by <e1> DRUG1 </e1> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g. , acetaminophen , tetracycline , levodopa , ethanol , <e2> DRUG2 </e2> ) . 	metoclopramide	cyclosporine
other	Absorption of drugs from the stomach may be diminished (e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g. , <e1> DRUG1 </e1> , tetracycline , <e2> DRUG2 </e2> , ethanol , cyclosporine ) . 	acetaminophen	levodopa
other	Absorption of drugs from the stomach may be diminished (e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g. , <e1> DRUG1 </e1> , tetracycline , levodopa , <e2> DRUG2 </e2> , cyclosporine ) . 	acetaminophen	ethanol
other	Absorption of drugs from the stomach may be diminished (e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g. , <e1> DRUG1 </e1> , tetracycline , levodopa , ethanol , <e2> DRUG2 </e2> ) . 	acetaminophen	cyclosporine
other	Absorption of drugs from the stomach may be diminished (e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g. , acetaminophen , <e1> DRUG1 </e1> , levodopa , <e2> DRUG2 </e2> , cyclosporine ) . 	tetracycline	ethanol
other	Absorption of drugs from the stomach may be diminished (e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g. , acetaminophen , <e1> DRUG1 </e1> , levodopa , ethanol , <e2> DRUG2 </e2> ) . 	tetracycline	cyclosporine
other	Absorption of drugs from the stomach may be diminished (e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g. , acetaminophen , tetracycline , <e1> DRUG1 </e1> , ethanol , <e2> DRUG2 </e2> ) . 	levodopa	cyclosporine
advise	Because the action of <e1> DRUG1 </e1> will influence the delivery of food to the intestines and thus the rate of absorption , <e2> DRUG2 </e2> dosage or timing of dosage may require adjustment . 	metoclopramide	insulin
other	<e1> DRUG1 </e1> : <e2> DRUG2 </e2> and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes . 	Diuretics	Furosemide
other	<e1> DRUG1 </e1> : Furosemide and probably other <e2> DRUG2 </e2> given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes . 	Diuretics	loop diuretics
other	<e1> DRUG1 </e1> : Furosemide and probably other loop diuretics given concomitantly with <e2> DRUG2 </e2> can cause unusually large or prolonged losses of fluid and electrolytes . 	Diuretics	metolazone
other	Diuretics : <e1> DRUG1 </e1> and probably other <e2> DRUG2 </e2> given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes . 	Furosemide	loop diuretics
effect	Diuretics : <e1> DRUG1 </e1> and probably other loop diuretics given concomitantly with <e2> DRUG2 </e2> can cause unusually large or prolonged losses of fluid and electrolytes . 	Furosemide	metolazone
effect	Diuretics : Furosemide and probably other <e1> DRUG1 </e1> given concomitantly with <e2> DRUG2 </e2> can cause unusually large or prolonged losses of fluid and electrolytes . 	loop diuretics	metolazone
other	Other <e1> DRUG1 </e1> : When <e2> DRUG2 </e2> Tablets are used with other antihypertensive drugs , care must be taken , especially during initial therapy . 	Antihypertensives	MYKROX
other	<e1> DRUG1 </e1> , Barbiturates , and <e2> DRUG2 </e2> : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy . 	Alcohol	Narcotics
other	<e1> DRUG1 </e1> , Barbiturates , and Narcotics : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with <e2> DRUG2 </e2> therapy . 	Alcohol	metolazone
other	Alcohol , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy . 	Barbiturates	Narcotics
other	Alcohol , <e1> DRUG1 </e1> , and Narcotics : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with <e2> DRUG2 </e2> therapy . 	Barbiturates	metolazone
other	Alcohol , Barbiturates , and <e1> DRUG1 </e1> : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with <e2> DRUG2 </e2> therapy . 	Narcotics	metolazone
other	<e1> DRUG1 </e1> : <e2> DRUG2 </e2> -induced hypokalemia can increase the sensitivity of the myocardium to digitalis . 	Digitalis Glycosides	Diuretic
other	<e1> DRUG1 </e1> : Diuretic -induced hypokalemia can increase the sensitivity of the myocardium to <e2> DRUG2 </e2> . 	Digitalis Glycosides	digitalis
effect	Digitalis Glycosides : <e1> DRUG1 </e1> -induced hypokalemia can increase the sensitivity of the myocardium to <e2> DRUG2 </e2> . 	Diuretic	digitalis
other	<e1> DRUG1 </e1> : <e2> DRUG2 </e2> -induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine ) the most serious effect would be respiratory depression which could proceed to apnea . 	Curariform Drugs	Diuretic
other	<e1> DRUG1 </e1> : Diuretic -induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as <e2> DRUG2 </e2> ) the most serious effect would be respiratory depression which could proceed to apnea . 	Curariform Drugs	tubocurarine
effect	Curariform Drugs : <e1> DRUG1 </e1> -induced hypokalemia may enhance neuromuscular blocking effects of <e2> DRUG2 </e2> (such as tubocurarine ) the most serious effect would be respiratory depression which could proceed to apnea . 	Diuretic	curariform drugs
effect	Curariform Drugs : <e1> DRUG1 </e1> -induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as <e2> DRUG2 </e2> ) the most serious effect would be respiratory depression which could proceed to apnea . 	Diuretic	tubocurarine
other	Curariform Drugs : Diuretic -induced hypokalemia may enhance neuromuscular blocking effects of <e1> DRUG1 </e1> (such as <e2> DRUG2 </e2> ) the most serious effect would be respiratory depression which could proceed to apnea . 	curariform drugs	tubocurarine
other	<e1> DRUG1 </e1> and Other <e2> DRUG2 </e2> : May decrease the antihypertensive effects of MYKROX Tablets . 	Salicylates	Non-Steroidal Anti-Inflammatory Drugs
effect	<e1> DRUG1 </e1> and Other Non-Steroidal Anti-Inflammatory Drugs : May decrease the antihypertensive effects of <e2> DRUG2 </e2> Tablets . 	Salicylates	MYKROX
effect	Salicylates and Other <e1> DRUG1 </e1> : May decrease the antihypertensive effects of <e2> DRUG2 </e2> Tablets . 	Non-Steroidal Anti-Inflammatory Drugs	MYKROX
other	<e1> DRUG1 </e1> : <e2> DRUG2 </e2> may decrease arterial responsiveness to norepinephrine , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use . 	Sympathomimetics	Metolazone
other	<e1> DRUG1 </e1> : Metolazone may decrease arterial responsiveness to <e2> DRUG2 </e2> , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use . 	Sympathomimetics	norepinephrine
effect	Sympathomimetics : <e1> DRUG1 </e1> may decrease arterial responsiveness to <e2> DRUG2 </e2> , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use . 	Metolazone	norepinephrine
effect	<e1> DRUG1 </e1> : Efficacy may be decreased due to urinary alkalizing effect of <e2> DRUG2 </e2> . 	Methenamine	metolazone
other	<e1> DRUG1 </e1> : <e2> DRUG2 </e2> , as well as other thiazide-like diuretics , may affect the hypoprothrombinemic response to anticoagulants ; 	Anticoagulants	Metolazone
other	<e1> DRUG1 </e1> : Metolazone , as well as other <e2> DRUG2 </e2> , may affect the hypoprothrombinemic response to anticoagulants ; 	Anticoagulants	thiazide-like diuretics
other	Anticoagulants : <e1> DRUG1 </e1> , as well as other <e2> DRUG2 </e2> , may affect the hypoprothrombinemic response to anticoagulants ; 	Metolazone	thiazide-like diuretics
effect	Anticoagulants : <e1> DRUG1 </e1> , as well as other thiazide-like diuretics , may affect the hypoprothrombinemic response to <e2> DRUG2 </e2> ; 	Metolazone	anticoagulants
other	Anticoagulants : Metolazone , as well as other <e1> DRUG1 </e1> , may affect the hypoprothrombinemic response to <e2> DRUG2 </e2> ; 	thiazide-like diuretics	anticoagulants
effect	Catecholamine-depleting drugs (e.g. , <e1> DRUG1 </e1> ) may have an additive effect when given with <e2> DRUG2 </e2> . 	reserpine	beta-blocking agents
effect	Oral <e1> DRUG1 </e1> has been reported to potentiate the anticoagulant effect of <e2> DRUG2 </e2> and warfarin , resulting in a prolongation of prothrombin time . 	metronidazole	coumarin
effect	Oral <e1> DRUG1 </e1> has been reported to potentiate the anticoagulant effect of coumarin and <e2> DRUG2 </e2> , resulting in a prolongation of prothrombin time . 	metronidazole	warfarin
other	Oral metronidazole has been reported to potentiate the anticoagulant effect of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> , resulting in a prolongation of prothrombin time . 	coumarin	warfarin
other	Drug interactions should be kept in mind when <e1> DRUG1 </e1> ( metronidazole gel) , 1% is prescribed for patients who are receiving anticoagulant treatment , although they are less likely to occur with topical <e2> DRUG2 </e2> administration because of low absorption . 	METROGEL	metronidazole
mechanism	The metabolism of <e1> DRUG1 </e1> is accelerated by <e2> DRUG2 </e2> ; 	Metopirone	phenytoin
mechanism	<e1> DRUG1 </e1> inhibits the glucuronidation of <e2> DRUG2 </e2> and could possibly potentiate acetaminophen toxicity . 	Metopirone	acetaminophen
effect	<e1> DRUG1 </e1> inhibits the glucuronidation of acetaminophen and could possibly potentiate <e2> DRUG2 </e2> toxicity . 	Metopirone	acetaminophen
advise	Caution should be observed in administering <e1> DRUG1 </e1> to patients receiving <e2> DRUG2 </e2> or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis . 	DEMSER	phenothiazines
advise	Caution should be observed in administering <e1> DRUG1 </e1> to patients receiving phenothiazines or <e2> DRUG2 </e2> because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis . 	DEMSER	haloperidol
effect	Concurrent use of <e1> DRUG1 </e1> with <e2> DRUG2 </e2> or other CNS depressants can increase their sedative effects . 	DEMSER	alcohol
effect	Concurrent use of <e1> DRUG1 </e1> with alcohol or other <e2> DRUG2 </e2> can increase their sedative effects . 	DEMSER	CNS depressants
other	Concurrent use of DEMSER with <e1> DRUG1 </e1> or other <e2> DRUG2 </e2> can increase their sedative effects . 	alcohol	CNS depressants
other	Since <e1> DRUG1 </e1> is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes , inhibition or induction of either of these enzymes would be expected to alter <e2> DRUG2 </e2> plasma concentrations . 	MEXITIL	mexiletine
mechanism	In a formal , single-dose interaction study (n = 6 males) the clearance of <e1> DRUG1 </e1> was decreased by 38% following the coadministration of <e2> DRUG2 </e2> , an inhibitor of CYP1A2 . 	mexiletine	fluvoxamine
other	In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6) , coadministration of <e1> DRUG1 </e1> did not alter the kinetics of <e2> DRUG2 </e2> in the poor CYP2D6 metabolizer group . 	propafenone	mexiletine
other	In this crossover steady state study , the pharmacokinetics of <e1> DRUG1 </e1> were unaffected in either phenotype by the coadministration of <e2> DRUG2 </e2> . 	propafenone	mexiletine
other	Addition of <e1> DRUG1 </e1> to <e2> DRUG2 </e2> did not lead to further electrocardiographic parameters changes of QRS , QTc , RR , and PR intervals than propafenone alone . 	mexiletine	propafenone
other	Addition of <e1> DRUG1 </e1> to propafenone did not lead to further electrocardiographic parameters changes of QRS , QTc , RR , and PR intervals than <e2> DRUG2 </e2> alone . 	mexiletine	propafenone
other	In a large compassionate use program <e1> DRUG1 </e1> has been used concurrently with commonly employed antianginal , <e2> DRUG2 </e2> , and anticoagulant drugs without observed interactions . 	Mexitil	antihypertensive
other	In a large compassionate use program <e1> DRUG1 </e1> has been used concurrently with commonly employed antianginal , antihypertensive , and <e2> DRUG2 </e2> without observed interactions . 	Mexitil	anticoagulant drugs
other	In a large compassionate use program Mexitil has been used concurrently with commonly employed antianginal , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> without observed interactions . 	antihypertensive	anticoagulant drugs
other	A variety of <e1> DRUG1 </e1> such as quinidine or <e2> DRUG2 </e2> were also added , sometimes with improved control of ventricular ectopy . 	antiarrhythmics	propranolol
other	When <e1> DRUG1 </e1> or other hepatic enzyme inducers such as <e2> DRUG2 </e2> and phenobarbital have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported . 	phenytoin	rifampin
other	When <e1> DRUG1 </e1> or other hepatic enzyme inducers such as rifampin and <e2> DRUG2 </e2> have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported . 	phenytoin	phenobarbital
mechanism	When <e1> DRUG1 </e1> or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with <e2> DRUG2 </e2> , lowered Mexitil plasma levels have been reported . 	phenytoin	Mexitil
other	When <e1> DRUG1 </e1> or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil , lowered <e2> DRUG2 </e2> plasma levels have been reported . 	phenytoin	Mexitil
other	When phenytoin or other hepatic enzyme inducers such as <e1> DRUG1 </e1> and <e2> DRUG2 </e2> have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported . 	rifampin	phenobarbital
mechanism	When phenytoin or other hepatic enzyme inducers such as <e1> DRUG1 </e1> and phenobarbital have been taken concurrently with <e2> DRUG2 </e2> , lowered Mexitil plasma levels have been reported . 	rifampin	Mexitil
other	When phenytoin or other hepatic enzyme inducers such as <e1> DRUG1 </e1> and phenobarbital have been taken concurrently with Mexitil , lowered <e2> DRUG2 </e2> plasma levels have been reported . 	rifampin	Mexitil
mechanism	When phenytoin or other hepatic enzyme inducers such as rifampin and <e1> DRUG1 </e1> have been taken concurrently with <e2> DRUG2 </e2> , lowered Mexitil plasma levels have been reported . 	phenobarbital	Mexitil
other	When phenytoin or other hepatic enzyme inducers such as rifampin and <e1> DRUG1 </e1> have been taken concurrently with Mexitil , lowered <e2> DRUG2 </e2> plasma levels have been reported . 	phenobarbital	Mexitil
other	In a formal study , <e1> DRUG1 </e1> were shown not to affect <e2> DRUG2 </e2> plasma concentrations . 	benzodiazepines	Mexitil
other	ECG intervals (PR , QRS , and QT) were not affected by concurrent <e1> DRUG1 </e1> and <e2> DRUG2 </e2> , diuretics , or propranolol . 	Mexitil	digoxin
other	ECG intervals (PR , QRS , and QT) were not affected by concurrent <e1> DRUG1 </e1> and digoxin , <e2> DRUG2 </e2> , or propranolol . 	Mexitil	diuretics
other	ECG intervals (PR , QRS , and QT) were not affected by concurrent <e1> DRUG1 </e1> and digoxin , diuretics , or <e2> DRUG2 </e2> . 	Mexitil	propranolol
other	ECG intervals (PR , QRS , and QT) were not affected by concurrent Mexitil and <e1> DRUG1 </e1> , diuretics , or <e2> DRUG2 </e2> . 	digoxin	propranolol
mechanism	Concurrent administration of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> has been reported to increase , decrease , or leave unchanged Mexitil plasma levels; 	cimetidine	Mexitil
other	Concurrent administration of <e1> DRUG1 </e1> and Mexitil has been reported to increase , decrease , or leave unchanged <e2> DRUG2 </e2> plasma levels; 	cimetidine	Mexitil
other	<e1> DRUG1 </e1> does not alter serum <e2> DRUG2 </e2> levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels . 	Mexitil	digoxin
other	<e1> DRUG1 </e1> does not alter serum digoxin levels but <e2> DRUG2 </e2> , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels . 	Mexitil	magnesium-aluminum hydroxide
other	<e1> DRUG1 </e1> does not alter serum digoxin levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum <e2> DRUG2 </e2> levels . 	Mexitil	digoxin
other	Mexitil does not alter serum <e1> DRUG1 </e1> levels but <e2> DRUG2 </e2> , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels . 	digoxin	magnesium-aluminum hydroxide
other	Mexitil does not alter serum <e1> DRUG1 </e1> levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to <e2> DRUG2 </e2> , has been reported to lower serum digoxin levels . 	digoxin	Mexitil
other	Mexitil does not alter serum digoxin levels but <e1> DRUG1 </e1> , when used to treat gastrointestinal symptoms due to <e2> DRUG2 </e2> , has been reported to lower serum digoxin levels . 	magnesium-aluminum hydroxide	Mexitil
mechanism	Mexitil does not alter serum digoxin levels but <e1> DRUG1 </e1> , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum <e2> DRUG2 </e2> levels . 	magnesium-aluminum hydroxide	digoxin
other	Mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to <e1> DRUG1 </e1> , has been reported to lower serum <e2> DRUG2 </e2> levels . 	Mexitil	digoxin
mechanism	Concurrent use of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> may lead to increased plasma theophylline levels . 	Mexitil	theophylline
other	Concurrent use of <e1> DRUG1 </e1> and theophylline may lead to increased plasma <e2> DRUG2 </e2> levels . 	Mexitil	theophylline
other	This increase was observed at the first test point which was the second day after starting Mexitil . <e1> DRUG1 </e1> plasma levels returned to pre- <e2> DRUG2 </e2> values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 	Theophylline	Mexitil
mechanism	This increase was observed at the first test point which was the second day after starting Mexitil . <e1> DRUG1 </e1> plasma levels returned to pre- Mexitil values within 48 hours after discontinuing <e2> DRUG2 </e2> . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 	Theophylline	Mexitil
advise	This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre- Mexitil values within 48 hours after discontinuing Mexitil . If <e1> DRUG1 </e1> and <e2> DRUG2 </e2> are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 	Mexitil	theophylline
other	This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre- Mexitil values within 48 hours after discontinuing Mexitil . If <e1> DRUG1 </e1> and theophylline are to be used concurrently , <e2> DRUG2 </e2> blood levels should be monitored , particularly when the Mexitil dose is changed . 	Mexitil	theophylline
other	This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre- Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and <e1> DRUG1 </e1> are to be used concurrently , theophylline blood levels should be monitored , particularly when the <e2> DRUG2 </e2> dose is changed . 	theophylline	Mexitil
other	This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre- Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , <e1> DRUG1 </e1> blood levels should be monitored , particularly when the <e2> DRUG2 </e2> dose is changed . 	theophylline	Mexitil
mechanism	Additionally , in one controlled study in five normal subjects and seven patients , the clearance of <e1> DRUG1 </e1> was decreased 50% following the administration of <e2> DRUG2 </e2> . 	caffeine	Mexitil
mechanism	<e1> DRUG1 </e1> inhibits some of the liver's ability to metabolize some other drugs - <e2> DRUG2 </e2> , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 	Posicor	terfenadine
mechanism	<e1> DRUG1 </e1> inhibits some of the liver's ability to metabolize some other drugs - terfenadine , <e2> DRUG2 </e2> , cisapride , cyclosporine , and tricyclic antidepressants . 	Posicor	astemizole
mechanism	<e1> DRUG1 </e1> inhibits some of the liver's ability to metabolize some other drugs - terfenadine , astemizole , <e2> DRUG2 </e2> , cyclosporine , and tricyclic antidepressants . 	Posicor	cisapride
mechanism	<e1> DRUG1 </e1> inhibits some of the liver's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , <e2> DRUG2 </e2> , and tricyclic antidepressants . 	Posicor	cyclosporine
mechanism	<e1> DRUG1 </e1> inhibits some of the liver's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and <e2> DRUG2 </e2> . 	Posicor	tricyclic antidepressants
other	Posicor inhibits some of the liver's ability to metabolize some other drugs - <e1> DRUG1 </e1> , astemizole , <e2> DRUG2 </e2> , cyclosporine , and tricyclic antidepressants . 	terfenadine	cisapride
other	Posicor inhibits some of the liver's ability to metabolize some other drugs - <e1> DRUG1 </e1> , astemizole , cisapride , <e2> DRUG2 </e2> , and tricyclic antidepressants . 	terfenadine	cyclosporine
other	Posicor inhibits some of the liver's ability to metabolize some other drugs - <e1> DRUG1 </e1> , astemizole , cisapride , cyclosporine , and <e2> DRUG2 </e2> . 	terfenadine	tricyclic antidepressants
other	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine , <e1> DRUG1 </e1> , cisapride , <e2> DRUG2 </e2> , and tricyclic antidepressants . 	astemizole	cyclosporine
other	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine , <e1> DRUG1 </e1> , cisapride , cyclosporine , and <e2> DRUG2 </e2> . 	astemizole	tricyclic antidepressants
other	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine , astemizole , <e1> DRUG1 </e1> , cyclosporine , and <e2> DRUG2 </e2> . 	cisapride	tricyclic antidepressants
other	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> . 	cyclosporine	tricyclic antidepressants
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1> DRUG1 </e1> and <e2> DRUG2 </e2> , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 	MYCAMINE	mycophenolate mofetil
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1> DRUG1 </e1> and mycophenolate mofetil , <e2> DRUG2 </e2> , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 	MYCAMINE	cyclosporine
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1> DRUG1 </e1> and mycophenolate mofetil , cyclosporine , <e2> DRUG2 </e2> , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 	MYCAMINE	tacrolimus
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1> DRUG1 </e1> and mycophenolate mofetil , cyclosporine , tacrolimus , <e2> DRUG2 </e2> , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 	MYCAMINE	prednisolone
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1> DRUG1 </e1> and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , <e2> DRUG2 </e2> , nifedipine , fluconazole , ritonavir , and rifampin . 	MYCAMINE	sirolimus
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1> DRUG1 </e1> and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , <e2> DRUG2 </e2> , fluconazole , ritonavir , and rifampin . 	MYCAMINE	nifedipine
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1> DRUG1 </e1> and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , <e2> DRUG2 </e2> , ritonavir , and rifampin . 	MYCAMINE	fluconazole
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1> DRUG1 </e1> and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , <e2> DRUG2 </e2> , and rifampin . 	MYCAMINE	ritonavir
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1> DRUG1 </e1> and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and <e2> DRUG2 </e2> . 	MYCAMINE	rifampin
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1> DRUG1 </e1> , cyclosporine , <e2> DRUG2 </e2> , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 	mycophenolate mofetil	tacrolimus
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1> DRUG1 </e1> , cyclosporine , tacrolimus , <e2> DRUG2 </e2> , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 	mycophenolate mofetil	prednisolone
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1> DRUG1 </e1> , cyclosporine , tacrolimus , prednisolone , <e2> DRUG2 </e2> , nifedipine , fluconazole , ritonavir , and rifampin . 	mycophenolate mofetil	sirolimus
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1> DRUG1 </e1> , cyclosporine , tacrolimus , prednisolone , sirolimus , <e2> DRUG2 </e2> , fluconazole , ritonavir , and rifampin . 	mycophenolate mofetil	nifedipine
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1> DRUG1 </e1> , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , <e2> DRUG2 </e2> , ritonavir , and rifampin . 	mycophenolate mofetil	fluconazole
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1> DRUG1 </e1> , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , <e2> DRUG2 </e2> , and rifampin . 	mycophenolate mofetil	ritonavir
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1> DRUG1 </e1> , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and <e2> DRUG2 </e2> . 	mycophenolate mofetil	rifampin
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , <e1> DRUG1 </e1> , tacrolimus , <e2> DRUG2 </e2> , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 	cyclosporine	prednisolone
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , <e1> DRUG1 </e1> , tacrolimus , prednisolone , <e2> DRUG2 </e2> , nifedipine , fluconazole , ritonavir , and rifampin . 	cyclosporine	sirolimus
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , <e1> DRUG1 </e1> , tacrolimus , prednisolone , sirolimus , <e2> DRUG2 </e2> , fluconazole , ritonavir , and rifampin . 	cyclosporine	nifedipine
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , <e1> DRUG1 </e1> , tacrolimus , prednisolone , sirolimus , nifedipine , <e2> DRUG2 </e2> , ritonavir , and rifampin . 	cyclosporine	fluconazole
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , <e1> DRUG1 </e1> , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , <e2> DRUG2 </e2> , and rifampin . 	cyclosporine	ritonavir
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , <e1> DRUG1 </e1> , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and <e2> DRUG2 </e2> . 	cyclosporine	rifampin
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , <e1> DRUG1 </e1> , prednisolone , <e2> DRUG2 </e2> , nifedipine , fluconazole , ritonavir , and rifampin . 	tacrolimus	sirolimus
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , <e1> DRUG1 </e1> , prednisolone , sirolimus , <e2> DRUG2 </e2> , fluconazole , ritonavir , and rifampin . 	tacrolimus	nifedipine
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , <e1> DRUG1 </e1> , prednisolone , sirolimus , nifedipine , <e2> DRUG2 </e2> , ritonavir , and rifampin . 	tacrolimus	fluconazole
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , <e1> DRUG1 </e1> , prednisolone , sirolimus , nifedipine , fluconazole , <e2> DRUG2 </e2> , and rifampin . 	tacrolimus	ritonavir
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , <e1> DRUG1 </e1> , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and <e2> DRUG2 </e2> . 	tacrolimus	rifampin
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , <e1> DRUG1 </e1> , sirolimus , <e2> DRUG2 </e2> , fluconazole , ritonavir , and rifampin . 	prednisolone	nifedipine
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , <e1> DRUG1 </e1> , sirolimus , nifedipine , <e2> DRUG2 </e2> , ritonavir , and rifampin . 	prednisolone	fluconazole
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , <e1> DRUG1 </e1> , sirolimus , nifedipine , fluconazole , <e2> DRUG2 </e2> , and rifampin . 	prednisolone	ritonavir
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , <e1> DRUG1 </e1> , sirolimus , nifedipine , fluconazole , ritonavir , and <e2> DRUG2 </e2> . 	prednisolone	rifampin
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , <e1> DRUG1 </e1> , nifedipine , <e2> DRUG2 </e2> , ritonavir , and rifampin . 	sirolimus	fluconazole
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , <e1> DRUG1 </e1> , nifedipine , fluconazole , <e2> DRUG2 </e2> , and rifampin . 	sirolimus	ritonavir
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , <e1> DRUG1 </e1> , nifedipine , fluconazole , ritonavir , and <e2> DRUG2 </e2> . 	sirolimus	rifampin
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , <e1> DRUG1 </e1> , fluconazole , <e2> DRUG2 </e2> , and rifampin . 	nifedipine	ritonavir
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , <e1> DRUG1 </e1> , fluconazole , ritonavir , and <e2> DRUG2 </e2> . 	nifedipine	rifampin
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , <e1> DRUG1 </e1> , ritonavir , and <e2> DRUG2 </e2> . 	fluconazole	rifampin
other	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> . 	ritonavir	rifampin
other	There was no effect of a single dose or multiple doses of <e1> DRUG1 </e1> on <e2> DRUG2 </e2> , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 	MYCAMINE	mycophenolate mofetil
other	There was no effect of a single dose or multiple doses of <e1> DRUG1 </e1> on mycophenolate mofetil , <e2> DRUG2 </e2> , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 	MYCAMINE	cyclosporine
other	There was no effect of a single dose or multiple doses of <e1> DRUG1 </e1> on mycophenolate mofetil , cyclosporine , <e2> DRUG2 </e2> , prednisolone , and fluconazole pharmacokinetics . 	MYCAMINE	tacrolimus
other	There was no effect of a single dose or multiple doses of <e1> DRUG1 </e1> on mycophenolate mofetil , cyclosporine , tacrolimus , <e2> DRUG2 </e2> , and fluconazole pharmacokinetics . 	MYCAMINE	prednisolone
other	There was no effect of a single dose or multiple doses of <e1> DRUG1 </e1> on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and <e2> DRUG2 </e2> pharmacokinetics . 	MYCAMINE	fluconazole
other	There was no effect of a single dose or multiple doses of MYCAMINE on <e1> DRUG1 </e1> , cyclosporine , <e2> DRUG2 </e2> , prednisolone , and fluconazole pharmacokinetics . 	mycophenolate mofetil	tacrolimus
other	There was no effect of a single dose or multiple doses of MYCAMINE on <e1> DRUG1 </e1> , cyclosporine , tacrolimus , <e2> DRUG2 </e2> , and fluconazole pharmacokinetics . 	mycophenolate mofetil	prednisolone
other	There was no effect of a single dose or multiple doses of MYCAMINE on <e1> DRUG1 </e1> , cyclosporine , tacrolimus , prednisolone , and <e2> DRUG2 </e2> pharmacokinetics . 	mycophenolate mofetil	fluconazole
other	There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , <e1> DRUG1 </e1> , tacrolimus , <e2> DRUG2 </e2> , and fluconazole pharmacokinetics . 	cyclosporine	prednisolone
other	There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , <e1> DRUG1 </e1> , tacrolimus , prednisolone , and <e2> DRUG2 </e2> pharmacokinetics . 	cyclosporine	fluconazole
other	There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , <e1> DRUG1 </e1> , prednisolone , and <e2> DRUG2 </e2> pharmacokinetics . 	tacrolimus	fluconazole
other	There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , tacrolimus , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> pharmacokinetics . 	prednisolone	fluconazole
mechanism	<e1> DRUG1 </e1> AUC was increased by 21% with no effect on Cmax in the presence of steady-state <e2> DRUG2 </e2> compared with sirolimus alone . 	Sirolimus	MYCAMINE
other	Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state <e1> DRUG1 </e1> compared with <e2> DRUG2 </e2> alone . 	MYCAMINE	sirolimus
mechanism	<e1> DRUG1 </e1> AUC and Cmax were increased by 18% and 42% , respectively , in the presence of steady-state <e2> DRUG2 </e2> compared with nifedipine alone . 	Nifedipine	MYCAMINE
other	Nifedipine AUC and Cmax were increased by 18% and 42% , respectively , in the presence of steady-state <e1> DRUG1 </e1> compared with <e2> DRUG2 </e2> alone . 	MYCAMINE	nifedipine
advise	Patients receiving <e1> DRUG1 </e1> or nifedipine in combination with <e2> DRUG2 </e2> should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 	sirolimus	MYCAMINE
other	Patients receiving <e1> DRUG1 </e1> or nifedipine in combination with MYCAMINE should be monitored for sirolimus or <e2> DRUG2 </e2> toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 	sirolimus	nifedipine
other	Patients receiving <e1> DRUG1 </e1> or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or <e2> DRUG2 </e2> dosage should be reduced if necessary . 	sirolimus	nifedipine
advise	Patients receiving sirolimus or <e1> DRUG1 </e1> in combination with <e2> DRUG2 </e2> should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 	nifedipine	MYCAMINE
other	Patients receiving sirolimus or <e1> DRUG1 </e1> in combination with MYCAMINE should be monitored for <e2> DRUG2 </e2> or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 	nifedipine	sirolimus
other	Patients receiving sirolimus or <e1> DRUG1 </e1> in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and <e2> DRUG2 </e2> or nifedipine dosage should be reduced if necessary . 	nifedipine	sirolimus
other	Patients receiving sirolimus or nifedipine in combination with <e1> DRUG1 </e1> should be monitored for <e2> DRUG2 </e2> or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 	MYCAMINE	sirolimus
other	Patients receiving sirolimus or nifedipine in combination with <e1> DRUG1 </e1> should be monitored for sirolimus or <e2> DRUG2 </e2> toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 	MYCAMINE	nifedipine
other	Patients receiving sirolimus or nifedipine in combination with <e1> DRUG1 </e1> should be monitored for sirolimus or nifedipine toxicity and <e2> DRUG2 </e2> or nifedipine dosage should be reduced if necessary . 	MYCAMINE	sirolimus
other	Patients receiving sirolimus or nifedipine in combination with <e1> DRUG1 </e1> should be monitored for sirolimus or nifedipine toxicity and sirolimus or <e2> DRUG2 </e2> dosage should be reduced if necessary . 	MYCAMINE	nifedipine
other	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for <e1> DRUG1 </e1> or nifedipine toxicity and sirolimus or <e2> DRUG2 </e2> dosage should be reduced if necessary . 	sirolimus	nifedipine
other	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or <e1> DRUG1 </e1> toxicity and <e2> DRUG2 </e2> or nifedipine dosage should be reduced if necessary . 	nifedipine	sirolimus
advise	Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when <e1> DRUG1 </e1> is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie , some drugs in the drug classes of <e2> DRUG2 </e2> , protease inhibitors , calcium channel antagonists , and macrolide antibiotics ) . 	midazolam	azole antimycotics
advise	Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when <e1> DRUG1 </e1> is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie , some drugs in the drug classes of azole antimycotics , <e2> DRUG2 </e2> , calcium channel antagonists , and macrolide antibiotics ) . 	midazolam	protease inhibitors
advise	Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when <e1> DRUG1 </e1> is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , <e2> DRUG2 </e2> , and macrolide antibiotics ) . 	midazolam	calcium channel antagonists
advise	Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when <e1> DRUG1 </e1> is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and <e2> DRUG2 </e2> ) . 	midazolam	macrolide antibiotics
other	Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie , some drugs in the drug classes of <e1> DRUG1 </e1> , protease inhibitors , <e2> DRUG2 </e2> , and macrolide antibiotics ) . 	azole antimycotics	calcium channel antagonists
other	Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie , some drugs in the drug classes of <e1> DRUG1 </e1> , protease inhibitors , calcium channel antagonists , and <e2> DRUG2 </e2> ) . 	azole antimycotics	macrolide antibiotics
other	Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie , some drugs in the drug classes of azole antimycotics , <e1> DRUG1 </e1> , calcium channel antagonists , and <e2> DRUG2 </e2> ) . 	protease inhibitors	macrolide antibiotics
other	Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> ) . 	calcium channel antagonists	macrolide antibiotics
other	Drugs such as <e1> DRUG1 </e1> , diltiazem , <e2> DRUG2 </e2> , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 	erythromycin	verapamil
other	Drugs such as <e1> DRUG1 </e1> , diltiazem , verapamil , <e2> DRUG2 </e2> , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 	erythromycin	ketoconazole
other	Drugs such as <e1> DRUG1 </e1> , diltiazem , verapamil , ketoconazole , <e2> DRUG2 </e2> and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 	erythromycin	fluconazole
other	Drugs such as <e1> DRUG1 </e1> , diltiazem , verapamil , ketoconazole , fluconazole and <e2> DRUG2 </e2> were shown to significantly increase the C max and AUC of orally administered midazolam . 	erythromycin	itraconazole
mechanism	Drugs such as <e1> DRUG1 </e1> , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered <e2> DRUG2 </e2> . 	erythromycin	midazolam
other	Drugs such as erythromycin , <e1> DRUG1 </e1> , verapamil , <e2> DRUG2 </e2> , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 	diltiazem	ketoconazole
other	Drugs such as erythromycin , <e1> DRUG1 </e1> , verapamil , ketoconazole , <e2> DRUG2 </e2> and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 	diltiazem	fluconazole
other	Drugs such as erythromycin , <e1> DRUG1 </e1> , verapamil , ketoconazole , fluconazole and <e2> DRUG2 </e2> were shown to significantly increase the C max and AUC of orally administered midazolam . 	diltiazem	itraconazole
mechanism	Drugs such as erythromycin , <e1> DRUG1 </e1> , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered <e2> DRUG2 </e2> . 	diltiazem	midazolam
other	Drugs such as erythromycin , diltiazem , <e1> DRUG1 </e1> , ketoconazole , <e2> DRUG2 </e2> and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 	verapamil	fluconazole
other	Drugs such as erythromycin , diltiazem , <e1> DRUG1 </e1> , ketoconazole , fluconazole and <e2> DRUG2 </e2> were shown to significantly increase the C max and AUC of orally administered midazolam . 	verapamil	itraconazole
mechanism	Drugs such as erythromycin , diltiazem , <e1> DRUG1 </e1> , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered <e2> DRUG2 </e2> . 	verapamil	midazolam
other	Drugs such as erythromycin , diltiazem , verapamil , <e1> DRUG1 </e1> , fluconazole and <e2> DRUG2 </e2> were shown to significantly increase the C max and AUC of orally administered midazolam . 	ketoconazole	itraconazole
mechanism	Drugs such as erythromycin , diltiazem , verapamil , <e1> DRUG1 </e1> , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered <e2> DRUG2 </e2> . 	ketoconazole	midazolam
other	Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , <e1> DRUG1 </e1> and <e2> DRUG2 </e2> were shown to significantly increase the C max and AUC of orally administered midazolam . 	fluconazole	itraconazole
mechanism	Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , <e1> DRUG1 </e1> and itraconazole were shown to significantly increase the C max and AUC of orally administered <e2> DRUG2 </e2> . 	fluconazole	midazolam
mechanism	Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and <e1> DRUG1 </e1> were shown to significantly increase the C max and AUC of orally administered <e2> DRUG2 </e2> . 	itraconazole	midazolam
other	Although not studied , the potent cytochrome P450 3A4 inhibitors <e1> DRUG1 </e1> and <e2> DRUG2 </e2> may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam . 	ritonavir	nelfinavir
mechanism	Although not studied , the potent cytochrome P450 3A4 inhibitors <e1> DRUG1 </e1> and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of <e2> DRUG2 </e2> . 	ritonavir	midazolam
mechanism	Although not studied , the potent cytochrome P450 3A4 inhibitors ritonavir and <e1> DRUG1 </e1> may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of <e2> DRUG2 </e2> . 	nelfinavir	midazolam
other	Inducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as <e1> DRUG1 </e1> , carbamazepine , and <e2> DRUG2 </e2> , induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies . 	rifampin	phenytoin
mechanism	Inducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as <e1> DRUG1 </e1> , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral <e2> DRUG2 </e2> in adult studies . 	rifampin	midazolam
other	Inducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as rifampin , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> , induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies . 	carbamazepine	phenytoin
mechanism	Inducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as rifampin , <e1> DRUG1 </e1> , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral <e2> DRUG2 </e2> in adult studies . 	carbamazepine	midazolam
mechanism	Inducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as rifampin , carbamazepine , and <e1> DRUG1 </e1> , induce metabolism and caused a markedly decreased C max and AUC of oral <e2> DRUG2 </e2> in adult studies . 	phenytoin	midazolam
other	The difficulty in achieving adequate sedation may have been the result of decreased absorption of the <e1> DRUG1 </e1> due to both the gastrointestinal effects and stimulant effects of <e2> DRUG2 </e2> . 	sedatives	methylphenidate
effect	The sedative effect of <e1> DRUG1 </e1> is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly <e2> DRUG2 </e2> (eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 	VERSED Syrup	narcotics
effect	The sedative effect of <e1> DRUG1 </e1> is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , <e2> DRUG2 </e2> , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 	VERSED Syrup	morphine
effect	The sedative effect of <e1> DRUG1 </e1> is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , <e2> DRUG2 </e2> and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 	VERSED Syrup	meperidine
effect	The sedative effect of <e1> DRUG1 </e1> is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , meperidine and <e2> DRUG2 </e2> ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 	VERSED Syrup	fentanyl
effect	The sedative effect of <e1> DRUG1 </e1> is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , meperidine and fentanyl ) , <e2> DRUG2 </e2> , ketamine , nitrous oxide , secobarbital and droperidol . 	VERSED Syrup	propofol
effect	The sedative effect of <e1> DRUG1 </e1> is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , meperidine and fentanyl ) , propofol , <e2> DRUG2 </e2> , nitrous oxide , secobarbital and droperidol . 	VERSED Syrup	ketamine
effect	The sedative effect of <e1> DRUG1 </e1> is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , meperidine and fentanyl ) , propofol , ketamine , <e2> DRUG2 </e2> , secobarbital and droperidol . 	VERSED Syrup	nitrous oxide
effect	The sedative effect of <e1> DRUG1 </e1> is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , <e2> DRUG2 </e2> and droperidol . 	VERSED Syrup	secobarbital
effect	The sedative effect of <e1> DRUG1 </e1> is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and <e2> DRUG2 </e2> . 	VERSED Syrup	droperidol
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly <e1> DRUG1 </e1> (eg , <e2> DRUG2 </e2> , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 	narcotics	morphine
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly <e1> DRUG1 </e1> (eg , morphine , <e2> DRUG2 </e2> and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 	narcotics	meperidine
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly <e1> DRUG1 </e1> (eg , morphine , meperidine and <e2> DRUG2 </e2> ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 	narcotics	fentanyl
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly <e1> DRUG1 </e1> (eg , morphine , meperidine and fentanyl ) , <e2> DRUG2 </e2> , ketamine , nitrous oxide , secobarbital and droperidol . 	narcotics	propofol
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly <e1> DRUG1 </e1> (eg , morphine , meperidine and fentanyl ) , propofol , <e2> DRUG2 </e2> , nitrous oxide , secobarbital and droperidol . 	narcotics	ketamine
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly <e1> DRUG1 </e1> (eg , morphine , meperidine and fentanyl ) , propofol , ketamine , <e2> DRUG2 </e2> , secobarbital and droperidol . 	narcotics	nitrous oxide
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly <e1> DRUG1 </e1> (eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , <e2> DRUG2 </e2> and droperidol . 	narcotics	secobarbital
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly <e1> DRUG1 </e1> (eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and <e2> DRUG2 </e2> . 	narcotics	droperidol
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , <e1> DRUG1 </e1> , meperidine and <e2> DRUG2 </e2> ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 	morphine	fentanyl
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , <e1> DRUG1 </e1> , meperidine and fentanyl ) , <e2> DRUG2 </e2> , ketamine , nitrous oxide , secobarbital and droperidol . 	morphine	propofol
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , <e1> DRUG1 </e1> , meperidine and fentanyl ) , propofol , <e2> DRUG2 </e2> , nitrous oxide , secobarbital and droperidol . 	morphine	ketamine
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , <e1> DRUG1 </e1> , meperidine and fentanyl ) , propofol , ketamine , <e2> DRUG2 </e2> , secobarbital and droperidol . 	morphine	nitrous oxide
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , <e1> DRUG1 </e1> , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , <e2> DRUG2 </e2> and droperidol . 	morphine	secobarbital
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , <e1> DRUG1 </e1> , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and <e2> DRUG2 </e2> . 	morphine	droperidol
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , <e1> DRUG1 </e1> and <e2> DRUG2 </e2> ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 	meperidine	fentanyl
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , <e1> DRUG1 </e1> and fentanyl ) , <e2> DRUG2 </e2> , ketamine , nitrous oxide , secobarbital and droperidol . 	meperidine	propofol
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , <e1> DRUG1 </e1> and fentanyl ) , propofol , <e2> DRUG2 </e2> , nitrous oxide , secobarbital and droperidol . 	meperidine	ketamine
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , <e1> DRUG1 </e1> and fentanyl ) , propofol , ketamine , <e2> DRUG2 </e2> , secobarbital and droperidol . 	meperidine	nitrous oxide
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , <e1> DRUG1 </e1> and fentanyl ) , propofol , ketamine , nitrous oxide , <e2> DRUG2 </e2> and droperidol . 	meperidine	secobarbital
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , <e1> DRUG1 </e1> and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and <e2> DRUG2 </e2> . 	meperidine	droperidol
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , meperidine and <e1> DRUG1 </e1> ) , <e2> DRUG2 </e2> , ketamine , nitrous oxide , secobarbital and droperidol . 	fentanyl	propofol
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , meperidine and <e1> DRUG1 </e1> ) , propofol , <e2> DRUG2 </e2> , nitrous oxide , secobarbital and droperidol . 	fentanyl	ketamine
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , meperidine and <e1> DRUG1 </e1> ) , propofol , ketamine , <e2> DRUG2 </e2> , secobarbital and droperidol . 	fentanyl	nitrous oxide
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , meperidine and <e1> DRUG1 </e1> ) , propofol , ketamine , nitrous oxide , <e2> DRUG2 </e2> and droperidol . 	fentanyl	secobarbital
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , meperidine and <e1> DRUG1 </e1> ) , propofol , ketamine , nitrous oxide , secobarbital and <e2> DRUG2 </e2> . 	fentanyl	droperidol
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , meperidine and fentanyl ) , <e1> DRUG1 </e1> , ketamine , <e2> DRUG2 </e2> , secobarbital and droperidol . 	propofol	nitrous oxide
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , meperidine and fentanyl ) , <e1> DRUG1 </e1> , ketamine , nitrous oxide , <e2> DRUG2 </e2> and droperidol . 	propofol	secobarbital
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , meperidine and fentanyl ) , <e1> DRUG1 </e1> , ketamine , nitrous oxide , secobarbital and <e2> DRUG2 </e2> . 	propofol	droperidol
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , meperidine and fentanyl ) , propofol , <e1> DRUG1 </e1> , nitrous oxide , <e2> DRUG2 </e2> and droperidol . 	ketamine	secobarbital
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , meperidine and fentanyl ) , propofol , <e1> DRUG1 </e1> , nitrous oxide , secobarbital and <e2> DRUG2 </e2> . 	ketamine	droperidol
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , meperidine and fentanyl ) , propofol , ketamine , <e1> DRUG1 </e1> , secobarbital and <e2> DRUG2 </e2> . 	nitrous oxide	droperidol
other	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics (eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	secobarbital	droperidol
other	No significant adverse interactions with common premedications (such as <e1> DRUG1 </e1> , scopolamine , <e2> DRUG2 </e2> , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed . 	atropine	glycopyrrolate
other	No significant adverse interactions with common premedications (such as <e1> DRUG1 </e1> , scopolamine , glycopyrrolate , <e2> DRUG2 </e2> , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed . 	atropine	diazepam
other	No significant adverse interactions with common premedications (such as <e1> DRUG1 </e1> , scopolamine , glycopyrrolate , diazepam , <e2> DRUG2 </e2> , and other muscle relaxants ) or local anesthetics have been observed . 	atropine	hydroxyzine
other	No significant adverse interactions with common premedications (such as <e1> DRUG1 </e1> , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other <e2> DRUG2 </e2> ) or local anesthetics have been observed . 	atropine	muscle relaxants
other	No significant adverse interactions with common premedications (such as <e1> DRUG1 </e1> , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local <e2> DRUG2 </e2> have been observed . 	atropine	anesthetics
other	No significant adverse interactions with common premedications (such as atropine , <e1> DRUG1 </e1> , glycopyrrolate , <e2> DRUG2 </e2> , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed . 	scopolamine	diazepam
other	No significant adverse interactions with common premedications (such as atropine , <e1> DRUG1 </e1> , glycopyrrolate , diazepam , <e2> DRUG2 </e2> , and other muscle relaxants ) or local anesthetics have been observed . 	scopolamine	hydroxyzine
other	No significant adverse interactions with common premedications (such as atropine , <e1> DRUG1 </e1> , glycopyrrolate , diazepam , hydroxyzine , and other <e2> DRUG2 </e2> ) or local anesthetics have been observed . 	scopolamine	muscle relaxants
other	No significant adverse interactions with common premedications (such as atropine , <e1> DRUG1 </e1> , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local <e2> DRUG2 </e2> have been observed . 	scopolamine	anesthetics
other	No significant adverse interactions with common premedications (such as atropine , scopolamine , <e1> DRUG1 </e1> , diazepam , <e2> DRUG2 </e2> , and other muscle relaxants ) or local anesthetics have been observed . 	glycopyrrolate	hydroxyzine
other	No significant adverse interactions with common premedications (such as atropine , scopolamine , <e1> DRUG1 </e1> , diazepam , hydroxyzine , and other <e2> DRUG2 </e2> ) or local anesthetics have been observed . 	glycopyrrolate	muscle relaxants
other	No significant adverse interactions with common premedications (such as atropine , scopolamine , <e1> DRUG1 </e1> , diazepam , hydroxyzine , and other muscle relaxants ) or local <e2> DRUG2 </e2> have been observed . 	glycopyrrolate	anesthetics
other	No significant adverse interactions with common premedications (such as atropine , scopolamine , glycopyrrolate , <e1> DRUG1 </e1> , hydroxyzine , and other <e2> DRUG2 </e2> ) or local anesthetics have been observed . 	diazepam	muscle relaxants
other	No significant adverse interactions with common premedications (such as atropine , scopolamine , glycopyrrolate , <e1> DRUG1 </e1> , hydroxyzine , and other muscle relaxants ) or local <e2> DRUG2 </e2> have been observed . 	diazepam	anesthetics
other	No significant adverse interactions with common premedications (such as atropine , scopolamine , glycopyrrolate , diazepam , <e1> DRUG1 </e1> , and other <e2> DRUG2 </e2> ) or local anesthetics have been observed . 	hydroxyzine	muscle relaxants
other	No significant adverse interactions with common premedications (such as atropine , scopolamine , glycopyrrolate , diazepam , <e1> DRUG1 </e1> , and other muscle relaxants ) or local <e2> DRUG2 </e2> have been observed . 	hydroxyzine	anesthetics
other	No significant adverse interactions with common premedications (such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other <e1> DRUG1 </e1> ) or local <e2> DRUG2 </e2> have been observed . 	muscle relaxants	anesthetics
other	The use of drugs that stimulate alpha-adrenergic receptors (e.g. , <e1> DRUG1 </e1> , pseudoephedrine , <e2> DRUG2 </e2> , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 	phenylephrine	ephedrine
other	The use of drugs that stimulate alpha-adrenergic receptors (e.g. , <e1> DRUG1 </e1> , pseudoephedrine , ephedrine , <e2> DRUG2 </e2> or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 	phenylephrine	phenylpropanolamine
other	The use of drugs that stimulate alpha-adrenergic receptors (e.g. , <e1> DRUG1 </e1> , pseudoephedrine , ephedrine , phenylpropanolamine or <e2> DRUG2 </e2> ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 	phenylephrine	dihydroergotamine
effect	The use of drugs that stimulate alpha-adrenergic receptors (e.g. , <e1> DRUG1 </e1> , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of <e2> DRUG2 </e2> . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 	phenylephrine	ProAmatine
other	The use of drugs that stimulate alpha-adrenergic receptors (e.g. , phenylephrine , <e1> DRUG1 </e1> , ephedrine , <e2> DRUG2 </e2> or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 	pseudoephedrine	phenylpropanolamine
other	The use of drugs that stimulate alpha-adrenergic receptors (e.g. , phenylephrine , <e1> DRUG1 </e1> , ephedrine , phenylpropanolamine or <e2> DRUG2 </e2> ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 	pseudoephedrine	dihydroergotamine
effect	The use of drugs that stimulate alpha-adrenergic receptors (e.g. , phenylephrine , <e1> DRUG1 </e1> , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of <e2> DRUG2 </e2> . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 	pseudoephedrine	ProAmatine
other	The use of drugs that stimulate alpha-adrenergic receptors (e.g. , phenylephrine , pseudoephedrine , <e1> DRUG1 </e1> , phenylpropanolamine or <e2> DRUG2 </e2> ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 	ephedrine	dihydroergotamine
effect	The use of drugs that stimulate alpha-adrenergic receptors (e.g. , phenylephrine , pseudoephedrine , <e1> DRUG1 </e1> , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of <e2> DRUG2 </e2> . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 	ephedrine	ProAmatine
effect	The use of drugs that stimulate alpha-adrenergic receptors (e.g. , phenylephrine , pseudoephedrine , ephedrine , <e1> DRUG1 </e1> or dihydroergotamine ) may enhance or potentiate the pressor effects of <e2> DRUG2 </e2> . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 	phenylpropanolamine	ProAmatine
effect	The use of drugs that stimulate alpha-adrenergic receptors (e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or <e1> DRUG1 </e1> ) may enhance or potentiate the pressor effects of <e2> DRUG2 </e2> . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 	dihydroergotamine	ProAmatine
other	<e1> DRUG1 </e1> has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e. , <e2> DRUG2 </e2> ) , with or without salt supplementation . 	ProAmatine	fludrocortisone acetate
other	<e1> DRUG1 </e1> . <e2> DRUG2 </e2> , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 	ProAmatine	Alpha-adrenergic blocking agents
other	ProAmatine . <e1> DRUG1 </e1> , such as <e2> DRUG2 </e2> , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 	Alpha-adrenergic blocking agents	prazosin
other	ProAmatine . <e1> DRUG1 </e1> , such as prazosin , <e2> DRUG2 </e2> , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 	Alpha-adrenergic blocking agents	terazosin
other	ProAmatine . <e1> DRUG1 </e1> , such as prazosin , terazosin , and <e2> DRUG2 </e2> , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 	Alpha-adrenergic blocking agents	doxazosin
effect	ProAmatine . <e1> DRUG1 </e1> , such as prazosin , terazosin , and doxazosin , can antagonize the effects of <e2> DRUG2 </e2> . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 	Alpha-adrenergic blocking agents	ProAmatine
other	ProAmatine . Alpha-adrenergic blocking agents , such as <e1> DRUG1 </e1> , terazosin , and <e2> DRUG2 </e2> , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 	prazosin	doxazosin
effect	ProAmatine . Alpha-adrenergic blocking agents , such as <e1> DRUG1 </e1> , terazosin , and doxazosin , can antagonize the effects of <e2> DRUG2 </e2> . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 	prazosin	ProAmatine
other	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 	terazosin	doxazosin
effect	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , <e1> DRUG1 </e1> , and doxazosin , can antagonize the effects of <e2> DRUG2 </e2> . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 	terazosin	ProAmatine
effect	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and <e1> DRUG1 </e1> , can antagonize the effects of <e2> DRUG2 </e2> . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 	doxazosin	ProAmatine
mechanism	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of <e1> DRUG1 </e1> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e2> DRUG2 </e2> , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 	desglymidodrine	metformin
mechanism	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of <e1> DRUG1 </e1> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , <e2> DRUG2 </e2> , ranitidine , procainamide , triamterene , flecainide , and quinidine . 	desglymidodrine	cimetidine
mechanism	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of <e1> DRUG1 </e1> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , <e2> DRUG2 </e2> , procainamide , triamterene , flecainide , and quinidine . 	desglymidodrine	ranitidine
mechanism	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of <e1> DRUG1 </e1> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , <e2> DRUG2 </e2> , triamterene , flecainide , and quinidine . 	desglymidodrine	procainamide
mechanism	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of <e1> DRUG1 </e1> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , <e2> DRUG2 </e2> , flecainide , and quinidine . 	desglymidodrine	triamterene
mechanism	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of <e1> DRUG1 </e1> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , <e2> DRUG2 </e2> , and quinidine . 	desglymidodrine	flecainide
mechanism	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of <e1> DRUG1 </e1> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and <e2> DRUG2 </e2> . 	desglymidodrine	quinidine
other	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e1> DRUG1 </e1> , cimetidine , <e2> DRUG2 </e2> , procainamide , triamterene , flecainide , and quinidine . 	metformin	ranitidine
other	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e1> DRUG1 </e1> , cimetidine , ranitidine , <e2> DRUG2 </e2> , triamterene , flecainide , and quinidine . 	metformin	procainamide
other	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e1> DRUG1 </e1> , cimetidine , ranitidine , procainamide , <e2> DRUG2 </e2> , flecainide , and quinidine . 	metformin	triamterene
other	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e1> DRUG1 </e1> , cimetidine , ranitidine , procainamide , triamterene , <e2> DRUG2 </e2> , and quinidine . 	metformin	flecainide
other	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e1> DRUG1 </e1> , cimetidine , ranitidine , procainamide , triamterene , flecainide , and <e2> DRUG2 </e2> . 	metformin	quinidine
other	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , <e1> DRUG1 </e1> , ranitidine , <e2> DRUG2 </e2> , triamterene , flecainide , and quinidine . 	cimetidine	procainamide
other	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , <e1> DRUG1 </e1> , ranitidine , procainamide , <e2> DRUG2 </e2> , flecainide , and quinidine . 	cimetidine	triamterene
other	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , <e1> DRUG1 </e1> , ranitidine , procainamide , triamterene , <e2> DRUG2 </e2> , and quinidine . 	cimetidine	flecainide
other	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , <e1> DRUG1 </e1> , ranitidine , procainamide , triamterene , flecainide , and <e2> DRUG2 </e2> . 	cimetidine	quinidine
other	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , <e1> DRUG1 </e1> , procainamide , <e2> DRUG2 </e2> , flecainide , and quinidine . 	ranitidine	triamterene
other	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , <e1> DRUG1 </e1> , procainamide , triamterene , <e2> DRUG2 </e2> , and quinidine . 	ranitidine	flecainide
other	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , <e1> DRUG1 </e1> , procainamide , triamterene , flecainide , and <e2> DRUG2 </e2> . 	ranitidine	quinidine
other	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , <e1> DRUG1 </e1> , triamterene , <e2> DRUG2 </e2> , and quinidine . 	procainamide	flecainide
other	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , <e1> DRUG1 </e1> , triamterene , flecainide , and <e2> DRUG2 </e2> . 	procainamide	quinidine
other	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , <e1> DRUG1 </e1> , flecainide , and <e2> DRUG2 </e2> . 	triamterene	quinidine
other	ProAmatine . Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> . 	flecainide	quinidine
other	Although specific drug or food interactions with <e1> DRUG1 </e1> have not been studied , on the basis of this drug   s metabolism by CYP 3A4 , it is possible that <e2> DRUG2 </e2> , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone ) . 	mifepristone	ketoconazole
other	Although specific drug or food interactions with <e1> DRUG1 </e1> have not been studied , on the basis of this drug   s metabolism by CYP 3A4 , it is possible that ketoconazole , <e2> DRUG2 </e2> , erythromycin , and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone ) . 	mifepristone	itraconazole
other	Although specific drug or food interactions with <e1> DRUG1 </e1> have not been studied , on the basis of this drug   s metabolism by CYP 3A4 , it is possible that ketoconazole , itraconazole , <e2> DRUG2 </e2> , and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone ) . 	mifepristone	erythromycin
other	Although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug   s metabolism by CYP 3A4 , it is possible that <e1> DRUG1 </e1> , itraconazole , <e2> DRUG2 </e2> , and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone ) . 	ketoconazole	erythromycin
mechanism	Although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug   s metabolism by CYP 3A4 , it is possible that <e1> DRUG1 </e1> , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism (increasing serum levels of <e2> DRUG2 </e2> ) . 	ketoconazole	mifepristone
mechanism	Although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug   s metabolism by CYP 3A4 , it is possible that ketoconazole , <e1> DRUG1 </e1> , erythromycin , and grapefruit juice may inhibit its metabolism (increasing serum levels of <e2> DRUG2 </e2> ) . 	itraconazole	mifepristone
mechanism	Although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug   s metabolism by CYP 3A4 , it is possible that ketoconazole , itraconazole , <e1> DRUG1 </e1> , and grapefruit juice may inhibit its metabolism (increasing serum levels of <e2> DRUG2 </e2> ) . 	erythromycin	mifepristone
other	John   s Wort , and certain <e1> DRUG1 </e1> ( phenytoin , <e2> DRUG2 </e2> , carbamazepine ) may induce mifepristone metabolism (lowering serum levels of mifepristone ) . 	anticonvulsants	phenobarbital
other	John   s Wort , and certain <e1> DRUG1 </e1> ( phenytoin , phenobarbital , <e2> DRUG2 </e2> ) may induce mifepristone metabolism (lowering serum levels of mifepristone ) . 	anticonvulsants	carbamazepine
mechanism	John   s Wort , and certain <e1> DRUG1 </e1> ( phenytoin , phenobarbital , carbamazepine ) may induce <e2> DRUG2 </e2> metabolism (lowering serum levels of mifepristone ) . 	anticonvulsants	mifepristone
other	John   s Wort , and certain <e1> DRUG1 </e1> ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism (lowering serum levels of <e2> DRUG2 </e2> ) . 	anticonvulsants	mifepristone
other	John   s Wort , and certain anticonvulsants ( <e1> DRUG1 </e1> , phenobarbital , <e2> DRUG2 </e2> ) may induce mifepristone metabolism (lowering serum levels of mifepristone ) . 	phenytoin	carbamazepine
mechanism	John   s Wort , and certain anticonvulsants ( <e1> DRUG1 </e1> , phenobarbital , carbamazepine ) may induce <e2> DRUG2 </e2> metabolism (lowering serum levels of mifepristone ) . 	phenytoin	mifepristone
other	John   s Wort , and certain anticonvulsants ( <e1> DRUG1 </e1> , phenobarbital , carbamazepine ) may induce mifepristone metabolism (lowering serum levels of <e2> DRUG2 </e2> ) . 	phenytoin	mifepristone
mechanism	John   s Wort , and certain anticonvulsants ( phenytoin , <e1> DRUG1 </e1> , carbamazepine ) may induce <e2> DRUG2 </e2> metabolism (lowering serum levels of mifepristone ) . 	phenobarbital	mifepristone
other	John   s Wort , and certain anticonvulsants ( phenytoin , <e1> DRUG1 </e1> , carbamazepine ) may induce mifepristone metabolism (lowering serum levels of <e2> DRUG2 </e2> ) . 	phenobarbital	mifepristone
mechanism	John   s Wort , and certain anticonvulsants ( phenytoin , phenobarbital , <e1> DRUG1 </e1> ) may induce <e2> DRUG2 </e2> metabolism (lowering serum levels of mifepristone ) . 	carbamazepine	mifepristone
other	John   s Wort , and certain anticonvulsants ( phenytoin , phenobarbital , <e1> DRUG1 </e1> ) may induce mifepristone metabolism (lowering serum levels of <e2> DRUG2 </e2> ) . 	carbamazepine	mifepristone
mechanism	While co-administration of <e1> DRUG1 </e1> appeared to increase the clearance of <e2> DRUG2 </e2> by 70% , these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme . 	ZAVESCA	Cerezyme
other	While co-administration of <e1> DRUG1 </e1> appeared to increase the clearance of Cerezyme by 70% , these results are not conclusive because of the small number of subjects studied and because patients took variable doses of <e2> DRUG2 </e2> . 	ZAVESCA	Cerezyme
advise	Combination therapy with <e1> DRUG1 </e1> ( imiglucerase ) and <e2> DRUG2 </e2> is not indicated . 	Cerezyme	ZAVESCA
advise	Combination therapy with Cerezyme ( <e1> DRUG1 </e1> ) and <e2> DRUG2 </e2> is not indicated . 	imiglucerase	ZAVESCA
advise	Because <e1> DRUG1 </e1> have been shown to depress plasma prothrombin activity , patients who are on <e2> DRUG2 </e2> therapy may require downward adjustment of their anticoagulant dosage . 	tetracyclines	anticoagulant
other	Because <e1> DRUG1 </e1> have been shown to depress plasma prothrombin activity , patients who are on anticoagulant therapy may require downward adjustment of their <e2> DRUG2 </e2> dosage . 	tetracyclines	anticoagulant
other	Since bacteriostatic drugs may interfere with the bactericidal action of <e1> DRUG1 </e1> , it is advisable to avoid giving <e2> DRUG2 </e2> in conjunction with penicillin . 	penicillin	tetracycline class drugs
advise	Since bacteriostatic drugs may interfere with the bactericidal action of penicillin , it is advisable to avoid giving <e1> DRUG1 </e1> in conjunction with <e2> DRUG2 </e2> . 	tetracycline class drugs	penicillin
other	Absorption of <e1> DRUG1 </e1> is impaired by <e2> DRUG2 </e2> containing aluminum , calcium or magnesium , and iron -containing preparations . 	tetracyclines	antacids
mechanism	Absorption of <e1> DRUG1 </e1> is impaired by antacids containing <e2> DRUG2 </e2> , calcium or magnesium , and iron -containing preparations . 	tetracyclines	aluminum
mechanism	Absorption of <e1> DRUG1 </e1> is impaired by antacids containing aluminum , <e2> DRUG2 </e2> or magnesium , and iron -containing preparations . 	tetracyclines	calcium
mechanism	Absorption of <e1> DRUG1 </e1> is impaired by antacids containing aluminum , calcium or <e2> DRUG2 </e2> , and iron -containing preparations . 	tetracyclines	magnesium
mechanism	Absorption of <e1> DRUG1 </e1> is impaired by antacids containing aluminum , calcium or magnesium , and <e2> DRUG2 </e2> -containing preparations . 	tetracyclines	iron
other	Absorption of tetracyclines is impaired by <e1> DRUG1 </e1> containing <e2> DRUG2 </e2> , calcium or magnesium , and iron -containing preparations . 	antacids	aluminum
other	Absorption of tetracyclines is impaired by <e1> DRUG1 </e1> containing aluminum , <e2> DRUG2 </e2> or magnesium , and iron -containing preparations . 	antacids	calcium
other	Absorption of tetracyclines is impaired by <e1> DRUG1 </e1> containing aluminum , calcium or <e2> DRUG2 </e2> , and iron -containing preparations . 	antacids	magnesium
other	Absorption of tetracyclines is impaired by <e1> DRUG1 </e1> containing aluminum , calcium or magnesium , and <e2> DRUG2 </e2> -containing preparations . 	antacids	iron
other	Absorption of tetracyclines is impaired by antacids containing <e1> DRUG1 </e1> , calcium or <e2> DRUG2 </e2> , and iron -containing preparations . 	aluminum	magnesium
other	Absorption of tetracyclines is impaired by antacids containing <e1> DRUG1 </e1> , calcium or magnesium , and <e2> DRUG2 </e2> -containing preparations . 	aluminum	iron
other	Absorption of tetracyclines is impaired by antacids containing aluminum , <e1> DRUG1 </e1> or magnesium , and <e2> DRUG2 </e2> -containing preparations . 	calcium	iron
other	Absorption of tetracyclines is impaired by antacids containing aluminum , calcium or <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> -containing preparations . 	magnesium	iron
effect	The concurrent use of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> has been reported to result in fatal renal toxicity . 	tetracycline	methoxyflurane
effect	Concurrent use of <e1> DRUG1 </e1> with oral <e2> DRUG2 </e2> may render oral contraceptives less effective . 	tetracyclines	contraceptives
other	Concurrent use of <e1> DRUG1 </e1> with oral contraceptives may render oral <e2> DRUG2 </e2> less effective . 	tetracyclines	contraceptives
other	Interaction with <e1> DRUG1 </e1> : Although <e2> DRUG2 </e2> does not itself cause orthostatic hypotension , its administration to patients already receiving guanethidine can result in profound orthostatic effects . 	Guanethidine	minoxidil
effect	Interaction with Guanethidine : Although <e1> DRUG1 </e1> does not itself cause orthostatic hypotension , its administration to patients already receiving <e2> DRUG2 </e2> can result in profound orthostatic effects . 	minoxidil	guanethidine
advise	If at all possible <e1> DRUG1 </e1> should be discontinued well before <e2> DRUG2 </e2> is begun . 	guanethidine	minoxidil
other	While in vitro studies have shown that <e1> DRUG1 </e1> is not a potent inhibitor of any of these enzymes , an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes , the concomitant use of <e2> DRUG2 </e2> with most other drugs metabolized by these enzymes has not been formally studied . 	mirtazapine	REMERON SolTab
other	While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes , an indication that <e1> DRUG1 </e1> is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes , the concomitant use of <e2> DRUG2 </e2> with most other drugs metabolized by these enzymes has not been formally studied . 	mirtazapine	REMERON SolTab
other	<e1> DRUG1 </e1> : Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of <e2> DRUG2 </e2> (15 mg) in 6 healthy male subjects . 	Alcohol	mirtazapine
mechanism	Alcohol : Concomitant administration of <e1> DRUG1 </e1> (equivalent to 60 g) had a minimal effect on plasma levels of <e2> DRUG2 </e2> (15 mg) in 6 healthy male subjects . 	alcohol	mirtazapine
effect	However , the impairment of cognitive and motor skills produced by <e1> DRUG1 </e1> were shown to be additive with those produced by <e2> DRUG2 </e2> . 	REMERON	alcohol
advise	Accordingly , patients should be advised to avoid <e1> DRUG1 </e1> while taking <e2> DRUG2 </e2> . Diazepam : Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects . 	alcohol	REMERON SolTab
other	Accordingly , patients should be advised to avoid alcohol while taking REMERON SolTab . <e1> DRUG1 </e1> : Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of <e2> DRUG2 </e2> (15 mg) in 12 healthy subjects . 	Diazepam	mirtazapine
mechanism	Accordingly , patients should be advised to avoid alcohol while taking REMERON SolTab . Diazepam : Concomitant administration of <e1> DRUG1 </e1> (15 mg) had a minimal effect on plasma levels of <e2> DRUG2 </e2> (15 mg) in 12 healthy subjects . 	diazepam	mirtazapine
effect	However , the impairment of motor skills produced by <e1> DRUG1 </e1> has been shown to be additive with those caused by <e2> DRUG2 </e2> . 	REMERON	diazepam
advise	Accordingly , patients should be advised to avoid <e1> DRUG1 </e1> and other similar drugs while taking <e2> DRUG2 </e2> . 	diazepam	REMERON SolTab
mechanism	<e1> DRUG1 </e1> has been reported to accelerate the metabolism of <e2> DRUG2 </e2> by the mechanism of hepatic microsomal enzyme induction , leading to an increase in dosage requirements for warfarin . 	Mitotane	warfarin
other	<e1> DRUG1 </e1> has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction , leading to an increase in dosage requirements for <e2> DRUG2 </e2> . 	Mitotane	warfarin
other	Therefore , physicians should closely monitor patients for a change in <e1> DRUG1 </e1> dosage requirements when administering <e2> DRUG2 </e2> to patients on coumarin-type anticoagulants . 	anticoagulant	Mitotane
other	Therefore , physicians should closely monitor patients for a change in <e1> DRUG1 </e1> dosage requirements when administering Mitotane to patients on <e2> DRUG2 </e2> . 	anticoagulant	coumarin-type anticoagulants
advise	Therefore , physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering <e1> DRUG1 </e1> to patients on <e2> DRUG2 </e2> . 	Mitotane	coumarin-type anticoagulants
other	Although <e1> DRUG1 </e1> (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation , the interaction between MIVACRON and <e2> DRUG2 </e2> has not been systematically studied . 	MIVACRON	succinylcholine
other	Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation , the interaction between <e1> DRUG1 </e1> and <e2> DRUG2 </e2> has not been systematically studied . 	MIVACRON	succinylcholine
effect	Prior administration of <e1> DRUG1 </e1> can potentiate the neuromuscular blocking effects of <e2> DRUG2 </e2> . 	succinylcholine	nondepolarizing agents
advise	Evidence of spontaneous recovery from <e1> DRUG1 </e1> should be observed before the administration of <e2> DRUG2 </e2> . 	succinylcholine	MIVACRON
other	The use of <e1> DRUG1 </e1> before <e2> DRUG2 </e2> to attenuate some of the side effects of succinylcholine has not been studied . 	MIVACRON	succinylcholine
other	The use of <e1> DRUG1 </e1> before succinylcholine to attenuate some of the side effects of <e2> DRUG2 </e2> has not been studied . 	MIVACRON	succinylcholine
other	There are no clinical data on the use of <e1> DRUG1 </e1> with other <e2> DRUG2 </e2> . 	MIVACRON	nondepolarizing neuromuscular blocking agents
other	<e1> DRUG1 </e1> and <e2> DRUG2 </e2> (administered with nitrous oxide / oxygen to achieve 1.25 M.C . 	Isoflurane	enflurane
other	<e1> DRUG1 </e1> and enflurane (administered with <e2> DRUG2 </e2> / oxygen to achieve 1.25 M.C . 	Isoflurane	nitrous oxide
other	<e1> DRUG1 </e1> and enflurane (administered with nitrous oxide / <e2> DRUG2 </e2> to achieve 1.25 M.C . 	Isoflurane	oxygen
other	Isoflurane and <e1> DRUG1 </e1> (administered with <e2> DRUG2 </e2> / oxygen to achieve 1.25 M.C . 	enflurane	nitrous oxide
other	Isoflurane and <e1> DRUG1 </e1> (administered with nitrous oxide / <e2> DRUG2 </e2> to achieve 1.25 M.C . 	enflurane	oxygen
other	Isoflurane and enflurane (administered with <e1> DRUG1 </e1> / <e2> DRUG2 </e2> to achieve 1.25 M.C . 	nitrous oxide	oxygen
other	A greater potentiation of the neuromuscular blocking effects of <e1> DRUG1 </e1> may be expected with higher concentrations of <e2> DRUG2 </e2> or isoflurane . 	MIVACRON	enflurane
other	A greater potentiation of the neuromuscular blocking effects of <e1> DRUG1 </e1> may be expected with higher concentrations of enflurane or <e2> DRUG2 </e2> . 	MIVACRON	isoflurane
int	Other drugs which may enhance the neuromuscular blocking action of <e1> DRUG1 </e1> such as MIVACRON include certain <e2> DRUG2 </e2> (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	nondepolarizing agents	antibiotics
int	Other drugs which may enhance the neuromuscular blocking action of <e1> DRUG1 </e1> such as MIVACRON include certain antibiotics (e.g. , <e2> DRUG2 </e2> , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	nondepolarizing agents	aminoglycosides
int	Other drugs which may enhance the neuromuscular blocking action of <e1> DRUG1 </e1> such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , <e2> DRUG2 </e2> , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	nondepolarizing agents	tetracyclines
int	Other drugs which may enhance the neuromuscular blocking action of <e1> DRUG1 </e1> such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , <e2> DRUG2 </e2> , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	nondepolarizing agents	bacitracin
int	Other drugs which may enhance the neuromuscular blocking action of <e1> DRUG1 </e1> such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , <e2> DRUG2 </e2> , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	nondepolarizing agents	polymyxins
int	Other drugs which may enhance the neuromuscular blocking action of <e1> DRUG1 </e1> such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , <e2> DRUG2 </e2> , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	nondepolarizing agents	lincomycin
int	Other drugs which may enhance the neuromuscular blocking action of <e1> DRUG1 </e1> such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , <e2> DRUG2 </e2> , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	nondepolarizing agents	clindamycin
int	Other drugs which may enhance the neuromuscular blocking action of <e1> DRUG1 </e1> such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , <e2> DRUG2 </e2> , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	nondepolarizing agents	colistin
int	Other drugs which may enhance the neuromuscular blocking action of <e1> DRUG1 </e1> such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and <e2> DRUG2 </e2> ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	nondepolarizing agents	sodium colistimethate
int	Other drugs which may enhance the neuromuscular blocking action of <e1> DRUG1 </e1> such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , <e2> DRUG2 </e2> salts , lithium , local anesthetics , procainamide , and quinidine . 	nondepolarizing agents	magnesium
int	Other drugs which may enhance the neuromuscular blocking action of <e1> DRUG1 </e1> such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , <e2> DRUG2 </e2> , local anesthetics , procainamide , and quinidine . 	nondepolarizing agents	lithium
int	Other drugs which may enhance the neuromuscular blocking action of <e1> DRUG1 </e1> such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local <e2> DRUG2 </e2> , procainamide , and quinidine . 	nondepolarizing agents	anesthetics
int	Other drugs which may enhance the neuromuscular blocking action of <e1> DRUG1 </e1> such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , <e2> DRUG2 </e2> , and quinidine . 	nondepolarizing agents	procainamide
int	Other drugs which may enhance the neuromuscular blocking action of <e1> DRUG1 </e1> such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and <e2> DRUG2 </e2> . 	nondepolarizing agents	quinidine
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> DRUG1 </e1> include certain <e2> DRUG2 </e2> (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	MIVACRON	antibiotics
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> DRUG1 </e1> include certain antibiotics (e.g. , <e2> DRUG2 </e2> , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	MIVACRON	aminoglycosides
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> DRUG1 </e1> include certain antibiotics (e.g. , aminoglycosides , <e2> DRUG2 </e2> , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	MIVACRON	tetracyclines
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> DRUG1 </e1> include certain antibiotics (e.g. , aminoglycosides , tetracyclines , <e2> DRUG2 </e2> , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	MIVACRON	bacitracin
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> DRUG1 </e1> include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , <e2> DRUG2 </e2> , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	MIVACRON	polymyxins
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> DRUG1 </e1> include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , <e2> DRUG2 </e2> , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	MIVACRON	lincomycin
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> DRUG1 </e1> include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , <e2> DRUG2 </e2> , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	MIVACRON	clindamycin
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> DRUG1 </e1> include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , <e2> DRUG2 </e2> , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	MIVACRON	colistin
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> DRUG1 </e1> include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and <e2> DRUG2 </e2> ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	MIVACRON	sodium colistimethate
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> DRUG1 </e1> include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , <e2> DRUG2 </e2> salts , lithium , local anesthetics , procainamide , and quinidine . 	MIVACRON	magnesium
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> DRUG1 </e1> include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , <e2> DRUG2 </e2> , local anesthetics , procainamide , and quinidine . 	MIVACRON	lithium
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> DRUG1 </e1> include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local <e2> DRUG2 </e2> , procainamide , and quinidine . 	MIVACRON	anesthetics
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> DRUG1 </e1> include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , <e2> DRUG2 </e2> , and quinidine . 	MIVACRON	procainamide
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> DRUG1 </e1> include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and <e2> DRUG2 </e2> . 	MIVACRON	quinidine
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> DRUG1 </e1> (e.g. , <e2> DRUG2 </e2> , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	antibiotics	aminoglycosides
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> DRUG1 </e1> (e.g. , aminoglycosides , <e2> DRUG2 </e2> , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	antibiotics	tetracyclines
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> DRUG1 </e1> (e.g. , aminoglycosides , tetracyclines , <e2> DRUG2 </e2> , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	antibiotics	bacitracin
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> DRUG1 </e1> (e.g. , aminoglycosides , tetracyclines , bacitracin , <e2> DRUG2 </e2> , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	antibiotics	polymyxins
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> DRUG1 </e1> (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , <e2> DRUG2 </e2> , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	antibiotics	lincomycin
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> DRUG1 </e1> (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , <e2> DRUG2 </e2> , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	antibiotics	clindamycin
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> DRUG1 </e1> (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , <e2> DRUG2 </e2> , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	antibiotics	colistin
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> DRUG1 </e1> (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and <e2> DRUG2 </e2> ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	antibiotics	sodium colistimethate
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> DRUG1 </e1> (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , <e2> DRUG2 </e2> salts , lithium , local anesthetics , procainamide , and quinidine . 	antibiotics	magnesium
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> DRUG1 </e1> (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , <e2> DRUG2 </e2> , local anesthetics , procainamide , and quinidine . 	antibiotics	lithium
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> DRUG1 </e1> (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local <e2> DRUG2 </e2> , procainamide , and quinidine . 	antibiotics	anesthetics
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> DRUG1 </e1> (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , <e2> DRUG2 </e2> , and quinidine . 	antibiotics	procainamide
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> DRUG1 </e1> (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and <e2> DRUG2 </e2> . 	antibiotics	quinidine
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , <e1> DRUG1 </e1> , tetracyclines , <e2> DRUG2 </e2> , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	aminoglycosides	bacitracin
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , <e1> DRUG1 </e1> , tetracyclines , bacitracin , <e2> DRUG2 </e2> , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	aminoglycosides	polymyxins
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , <e1> DRUG1 </e1> , tetracyclines , bacitracin , polymyxins , <e2> DRUG2 </e2> , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	aminoglycosides	lincomycin
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , <e1> DRUG1 </e1> , tetracyclines , bacitracin , polymyxins , lincomycin , <e2> DRUG2 </e2> , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	aminoglycosides	clindamycin
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , <e1> DRUG1 </e1> , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , <e2> DRUG2 </e2> , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	aminoglycosides	colistin
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , <e1> DRUG1 </e1> , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and <e2> DRUG2 </e2> ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	aminoglycosides	sodium colistimethate
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , <e1> DRUG1 </e1> , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , <e2> DRUG2 </e2> salts , lithium , local anesthetics , procainamide , and quinidine . 	aminoglycosides	magnesium
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , <e1> DRUG1 </e1> , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , <e2> DRUG2 </e2> , local anesthetics , procainamide , and quinidine . 	aminoglycosides	lithium
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , <e1> DRUG1 </e1> , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local <e2> DRUG2 </e2> , procainamide , and quinidine . 	aminoglycosides	anesthetics
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , <e1> DRUG1 </e1> , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , <e2> DRUG2 </e2> , and quinidine . 	aminoglycosides	procainamide
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , <e1> DRUG1 </e1> , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and <e2> DRUG2 </e2> . 	aminoglycosides	quinidine
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , <e1> DRUG1 </e1> , bacitracin , <e2> DRUG2 </e2> , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	tetracyclines	polymyxins
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , <e1> DRUG1 </e1> , bacitracin , polymyxins , <e2> DRUG2 </e2> , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	tetracyclines	lincomycin
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , <e1> DRUG1 </e1> , bacitracin , polymyxins , lincomycin , <e2> DRUG2 </e2> , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	tetracyclines	clindamycin
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , <e1> DRUG1 </e1> , bacitracin , polymyxins , lincomycin , clindamycin , <e2> DRUG2 </e2> , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	tetracyclines	colistin
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , <e1> DRUG1 </e1> , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and <e2> DRUG2 </e2> ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	tetracyclines	sodium colistimethate
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , <e1> DRUG1 </e1> , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , <e2> DRUG2 </e2> salts , lithium , local anesthetics , procainamide , and quinidine . 	tetracyclines	magnesium
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , <e1> DRUG1 </e1> , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , <e2> DRUG2 </e2> , local anesthetics , procainamide , and quinidine . 	tetracyclines	lithium
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , <e1> DRUG1 </e1> , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local <e2> DRUG2 </e2> , procainamide , and quinidine . 	tetracyclines	anesthetics
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , <e1> DRUG1 </e1> , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , <e2> DRUG2 </e2> , and quinidine . 	tetracyclines	procainamide
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , <e1> DRUG1 </e1> , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and <e2> DRUG2 </e2> . 	tetracyclines	quinidine
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , <e1> DRUG1 </e1> , polymyxins , <e2> DRUG2 </e2> , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	bacitracin	lincomycin
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , <e1> DRUG1 </e1> , polymyxins , lincomycin , <e2> DRUG2 </e2> , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	bacitracin	clindamycin
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , <e1> DRUG1 </e1> , polymyxins , lincomycin , clindamycin , <e2> DRUG2 </e2> , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	bacitracin	colistin
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , <e1> DRUG1 </e1> , polymyxins , lincomycin , clindamycin , colistin , and <e2> DRUG2 </e2> ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	bacitracin	sodium colistimethate
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , <e1> DRUG1 </e1> , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , <e2> DRUG2 </e2> salts , lithium , local anesthetics , procainamide , and quinidine . 	bacitracin	magnesium
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , <e1> DRUG1 </e1> , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , <e2> DRUG2 </e2> , local anesthetics , procainamide , and quinidine . 	bacitracin	lithium
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , <e1> DRUG1 </e1> , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local <e2> DRUG2 </e2> , procainamide , and quinidine . 	bacitracin	anesthetics
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , <e1> DRUG1 </e1> , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , <e2> DRUG2 </e2> , and quinidine . 	bacitracin	procainamide
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , <e1> DRUG1 </e1> , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and <e2> DRUG2 </e2> . 	bacitracin	quinidine
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , <e1> DRUG1 </e1> , lincomycin , <e2> DRUG2 </e2> , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	polymyxins	clindamycin
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , <e1> DRUG1 </e1> , lincomycin , clindamycin , <e2> DRUG2 </e2> , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	polymyxins	colistin
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , <e1> DRUG1 </e1> , lincomycin , clindamycin , colistin , and <e2> DRUG2 </e2> ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	polymyxins	sodium colistimethate
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , <e1> DRUG1 </e1> , lincomycin , clindamycin , colistin , and sodium colistimethate ) , <e2> DRUG2 </e2> salts , lithium , local anesthetics , procainamide , and quinidine . 	polymyxins	magnesium
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , <e1> DRUG1 </e1> , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , <e2> DRUG2 </e2> , local anesthetics , procainamide , and quinidine . 	polymyxins	lithium
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , <e1> DRUG1 </e1> , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local <e2> DRUG2 </e2> , procainamide , and quinidine . 	polymyxins	anesthetics
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , <e1> DRUG1 </e1> , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , <e2> DRUG2 </e2> , and quinidine . 	polymyxins	procainamide
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , <e1> DRUG1 </e1> , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and <e2> DRUG2 </e2> . 	polymyxins	quinidine
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , <e1> DRUG1 </e1> , clindamycin , <e2> DRUG2 </e2> , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	lincomycin	colistin
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , <e1> DRUG1 </e1> , clindamycin , colistin , and <e2> DRUG2 </e2> ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	lincomycin	sodium colistimethate
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , <e1> DRUG1 </e1> , clindamycin , colistin , and sodium colistimethate ) , <e2> DRUG2 </e2> salts , lithium , local anesthetics , procainamide , and quinidine . 	lincomycin	magnesium
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , <e1> DRUG1 </e1> , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , <e2> DRUG2 </e2> , local anesthetics , procainamide , and quinidine . 	lincomycin	lithium
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , <e1> DRUG1 </e1> , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local <e2> DRUG2 </e2> , procainamide , and quinidine . 	lincomycin	anesthetics
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , <e1> DRUG1 </e1> , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , <e2> DRUG2 </e2> , and quinidine . 	lincomycin	procainamide
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , <e1> DRUG1 </e1> , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and <e2> DRUG2 </e2> . 	lincomycin	quinidine
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , <e1> DRUG1 </e1> , colistin , and <e2> DRUG2 </e2> ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	clindamycin	sodium colistimethate
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , <e1> DRUG1 </e1> , colistin , and sodium colistimethate ) , <e2> DRUG2 </e2> salts , lithium , local anesthetics , procainamide , and quinidine . 	clindamycin	magnesium
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , <e1> DRUG1 </e1> , colistin , and sodium colistimethate ) , magnesium salts , <e2> DRUG2 </e2> , local anesthetics , procainamide , and quinidine . 	clindamycin	lithium
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , <e1> DRUG1 </e1> , colistin , and sodium colistimethate ) , magnesium salts , lithium , local <e2> DRUG2 </e2> , procainamide , and quinidine . 	clindamycin	anesthetics
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , <e1> DRUG1 </e1> , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , <e2> DRUG2 </e2> , and quinidine . 	clindamycin	procainamide
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , <e1> DRUG1 </e1> , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and <e2> DRUG2 </e2> . 	clindamycin	quinidine
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 	colistin	sodium colistimethate
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , <e1> DRUG1 </e1> , and sodium colistimethate ) , <e2> DRUG2 </e2> salts , lithium , local anesthetics , procainamide , and quinidine . 	colistin	magnesium
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , <e1> DRUG1 </e1> , and sodium colistimethate ) , magnesium salts , <e2> DRUG2 </e2> , local anesthetics , procainamide , and quinidine . 	colistin	lithium
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , <e1> DRUG1 </e1> , and sodium colistimethate ) , magnesium salts , lithium , local <e2> DRUG2 </e2> , procainamide , and quinidine . 	colistin	anesthetics
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , <e1> DRUG1 </e1> , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , <e2> DRUG2 </e2> , and quinidine . 	colistin	procainamide
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , <e1> DRUG1 </e1> , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and <e2> DRUG2 </e2> . 	colistin	quinidine
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and <e1> DRUG1 </e1> ) , <e2> DRUG2 </e2> salts , lithium , local anesthetics , procainamide , and quinidine . 	sodium colistimethate	magnesium
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and <e1> DRUG1 </e1> ) , magnesium salts , <e2> DRUG2 </e2> , local anesthetics , procainamide , and quinidine . 	sodium colistimethate	lithium
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and <e1> DRUG1 </e1> ) , magnesium salts , lithium , local <e2> DRUG2 </e2> , procainamide , and quinidine . 	sodium colistimethate	anesthetics
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and <e1> DRUG1 </e1> ) , magnesium salts , lithium , local anesthetics , <e2> DRUG2 </e2> , and quinidine . 	sodium colistimethate	procainamide
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and <e1> DRUG1 </e1> ) , magnesium salts , lithium , local anesthetics , procainamide , and <e2> DRUG2 </e2> . 	sodium colistimethate	quinidine
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , <e1> DRUG1 </e1> salts , <e2> DRUG2 </e2> , local anesthetics , procainamide , and quinidine . 	magnesium	lithium
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , <e1> DRUG1 </e1> salts , lithium , local <e2> DRUG2 </e2> , procainamide , and quinidine . 	magnesium	anesthetics
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , <e1> DRUG1 </e1> salts , lithium , local anesthetics , <e2> DRUG2 </e2> , and quinidine . 	magnesium	procainamide
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , <e1> DRUG1 </e1> salts , lithium , local anesthetics , procainamide , and <e2> DRUG2 </e2> . 	magnesium	quinidine
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , <e1> DRUG1 </e1> , local <e2> DRUG2 </e2> , procainamide , and quinidine . 	lithium	anesthetics
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , <e1> DRUG1 </e1> , local anesthetics , <e2> DRUG2 </e2> , and quinidine . 	lithium	procainamide
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , <e1> DRUG1 </e1> , local anesthetics , procainamide , and <e2> DRUG2 </e2> . 	lithium	quinidine
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local <e1> DRUG1 </e1> , procainamide , and <e2> DRUG2 </e2> . 	anesthetics	quinidine
other	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> . 	procainamide	quinidine
effect	The neuromuscular blocking effect of <e1> DRUG1 </e1> may be enhanced by drugs that reduce plasma cholinesterase activity (e.g. , chronically administered oral <e2> DRUG2 </e2> , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 	MIVACRON	contraceptives
effect	The neuromuscular blocking effect of <e1> DRUG1 </e1> may be enhanced by drugs that reduce plasma cholinesterase activity (e.g. , chronically administered oral contraceptives , <e2> DRUG2 </e2> , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 	MIVACRON	glucocorticoids
effect	The neuromuscular blocking effect of <e1> DRUG1 </e1> may be enhanced by drugs that reduce plasma cholinesterase activity (e.g. , chronically administered oral contraceptives , glucocorticoids , or certain <e2> DRUG2 </e2> ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 	MIVACRON	monoamine oxidase inhibitors
other	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g. , chronically administered oral <e1> DRUG1 </e1> , glucocorticoids , or certain <e2> DRUG2 </e2> ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 	contraceptives	monoamine oxidase inhibitors
other	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g. , chronically administered oral contraceptives , <e1> DRUG1 </e1> , or certain <e2> DRUG2 </e2> ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 	glucocorticoids	monoamine oxidase inhibitors
effect	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing <e1> DRUG1 </e1> has been demonstrated in patients chronically administered <e2> DRUG2 </e2> or carbamazepine . 	neuromuscular blocking agents	phenytoin
effect	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing <e1> DRUG1 </e1> has been demonstrated in patients chronically administered phenytoin or <e2> DRUG2 </e2> . 	neuromuscular blocking agents	carbamazepine
effect	While the effects of chronic <e1> DRUG1 </e1> or carbamazepine therapy on the action of <e2> DRUG2 </e2> are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher . 	phenytoin	MIVACRON
effect	While the effects of chronic phenytoin or <e1> DRUG1 </e1> therapy on the action of <e2> DRUG2 </e2> are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher . 	carbamazepine	MIVACRON
other	Some drug interactions are :  - birth control pills - <e1> DRUG1 </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e2> DRUG2 </e2> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	corticosteroids	phenytoin
other	Some drug interactions are :  - birth control pills - <e1> DRUG1 </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e2> DRUG2 </e2> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	corticosteroids	carbamazepine
other	Some drug interactions are :  - birth control pills - <e1> DRUG1 </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e2> DRUG2 </e2> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	corticosteroids	antibiotics
other	Some drug interactions are :  - birth control pills - <e1> DRUG1 </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e2> DRUG2 </e2> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	corticosteroids	cisplatin
other	Some drug interactions are :  - birth control pills - <e1> DRUG1 </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e2> DRUG2 </e2> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	corticosteroids	edrophonium
other	Some drug interactions are :  - birth control pills - <e1> DRUG1 </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e2> DRUG2 </e2> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	corticosteroids	neostigmine
other	Some drug interactions are :  - birth control pills - <e1> DRUG1 </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e2> DRUG2 </e2> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	corticosteroids	polymyxin B
other	Some drug interactions are :  - birth control pills - <e1> DRUG1 </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e2> DRUG2 </e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	corticosteroids	bacitracin
other	Some drug interactions are :  - birth control pills - <e1> DRUG1 </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local <e2> DRUG2 </e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	corticosteroids	anesthetics
other	Some drug interactions are :  - birth control pills - <e1> DRUG1 </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e2> DRUG2 </e2> - general anesthetics - succinylcholine or other muscle relaxants 	corticosteroids	procaine
other	Some drug interactions are :  - birth control pills - <e1> DRUG1 </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e2> DRUG2 </e2> - succinylcholine or other muscle relaxants 	corticosteroids	anesthetics
other	Some drug interactions are :  - birth control pills - <e1> DRUG1 </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e2> DRUG2 </e2> or other muscle relaxants 	corticosteroids	succinylcholine
other	Some drug interactions are :  - birth control pills - <e1> DRUG1 </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2> DRUG2 </e2> 	corticosteroids	muscle relaxants
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> DRUG1 </e1> or carbamazepine - certain <e2> DRUG2 </e2> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	phenytoin	antibiotics
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> DRUG1 </e1> or carbamazepine - certain antibiotics given by injection - <e2> DRUG2 </e2> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	phenytoin	cisplatin
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> DRUG1 </e1> or carbamazepine - certain antibiotics given by injection - cisplatin - <e2> DRUG2 </e2> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	phenytoin	edrophonium
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> DRUG1 </e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e2> DRUG2 </e2> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	phenytoin	neostigmine
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> DRUG1 </e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e2> DRUG2 </e2> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	phenytoin	polymyxin B
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> DRUG1 </e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e2> DRUG2 </e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	phenytoin	bacitracin
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> DRUG1 </e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local <e2> DRUG2 </e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	phenytoin	anesthetics
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> DRUG1 </e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e2> DRUG2 </e2> - general anesthetics - succinylcholine or other muscle relaxants 	phenytoin	procaine
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> DRUG1 </e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e2> DRUG2 </e2> - succinylcholine or other muscle relaxants 	phenytoin	anesthetics
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> DRUG1 </e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e2> DRUG2 </e2> or other muscle relaxants 	phenytoin	succinylcholine
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> DRUG1 </e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2> DRUG2 </e2> 	phenytoin	muscle relaxants
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1> DRUG1 </e1> - certain <e2> DRUG2 </e2> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	carbamazepine	antibiotics
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1> DRUG1 </e1> - certain antibiotics given by injection - <e2> DRUG2 </e2> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	carbamazepine	cisplatin
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1> DRUG1 </e1> - certain antibiotics given by injection - cisplatin - <e2> DRUG2 </e2> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	carbamazepine	edrophonium
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1> DRUG1 </e1> - certain antibiotics given by injection - cisplatin - edrophonium - <e2> DRUG2 </e2> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	carbamazepine	neostigmine
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1> DRUG1 </e1> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e2> DRUG2 </e2> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	carbamazepine	polymyxin B
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1> DRUG1 </e1> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e2> DRUG2 </e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	carbamazepine	bacitracin
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1> DRUG1 </e1> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local <e2> DRUG2 </e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	carbamazepine	anesthetics
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1> DRUG1 </e1> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e2> DRUG2 </e2> - general anesthetics - succinylcholine or other muscle relaxants 	carbamazepine	procaine
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1> DRUG1 </e1> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e2> DRUG2 </e2> - succinylcholine or other muscle relaxants 	carbamazepine	anesthetics
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1> DRUG1 </e1> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e2> DRUG2 </e2> or other muscle relaxants 	carbamazepine	succinylcholine
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1> DRUG1 </e1> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2> DRUG2 </e2> 	carbamazepine	muscle relaxants
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1> DRUG1 </e1> given by injection - <e2> DRUG2 </e2> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	antibiotics	cisplatin
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1> DRUG1 </e1> given by injection - cisplatin - <e2> DRUG2 </e2> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	antibiotics	edrophonium
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1> DRUG1 </e1> given by injection - cisplatin - edrophonium - <e2> DRUG2 </e2> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	antibiotics	neostigmine
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1> DRUG1 </e1> given by injection - cisplatin - edrophonium - neostigmine - <e2> DRUG2 </e2> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	antibiotics	polymyxin B
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1> DRUG1 </e1> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e2> DRUG2 </e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	antibiotics	bacitracin
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1> DRUG1 </e1> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local <e2> DRUG2 </e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	antibiotics	anesthetics
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1> DRUG1 </e1> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e2> DRUG2 </e2> - general anesthetics - succinylcholine or other muscle relaxants 	antibiotics	procaine
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1> DRUG1 </e1> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e2> DRUG2 </e2> - succinylcholine or other muscle relaxants 	antibiotics	anesthetics
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1> DRUG1 </e1> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e2> DRUG2 </e2> or other muscle relaxants 	antibiotics	succinylcholine
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1> DRUG1 </e1> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2> DRUG2 </e2> 	antibiotics	muscle relaxants
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1> DRUG1 </e1> - edrophonium - <e2> DRUG2 </e2> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	cisplatin	neostigmine
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1> DRUG1 </e1> - edrophonium - neostigmine - <e2> DRUG2 </e2> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	cisplatin	polymyxin B
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1> DRUG1 </e1> - edrophonium - neostigmine - polymyxin B or <e2> DRUG2 </e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	cisplatin	bacitracin
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1> DRUG1 </e1> - edrophonium - neostigmine - polymyxin B or bacitracin - local <e2> DRUG2 </e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	cisplatin	anesthetics
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1> DRUG1 </e1> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e2> DRUG2 </e2> - general anesthetics - succinylcholine or other muscle relaxants 	cisplatin	procaine
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1> DRUG1 </e1> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e2> DRUG2 </e2> - succinylcholine or other muscle relaxants 	cisplatin	anesthetics
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1> DRUG1 </e1> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e2> DRUG2 </e2> or other muscle relaxants 	cisplatin	succinylcholine
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1> DRUG1 </e1> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2> DRUG2 </e2> 	cisplatin	muscle relaxants
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1> DRUG1 </e1> - neostigmine - <e2> DRUG2 </e2> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	edrophonium	polymyxin B
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1> DRUG1 </e1> - neostigmine - polymyxin B or <e2> DRUG2 </e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	edrophonium	bacitracin
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1> DRUG1 </e1> - neostigmine - polymyxin B or bacitracin - local <e2> DRUG2 </e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	edrophonium	anesthetics
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1> DRUG1 </e1> - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e2> DRUG2 </e2> - general anesthetics - succinylcholine or other muscle relaxants 	edrophonium	procaine
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1> DRUG1 </e1> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e2> DRUG2 </e2> - succinylcholine or other muscle relaxants 	edrophonium	anesthetics
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1> DRUG1 </e1> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e2> DRUG2 </e2> or other muscle relaxants 	edrophonium	succinylcholine
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1> DRUG1 </e1> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2> DRUG2 </e2> 	edrophonium	muscle relaxants
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e1> DRUG1 </e1> - polymyxin B or <e2> DRUG2 </e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	neostigmine	bacitracin
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e1> DRUG1 </e1> - polymyxin B or bacitracin - local <e2> DRUG2 </e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	neostigmine	anesthetics
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e1> DRUG1 </e1> - polymyxin B or bacitracin - local anesthetics such as <e2> DRUG2 </e2> - general anesthetics - succinylcholine or other muscle relaxants 	neostigmine	procaine
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e1> DRUG1 </e1> - polymyxin B or bacitracin - local anesthetics such as procaine - general <e2> DRUG2 </e2> - succinylcholine or other muscle relaxants 	neostigmine	anesthetics
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e1> DRUG1 </e1> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e2> DRUG2 </e2> or other muscle relaxants 	neostigmine	succinylcholine
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e1> DRUG1 </e1> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2> DRUG2 </e2> 	neostigmine	muscle relaxants
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e1> DRUG1 </e1> or bacitracin - local <e2> DRUG2 </e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	polymyxin B	anesthetics
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e1> DRUG1 </e1> or bacitracin - local anesthetics such as <e2> DRUG2 </e2> - general anesthetics - succinylcholine or other muscle relaxants 	polymyxin B	procaine
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e1> DRUG1 </e1> or bacitracin - local anesthetics such as procaine - general <e2> DRUG2 </e2> - succinylcholine or other muscle relaxants 	polymyxin B	anesthetics
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e1> DRUG1 </e1> or bacitracin - local anesthetics such as procaine - general anesthetics - <e2> DRUG2 </e2> or other muscle relaxants 	polymyxin B	succinylcholine
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e1> DRUG1 </e1> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2> DRUG2 </e2> 	polymyxin B	muscle relaxants
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e1> DRUG1 </e1> - local <e2> DRUG2 </e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants 	bacitracin	anesthetics
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e1> DRUG1 </e1> - local anesthetics such as <e2> DRUG2 </e2> - general anesthetics - succinylcholine or other muscle relaxants 	bacitracin	procaine
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e1> DRUG1 </e1> - local anesthetics such as procaine - general <e2> DRUG2 </e2> - succinylcholine or other muscle relaxants 	bacitracin	anesthetics
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e1> DRUG1 </e1> - local anesthetics such as procaine - general anesthetics - <e2> DRUG2 </e2> or other muscle relaxants 	bacitracin	succinylcholine
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e1> DRUG1 </e1> - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2> DRUG2 </e2> 	bacitracin	muscle relaxants
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local <e1> DRUG1 </e1> such as procaine - general anesthetics - <e2> DRUG2 </e2> or other muscle relaxants 	anesthetics	succinylcholine
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local <e1> DRUG1 </e1> such as procaine - general anesthetics - succinylcholine or other <e2> DRUG2 </e2> 	anesthetics	muscle relaxants
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e1> DRUG1 </e1> - general <e2> DRUG2 </e2> - succinylcholine or other muscle relaxants 	procaine	anesthetics
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e1> DRUG1 </e1> - general anesthetics - <e2> DRUG2 </e2> or other muscle relaxants 	procaine	succinylcholine
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e1> DRUG1 </e1> - general anesthetics - succinylcholine or other <e2> DRUG2 </e2> 	procaine	muscle relaxants
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e1> DRUG1 </e1> - succinylcholine or other <e2> DRUG2 </e2> 	anesthetics	muscle relaxants
other	Some drug interactions are :  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e1> DRUG1 </e1> or other <e2> DRUG2 </e2> 	succinylcholine	muscle relaxants
other	<e1> DRUG1 </e1> : Excessive reductions in blood pressure may occur in patients on diuretic therapy when <e2> DRUG2 </e2> are started . 	Diuretics	ACE inhibitors
other	Potassium Supplements and <e1> DRUG1 </e1> : <e2> DRUG2 </e2> can increase serum potassium because it decreases aldosterone secretion . 	Potassium-Sparing Diuretics	UNIVASC
other	Use of <e1> DRUG1 </e1> ( spironolactone , <e2> DRUG2 </e2> , amiloride ) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 	potassium-sparing diuretics	triamterene
other	Use of <e1> DRUG1 </e1> ( spironolactone , triamterene , <e2> DRUG2 </e2> ) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 	potassium-sparing diuretics	amiloride
other	Use of <e1> DRUG1 </e1> ( spironolactone , triamterene , amiloride ) or <e2> DRUG2 </e2> supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 	potassium-sparing diuretics	potassium
effect	Use of <e1> DRUG1 </e1> ( spironolactone , triamterene , amiloride ) or potassium supplements concomitantly with <e2> DRUG2 </e2> can increase the risk of hyperkalemia . 	potassium-sparing diuretics	ACE inhibitors
other	Use of potassium-sparing diuretics ( <e1> DRUG1 </e1> , triamterene , <e2> DRUG2 </e2> ) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 	spironolactone	amiloride
other	Use of potassium-sparing diuretics ( <e1> DRUG1 </e1> , triamterene , amiloride ) or <e2> DRUG2 </e2> supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 	spironolactone	potassium
effect	Use of potassium-sparing diuretics ( <e1> DRUG1 </e1> , triamterene , amiloride ) or potassium supplements concomitantly with <e2> DRUG2 </e2> can increase the risk of hyperkalemia . 	spironolactone	ACE inhibitors
other	Use of potassium-sparing diuretics ( spironolactone , <e1> DRUG1 </e1> , amiloride ) or <e2> DRUG2 </e2> supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 	triamterene	potassium
effect	Use of potassium-sparing diuretics ( spironolactone , <e1> DRUG1 </e1> , amiloride ) or potassium supplements concomitantly with <e2> DRUG2 </e2> can increase the risk of hyperkalemia . 	triamterene	ACE inhibitors
other	Use of potassium-sparing diuretics ( spironolactone , triamterene , <e1> DRUG1 </e1> ) or <e2> DRUG2 </e2> supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 	amiloride	potassium
effect	Use of potassium-sparing diuretics ( spironolactone , triamterene , <e1> DRUG1 </e1> ) or potassium supplements concomitantly with <e2> DRUG2 </e2> can increase the risk of hyperkalemia . 	amiloride	ACE inhibitors
effect	Use of potassium-sparing diuretics ( spironolactone , triamterene , amiloride ) or <e1> DRUG1 </e1> supplements concomitantly with <e2> DRUG2 </e2> can increase the risk of hyperkalemia . 	potassium	ACE inhibitors
other	Oral <e1> DRUG1 </e1> : Interaction studies with <e2> DRUG2 </e2> failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect . 	Anticoagulants	warfarin
other	Oral <e1> DRUG1 </e1> : Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the <e2> DRUG2 </e2> or on its anticoagulant effect . 	Anticoagulants	anticoagulant
other	Oral Anticoagulants : Interaction studies with <e1> DRUG1 </e1> failed to identify any clinically important effect on the serum concentrations of the <e2> DRUG2 </e2> or on its anticoagulant effect . 	warfarin	anticoagulant
other	<e1> DRUG1 </e1> : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving <e2> DRUG2 </e2> during therapy with lithium . 	Lithium	ACE inhibitors
other	Lithium : Increased serum <e1> DRUG1 </e1> levels and symptoms of lithium toxicity have been reported in patients receiving <e2> DRUG2 </e2> during therapy with lithium . 	lithium	ACE inhibitors
other	Lithium : Increased serum lithium levels and symptoms of <e1> DRUG1 </e1> toxicity have been reported in patients receiving <e2> DRUG2 </e2> during therapy with lithium . 	lithium	ACE inhibitors
effect	Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving <e1> DRUG1 </e1> during therapy with <e2> DRUG2 </e2> . 	ACE inhibitors	lithium
effect	If a <e1> DRUG1 </e1> is also used , the risk of <e2> DRUG2 </e2> toxicity may be increased . 	diuretic	lithium
other	Other Agents : No clinically important pharmacokinetic interactions occurred when <e1> DRUG1 </e1> was administered concomitantly with <e2> DRUG2 </e2> , digoxin , or cimetidine . 	UNIVASC	hydrochlorothiazide
other	Other Agents : No clinically important pharmacokinetic interactions occurred when <e1> DRUG1 </e1> was administered concomitantly with hydrochlorothiazide , <e2> DRUG2 </e2> , or cimetidine . 	UNIVASC	digoxin
other	Other Agents : No clinically important pharmacokinetic interactions occurred when <e1> DRUG1 </e1> was administered concomitantly with hydrochlorothiazide , digoxin , or <e2> DRUG2 </e2> . 	UNIVASC	cimetidine
other	Other Agents : No clinically important pharmacokinetic interactions occurred when UNIVASC was administered concomitantly with <e1> DRUG1 </e1> , digoxin , or <e2> DRUG2 </e2> . 	hydrochlorothiazide	cimetidine
other	<e1> DRUG1 </e1> has been used in clinical trials concomitantly with <e2> DRUG2 </e2> , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 	UNIVASC	calcium-channel-blocking agents
other	<e1> DRUG1 </e1> has been used in clinical trials concomitantly with calcium-channel-blocking agents , <e2> DRUG2 </e2> , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 	UNIVASC	diuretics
other	<e1> DRUG1 </e1> has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , <e2> DRUG2 </e2> , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 	UNIVASC	H2 blockers
other	<e1> DRUG1 </e1> has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , <e2> DRUG2 </e2> , oral hypoglycemic agents , and cholesterol-lowering agents . 	UNIVASC	digoxin
other	<e1> DRUG1 </e1> has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , digoxin , oral <e2> DRUG2 </e2> , and cholesterol-lowering agents . 	UNIVASC	hypoglycemic agents
other	UNIVASC has been used in clinical trials concomitantly with <e1> DRUG1 </e1> , diuretics , <e2> DRUG2 </e2> , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 	calcium-channel-blocking agents	H2 blockers
other	UNIVASC has been used in clinical trials concomitantly with <e1> DRUG1 </e1> , diuretics , H2 blockers , <e2> DRUG2 </e2> , oral hypoglycemic agents , and cholesterol-lowering agents . 	calcium-channel-blocking agents	digoxin
other	UNIVASC has been used in clinical trials concomitantly with <e1> DRUG1 </e1> , diuretics , H2 blockers , digoxin , oral <e2> DRUG2 </e2> , and cholesterol-lowering agents . 	calcium-channel-blocking agents	hypoglycemic agents
other	UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , <e1> DRUG1 </e1> , H2 blockers , <e2> DRUG2 </e2> , oral hypoglycemic agents , and cholesterol-lowering agents . 	diuretics	digoxin
other	UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , <e1> DRUG1 </e1> , H2 blockers , digoxin , oral <e2> DRUG2 </e2> , and cholesterol-lowering agents . 	diuretics	hypoglycemic agents
other	UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , <e1> DRUG1 </e1> , digoxin , oral <e2> DRUG2 </e2> , and cholesterol-lowering agents . 	H2 blockers	hypoglycemic agents
other	UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , <e1> DRUG1 </e1> , oral <e2> DRUG2 </e2> , and cholesterol-lowering agents . 	digoxin	hypoglycemic agents
mechanism	However , <e1> DRUG1 </e1> , a potent inhibitor of cytochrome P450 3A4 , may increase plasma levels of <e2> DRUG2 </e2> during concomitant dosing . 	ketoconazole	mometasone furoate
other	- did not change the plasma concentration profile of <e1> DRUG1 </e1> (a substrate of cytochrome P450 3A4) or <e2> DRUG2 </e2> , its carboxylated metabolite , and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily . 	terfenadine	fexofenadine
other	- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome P450 3A4) or <e1> DRUG1 </e1> , its carboxylated metabolite , and did not prolong the QTc interval following co-administration with <e2> DRUG2 </e2> 60 mg twice daily . 	fexofenadine	terfenadine
other	Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State :  - did not significantly alter the plasma concentrations of either component of an oral <e1> DRUG1 </e1> containing <e2> DRUG2 </e2> 1 mg/ethinyl estradiol 35 mcg . 	contraceptive	norethindrone
other	Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State :  - did not significantly alter the plasma concentrations of either component of an oral <e1> DRUG1 </e1> containing norethindrone 1 mg/ethinyl <e2> DRUG2 </e2> 35 mcg . 	contraceptive	estradiol
other	Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State :  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing <e1> DRUG1 </e1> 1 mg/ethinyl <e2> DRUG2 </e2> 35 mcg . 	norethindrone	estradiol
other	- did not cause any clinically significant change in plasma profiles of <e1> DRUG1 </e1> or prednisolone following administration of either oral prednisone or intravenous <e2> DRUG2 </e2> . 	prednisone	prednisolone
other	- did not cause any clinically significant change in plasma profiles of prednisone or <e1> DRUG1 </e1> following administration of either oral <e2> DRUG2 </e2> or intravenous prednisolone . 	prednisolone	prednisone
other	- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral <e1> DRUG1 </e1> or intravenous <e2> DRUG2 </e2> . 	prednisone	prednisolone
other	<e1> DRUG1 </e1> , which induces hepatic metabolism , decreased the AUC of <e2> DRUG2 </e2> approximately 40% following a single 10-mg dose of montelukast . 	Phenobarbital	montelukast
other	<e1> DRUG1 </e1> , which induces hepatic metabolism , decreased the AUC of montelukast approximately 40% following a single 10-mg dose of <e2> DRUG2 </e2> . 	Phenobarbital	montelukast
advise	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers , such as <e1> DRUG1 </e1> or rifampin , are co-administered with <e2> DRUG2 </e2> . 	phenobarbital	montelukast
advise	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers , such as phenobarbital or <e1> DRUG1 </e1> , are co-administered with <e2> DRUG2 </e2> . 	rifampin	montelukast
other	In drug-interaction studies , the recommended clinical dose of <e1> DRUG1 </e1> did not have clinically important effects on the pharmacokinetics of the following drugs : <e2> DRUG2 </e2> , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , digoxin , and warfarin . 	montelukast	theophylline
other	In drug-interaction studies , the recommended clinical dose of <e1> DRUG1 </e1> did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , <e2> DRUG2 </e2> , prednisolone , oral contraceptives ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , digoxin , and warfarin . 	montelukast	prednisone
other	In drug-interaction studies , the recommended clinical dose of <e1> DRUG1 </e1> did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , <e2> DRUG2 </e2> , oral contraceptives ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , digoxin , and warfarin . 	montelukast	prednisolone
other	In drug-interaction studies , the recommended clinical dose of <e1> DRUG1 </e1> did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral <e2> DRUG2 </e2> ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , digoxin , and warfarin . 	montelukast	contraceptives
other	In drug-interaction studies , the recommended clinical dose of <e1> DRUG1 </e1> did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( <e2> DRUG2 </e2> 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , digoxin , and warfarin . 	montelukast	norethindrone
other	In drug-interaction studies , the recommended clinical dose of <e1> DRUG1 </e1> did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ <e2> DRUG2 </e2> 35 mcg) , terfenadine , digoxin , and warfarin . 	montelukast	ethinyl estradiol
other	In drug-interaction studies , the recommended clinical dose of <e1> DRUG1 </e1> did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , <e2> DRUG2 </e2> , digoxin , and warfarin . 	montelukast	terfenadine
other	In drug-interaction studies , the recommended clinical dose of <e1> DRUG1 </e1> did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , <e2> DRUG2 </e2> , and warfarin . 	montelukast	digoxin
other	In drug-interaction studies , the recommended clinical dose of <e1> DRUG1 </e1> did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , digoxin , and <e2> DRUG2 </e2> . 	montelukast	warfarin
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : <e1> DRUG1 </e1> , prednisone , <e2> DRUG2 </e2> , oral contraceptives ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , digoxin , and warfarin . 	theophylline	prednisolone
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : <e1> DRUG1 </e1> , prednisone , prednisolone , oral <e2> DRUG2 </e2> ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , digoxin , and warfarin . 	theophylline	contraceptives
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : <e1> DRUG1 </e1> , prednisone , prednisolone , oral contraceptives ( <e2> DRUG2 </e2> 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , digoxin , and warfarin . 	theophylline	norethindrone
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : <e1> DRUG1 </e1> , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ <e2> DRUG2 </e2> 35 mcg) , terfenadine , digoxin , and warfarin . 	theophylline	ethinyl estradiol
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : <e1> DRUG1 </e1> , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , <e2> DRUG2 </e2> , digoxin , and warfarin . 	theophylline	terfenadine
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : <e1> DRUG1 </e1> , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , <e2> DRUG2 </e2> , and warfarin . 	theophylline	digoxin
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : <e1> DRUG1 </e1> , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , digoxin , and <e2> DRUG2 </e2> . 	theophylline	warfarin
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , <e1> DRUG1 </e1> , prednisolone , oral <e2> DRUG2 </e2> ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , digoxin , and warfarin . 	prednisone	contraceptives
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , <e1> DRUG1 </e1> , prednisolone , oral contraceptives ( <e2> DRUG2 </e2> 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , digoxin , and warfarin . 	prednisone	norethindrone
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , <e1> DRUG1 </e1> , prednisolone , oral contraceptives ( norethindrone 1 mg/ <e2> DRUG2 </e2> 35 mcg) , terfenadine , digoxin , and warfarin . 	prednisone	ethinyl estradiol
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , <e1> DRUG1 </e1> , prednisolone , oral contraceptives ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , <e2> DRUG2 </e2> , digoxin , and warfarin . 	prednisone	terfenadine
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , <e1> DRUG1 </e1> , prednisolone , oral contraceptives ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , <e2> DRUG2 </e2> , and warfarin . 	prednisone	digoxin
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , <e1> DRUG1 </e1> , prednisolone , oral contraceptives ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , digoxin , and <e2> DRUG2 </e2> . 	prednisone	warfarin
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , <e1> DRUG1 </e1> , oral <e2> DRUG2 </e2> ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , digoxin , and warfarin . 	prednisolone	contraceptives
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , <e1> DRUG1 </e1> , oral contraceptives ( <e2> DRUG2 </e2> 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , digoxin , and warfarin . 	prednisolone	norethindrone
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , <e1> DRUG1 </e1> , oral contraceptives ( norethindrone 1 mg/ <e2> DRUG2 </e2> 35 mcg) , terfenadine , digoxin , and warfarin . 	prednisolone	ethinyl estradiol
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , <e1> DRUG1 </e1> , oral contraceptives ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , <e2> DRUG2 </e2> , digoxin , and warfarin . 	prednisolone	terfenadine
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , <e1> DRUG1 </e1> , oral contraceptives ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , <e2> DRUG2 </e2> , and warfarin . 	prednisolone	digoxin
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , <e1> DRUG1 </e1> , oral contraceptives ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , digoxin , and <e2> DRUG2 </e2> . 	prednisolone	warfarin
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral <e1> DRUG1 </e1> ( norethindrone 1 mg/ <e2> DRUG2 </e2> 35 mcg) , terfenadine , digoxin , and warfarin . 	contraceptives	ethinyl estradiol
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral <e1> DRUG1 </e1> ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , <e2> DRUG2 </e2> , digoxin , and warfarin . 	contraceptives	terfenadine
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral <e1> DRUG1 </e1> ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , <e2> DRUG2 </e2> , and warfarin . 	contraceptives	digoxin
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral <e1> DRUG1 </e1> ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , digoxin , and <e2> DRUG2 </e2> . 	contraceptives	warfarin
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( <e1> DRUG1 </e1> 1 mg/ <e2> DRUG2 </e2> 35 mcg) , terfenadine , digoxin , and warfarin . 	norethindrone	ethinyl estradiol
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( <e1> DRUG1 </e1> 1 mg/ ethinyl estradiol 35 mcg) , <e2> DRUG2 </e2> , digoxin , and warfarin . 	norethindrone	terfenadine
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( <e1> DRUG1 </e1> 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , <e2> DRUG2 </e2> , and warfarin . 	norethindrone	digoxin
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( <e1> DRUG1 </e1> 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , digoxin , and <e2> DRUG2 </e2> . 	norethindrone	warfarin
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ <e1> DRUG1 </e1> 35 mcg) , <e2> DRUG2 </e2> , digoxin , and warfarin . 	ethinyl estradiol	terfenadine
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ <e1> DRUG1 </e1> 35 mcg) , terfenadine , <e2> DRUG2 </e2> , and warfarin . 	ethinyl estradiol	digoxin
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ <e1> DRUG1 </e1> 35 mcg) , terfenadine , digoxin , and <e2> DRUG2 </e2> . 	ethinyl estradiol	warfarin
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , <e1> DRUG1 </e1> , digoxin , and <e2> DRUG2 </e2> . 	terfenadine	warfarin
other	In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ ethinyl estradiol 35 mcg) , terfenadine , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> . 	digoxin	warfarin
other	These medications included <e1> DRUG1 </e1> , sedative hypnotics , <e2> DRUG2 </e2> , benzodiazepines , and decongestants . 	thyroid hormones	non-steroidal anti-inflammatory agents
other	These medications included <e1> DRUG1 </e1> , sedative hypnotics , non-steroidal anti-inflammatory agents , <e2> DRUG2 </e2> , and decongestants . 	thyroid hormones	benzodiazepines
other	These medications included <e1> DRUG1 </e1> , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and <e2> DRUG2 </e2> . 	thyroid hormones	decongestants
other	These medications included thyroid hormones , <e1> DRUG1 </e1> , non-steroidal anti-inflammatory agents , <e2> DRUG2 </e2> , and decongestants . 	sedative hypnotics	benzodiazepines
other	These medications included thyroid hormones , <e1> DRUG1 </e1> , non-steroidal anti-inflammatory agents , benzodiazepines , and <e2> DRUG2 </e2> . 	sedative hypnotics	decongestants
other	These medications included thyroid hormones , sedative hypnotics , <e1> DRUG1 </e1> , benzodiazepines , and <e2> DRUG2 </e2> . 	non-steroidal anti-inflammatory agents	decongestants
other	These medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> . 	benzodiazepines	decongestants
other	<e1> DRUG1 </e1> , which induces hepatic metabolism , decreased the AUC of <e2> DRUG2 </e2> approximately 40% following a single 10-mg dose of montelukast . 	Phenobarbital	montelukast
other	<e1> DRUG1 </e1> , which induces hepatic metabolism , decreased the AUC of montelukast approximately 40% following a single 10-mg dose of <e2> DRUG2 </e2> . 	Phenobarbital	montelukast
advise	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers , such as <e1> DRUG1 </e1> or rifampin , are co-administered with <e2> DRUG2 </e2> . 	phenobarbital	montelukast
advise	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers , such as phenobarbital or <e1> DRUG1 </e1> , are co-administered with <e2> DRUG2 </e2> . 	rifampin	montelukast
other	Use with Other <e1> DRUG1 </e1> : The depressant effects of <e2> DRUG2 </e2> are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 	Central Nervous System Depressants	morphine
other	Use with Other <e1> DRUG1 </e1> : The depressant effects of morphine are potentiated by the presence of other <e2> DRUG2 </e2> such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 	Central Nervous System Depressants	CNS depressants
other	Use with Other <e1> DRUG1 </e1> : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as <e2> DRUG2 </e2> , sedatives , antihistaminics , or psychotropic drugs . 	Central Nervous System Depressants	alcohol
other	Use with Other <e1> DRUG1 </e1> : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , <e2> DRUG2 </e2> , antihistaminics , or psychotropic drugs . 	Central Nervous System Depressants	sedatives
other	Use with Other <e1> DRUG1 </e1> : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , <e2> DRUG2 </e2> , or psychotropic drugs . 	Central Nervous System Depressants	antihistaminics
other	Use with Other <e1> DRUG1 </e1> : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or <e2> DRUG2 </e2> . 	Central Nervous System Depressants	psychotropic drugs
effect	Use with Other Central Nervous System Depressants : The depressant effects of <e1> DRUG1 </e1> are potentiated by the presence of other <e2> DRUG2 </e2> such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 	morphine	CNS depressants
effect	Use with Other Central Nervous System Depressants : The depressant effects of <e1> DRUG1 </e1> are potentiated by the presence of other CNS depressants such as <e2> DRUG2 </e2> , sedatives , antihistaminics , or psychotropic drugs . 	morphine	alcohol
effect	Use with Other Central Nervous System Depressants : The depressant effects of <e1> DRUG1 </e1> are potentiated by the presence of other CNS depressants such as alcohol , <e2> DRUG2 </e2> , antihistaminics , or psychotropic drugs . 	morphine	sedatives
effect	Use with Other Central Nervous System Depressants : The depressant effects of <e1> DRUG1 </e1> are potentiated by the presence of other CNS depressants such as alcohol , sedatives , <e2> DRUG2 </e2> , or psychotropic drugs . 	morphine	antihistaminics
effect	Use with Other Central Nervous System Depressants : The depressant effects of <e1> DRUG1 </e1> are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or <e2> DRUG2 </e2> . 	morphine	psychotropic drugs
other	Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other <e1> DRUG1 </e1> such as alcohol , <e2> DRUG2 </e2> , antihistaminics , or psychotropic drugs . 	CNS depressants	sedatives
other	Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other <e1> DRUG1 </e1> such as alcohol , sedatives , <e2> DRUG2 </e2> , or psychotropic drugs . 	CNS depressants	antihistaminics
other	Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other <e1> DRUG1 </e1> such as alcohol , sedatives , antihistaminics , or <e2> DRUG2 </e2> . 	CNS depressants	psychotropic drugs
other	Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as <e1> DRUG1 </e1> , sedatives , <e2> DRUG2 </e2> , or psychotropic drugs . 	alcohol	antihistaminics
other	Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as <e1> DRUG1 </e1> , sedatives , antihistaminics , or <e2> DRUG2 </e2> . 	alcohol	psychotropic drugs
other	Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , <e1> DRUG1 </e1> , antihistaminics , or <e2> DRUG2 </e2> . 	sedatives	psychotropic drugs
effect	Use of <e1> DRUG1 </e1> in conjunction with oral <e2> DRUG2 </e2> may increase the risk of respiratory depression , hypotension and profound sedation or coma . 	neuroleptics	morphine
other	Interaction with <e1> DRUG1 </e1> : <e2> DRUG2 </e2> (i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 	Mixed Agonist/Antagonist Opioid Analgesics	Agonist/antagonist analgesics
other	Interaction with <e1> DRUG1 </e1> : Agonist/antagonist analgesics (i.e. , <e2> DRUG2 </e2> , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 	Mixed Agonist/Antagonist Opioid Analgesics	pentazocine
other	Interaction with <e1> DRUG1 </e1> : Agonist/antagonist analgesics (i.e. , pentazocine , <e2> DRUG2 </e2> , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 	Mixed Agonist/Antagonist Opioid Analgesics	nalbuphine
other	Interaction with <e1> DRUG1 </e1> : Agonist/antagonist analgesics (i.e. , pentazocine , nalbuphine , <e2> DRUG2 </e2> , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 	Mixed Agonist/Antagonist Opioid Analgesics	butorphanol
other	Interaction with <e1> DRUG1 </e1> : Agonist/antagonist analgesics (i.e. , pentazocine , nalbuphine , butorphanol , or <e2> DRUG2 </e2> ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 	Mixed Agonist/Antagonist Opioid Analgesics	buprenorphine
other	Interaction with <e1> DRUG1 </e1> : Agonist/antagonist analgesics (i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e2> DRUG2 </e2> . 	Mixed Agonist/Antagonist Opioid Analgesics	opioid agonist analgesic
other	Interaction with Mixed Agonist/Antagonist Opioid Analgesics : <e1> DRUG1 </e1> (i.e. , <e2> DRUG2 </e2> , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 	Agonist/antagonist analgesics	pentazocine
other	Interaction with Mixed Agonist/Antagonist Opioid Analgesics : <e1> DRUG1 </e1> (i.e. , pentazocine , <e2> DRUG2 </e2> , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 	Agonist/antagonist analgesics	nalbuphine
other	Interaction with Mixed Agonist/Antagonist Opioid Analgesics : <e1> DRUG1 </e1> (i.e. , pentazocine , nalbuphine , <e2> DRUG2 </e2> , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 	Agonist/antagonist analgesics	butorphanol
other	Interaction with Mixed Agonist/Antagonist Opioid Analgesics : <e1> DRUG1 </e1> (i.e. , pentazocine , nalbuphine , butorphanol , or <e2> DRUG2 </e2> ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 	Agonist/antagonist analgesics	buprenorphine
advise	Interaction with Mixed Agonist/Antagonist Opioid Analgesics : <e1> DRUG1 </e1> (i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e2> DRUG2 </e2> . 	Agonist/antagonist analgesics	opioid agonist analgesic
other	Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics (i.e. , <e1> DRUG1 </e1> , nalbuphine , <e2> DRUG2 </e2> , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 	pentazocine	butorphanol
other	Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics (i.e. , <e1> DRUG1 </e1> , nalbuphine , butorphanol , or <e2> DRUG2 </e2> ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 	pentazocine	buprenorphine
advise	Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics (i.e. , <e1> DRUG1 </e1> , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e2> DRUG2 </e2> . 	pentazocine	opioid agonist analgesic
other	Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics (i.e. , pentazocine , <e1> DRUG1 </e1> , butorphanol , or <e2> DRUG2 </e2> ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 	nalbuphine	buprenorphine
advise	Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics (i.e. , pentazocine , <e1> DRUG1 </e1> , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e2> DRUG2 </e2> . 	nalbuphine	opioid agonist analgesic
advise	Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics (i.e. , pentazocine , nalbuphine , <e1> DRUG1 </e1> , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e2> DRUG2 </e2> . 	butorphanol	opioid agonist analgesic
advise	Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics (i.e. , pentazocine , nalbuphine , butorphanol , or <e1> DRUG1 </e1> ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e2> DRUG2 </e2> . 	buprenorphine	opioid agonist analgesic
other	<e1> DRUG1 </e1> : Absorption of a single dose of <e2> DRUG2 </e2> was decreased when administered to 12 stable renal transplant patients also taking magnesium - aluminum containing antacids (30 mL) : the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower , respectively , than when Myfortic was administered alone under fasting conditions . 	Antacids	Myfortic
other	<e1> DRUG1 </e1> : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking <e2> DRUG2 </e2> - aluminum containing antacids (30 mL) : the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower , respectively , than when Myfortic was administered alone under fasting conditions . 	Antacids	magnesium
other	<e1> DRUG1 </e1> : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium - <e2> DRUG2 </e2> containing antacids (30 mL) : the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower , respectively , than when Myfortic was administered alone under fasting conditions . 	Antacids	aluminum
other	<e1> DRUG1 </e1> : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium - aluminum containing antacids (30 mL) : the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower , respectively , than when <e2> DRUG2 </e2> was administered alone under fasting conditions . 	Antacids	Myfortic
mechanism	Antacids : Absorption of a single dose of <e1> DRUG1 </e1> was decreased when administered to 12 stable renal transplant patients also taking <e2> DRUG2 </e2> - aluminum containing antacids (30 mL) : the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower , respectively , than when Myfortic was administered alone under fasting conditions . 	Myfortic	magnesium
mechanism	Antacids : Absorption of a single dose of <e1> DRUG1 </e1> was decreased when administered to 12 stable renal transplant patients also taking magnesium - <e2> DRUG2 </e2> containing antacids (30 mL) : the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower , respectively , than when Myfortic was administered alone under fasting conditions . 	Myfortic	aluminum
other	Antacids : Absorption of a single dose of <e1> DRUG1 </e1> was decreased when administered to 12 stable renal transplant patients also taking magnesium - aluminum containing <e2> DRUG2 </e2> (30 mL) : the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower , respectively , than when Myfortic was administered alone under fasting conditions . 	Myfortic	antacids
other	Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking <e1> DRUG1 </e1> - aluminum containing <e2> DRUG2 </e2> (30 mL) : the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower , respectively , than when Myfortic was administered alone under fasting conditions . 	magnesium	antacids
other	Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking <e1> DRUG1 </e1> - aluminum containing antacids (30 mL) : the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower , respectively , than when <e2> DRUG2 </e2> was administered alone under fasting conditions . 	magnesium	Myfortic
other	Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium - <e1> DRUG1 </e1> containing <e2> DRUG2 </e2> (30 mL) : the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower , respectively , than when Myfortic was administered alone under fasting conditions . 	aluminum	antacids
other	Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium - <e1> DRUG1 </e1> containing antacids (30 mL) : the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower , respectively , than when <e2> DRUG2 </e2> was administered alone under fasting conditions . 	aluminum	Myfortic
other	Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium - aluminum containing <e1> DRUG1 </e1> (30 mL) : the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower , respectively , than when <e2> DRUG2 </e2> was administered alone under fasting conditions . 	antacids	Myfortic
advise	It is recommended that <e1> DRUG1 </e1> and <e2> DRUG2 </e2> not be administered simultaneously . 	Myfortic	antacids
other	<e1> DRUG1 </e1> : When studied in stable renal transplant patients , cyclosporine , USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of <e2> DRUG2 </e2> . 	Cyclosporine	Myfortic
other	Cyclosporine : When studied in stable renal transplant patients , <e1> DRUG1 </e1> , USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of <e2> DRUG2 </e2> . 	cyclosporine	Myfortic
other	<e1> DRUG1 </e1> / <e2> DRUG2 </e2> : may be taken with Myfortic ; 	Acyclovir	Ganciclovir
other	<e1> DRUG1 </e1> / Ganciclovir : may be taken with <e2> DRUG2 </e2> ; 	Acyclovir	Myfortic
other	Acyclovir / <e1> DRUG1 </e1> : may be taken with <e2> DRUG2 </e2> ; 	Ganciclovir	Myfortic
other	Both <e1> DRUG1 </e1> / <e2> DRUG2 </e2> and MPAG concentrations are increased in the presence of renal impairment , their coexistence may compete for tubular secretion and further increase in the concentrations of the two . 	acyclovir	ganciclovir
other	Both <e1> DRUG1 </e1> / ganciclovir and <e2> DRUG2 </e2> concentrations are increased in the presence of renal impairment , their coexistence may compete for tubular secretion and further increase in the concentrations of the two . 	acyclovir	MPAG
other	Both acyclovir / <e1> DRUG1 </e1> and <e2> DRUG2 </e2> concentrations are increased in the presence of renal impairment , their coexistence may compete for tubular secretion and further increase in the concentrations of the two . 	ganciclovir	MPAG
other	<e1> DRUG1 </e1> / <e2> DRUG2 </e2> : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 	Azathioprine	Mycophenolate Mofetil
other	<e1> DRUG1 </e1> / Mycophenolate Mofetil : Given that azathioprine and <e2> DRUG2 </e2> inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 	Azathioprine	mycophenolate mofetil
other	<e1> DRUG1 </e1> / Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that <e2> DRUG2 </e2> not be administered concomitantly with azathioprine or mycophenolate mofetil . 	Azathioprine	Myfortic
other	<e1> DRUG1 </e1> / Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or <e2> DRUG2 </e2> . 	Azathioprine	mycophenolate mofetil
other	Azathioprine / <e1> DRUG1 </e1> : Given that <e2> DRUG2 </e2> and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 	Mycophenolate Mofetil	azathioprine
other	Azathioprine / <e1> DRUG1 </e1> : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that <e2> DRUG2 </e2> not be administered concomitantly with azathioprine or mycophenolate mofetil . 	Mycophenolate Mofetil	Myfortic
other	Azathioprine / <e1> DRUG1 </e1> : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with <e2> DRUG2 </e2> or mycophenolate mofetil . 	Mycophenolate Mofetil	azathioprine
other	Azathioprine / Mycophenolate Mofetil : Given that <e1> DRUG1 </e1> and <e2> DRUG2 </e2> inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 	azathioprine	mycophenolate mofetil
other	Azathioprine / Mycophenolate Mofetil : Given that <e1> DRUG1 </e1> and mycophenolate mofetil inhibit purine metabolism , it is recommended that <e2> DRUG2 </e2> not be administered concomitantly with azathioprine or mycophenolate mofetil . 	azathioprine	Myfortic
other	Azathioprine / Mycophenolate Mofetil : Given that <e1> DRUG1 </e1> and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or <e2> DRUG2 </e2> . 	azathioprine	mycophenolate mofetil
other	Azathioprine / Mycophenolate Mofetil : Given that azathioprine and <e1> DRUG1 </e1> inhibit purine metabolism , it is recommended that <e2> DRUG2 </e2> not be administered concomitantly with azathioprine or mycophenolate mofetil . 	mycophenolate mofetil	Myfortic
other	Azathioprine / Mycophenolate Mofetil : Given that azathioprine and <e1> DRUG1 </e1> inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with <e2> DRUG2 </e2> or mycophenolate mofetil . 	mycophenolate mofetil	azathioprine
advise	Azathioprine / Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that <e1> DRUG1 </e1> not be administered concomitantly with <e2> DRUG2 </e2> or mycophenolate mofetil . 	Myfortic	azathioprine
advise	Azathioprine / Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that <e1> DRUG1 </e1> not be administered concomitantly with azathioprine or <e2> DRUG2 </e2> . 	Myfortic	mycophenolate mofetil
other	Cholestyramine and Drugs that Bind Bile Acids : These drugs interrupt enterohepatic recirculation and reduce <e1> DRUG1 </e1> exposure when coadministered with <e2> DRUG2 </e2> . 	MPA	mycophenolate mofetil
advise	Therefore , do not administer <e1> DRUG1 </e1> with <e2> DRUG2 </e2> or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of Myfortic . 	Myfortic	cholestyramine
advise	Therefore , do not administer <e1> DRUG1 </e1> with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral <e2> DRUG2 </e2> , because of the potential to reduce the efficacy of Myfortic . 	Myfortic	activated charcoal
other	Therefore , do not administer Myfortic with <e1> DRUG1 </e1> or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral <e2> DRUG2 </e2> , because of the potential to reduce the efficacy of Myfortic . 	cholestyramine	activated charcoal
other	Therefore , do not administer Myfortic with <e1> DRUG1 </e1> or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of <e2> DRUG2 </e2> . 	cholestyramine	Myfortic
other	Therefore , do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral <e1> DRUG1 </e1> , because of the potential to reduce the efficacy of <e2> DRUG2 </e2> . 	activated charcoal	Myfortic
other	Oral <e1> DRUG1 </e1> : Given the different metabolism of <e2> DRUG2 </e2> and oral contraceptives , no drug interaction between these two classes of drug is expected . 	Contraceptives	Myfortic
other	Oral Contraceptives : Given the different metabolism of <e1> DRUG1 </e1> and oral <e2> DRUG2 </e2> , no drug interaction between these two classes of drug is expected . 	Myfortic	contraceptives
mechanism	However , in a drug-drug interaction study , mean <e1> DRUG1 </e1> AUC was decreased by 15% when coadministered with <e2> DRUG2 </e2> . 	levonorgesterol	mycophenolate mofetil
advise	Therefore , it is recommended that oral <e1> DRUG1 </e1> are co- administered with <e2> DRUG2 </e2> with caution and additional birth control methods be considered . 	contraceptives	Myfortic
other	<e1> DRUG1 </e1> : During treatment with <e2> DRUG2 </e2> , the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective . 	Live Vaccines	Myfortic
other	<e1> DRUG1 </e1> : During treatment with Myfortic , the use of <e2> DRUG2 </e2> should be avoided and patients should be advised that vaccinations may be less effective . 	Live Vaccines	live attenuated vaccines
advise	Live Vaccines : During treatment with <e1> DRUG1 </e1> , the use of <e2> DRUG2 </e2> should be avoided and patients should be advised that vaccinations may be less effective . 	Myfortic	live attenuated vaccines
other	Interference of <e1> DRUG1 </e1> hydrolysis may lead to less <e2> DRUG2 </e2> available for absorption . 	MPAG	MPA
other	<e1> DRUG1 </e1> , Carbamazepine , and <e2> DRUG2 </e2> : In patients treated with potent inducers of CYP3A4 (i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 	Phenytoin	Rifampicin
other	<e1> DRUG1 </e1> , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i.e. , phenytoin , <e2> DRUG2 </e2> , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 	Phenytoin	carbamazepine
other	<e1> DRUG1 </e1> , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i.e. , phenytoin , carbamazepine , and <e2> DRUG2 </e2> ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 	Phenytoin	rifampicin
other	<e1> DRUG1 </e1> , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of <e2> DRUG2 </e2> was significantly increased and ondansetron blood concentrations were decreased . 	Phenytoin	ondansetron
other	<e1> DRUG1 </e1> , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and <e2> DRUG2 </e2> blood concentrations were decreased . 	Phenytoin	ondansetron
other	Phenytoin , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> : In patients treated with potent inducers of CYP3A4 (i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 	Carbamazepine	Rifampicin
other	Phenytoin , <e1> DRUG1 </e1> , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i.e. , <e2> DRUG2 </e2> , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 	Carbamazepine	phenytoin
other	Phenytoin , <e1> DRUG1 </e1> , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i.e. , phenytoin , carbamazepine , and <e2> DRUG2 </e2> ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 	Carbamazepine	rifampicin
other	Phenytoin , <e1> DRUG1 </e1> , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of <e2> DRUG2 </e2> was significantly increased and ondansetron blood concentrations were decreased . 	Carbamazepine	ondansetron
other	Phenytoin , <e1> DRUG1 </e1> , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and <e2> DRUG2 </e2> blood concentrations were decreased . 	Carbamazepine	ondansetron
other	Phenytoin , Carbamazepine , and <e1> DRUG1 </e1> : In patients treated with potent inducers of CYP3A4 (i.e. , <e2> DRUG2 </e2> , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 	Rifampicin	phenytoin
other	Phenytoin , Carbamazepine , and <e1> DRUG1 </e1> : In patients treated with potent inducers of CYP3A4 (i.e. , phenytoin , <e2> DRUG2 </e2> , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 	Rifampicin	carbamazepine
other	Phenytoin , Carbamazepine , and <e1> DRUG1 </e1> : In patients treated with potent inducers of CYP3A4 (i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of <e2> DRUG2 </e2> was significantly increased and ondansetron blood concentrations were decreased . 	Rifampicin	ondansetron
other	Phenytoin , Carbamazepine , and <e1> DRUG1 </e1> : In patients treated with potent inducers of CYP3A4 (i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and <e2> DRUG2 </e2> blood concentrations were decreased . 	Rifampicin	ondansetron
other	Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i.e. , <e1> DRUG1 </e1> , carbamazepine , and <e2> DRUG2 </e2> ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 	phenytoin	rifampicin
mechanism	Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i.e. , <e1> DRUG1 </e1> , carbamazepine , and rifampicin ) , the clearance of <e2> DRUG2 </e2> was significantly increased and ondansetron blood concentrations were decreased . 	phenytoin	ondansetron
mechanism	Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i.e. , <e1> DRUG1 </e1> , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and <e2> DRUG2 </e2> blood concentrations were decreased . 	phenytoin	ondansetron
other	Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i.e. , phenytoin , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 	carbamazepine	rifampicin
mechanism	Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i.e. , phenytoin , <e1> DRUG1 </e1> , and rifampicin ) , the clearance of <e2> DRUG2 </e2> was significantly increased and ondansetron blood concentrations were decreased . 	carbamazepine	ondansetron
mechanism	Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i.e. , phenytoin , <e1> DRUG1 </e1> , and rifampicin ) , the clearance of ondansetron was significantly increased and <e2> DRUG2 </e2> blood concentrations were decreased . 	carbamazepine	ondansetron
mechanism	Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i.e. , phenytoin , carbamazepine , and <e1> DRUG1 </e1> ) , the clearance of <e2> DRUG2 </e2> was significantly increased and ondansetron blood concentrations were decreased . 	rifampicin	ondansetron
mechanism	Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i.e. , phenytoin , carbamazepine , and <e1> DRUG1 </e1> ) , the clearance of ondansetron was significantly increased and <e2> DRUG2 </e2> blood concentrations were decreased . 	rifampicin	ondansetron
other	However , on the basis of available data , no dosage adjustment for <e1> DRUG1 </e1> is recommended for patients on these drugs.1,3 <e2> DRUG2 </e2> : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol .4,5  Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 	ondansetron	Tramadol
other	However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 <e1> DRUG1 </e1> : Although no pharmacokinetic drug interaction between <e2> DRUG2 </e2> and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol .4,5  Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 	Tramadol	ondansetron
other	However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 <e1> DRUG1 </e1> : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol .4,5  Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by <e2> DRUG2 </e2> . 	Tramadol	ondansetron
other	However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between <e1> DRUG1 </e1> and <e2> DRUG2 </e2> has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol .4,5  Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 	ondansetron	tramadol
other	However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between <e1> DRUG1 </e1> and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of <e2> DRUG2 </e2> .4,5  Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 	ondansetron	tramadol
other	However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and <e1> DRUG1 </e1> has been observed , data from 2 small studies indicate that <e2> DRUG2 </e2> may be associated with an increase in patient controlled administration of tramadol .4,5  Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 	tramadol	ondansetron
other	However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and <e1> DRUG1 </e1> has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol .4,5  Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by <e2> DRUG2 </e2> . 	tramadol	ondansetron
effect	However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that <e1> DRUG1 </e1> may be associated with an increase in patient controlled administration of <e2> DRUG2 </e2> .4,5  Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 	ondansetron	tramadol
other	However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of <e1> DRUG1 </e1> .4,5  Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by <e2> DRUG2 </e2> . 	tramadol	ondansetron
other	In humans , <e1> DRUG1 </e1> , etoposide , and <e2> DRUG2 </e2> do not affect the pharmacokinetics of ondansetron . 	carmustine	cisplatin
other	In humans , <e1> DRUG1 </e1> , etoposide , and cisplatin do not affect the pharmacokinetics of <e2> DRUG2 </e2> . 	carmustine	ondansetron
other	In humans , carmustine , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> do not affect the pharmacokinetics of ondansetron . 	etoposide	cisplatin
other	In humans , carmustine , <e1> DRUG1 </e1> , and cisplatin do not affect the pharmacokinetics of <e2> DRUG2 </e2> . 	etoposide	ondansetron
other	In humans , carmustine , etoposide , and <e1> DRUG1 </e1> do not affect the pharmacokinetics of <e2> DRUG2 </e2> . 	cisplatin	ondansetron
other	<e1> DRUG1 </e1> did not increase blood levels of high-dose <e2> DRUG2 </e2> . 	ondansetron	methotrexate
advise	Other <e1> DRUG1 </e1> should not be used concomitantly with <e2> DRUG2 </e2> ( metaproterenol sulfate USP) because they may have additive effects . 	beta adrenergic aerosol bronchodilators	Alupent
advise	Other <e1> DRUG1 </e1> should not be used concomitantly with Alupent ( <e2> DRUG2 </e2> USP) because they may have additive effects . 	beta adrenergic aerosol bronchodilators	metaproterenol sulfate
advise	<e1> DRUG1 </e1> should be administered with caution to patients being treated with <e2> DRUG2 </e2> or tricyclic antidepressants , since the action of beta adrenergic agonists on the vascular system may be potentiated . 	Beta adrenergic agonists	monoamine oxidase inhibitors
advise	<e1> DRUG1 </e1> should be administered with caution to patients being treated with monoamine oxidase inhibitors or <e2> DRUG2 </e2> , since the action of beta adrenergic agonists on the vascular system may be potentiated . 	Beta adrenergic agonists	tricyclic antidepressants
other	Beta adrenergic agonists should be administered with caution to patients being treated with <e1> DRUG1 </e1> or tricyclic antidepressants , since the action of <e2> DRUG2 </e2> on the vascular system may be potentiated . 	monoamine oxidase inhibitors	beta adrenergic agonists
other	Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or <e1> DRUG1 </e1> , since the action of <e2> DRUG2 </e2> on the vascular system may be potentiated . 	tricyclic antidepressants	beta adrenergic agonists
other	<e1> DRUG1 </e1> : In a multiple-dose study in 30 normal weight subjects , coadministration of <e2> DRUG2 </e2> and 40 grams of alcohol (e.g. , approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics (fecal fat excretion) , or systemic exposure to orlistat . 	Alcohol	XENICAL
other	<e1> DRUG1 </e1> : In a multiple-dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol (e.g. , approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics , <e2> DRUG2 </e2> pharmacodynamics (fecal fat excretion) , or systemic exposure to orlistat . 	Alcohol	orlistat
other	<e1> DRUG1 </e1> : In a multiple-dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol (e.g. , approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics (fecal fat excretion) , or systemic exposure to <e2> DRUG2 </e2> . 	Alcohol	orlistat
other	Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of <e1> DRUG1 </e1> and 40 grams of <e2> DRUG2 </e2> (e.g. , approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics (fecal fat excretion) , or systemic exposure to orlistat . 	XENICAL	alcohol
other	Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of <e1> DRUG1 </e1> and 40 grams of alcohol (e.g. , approximately 3 glasses of wine) did not result in alteration of <e2> DRUG2 </e2> pharmacokinetics , orlistat pharmacodynamics (fecal fat excretion) , or systemic exposure to orlistat . 	XENICAL	alcohol
other	Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of <e1> DRUG1 </e1> and 40 grams of alcohol (e.g. , approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics , <e2> DRUG2 </e2> pharmacodynamics (fecal fat excretion) , or systemic exposure to orlistat . 	XENICAL	orlistat
other	Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of <e1> DRUG1 </e1> and 40 grams of alcohol (e.g. , approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics (fecal fat excretion) , or systemic exposure to <e2> DRUG2 </e2> . 	XENICAL	orlistat
other	Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of <e1> DRUG1 </e1> (e.g. , approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics , <e2> DRUG2 </e2> pharmacodynamics (fecal fat excretion) , or systemic exposure to orlistat . 	alcohol	orlistat
other	Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of <e1> DRUG1 </e1> (e.g. , approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics (fecal fat excretion) , or systemic exposure to <e2> DRUG2 </e2> . 	alcohol	orlistat
other	Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol (e.g. , approximately 3 glasses of wine) did not result in alteration of <e1> DRUG1 </e1> pharmacokinetics , <e2> DRUG2 </e2> pharmacodynamics (fecal fat excretion) , or systemic exposure to orlistat . 	alcohol	orlistat
other	Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol (e.g. , approximately 3 glasses of wine) did not result in alteration of <e1> DRUG1 </e1> pharmacokinetics , orlistat pharmacodynamics (fecal fat excretion) , or systemic exposure to <e2> DRUG2 </e2> . 	alcohol	orlistat
other	<e1> DRUG1 </e1> : Preliminary data from a <e2> DRUG2 </e2> and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 	Cyclosporine	XENICAL
other	<e1> DRUG1 </e1> : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when <e2> DRUG2 </e2> was coadministered with cyclosporine . 	Cyclosporine	XENICAL
other	Cyclosporine : Preliminary data from a <e1> DRUG1 </e1> and <e2> DRUG2 </e2> drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 	XENICAL	cyclosporine
other	Cyclosporine : Preliminary data from a <e1> DRUG1 </e1> and cyclosporine drug interaction study indicate a reduction in <e2> DRUG2 </e2> plasma levels when XENICAL was coadministered with cyclosporine . 	XENICAL	cyclosporine
other	Cyclosporine : Preliminary data from a <e1> DRUG1 </e1> and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with <e2> DRUG2 </e2> . 	XENICAL	cyclosporine
other	Cyclosporine : Preliminary data from a XENICAL and <e1> DRUG1 </e1> drug interaction study indicate a reduction in cyclosporine plasma levels when <e2> DRUG2 </e2> was coadministered with cyclosporine . 	cyclosporine	XENICAL
other	Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in <e1> DRUG1 </e1> plasma levels when <e2> DRUG2 </e2> was coadministered with cyclosporine . 	cyclosporine	XENICAL
mechanism	Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when <e1> DRUG1 </e1> was coadministered with <e2> DRUG2 </e2> . 	XENICAL	cyclosporine
other	<e1> DRUG1 </e1> : In 12 normal-weight subjects receiving <e2> DRUG2 </e2> 120 mg three times a day for 6 days , XENICAL did not alter the pharmacokinetics of a single dose of digoxin . 	Digoxin	XENICAL
other	<e1> DRUG1 </e1> : In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days , <e2> DRUG2 </e2> did not alter the pharmacokinetics of a single dose of digoxin . 	Digoxin	XENICAL
other	Digoxin : In 12 normal-weight subjects receiving <e1> DRUG1 </e1> 120 mg three times a day for 6 days , XENICAL did not alter the pharmacokinetics of a single dose of <e2> DRUG2 </e2> . 	XENICAL	digoxin
other	Digoxin : In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days , <e1> DRUG1 </e1> did not alter the pharmacokinetics of a single dose of <e2> DRUG2 </e2> . 	XENICAL	digoxin
other	<e1> DRUG1 </e1> and Analogues : A pharmacokinetic interaction study showed a 30% reduction in <e2> DRUG2 </e2> supplement absorption when concomitantly administered with XENICAL . 	Fat-soluble Vitamin Supplements	beta-carotene
other	<e1> DRUG1 </e1> and Analogues : A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with <e2> DRUG2 </e2> . 	Fat-soluble Vitamin Supplements	XENICAL
mechanism	Fat-soluble Vitamin Supplements and Analogues : A pharmacokinetic interaction study showed a 30% reduction in <e1> DRUG1 </e1> supplement absorption when concomitantly administered with <e2> DRUG2 </e2> . 	beta-carotene	XENICAL
mechanism	<e1> DRUG1 </e1> inhibited absorption of a <e2> DRUG2 </e2> supplement by approximately 60% . 	XENICAL	vitamin E acetate
other	The effect of <e1> DRUG1 </e1> on the absorption of supplemental <e2> DRUG2 </e2> , vitamin A , and nutritionally-derived vitamin K is not known at this time . 	orlistat	vitamin D
other	The effect of <e1> DRUG1 </e1> on the absorption of supplemental vitamin D , <e2> DRUG2 </e2> , and nutritionally-derived vitamin K is not known at this time . 	orlistat	vitamin A
other	The effect of <e1> DRUG1 </e1> on the absorption of supplemental vitamin D , vitamin A , and nutritionally-derived <e2> DRUG2 </e2> is not known at this time . 	orlistat	vitamin K
other	The effect of orlistat on the absorption of supplemental <e1> DRUG1 </e1> , vitamin A , and nutritionally-derived <e2> DRUG2 </e2> is not known at this time . 	vitamin D	vitamin K
other	The effect of orlistat on the absorption of supplemental vitamin D , <e1> DRUG1 </e1> , and nutritionally-derived <e2> DRUG2 </e2> is not known at this time . 	vitamin A	vitamin K
other	<e1> DRUG1 </e1> : In 12 normal-weight subjects receiving <e2> DRUG2 </e2> 80 mg three times a day for 5 days , orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide . 	Glyburide	orlistat
other	<e1> DRUG1 </e1> : In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days , <e2> DRUG2 </e2> did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide . 	Glyburide	orlistat
other	Glyburide : In 12 normal-weight subjects receiving <e1> DRUG1 </e1> 80 mg three times a day for 5 days , orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of <e2> DRUG2 </e2> . 	orlistat	glyburide
other	Glyburide : In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days , <e1> DRUG1 </e1> did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of <e2> DRUG2 </e2> . 	orlistat	glyburide
other	Nifedipine (extended-release tablets) : In 17 normal-weight subjects receiving <e1> DRUG1 </e1> 120 mg three times a day for 6 days , XENICAL did not alter the bioavailability of <e2> DRUG2 </e2> (extended-release tablets) . 	XENICAL	nifedipine
other	Nifedipine (extended-release tablets) : In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days , <e1> DRUG1 </e1> did not alter the bioavailability of <e2> DRUG2 </e2> (extended-release tablets) . 	XENICAL	nifedipine
other	Oral <e1> DRUG1 </e1> : In 20 normal-weight female subjects , the treatment of <e2> DRUG2 </e2> 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives . 	Contraceptives	XENICAL
other	Oral Contraceptives : In 20 normal-weight female subjects , the treatment of <e1> DRUG1 </e1> 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral <e2> DRUG2 </e2> . 	XENICAL	contraceptives
other	<e1> DRUG1 </e1> : In 12 normal-weight subjects receiving <e2> DRUG2 </e2> 120 mg three times a day for 7 days , XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin . 	Phenytoin	XENICAL
other	<e1> DRUG1 </e1> : In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days , <e2> DRUG2 </e2> did not alter the pharmacokinetics of a single 300-mg dose of phenytoin . 	Phenytoin	XENICAL
other	Phenytoin : In 12 normal-weight subjects receiving <e1> DRUG1 </e1> 120 mg three times a day for 7 days , XENICAL did not alter the pharmacokinetics of a single 300-mg dose of <e2> DRUG2 </e2> . 	XENICAL	phenytoin
other	Phenytoin : In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days , <e1> DRUG1 </e1> did not alter the pharmacokinetics of a single 300-mg dose of <e2> DRUG2 </e2> . 	XENICAL	phenytoin
other	<e1> DRUG1 </e1> : In a 2-way crossover study of 24 normal-weight , mildly hypercholesterolemic patients receiving <e2> DRUG2 </e2> 120 mg three times a day for 6 days , XENICAL did not affect the pharmacokinetics of pravastatin . 	Pravastatin	XENICAL
other	<e1> DRUG1 </e1> : In a 2-way crossover study of 24 normal-weight , mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days , <e2> DRUG2 </e2> did not affect the pharmacokinetics of pravastatin . 	Pravastatin	XENICAL
other	Pravastatin : In a 2-way crossover study of 24 normal-weight , mildly hypercholesterolemic patients receiving <e1> DRUG1 </e1> 120 mg three times a day for 6 days , XENICAL did not affect the pharmacokinetics of <e2> DRUG2 </e2> . 	XENICAL	pravastatin
other	Pravastatin : In a 2-way crossover study of 24 normal-weight , mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days , <e1> DRUG1 </e1> did not affect the pharmacokinetics of <e2> DRUG2 </e2> . 	XENICAL	pravastatin
other	<e1> DRUG1 </e1> : In 12 normal-weight subjects , administration of <e2> DRUG2 </e2> 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII) . 	Warfarin	XENICAL
other	Warfarin : In 12 normal-weight subjects , administration of <e1> DRUG1 </e1> 120 mg three times a day for 16 days did not result in any change in either <e2> DRUG2 </e2> pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII) . 	XENICAL	warfarin
mechanism	Therefore , as <e1> DRUG1 </e1> absorption may be decreased with <e2> DRUG2 </e2> , patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters . 	vitamin K	XENICAL
other	Therefore , as <e1> DRUG1 </e1> absorption may be decreased with XENICAL , patients on chronic stable doses of <e2> DRUG2 </e2> who are prescribed XENICAL should be monitored closely for changes in coagulation parameters . 	vitamin K	warfarin
other	Therefore , as <e1> DRUG1 </e1> absorption may be decreased with XENICAL , patients on chronic stable doses of warfarin who are prescribed <e2> DRUG2 </e2> should be monitored closely for changes in coagulation parameters . 	vitamin K	XENICAL
other	Therefore , as vitamin K absorption may be decreased with <e1> DRUG1 </e1> , patients on chronic stable doses of <e2> DRUG2 </e2> who are prescribed XENICAL should be monitored closely for changes in coagulation parameters . 	XENICAL	warfarin
advise	Therefore , as vitamin K absorption may be decreased with XENICAL , patients on chronic stable doses of <e1> DRUG1 </e1> who are prescribed <e2> DRUG2 </e2> should be monitored closely for changes in coagulation parameters . 	warfarin	XENICAL
other	<e1> DRUG1 </e1> , a bacteriostatic <e2> DRUG2 </e2> , may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided . 	Tetracycline	antibiotic
effect	<e1> DRUG1 </e1> , a bacteriostatic antibiotic , may antagonize the bactericidal effect of <e2> DRUG2 </e2> and concurrent use of these drugs should be avoided . 	Tetracycline	penicillin
other	Tetracycline , a bacteriostatic <e1> DRUG1 </e1> , may antagonize the bactericidal effect of <e2> DRUG2 </e2> and concurrent use of these drugs should be avoided . 	antibiotic	penicillin
other	No pharmacokinetic interaction between 85 mg/m2 <e1> DRUG1 </e1> and infusional <e2> DRUG2 </e2> has been observed in patients treated every 2 weeks . 	ELOXATIN	5-FU
mechanism	Increases of <e1> DRUG1 </e1> plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 <e2> DRUG2 </e2> dosed every 3 weeks . 	5-FU	ELOXATIN
effect	Anticoagulants <e1> DRUG1 </e1> may increase sensitivity to oral <e2> DRUG2 </e2> . 	Anabolic steroids	anticoagulants
other	<e1> DRUG1 </e1> : A multidose study of <e2> DRUG2 </e2> , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL : similar increases in R-warfarin half-life and AUC were also detected . 	Warfarin	oxandrolone
other	<e1> DRUG1 </e1> : A multidose study of oxandrolone , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in <e2> DRUG2 </e2> half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL : similar increases in R-warfarin half-life and AUC were also detected . 	Warfarin	S-warfarin
other	<e1> DRUG1 </e1> : A multidose study of oxandrolone , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL : similar increases in <e2> DRUG2 </e2> half-life and AUC were also detected . 	Warfarin	R-warfarin
mechanism	Warfarin : A multidose study of <e1> DRUG1 </e1> , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with <e2> DRUG2 </e2> , resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL : similar increases in R-warfarin half-life and AUC were also detected . 	oxandrolone	warfarin
other	Warfarin : A multidose study of <e1> DRUG1 </e1> , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in <e2> DRUG2 </e2> half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL : similar increases in R-warfarin half-life and AUC were also detected . 	oxandrolone	S-warfarin
other	Warfarin : A multidose study of <e1> DRUG1 </e1> , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL : similar increases in <e2> DRUG2 </e2> half-life and AUC were also detected . 	oxandrolone	R-warfarin
other	Warfarin : A multidose study of oxandrolone , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with <e1> DRUG1 </e1> , resulted in a mean increase in <e2> DRUG2 </e2> half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL : similar increases in R-warfarin half-life and AUC were also detected . 	warfarin	S-warfarin
other	Warfarin : A multidose study of oxandrolone , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with <e1> DRUG1 </e1> , resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL : similar increases in <e2> DRUG2 </e2> half-life and AUC were also detected . 	warfarin	R-warfarin
other	Warfarin : A multidose study of oxandrolone , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in <e1> DRUG1 </e1> half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL : similar increases in <e2> DRUG2 </e2> half-life and AUC were also detected . 	S-warfarin	R-warfarin
advise	When <e1> DRUG1 </e1> therapy is initiated in a patient already receiving treatment with <e2> DRUG2 </e2> , the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved . 	oxandrolone	warfarin
other	When <e1> DRUG1 </e1> therapy is initiated in a patient already receiving treatment with warfarin , the INR or prothrombin time (PT) should be monitored closely and the dose of <e2> DRUG2 </e2> adjusted as necessary until a stable target INR or PT has been achieved . 	oxandrolone	warfarin
advise	Furthermore , in patients receiving both drugs , careful monitoring of the INR or PT , and adjustment of the <e1> DRUG1 </e1> dosage if indicated are recommended when the <e2> DRUG2 </e2> dose is changed or discontinued . 	warfarin	oxandrolone
mechanism	Oral hypoglycemic agents <e1> DRUG1 </e1> may inhibit the metabolism of oral <e2> DRUG2 </e2> . 	Oxandrolone	hypoglycemic agents
effect	The concomitant use of <e1> DRUG1 </e1> with other <e2> DRUG2 </e2> or with other agents which produce dry mouth , constipation , somnolence (drowsiness) , and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects . 	oxybutynin	anticholinergic drugs
other	Mean <e1> DRUG1 </e1> plasma concentrations were approximately 2 fold higher when <e2> DRUG2 </e2> was administered with ketoconazole , a potent CYP3A4 inhibitor . 	oxybutynin chloride	DITROPAN XL
other	Mean <e1> DRUG1 </e1> plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with <e2> DRUG2 </e2> , a potent CYP3A4 inhibitor . 	oxybutynin chloride	ketoconazole
mechanism	Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when <e1> DRUG1 </e1> was administered with <e2> DRUG2 </e2> , a potent CYP3A4 inhibitor . 	DITROPAN XL	ketoconazole
other	Other inhibitors of the cytochrome P450 3A4 enzyme system , such as <e1> DRUG1 </e1> (e.g. , <e2> DRUG2 </e2> and miconazole ) or macrolide antibiotics (e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters (i.e. , Cmax and AUC) . 	antimycotic agents	itraconazole
other	Other inhibitors of the cytochrome P450 3A4 enzyme system , such as <e1> DRUG1 </e1> (e.g. , itraconazole and <e2> DRUG2 </e2> ) or macrolide antibiotics (e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters (i.e. , Cmax and AUC) . 	antimycotic agents	miconazole
other	Other inhibitors of the cytochrome P450 3A4 enzyme system , such as <e1> DRUG1 </e1> (e.g. , itraconazole and miconazole ) or <e2> DRUG2 </e2> (e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters (i.e. , Cmax and AUC) . 	antimycotic agents	macrolide antibiotics
other	Other inhibitors of the cytochrome P450 3A4 enzyme system , such as <e1> DRUG1 </e1> (e.g. , itraconazole and miconazole ) or macrolide antibiotics (e.g. , <e2> DRUG2 </e2> and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters (i.e. , Cmax and AUC) . 	antimycotic agents	erythromycin
other	Other inhibitors of the cytochrome P450 3A4 enzyme system , such as <e1> DRUG1 </e1> (e.g. , itraconazole and miconazole ) or macrolide antibiotics (e.g. , erythromycin and <e2> DRUG2 </e2> ) , may alter oxybutynin mean pharmacokinetic parameters (i.e. , Cmax and AUC) . 	antimycotic agents	clarithromycin
mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system , such as <e1> DRUG1 </e1> (e.g. , itraconazole and miconazole ) or macrolide antibiotics (e.g. , erythromycin and clarithromycin ) , may alter <e2> DRUG2 </e2> mean pharmacokinetic parameters (i.e. , Cmax and AUC) . 	antimycotic agents	oxybutynin
other	Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents (e.g. , <e1> DRUG1 </e1> and <e2> DRUG2 </e2> ) or macrolide antibiotics (e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters (i.e. , Cmax and AUC) . 	itraconazole	miconazole
other	Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents (e.g. , <e1> DRUG1 </e1> and miconazole ) or <e2> DRUG2 </e2> (e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters (i.e. , Cmax and AUC) . 	itraconazole	macrolide antibiotics
other	Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents (e.g. , <e1> DRUG1 </e1> and miconazole ) or macrolide antibiotics (e.g. , <e2> DRUG2 </e2> and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters (i.e. , Cmax and AUC) . 	itraconazole	erythromycin
other	Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents (e.g. , <e1> DRUG1 </e1> and miconazole ) or macrolide antibiotics (e.g. , erythromycin and <e2> DRUG2 </e2> ) , may alter oxybutynin mean pharmacokinetic parameters (i.e. , Cmax and AUC) . 	itraconazole	clarithromycin
mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents (e.g. , <e1> DRUG1 </e1> and miconazole ) or macrolide antibiotics (e.g. , erythromycin and clarithromycin ) , may alter <e2> DRUG2 </e2> mean pharmacokinetic parameters (i.e. , Cmax and AUC) . 	itraconazole	oxybutynin
other	Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents (e.g. , itraconazole and <e1> DRUG1 </e1> ) or <e2> DRUG2 </e2> (e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters (i.e. , Cmax and AUC) . 	miconazole	macrolide antibiotics
other	Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents (e.g. , itraconazole and <e1> DRUG1 </e1> ) or macrolide antibiotics (e.g. , <e2> DRUG2 </e2> and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters (i.e. , Cmax and AUC) . 	miconazole	erythromycin
other	Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents (e.g. , itraconazole and <e1> DRUG1 </e1> ) or macrolide antibiotics (e.g. , erythromycin and <e2> DRUG2 </e2> ) , may alter oxybutynin mean pharmacokinetic parameters (i.e. , Cmax and AUC) . 	miconazole	clarithromycin
mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents (e.g. , itraconazole and <e1> DRUG1 </e1> ) or macrolide antibiotics (e.g. , erythromycin and clarithromycin ) , may alter <e2> DRUG2 </e2> mean pharmacokinetic parameters (i.e. , Cmax and AUC) . 	miconazole	oxybutynin
other	Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents (e.g. , itraconazole and miconazole ) or <e1> DRUG1 </e1> (e.g. , <e2> DRUG2 </e2> and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters (i.e. , Cmax and AUC) . 	macrolide antibiotics	erythromycin
other	Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents (e.g. , itraconazole and miconazole ) or <e1> DRUG1 </e1> (e.g. , erythromycin and <e2> DRUG2 </e2> ) , may alter oxybutynin mean pharmacokinetic parameters (i.e. , Cmax and AUC) . 	macrolide antibiotics	clarithromycin
mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents (e.g. , itraconazole and miconazole ) or <e1> DRUG1 </e1> (e.g. , erythromycin and clarithromycin ) , may alter <e2> DRUG2 </e2> mean pharmacokinetic parameters (i.e. , Cmax and AUC) . 	macrolide antibiotics	oxybutynin
other	Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents (e.g. , itraconazole and miconazole ) or macrolide antibiotics (e.g. , <e1> DRUG1 </e1> and <e2> DRUG2 </e2> ) , may alter oxybutynin mean pharmacokinetic parameters (i.e. , Cmax and AUC) . 	erythromycin	clarithromycin
mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents (e.g. , itraconazole and miconazole ) or macrolide antibiotics (e.g. , <e1> DRUG1 </e1> and clarithromycin ) , may alter <e2> DRUG2 </e2> mean pharmacokinetic parameters (i.e. , Cmax and AUC) . 	erythromycin	oxybutynin
mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents (e.g. , itraconazole and miconazole ) or macrolide antibiotics (e.g. , erythromycin and <e1> DRUG1 </e1> ) , may alter <e2> DRUG2 </e2> mean pharmacokinetic parameters (i.e. , Cmax and AUC) . 	clarithromycin	oxybutynin
other	Concurrent ingestion of <e1> DRUG1 </e1> (20 mL of antacid containing <e2> DRUG2 </e2> , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 	antacid	aluminum hydroxide
other	Concurrent ingestion of <e1> DRUG1 </e1> (20 mL of antacid containing aluminum hydroxide , <e2> DRUG2 </e2> , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 	antacid	magnesium hydroxide
other	Concurrent ingestion of <e1> DRUG1 </e1> (20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and <e2> DRUG2 </e2> ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 	antacid	simethicone
other	Concurrent ingestion of <e1> DRUG1 </e1> (20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of <e2> DRUG2 </e2> or desethyloxybutynin . 	antacid	oxybutynin
other	Concurrent ingestion of <e1> DRUG1 </e1> (20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or <e2> DRUG2 </e2> . 	antacid	desethyloxybutynin
other	Concurrent ingestion of antacid (20 mL of <e1> DRUG1 </e1> containing <e2> DRUG2 </e2> , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 	antacid	aluminum hydroxide
other	Concurrent ingestion of antacid (20 mL of <e1> DRUG1 </e1> containing aluminum hydroxide , <e2> DRUG2 </e2> , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 	antacid	magnesium hydroxide
other	Concurrent ingestion of antacid (20 mL of <e1> DRUG1 </e1> containing aluminum hydroxide , magnesium hydroxide , and <e2> DRUG2 </e2> ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 	antacid	simethicone
other	Concurrent ingestion of antacid (20 mL of <e1> DRUG1 </e1> containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of <e2> DRUG2 </e2> or desethyloxybutynin . 	antacid	oxybutynin
other	Concurrent ingestion of antacid (20 mL of <e1> DRUG1 </e1> containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or <e2> DRUG2 </e2> . 	antacid	desethyloxybutynin
other	Concurrent ingestion of antacid (20 mL of antacid containing <e1> DRUG1 </e1> , magnesium hydroxide , and <e2> DRUG2 </e2> ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 	aluminum hydroxide	simethicone
other	Concurrent ingestion of antacid (20 mL of antacid containing <e1> DRUG1 </e1> , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of <e2> DRUG2 </e2> or desethyloxybutynin . 	aluminum hydroxide	oxybutynin
other	Concurrent ingestion of antacid (20 mL of antacid containing <e1> DRUG1 </e1> , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or <e2> DRUG2 </e2> . 	aluminum hydroxide	desethyloxybutynin
other	Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 	magnesium hydroxide	simethicone
other	Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide , <e1> DRUG1 </e1> , and simethicone ) did not significantly affect the exposure of <e2> DRUG2 </e2> or desethyloxybutynin . 	magnesium hydroxide	oxybutynin
other	Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide , <e1> DRUG1 </e1> , and simethicone ) did not significantly affect the exposure of oxybutynin or <e2> DRUG2 </e2> . 	magnesium hydroxide	desethyloxybutynin
other	Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and <e1> DRUG1 </e1> ) did not significantly affect the exposure of <e2> DRUG2 </e2> or desethyloxybutynin . 	simethicone	oxybutynin
other	Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and <e1> DRUG1 </e1> ) did not significantly affect the exposure of oxybutynin or <e2> DRUG2 </e2> . 	simethicone	desethyloxybutynin
effect	The CNS depressant effects of <e1> DRUG1 </e1> may be additive with that of other <e2> DRUG2 </e2> . . 	oxycodone hydrochloride	CNS depressants
other	The concomitant use of other <e1> DRUG1 </e1> including <e2> DRUG2 </e2> , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	CNS depressants	sedatives
other	The concomitant use of other <e1> DRUG1 </e1> including sedatives , <e2> DRUG2 </e2> , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	CNS depressants	hypnotics
other	The concomitant use of other <e1> DRUG1 </e1> including sedatives , hypnotics , <e2> DRUG2 </e2> , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	CNS depressants	tranquilizers
other	The concomitant use of other <e1> DRUG1 </e1> including sedatives , hypnotics , tranquilizers , general <e2> DRUG2 </e2> , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	CNS depressants	anesthetics
other	The concomitant use of other <e1> DRUG1 </e1> including sedatives , hypnotics , tranquilizers , general anesthetics , <e2> DRUG2 </e2> , other opioids , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	CNS depressants	phenothiazines
other	The concomitant use of other <e1> DRUG1 </e1> including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other <e2> DRUG2 </e2> , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	CNS depressants	opioids
other	The concomitant use of other <e1> DRUG1 </e1> including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , <e2> DRUG2 </e2> , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	CNS depressants	tricyclic antidepressants
other	The concomitant use of other <e1> DRUG1 </e1> including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , <e2> DRUG2 </e2> , and alcohol may produce additive CNS depressant effects . 	CNS depressants	monoamine oxidase (MAO) inhibitors
other	The concomitant use of other <e1> DRUG1 </e1> including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and <e2> DRUG2 </e2> may produce additive CNS depressant effects . 	CNS depressants	alcohol
other	The concomitant use of other CNS depressants including <e1> DRUG1 </e1> , hypnotics , <e2> DRUG2 </e2> , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	sedatives	tranquilizers
other	The concomitant use of other CNS depressants including <e1> DRUG1 </e1> , hypnotics , tranquilizers , general <e2> DRUG2 </e2> , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	sedatives	anesthetics
other	The concomitant use of other CNS depressants including <e1> DRUG1 </e1> , hypnotics , tranquilizers , general anesthetics , <e2> DRUG2 </e2> , other opioids , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	sedatives	phenothiazines
other	The concomitant use of other CNS depressants including <e1> DRUG1 </e1> , hypnotics , tranquilizers , general anesthetics , phenothiazines , other <e2> DRUG2 </e2> , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	sedatives	opioids
other	The concomitant use of other CNS depressants including <e1> DRUG1 </e1> , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , <e2> DRUG2 </e2> , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	sedatives	tricyclic antidepressants
other	The concomitant use of other CNS depressants including <e1> DRUG1 </e1> , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , <e2> DRUG2 </e2> , and alcohol may produce additive CNS depressant effects . 	sedatives	monoamine oxidase (MAO) inhibitors
other	The concomitant use of other CNS depressants including <e1> DRUG1 </e1> , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and <e2> DRUG2 </e2> may produce additive CNS depressant effects . 	sedatives	alcohol
other	The concomitant use of other CNS depressants including sedatives , <e1> DRUG1 </e1> , tranquilizers , general <e2> DRUG2 </e2> , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	hypnotics	anesthetics
other	The concomitant use of other CNS depressants including sedatives , <e1> DRUG1 </e1> , tranquilizers , general anesthetics , <e2> DRUG2 </e2> , other opioids , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	hypnotics	phenothiazines
other	The concomitant use of other CNS depressants including sedatives , <e1> DRUG1 </e1> , tranquilizers , general anesthetics , phenothiazines , other <e2> DRUG2 </e2> , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	hypnotics	opioids
other	The concomitant use of other CNS depressants including sedatives , <e1> DRUG1 </e1> , tranquilizers , general anesthetics , phenothiazines , other opioids , <e2> DRUG2 </e2> , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	hypnotics	tricyclic antidepressants
other	The concomitant use of other CNS depressants including sedatives , <e1> DRUG1 </e1> , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , <e2> DRUG2 </e2> , and alcohol may produce additive CNS depressant effects . 	hypnotics	monoamine oxidase (MAO) inhibitors
other	The concomitant use of other CNS depressants including sedatives , <e1> DRUG1 </e1> , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and <e2> DRUG2 </e2> may produce additive CNS depressant effects . 	hypnotics	alcohol
other	The concomitant use of other CNS depressants including sedatives , hypnotics , <e1> DRUG1 </e1> , general <e2> DRUG2 </e2> , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	tranquilizers	anesthetics
other	The concomitant use of other CNS depressants including sedatives , hypnotics , <e1> DRUG1 </e1> , general anesthetics , <e2> DRUG2 </e2> , other opioids , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	tranquilizers	phenothiazines
other	The concomitant use of other CNS depressants including sedatives , hypnotics , <e1> DRUG1 </e1> , general anesthetics , phenothiazines , other <e2> DRUG2 </e2> , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	tranquilizers	opioids
other	The concomitant use of other CNS depressants including sedatives , hypnotics , <e1> DRUG1 </e1> , general anesthetics , phenothiazines , other opioids , <e2> DRUG2 </e2> , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	tranquilizers	tricyclic antidepressants
other	The concomitant use of other CNS depressants including sedatives , hypnotics , <e1> DRUG1 </e1> , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , <e2> DRUG2 </e2> , and alcohol may produce additive CNS depressant effects . 	tranquilizers	monoamine oxidase (MAO) inhibitors
other	The concomitant use of other CNS depressants including sedatives , hypnotics , <e1> DRUG1 </e1> , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and <e2> DRUG2 </e2> may produce additive CNS depressant effects . 	tranquilizers	alcohol
other	The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general <e1> DRUG1 </e1> , phenothiazines , other <e2> DRUG2 </e2> , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	anesthetics	opioids
other	The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general <e1> DRUG1 </e1> , phenothiazines , other opioids , <e2> DRUG2 </e2> , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	anesthetics	tricyclic antidepressants
other	The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general <e1> DRUG1 </e1> , phenothiazines , other opioids , tricyclic antidepressants , <e2> DRUG2 </e2> , and alcohol may produce additive CNS depressant effects . 	anesthetics	monoamine oxidase (MAO) inhibitors
other	The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general <e1> DRUG1 </e1> , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and <e2> DRUG2 </e2> may produce additive CNS depressant effects . 	anesthetics	alcohol
other	The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , <e1> DRUG1 </e1> , other <e2> DRUG2 </e2> , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	phenothiazines	opioids
other	The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , <e1> DRUG1 </e1> , other opioids , <e2> DRUG2 </e2> , monoamine oxidase (MAO) inhibitors , and alcohol may produce additive CNS depressant effects . 	phenothiazines	tricyclic antidepressants
other	The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , <e1> DRUG1 </e1> , other opioids , tricyclic antidepressants , <e2> DRUG2 </e2> , and alcohol may produce additive CNS depressant effects . 	phenothiazines	monoamine oxidase (MAO) inhibitors
other	The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , <e1> DRUG1 </e1> , other opioids , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and <e2> DRUG2 </e2> may produce additive CNS depressant effects . 	phenothiazines	alcohol
other	The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other <e1> DRUG1 </e1> , tricyclic antidepressants , <e2> DRUG2 </e2> , and alcohol may produce additive CNS depressant effects . 	opioids	monoamine oxidase (MAO) inhibitors
other	The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other <e1> DRUG1 </e1> , tricyclic antidepressants , monoamine oxidase (MAO) inhibitors , and <e2> DRUG2 </e2> may produce additive CNS depressant effects . 	opioids	alcohol
other	The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , <e1> DRUG1 </e1> , monoamine oxidase (MAO) inhibitors , and <e2> DRUG2 </e2> may produce additive CNS depressant effects . 	tricyclic antidepressants	alcohol
other	The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> may produce additive CNS depressant effects . 	monoamine oxidase (MAO) inhibitors	alcohol
effect	<e1> DRUG1 </e1> or other medications with anticholinergic activity when used concurrently with <e2> DRUG2 </e2> may result in increased risk of urinary retention and/or severe constipation , which may lead to paralytic ileus . 	Anticholinergics	opioid analgesics
effect	It has been reported that the incidence of bradycardia was increased when <e1> DRUG1 </e1> was combined with <e2> DRUG2 </e2> for induction of anesthesia . 	oxymorphone	propofol
effect	In addition , CNS toxicity has been reported (confusion , disorientation , respiratory depression , apnea , seizures) following coadministration of <e1> DRUG1 </e1> with <e2> DRUG2 </e2> ; 	cimetidine	opioid analgesics
advise	Given the primary CNS effects of <e1> DRUG1 </e1> , INVEGA should be used with caution in combination with other <e2> DRUG2 </e2> and alcohol . 	paliperidone	centrally acting drugs
advise	Given the primary CNS effects of <e1> DRUG1 </e1> , INVEGA should be used with caution in combination with other centrally acting drugs and <e2> DRUG2 </e2> . 	paliperidone	alcohol
advise	Given the primary CNS effects of paliperidone , <e1> DRUG1 </e1> should be used with caution in combination with other <e2> DRUG2 </e2> and alcohol . 	INVEGA	centrally acting drugs
advise	Given the primary CNS effects of paliperidone , <e1> DRUG1 </e1> should be used with caution in combination with other centrally acting drugs and <e2> DRUG2 </e2> . 	INVEGA	alcohol
other	Given the primary CNS effects of paliperidone , INVEGA should be used with caution in combination with other <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	centrally acting drugs	alcohol
effect	<e1> DRUG1 </e1> may antagonize the effect of <e2> DRUG2 </e2> and other dopamine agonists . 	Paliperidone	levodopa
effect	<e1> DRUG1 </e1> may antagonize the effect of levodopa and other <e2> DRUG2 </e2> . 	Paliperidone	dopamine agonists
other	Paliperidone may antagonize the effect of <e1> DRUG1 </e1> and other <e2> DRUG2 </e2> . 	levodopa	dopamine agonists
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : <e2> DRUG2 </e2> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	pantoprazole	theophylline
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , <e2> DRUG2 </e2> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	pantoprazole	cisapride
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , <e2> DRUG2 </e2> , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	pantoprazole	antipyrine
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , <e2> DRUG2 </e2> , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	pantoprazole	caffeine
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , <e2> DRUG2 </e2> , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	pantoprazole	carbamazepine
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e2> DRUG2 </e2> (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	pantoprazole	diazepam
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , <e2> DRUG2 </e2> ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	pantoprazole	desmethyldiazepam
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , <e2> DRUG2 </e2> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	pantoprazole	diclofenac
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , <e2> DRUG2 </e2> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	pantoprazole	naproxen
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , <e2> DRUG2 </e2> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	pantoprazole	piroxicam
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , <e2> DRUG2 </e2> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	pantoprazole	digoxin
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , <e2> DRUG2 </e2> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	pantoprazole	ethanol
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , <e2> DRUG2 </e2> , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	pantoprazole	glyburide
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e2> DRUG2 </e2> ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	pantoprazole	contraceptive
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e2> DRUG2 </e2> / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	pantoprazole	levonorgestrel
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e2> DRUG2 </e2> ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	pantoprazole	ethinyl estradiol
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , <e2> DRUG2 </e2> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	pantoprazole	metoprolol
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , <e2> DRUG2 </e2> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	pantoprazole	nifedipine
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , <e2> DRUG2 </e2> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	pantoprazole	phenytoin
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , <e2> DRUG2 </e2> , midazolam , clarithromycin , metronidazole , or amoxicillin . 	pantoprazole	warfarin
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , <e2> DRUG2 </e2> , clarithromycin , metronidazole , or amoxicillin . 	pantoprazole	midazolam
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e2> DRUG2 </e2> , metronidazole , or amoxicillin . 	pantoprazole	clarithromycin
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e2> DRUG2 </e2> , or amoxicillin . 	pantoprazole	metronidazole
other	Based on studies evaluating possible interactions of <e1> DRUG1 </e1> with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e2> DRUG2 </e2> . 	pantoprazole	amoxicillin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : <e1> DRUG1 </e1> , cisapride , <e2> DRUG2 </e2> , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	theophylline	antipyrine
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : <e1> DRUG1 </e1> , cisapride , antipyrine , <e2> DRUG2 </e2> , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	theophylline	caffeine
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : <e1> DRUG1 </e1> , cisapride , antipyrine , caffeine , <e2> DRUG2 </e2> , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	theophylline	carbamazepine
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : <e1> DRUG1 </e1> , cisapride , antipyrine , caffeine , carbamazepine , <e2> DRUG2 </e2> (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	theophylline	diazepam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : <e1> DRUG1 </e1> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , <e2> DRUG2 </e2> ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	theophylline	desmethyldiazepam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : <e1> DRUG1 </e1> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , <e2> DRUG2 </e2> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	theophylline	diclofenac
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : <e1> DRUG1 </e1> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , <e2> DRUG2 </e2> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	theophylline	naproxen
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : <e1> DRUG1 </e1> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , <e2> DRUG2 </e2> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	theophylline	piroxicam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : <e1> DRUG1 </e1> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , <e2> DRUG2 </e2> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	theophylline	digoxin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : <e1> DRUG1 </e1> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , <e2> DRUG2 </e2> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	theophylline	ethanol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : <e1> DRUG1 </e1> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , <e2> DRUG2 </e2> , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	theophylline	glyburide
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : <e1> DRUG1 </e1> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e2> DRUG2 </e2> ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	theophylline	contraceptive
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : <e1> DRUG1 </e1> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e2> DRUG2 </e2> / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	theophylline	levonorgestrel
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : <e1> DRUG1 </e1> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e2> DRUG2 </e2> ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	theophylline	ethinyl estradiol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : <e1> DRUG1 </e1> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , <e2> DRUG2 </e2> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	theophylline	metoprolol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : <e1> DRUG1 </e1> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , <e2> DRUG2 </e2> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	theophylline	nifedipine
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : <e1> DRUG1 </e1> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , <e2> DRUG2 </e2> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	theophylline	phenytoin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : <e1> DRUG1 </e1> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , <e2> DRUG2 </e2> , midazolam , clarithromycin , metronidazole , or amoxicillin . 	theophylline	warfarin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : <e1> DRUG1 </e1> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , <e2> DRUG2 </e2> , clarithromycin , metronidazole , or amoxicillin . 	theophylline	midazolam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : <e1> DRUG1 </e1> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e2> DRUG2 </e2> , metronidazole , or amoxicillin . 	theophylline	clarithromycin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : <e1> DRUG1 </e1> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e2> DRUG2 </e2> , or amoxicillin . 	theophylline	metronidazole
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : <e1> DRUG1 </e1> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e2> DRUG2 </e2> . 	theophylline	amoxicillin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , <e1> DRUG1 </e1> , antipyrine , <e2> DRUG2 </e2> , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	cisapride	caffeine
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , <e1> DRUG1 </e1> , antipyrine , caffeine , <e2> DRUG2 </e2> , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	cisapride	carbamazepine
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , <e1> DRUG1 </e1> , antipyrine , caffeine , carbamazepine , <e2> DRUG2 </e2> (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	cisapride	diazepam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , <e1> DRUG1 </e1> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , <e2> DRUG2 </e2> ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	cisapride	desmethyldiazepam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , <e1> DRUG1 </e1> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , <e2> DRUG2 </e2> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	cisapride	diclofenac
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , <e1> DRUG1 </e1> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , <e2> DRUG2 </e2> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	cisapride	naproxen
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , <e1> DRUG1 </e1> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , <e2> DRUG2 </e2> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	cisapride	piroxicam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , <e1> DRUG1 </e1> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , <e2> DRUG2 </e2> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	cisapride	digoxin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , <e1> DRUG1 </e1> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , <e2> DRUG2 </e2> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	cisapride	ethanol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , <e1> DRUG1 </e1> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , <e2> DRUG2 </e2> , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	cisapride	glyburide
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , <e1> DRUG1 </e1> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e2> DRUG2 </e2> ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	cisapride	contraceptive
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , <e1> DRUG1 </e1> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e2> DRUG2 </e2> / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	cisapride	levonorgestrel
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , <e1> DRUG1 </e1> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e2> DRUG2 </e2> ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	cisapride	ethinyl estradiol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , <e1> DRUG1 </e1> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , <e2> DRUG2 </e2> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	cisapride	metoprolol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , <e1> DRUG1 </e1> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , <e2> DRUG2 </e2> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	cisapride	nifedipine
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , <e1> DRUG1 </e1> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , <e2> DRUG2 </e2> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	cisapride	phenytoin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , <e1> DRUG1 </e1> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , <e2> DRUG2 </e2> , midazolam , clarithromycin , metronidazole , or amoxicillin . 	cisapride	warfarin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , <e1> DRUG1 </e1> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , <e2> DRUG2 </e2> , clarithromycin , metronidazole , or amoxicillin . 	cisapride	midazolam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , <e1> DRUG1 </e1> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e2> DRUG2 </e2> , metronidazole , or amoxicillin . 	cisapride	clarithromycin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , <e1> DRUG1 </e1> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e2> DRUG2 </e2> , or amoxicillin . 	cisapride	metronidazole
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , <e1> DRUG1 </e1> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e2> DRUG2 </e2> . 	cisapride	amoxicillin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , <e1> DRUG1 </e1> , caffeine , <e2> DRUG2 </e2> , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	antipyrine	carbamazepine
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , <e1> DRUG1 </e1> , caffeine , carbamazepine , <e2> DRUG2 </e2> (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	antipyrine	diazepam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , <e1> DRUG1 </e1> , caffeine , carbamazepine , diazepam (and its active metabolite , <e2> DRUG2 </e2> ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	antipyrine	desmethyldiazepam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , <e1> DRUG1 </e1> , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , <e2> DRUG2 </e2> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	antipyrine	diclofenac
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , <e1> DRUG1 </e1> , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , <e2> DRUG2 </e2> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	antipyrine	naproxen
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , <e1> DRUG1 </e1> , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , <e2> DRUG2 </e2> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	antipyrine	piroxicam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , <e1> DRUG1 </e1> , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , <e2> DRUG2 </e2> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	antipyrine	digoxin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , <e1> DRUG1 </e1> , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , <e2> DRUG2 </e2> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	antipyrine	ethanol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , <e1> DRUG1 </e1> , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , <e2> DRUG2 </e2> , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	antipyrine	glyburide
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , <e1> DRUG1 </e1> , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e2> DRUG2 </e2> ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	antipyrine	contraceptive
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , <e1> DRUG1 </e1> , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e2> DRUG2 </e2> / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	antipyrine	levonorgestrel
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , <e1> DRUG1 </e1> , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e2> DRUG2 </e2> ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	antipyrine	ethinyl estradiol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , <e1> DRUG1 </e1> , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , <e2> DRUG2 </e2> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	antipyrine	metoprolol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , <e1> DRUG1 </e1> , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , <e2> DRUG2 </e2> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	antipyrine	nifedipine
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , <e1> DRUG1 </e1> , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , <e2> DRUG2 </e2> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	antipyrine	phenytoin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , <e1> DRUG1 </e1> , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , <e2> DRUG2 </e2> , midazolam , clarithromycin , metronidazole , or amoxicillin . 	antipyrine	warfarin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , <e1> DRUG1 </e1> , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , <e2> DRUG2 </e2> , clarithromycin , metronidazole , or amoxicillin . 	antipyrine	midazolam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , <e1> DRUG1 </e1> , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e2> DRUG2 </e2> , metronidazole , or amoxicillin . 	antipyrine	clarithromycin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , <e1> DRUG1 </e1> , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e2> DRUG2 </e2> , or amoxicillin . 	antipyrine	metronidazole
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , <e1> DRUG1 </e1> , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e2> DRUG2 </e2> . 	antipyrine	amoxicillin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , <e1> DRUG1 </e1> , carbamazepine , <e2> DRUG2 </e2> (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	caffeine	diazepam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , <e1> DRUG1 </e1> , carbamazepine , diazepam (and its active metabolite , <e2> DRUG2 </e2> ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	caffeine	desmethyldiazepam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , <e1> DRUG1 </e1> , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , <e2> DRUG2 </e2> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	caffeine	diclofenac
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , <e1> DRUG1 </e1> , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , <e2> DRUG2 </e2> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	caffeine	naproxen
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , <e1> DRUG1 </e1> , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , <e2> DRUG2 </e2> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	caffeine	piroxicam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , <e1> DRUG1 </e1> , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , <e2> DRUG2 </e2> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	caffeine	digoxin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , <e1> DRUG1 </e1> , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , <e2> DRUG2 </e2> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	caffeine	ethanol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , <e1> DRUG1 </e1> , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , <e2> DRUG2 </e2> , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	caffeine	glyburide
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , <e1> DRUG1 </e1> , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e2> DRUG2 </e2> ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	caffeine	contraceptive
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , <e1> DRUG1 </e1> , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e2> DRUG2 </e2> / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	caffeine	levonorgestrel
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , <e1> DRUG1 </e1> , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e2> DRUG2 </e2> ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	caffeine	ethinyl estradiol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , <e1> DRUG1 </e1> , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , <e2> DRUG2 </e2> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	caffeine	metoprolol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , <e1> DRUG1 </e1> , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , <e2> DRUG2 </e2> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	caffeine	nifedipine
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , <e1> DRUG1 </e1> , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , <e2> DRUG2 </e2> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	caffeine	phenytoin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , <e1> DRUG1 </e1> , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , <e2> DRUG2 </e2> , midazolam , clarithromycin , metronidazole , or amoxicillin . 	caffeine	warfarin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , <e1> DRUG1 </e1> , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , <e2> DRUG2 </e2> , clarithromycin , metronidazole , or amoxicillin . 	caffeine	midazolam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , <e1> DRUG1 </e1> , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e2> DRUG2 </e2> , metronidazole , or amoxicillin . 	caffeine	clarithromycin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , <e1> DRUG1 </e1> , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e2> DRUG2 </e2> , or amoxicillin . 	caffeine	metronidazole
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , <e1> DRUG1 </e1> , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e2> DRUG2 </e2> . 	caffeine	amoxicillin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , <e1> DRUG1 </e1> , diazepam (and its active metabolite , <e2> DRUG2 </e2> ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	carbamazepine	desmethyldiazepam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , <e1> DRUG1 </e1> , diazepam (and its active metabolite , desmethyldiazepam ) , <e2> DRUG2 </e2> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	carbamazepine	diclofenac
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , <e1> DRUG1 </e1> , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , <e2> DRUG2 </e2> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	carbamazepine	naproxen
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , <e1> DRUG1 </e1> , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , <e2> DRUG2 </e2> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	carbamazepine	piroxicam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , <e1> DRUG1 </e1> , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , <e2> DRUG2 </e2> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	carbamazepine	digoxin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , <e1> DRUG1 </e1> , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , <e2> DRUG2 </e2> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	carbamazepine	ethanol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , <e1> DRUG1 </e1> , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , <e2> DRUG2 </e2> , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	carbamazepine	glyburide
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , <e1> DRUG1 </e1> , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e2> DRUG2 </e2> ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	carbamazepine	contraceptive
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , <e1> DRUG1 </e1> , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e2> DRUG2 </e2> / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	carbamazepine	levonorgestrel
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , <e1> DRUG1 </e1> , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e2> DRUG2 </e2> ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	carbamazepine	ethinyl estradiol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , <e1> DRUG1 </e1> , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , <e2> DRUG2 </e2> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	carbamazepine	metoprolol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , <e1> DRUG1 </e1> , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , <e2> DRUG2 </e2> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	carbamazepine	nifedipine
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , <e1> DRUG1 </e1> , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , <e2> DRUG2 </e2> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	carbamazepine	phenytoin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , <e1> DRUG1 </e1> , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , <e2> DRUG2 </e2> , midazolam , clarithromycin , metronidazole , or amoxicillin . 	carbamazepine	warfarin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , <e1> DRUG1 </e1> , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , <e2> DRUG2 </e2> , clarithromycin , metronidazole , or amoxicillin . 	carbamazepine	midazolam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , <e1> DRUG1 </e1> , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e2> DRUG2 </e2> , metronidazole , or amoxicillin . 	carbamazepine	clarithromycin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , <e1> DRUG1 </e1> , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e2> DRUG2 </e2> , or amoxicillin . 	carbamazepine	metronidazole
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , <e1> DRUG1 </e1> , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e2> DRUG2 </e2> . 	carbamazepine	amoxicillin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e1> DRUG1 </e1> (and its active metabolite , <e2> DRUG2 </e2> ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diazepam	desmethyldiazepam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e1> DRUG1 </e1> (and its active metabolite , desmethyldiazepam ) , <e2> DRUG2 </e2> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diazepam	diclofenac
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e1> DRUG1 </e1> (and its active metabolite , desmethyldiazepam ) , diclofenac , <e2> DRUG2 </e2> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diazepam	naproxen
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e1> DRUG1 </e1> (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , <e2> DRUG2 </e2> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diazepam	piroxicam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e1> DRUG1 </e1> (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , <e2> DRUG2 </e2> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diazepam	digoxin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e1> DRUG1 </e1> (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , <e2> DRUG2 </e2> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diazepam	ethanol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e1> DRUG1 </e1> (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , <e2> DRUG2 </e2> , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diazepam	glyburide
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e1> DRUG1 </e1> (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e2> DRUG2 </e2> ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diazepam	contraceptive
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e1> DRUG1 </e1> (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e2> DRUG2 </e2> / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diazepam	levonorgestrel
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e1> DRUG1 </e1> (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e2> DRUG2 </e2> ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diazepam	ethinyl estradiol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e1> DRUG1 </e1> (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , <e2> DRUG2 </e2> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diazepam	metoprolol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e1> DRUG1 </e1> (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , <e2> DRUG2 </e2> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diazepam	nifedipine
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e1> DRUG1 </e1> (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , <e2> DRUG2 </e2> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diazepam	phenytoin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e1> DRUG1 </e1> (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , <e2> DRUG2 </e2> , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diazepam	warfarin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e1> DRUG1 </e1> (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , <e2> DRUG2 </e2> , clarithromycin , metronidazole , or amoxicillin . 	diazepam	midazolam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e1> DRUG1 </e1> (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e2> DRUG2 </e2> , metronidazole , or amoxicillin . 	diazepam	clarithromycin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e1> DRUG1 </e1> (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e2> DRUG2 </e2> , or amoxicillin . 	diazepam	metronidazole
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e1> DRUG1 </e1> (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e2> DRUG2 </e2> . 	diazepam	amoxicillin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , <e1> DRUG1 </e1> ) , <e2> DRUG2 </e2> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	desmethyldiazepam	diclofenac
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , <e1> DRUG1 </e1> ) , diclofenac , <e2> DRUG2 </e2> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	desmethyldiazepam	naproxen
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , <e1> DRUG1 </e1> ) , diclofenac , naproxen , <e2> DRUG2 </e2> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	desmethyldiazepam	piroxicam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , <e1> DRUG1 </e1> ) , diclofenac , naproxen , piroxicam , <e2> DRUG2 </e2> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	desmethyldiazepam	digoxin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , <e1> DRUG1 </e1> ) , diclofenac , naproxen , piroxicam , digoxin , <e2> DRUG2 </e2> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	desmethyldiazepam	ethanol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , <e1> DRUG1 </e1> ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , <e2> DRUG2 </e2> , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	desmethyldiazepam	glyburide
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , <e1> DRUG1 </e1> ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e2> DRUG2 </e2> ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	desmethyldiazepam	contraceptive
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , <e1> DRUG1 </e1> ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e2> DRUG2 </e2> / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	desmethyldiazepam	levonorgestrel
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , <e1> DRUG1 </e1> ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e2> DRUG2 </e2> ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	desmethyldiazepam	ethinyl estradiol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , <e1> DRUG1 </e1> ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , <e2> DRUG2 </e2> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	desmethyldiazepam	metoprolol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , <e1> DRUG1 </e1> ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , <e2> DRUG2 </e2> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	desmethyldiazepam	nifedipine
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , <e1> DRUG1 </e1> ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , <e2> DRUG2 </e2> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	desmethyldiazepam	phenytoin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , <e1> DRUG1 </e1> ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , <e2> DRUG2 </e2> , midazolam , clarithromycin , metronidazole , or amoxicillin . 	desmethyldiazepam	warfarin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , <e1> DRUG1 </e1> ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , <e2> DRUG2 </e2> , clarithromycin , metronidazole , or amoxicillin . 	desmethyldiazepam	midazolam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , <e1> DRUG1 </e1> ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e2> DRUG2 </e2> , metronidazole , or amoxicillin . 	desmethyldiazepam	clarithromycin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , <e1> DRUG1 </e1> ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e2> DRUG2 </e2> , or amoxicillin . 	desmethyldiazepam	metronidazole
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , <e1> DRUG1 </e1> ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e2> DRUG2 </e2> . 	desmethyldiazepam	amoxicillin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , <e1> DRUG1 </e1> , naproxen , <e2> DRUG2 </e2> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diclofenac	piroxicam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , <e1> DRUG1 </e1> , naproxen , piroxicam , <e2> DRUG2 </e2> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diclofenac	digoxin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , <e1> DRUG1 </e1> , naproxen , piroxicam , digoxin , <e2> DRUG2 </e2> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diclofenac	ethanol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , <e1> DRUG1 </e1> , naproxen , piroxicam , digoxin , ethanol , <e2> DRUG2 </e2> , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diclofenac	glyburide
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , <e1> DRUG1 </e1> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e2> DRUG2 </e2> ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diclofenac	contraceptive
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , <e1> DRUG1 </e1> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e2> DRUG2 </e2> / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diclofenac	levonorgestrel
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , <e1> DRUG1 </e1> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e2> DRUG2 </e2> ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diclofenac	ethinyl estradiol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , <e1> DRUG1 </e1> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , <e2> DRUG2 </e2> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diclofenac	metoprolol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , <e1> DRUG1 </e1> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , <e2> DRUG2 </e2> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diclofenac	nifedipine
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , <e1> DRUG1 </e1> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , <e2> DRUG2 </e2> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diclofenac	phenytoin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , <e1> DRUG1 </e1> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , <e2> DRUG2 </e2> , midazolam , clarithromycin , metronidazole , or amoxicillin . 	diclofenac	warfarin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , <e1> DRUG1 </e1> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , <e2> DRUG2 </e2> , clarithromycin , metronidazole , or amoxicillin . 	diclofenac	midazolam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , <e1> DRUG1 </e1> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e2> DRUG2 </e2> , metronidazole , or amoxicillin . 	diclofenac	clarithromycin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , <e1> DRUG1 </e1> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e2> DRUG2 </e2> , or amoxicillin . 	diclofenac	metronidazole
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , <e1> DRUG1 </e1> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e2> DRUG2 </e2> . 	diclofenac	amoxicillin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , <e1> DRUG1 </e1> , piroxicam , <e2> DRUG2 </e2> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	naproxen	digoxin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , <e1> DRUG1 </e1> , piroxicam , digoxin , <e2> DRUG2 </e2> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	naproxen	ethanol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , <e1> DRUG1 </e1> , piroxicam , digoxin , ethanol , <e2> DRUG2 </e2> , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	naproxen	glyburide
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , <e1> DRUG1 </e1> , piroxicam , digoxin , ethanol , glyburide , an oral <e2> DRUG2 </e2> ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	naproxen	contraceptive
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , <e1> DRUG1 </e1> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e2> DRUG2 </e2> / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	naproxen	levonorgestrel
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , <e1> DRUG1 </e1> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e2> DRUG2 </e2> ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	naproxen	ethinyl estradiol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , <e1> DRUG1 </e1> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , <e2> DRUG2 </e2> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	naproxen	metoprolol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , <e1> DRUG1 </e1> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , <e2> DRUG2 </e2> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	naproxen	nifedipine
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , <e1> DRUG1 </e1> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , <e2> DRUG2 </e2> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	naproxen	phenytoin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , <e1> DRUG1 </e1> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , <e2> DRUG2 </e2> , midazolam , clarithromycin , metronidazole , or amoxicillin . 	naproxen	warfarin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , <e1> DRUG1 </e1> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , <e2> DRUG2 </e2> , clarithromycin , metronidazole , or amoxicillin . 	naproxen	midazolam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , <e1> DRUG1 </e1> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e2> DRUG2 </e2> , metronidazole , or amoxicillin . 	naproxen	clarithromycin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , <e1> DRUG1 </e1> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e2> DRUG2 </e2> , or amoxicillin . 	naproxen	metronidazole
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , <e1> DRUG1 </e1> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e2> DRUG2 </e2> . 	naproxen	amoxicillin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , <e1> DRUG1 </e1> , digoxin , <e2> DRUG2 </e2> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	piroxicam	ethanol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , <e1> DRUG1 </e1> , digoxin , ethanol , <e2> DRUG2 </e2> , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	piroxicam	glyburide
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , <e1> DRUG1 </e1> , digoxin , ethanol , glyburide , an oral <e2> DRUG2 </e2> ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	piroxicam	contraceptive
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , <e1> DRUG1 </e1> , digoxin , ethanol , glyburide , an oral contraceptive ( <e2> DRUG2 </e2> / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	piroxicam	levonorgestrel
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , <e1> DRUG1 </e1> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e2> DRUG2 </e2> ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	piroxicam	ethinyl estradiol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , <e1> DRUG1 </e1> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , <e2> DRUG2 </e2> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	piroxicam	metoprolol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , <e1> DRUG1 </e1> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , <e2> DRUG2 </e2> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	piroxicam	nifedipine
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , <e1> DRUG1 </e1> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , <e2> DRUG2 </e2> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	piroxicam	phenytoin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , <e1> DRUG1 </e1> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , <e2> DRUG2 </e2> , midazolam , clarithromycin , metronidazole , or amoxicillin . 	piroxicam	warfarin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , <e1> DRUG1 </e1> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , <e2> DRUG2 </e2> , clarithromycin , metronidazole , or amoxicillin . 	piroxicam	midazolam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , <e1> DRUG1 </e1> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e2> DRUG2 </e2> , metronidazole , or amoxicillin . 	piroxicam	clarithromycin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , <e1> DRUG1 </e1> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e2> DRUG2 </e2> , or amoxicillin . 	piroxicam	metronidazole
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , <e1> DRUG1 </e1> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e2> DRUG2 </e2> . 	piroxicam	amoxicillin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , <e1> DRUG1 </e1> , ethanol , <e2> DRUG2 </e2> , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	digoxin	glyburide
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , <e1> DRUG1 </e1> , ethanol , glyburide , an oral <e2> DRUG2 </e2> ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	digoxin	contraceptive
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , <e1> DRUG1 </e1> , ethanol , glyburide , an oral contraceptive ( <e2> DRUG2 </e2> / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	digoxin	levonorgestrel
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , <e1> DRUG1 </e1> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e2> DRUG2 </e2> ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	digoxin	ethinyl estradiol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , <e1> DRUG1 </e1> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , <e2> DRUG2 </e2> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	digoxin	metoprolol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , <e1> DRUG1 </e1> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , <e2> DRUG2 </e2> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	digoxin	nifedipine
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , <e1> DRUG1 </e1> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , <e2> DRUG2 </e2> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	digoxin	phenytoin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , <e1> DRUG1 </e1> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , <e2> DRUG2 </e2> , midazolam , clarithromycin , metronidazole , or amoxicillin . 	digoxin	warfarin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , <e1> DRUG1 </e1> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , <e2> DRUG2 </e2> , clarithromycin , metronidazole , or amoxicillin . 	digoxin	midazolam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , <e1> DRUG1 </e1> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e2> DRUG2 </e2> , metronidazole , or amoxicillin . 	digoxin	clarithromycin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , <e1> DRUG1 </e1> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e2> DRUG2 </e2> , or amoxicillin . 	digoxin	metronidazole
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , <e1> DRUG1 </e1> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e2> DRUG2 </e2> . 	digoxin	amoxicillin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , <e1> DRUG1 </e1> , glyburide , an oral <e2> DRUG2 </e2> ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	ethanol	contraceptive
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , <e1> DRUG1 </e1> , glyburide , an oral contraceptive ( <e2> DRUG2 </e2> / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	ethanol	levonorgestrel
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , <e1> DRUG1 </e1> , glyburide , an oral contraceptive ( levonorgestrel / <e2> DRUG2 </e2> ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	ethanol	ethinyl estradiol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , <e1> DRUG1 </e1> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , <e2> DRUG2 </e2> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	ethanol	metoprolol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , <e1> DRUG1 </e1> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , <e2> DRUG2 </e2> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	ethanol	nifedipine
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , <e1> DRUG1 </e1> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , <e2> DRUG2 </e2> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	ethanol	phenytoin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , <e1> DRUG1 </e1> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , <e2> DRUG2 </e2> , midazolam , clarithromycin , metronidazole , or amoxicillin . 	ethanol	warfarin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , <e1> DRUG1 </e1> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , <e2> DRUG2 </e2> , clarithromycin , metronidazole , or amoxicillin . 	ethanol	midazolam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , <e1> DRUG1 </e1> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e2> DRUG2 </e2> , metronidazole , or amoxicillin . 	ethanol	clarithromycin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , <e1> DRUG1 </e1> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e2> DRUG2 </e2> , or amoxicillin . 	ethanol	metronidazole
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , <e1> DRUG1 </e1> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e2> DRUG2 </e2> . 	ethanol	amoxicillin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , <e1> DRUG1 </e1> , an oral <e2> DRUG2 </e2> ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	glyburide	contraceptive
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , <e1> DRUG1 </e1> , an oral contraceptive ( <e2> DRUG2 </e2> / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	glyburide	levonorgestrel
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , <e1> DRUG1 </e1> , an oral contraceptive ( levonorgestrel / <e2> DRUG2 </e2> ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	glyburide	ethinyl estradiol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , <e1> DRUG1 </e1> , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , <e2> DRUG2 </e2> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	glyburide	metoprolol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , <e1> DRUG1 </e1> , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , <e2> DRUG2 </e2> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	glyburide	nifedipine
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , <e1> DRUG1 </e1> , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , <e2> DRUG2 </e2> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	glyburide	phenytoin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , <e1> DRUG1 </e1> , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , <e2> DRUG2 </e2> , midazolam , clarithromycin , metronidazole , or amoxicillin . 	glyburide	warfarin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , <e1> DRUG1 </e1> , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , <e2> DRUG2 </e2> , clarithromycin , metronidazole , or amoxicillin . 	glyburide	midazolam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , <e1> DRUG1 </e1> , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e2> DRUG2 </e2> , metronidazole , or amoxicillin . 	glyburide	clarithromycin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , <e1> DRUG1 </e1> , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e2> DRUG2 </e2> , or amoxicillin . 	glyburide	metronidazole
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , <e1> DRUG1 </e1> , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e2> DRUG2 </e2> . 	glyburide	amoxicillin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e1> DRUG1 </e1> ( levonorgestrel / <e2> DRUG2 </e2> ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	contraceptive	ethinyl estradiol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e1> DRUG1 </e1> ( levonorgestrel / ethinyl estradiol ) , <e2> DRUG2 </e2> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	contraceptive	metoprolol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e1> DRUG1 </e1> ( levonorgestrel / ethinyl estradiol ) , metoprolol , <e2> DRUG2 </e2> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	contraceptive	nifedipine
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e1> DRUG1 </e1> ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , <e2> DRUG2 </e2> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	contraceptive	phenytoin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e1> DRUG1 </e1> ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , <e2> DRUG2 </e2> , midazolam , clarithromycin , metronidazole , or amoxicillin . 	contraceptive	warfarin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e1> DRUG1 </e1> ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , <e2> DRUG2 </e2> , clarithromycin , metronidazole , or amoxicillin . 	contraceptive	midazolam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e1> DRUG1 </e1> ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e2> DRUG2 </e2> , metronidazole , or amoxicillin . 	contraceptive	clarithromycin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e1> DRUG1 </e1> ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e2> DRUG2 </e2> , or amoxicillin . 	contraceptive	metronidazole
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e1> DRUG1 </e1> ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e2> DRUG2 </e2> . 	contraceptive	amoxicillin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e1> DRUG1 </e1> / <e2> DRUG2 </e2> ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	levonorgestrel	ethinyl estradiol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e1> DRUG1 </e1> / ethinyl estradiol ) , <e2> DRUG2 </e2> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	levonorgestrel	metoprolol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e1> DRUG1 </e1> / ethinyl estradiol ) , metoprolol , <e2> DRUG2 </e2> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	levonorgestrel	nifedipine
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e1> DRUG1 </e1> / ethinyl estradiol ) , metoprolol , nifedipine , <e2> DRUG2 </e2> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	levonorgestrel	phenytoin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e1> DRUG1 </e1> / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , <e2> DRUG2 </e2> , midazolam , clarithromycin , metronidazole , or amoxicillin . 	levonorgestrel	warfarin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e1> DRUG1 </e1> / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , <e2> DRUG2 </e2> , clarithromycin , metronidazole , or amoxicillin . 	levonorgestrel	midazolam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e1> DRUG1 </e1> / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e2> DRUG2 </e2> , metronidazole , or amoxicillin . 	levonorgestrel	clarithromycin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e1> DRUG1 </e1> / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e2> DRUG2 </e2> , or amoxicillin . 	levonorgestrel	metronidazole
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e1> DRUG1 </e1> / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e2> DRUG2 </e2> . 	levonorgestrel	amoxicillin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e1> DRUG1 </e1> ) , <e2> DRUG2 </e2> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	ethinyl estradiol	metoprolol
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e1> DRUG1 </e1> ) , metoprolol , <e2> DRUG2 </e2> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	ethinyl estradiol	nifedipine
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e1> DRUG1 </e1> ) , metoprolol , nifedipine , <e2> DRUG2 </e2> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	ethinyl estradiol	phenytoin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e1> DRUG1 </e1> ) , metoprolol , nifedipine , phenytoin , <e2> DRUG2 </e2> , midazolam , clarithromycin , metronidazole , or amoxicillin . 	ethinyl estradiol	warfarin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e1> DRUG1 </e1> ) , metoprolol , nifedipine , phenytoin , warfarin , <e2> DRUG2 </e2> , clarithromycin , metronidazole , or amoxicillin . 	ethinyl estradiol	midazolam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e1> DRUG1 </e1> ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e2> DRUG2 </e2> , metronidazole , or amoxicillin . 	ethinyl estradiol	clarithromycin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e1> DRUG1 </e1> ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e2> DRUG2 </e2> , or amoxicillin . 	ethinyl estradiol	metronidazole
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e1> DRUG1 </e1> ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e2> DRUG2 </e2> . 	ethinyl estradiol	amoxicillin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , <e1> DRUG1 </e1> , nifedipine , <e2> DRUG2 </e2> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 	metoprolol	phenytoin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , <e1> DRUG1 </e1> , nifedipine , phenytoin , <e2> DRUG2 </e2> , midazolam , clarithromycin , metronidazole , or amoxicillin . 	metoprolol	warfarin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , <e1> DRUG1 </e1> , nifedipine , phenytoin , warfarin , <e2> DRUG2 </e2> , clarithromycin , metronidazole , or amoxicillin . 	metoprolol	midazolam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , <e1> DRUG1 </e1> , nifedipine , phenytoin , warfarin , midazolam , <e2> DRUG2 </e2> , metronidazole , or amoxicillin . 	metoprolol	clarithromycin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , <e1> DRUG1 </e1> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e2> DRUG2 </e2> , or amoxicillin . 	metoprolol	metronidazole
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , <e1> DRUG1 </e1> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e2> DRUG2 </e2> . 	metoprolol	amoxicillin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , <e1> DRUG1 </e1> , phenytoin , <e2> DRUG2 </e2> , midazolam , clarithromycin , metronidazole , or amoxicillin . 	nifedipine	warfarin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , <e1> DRUG1 </e1> , phenytoin , warfarin , <e2> DRUG2 </e2> , clarithromycin , metronidazole , or amoxicillin . 	nifedipine	midazolam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , <e1> DRUG1 </e1> , phenytoin , warfarin , midazolam , <e2> DRUG2 </e2> , metronidazole , or amoxicillin . 	nifedipine	clarithromycin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , <e1> DRUG1 </e1> , phenytoin , warfarin , midazolam , clarithromycin , <e2> DRUG2 </e2> , or amoxicillin . 	nifedipine	metronidazole
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , <e1> DRUG1 </e1> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e2> DRUG2 </e2> . 	nifedipine	amoxicillin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , <e1> DRUG1 </e1> , warfarin , <e2> DRUG2 </e2> , clarithromycin , metronidazole , or amoxicillin . 	phenytoin	midazolam
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , <e1> DRUG1 </e1> , warfarin , midazolam , <e2> DRUG2 </e2> , metronidazole , or amoxicillin . 	phenytoin	clarithromycin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , <e1> DRUG1 </e1> , warfarin , midazolam , clarithromycin , <e2> DRUG2 </e2> , or amoxicillin . 	phenytoin	metronidazole
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , <e1> DRUG1 </e1> , warfarin , midazolam , clarithromycin , metronidazole , or <e2> DRUG2 </e2> . 	phenytoin	amoxicillin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , <e1> DRUG1 </e1> , midazolam , <e2> DRUG2 </e2> , metronidazole , or amoxicillin . 	warfarin	clarithromycin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , <e1> DRUG1 </e1> , midazolam , clarithromycin , <e2> DRUG2 </e2> , or amoxicillin . 	warfarin	metronidazole
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , <e1> DRUG1 </e1> , midazolam , clarithromycin , metronidazole , or <e2> DRUG2 </e2> . 	warfarin	amoxicillin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , <e1> DRUG1 </e1> , clarithromycin , <e2> DRUG2 </e2> , or amoxicillin . 	midazolam	metronidazole
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , <e1> DRUG1 </e1> , clarithromycin , metronidazole , or <e2> DRUG2 </e2> . 	midazolam	amoxicillin
other	Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e1> DRUG1 </e1> , metronidazole , or <e2> DRUG2 </e2> . 	clarithromycin	amoxicillin
other	There have been postmarketing reports of increased INR and prothrombin time in patients receiving <e1> DRUG1 </e1> , including <e2> DRUG2 </e2> , and warfarin concomitantly . 	proton pump inhibitors	pantoprazole
effect	There have been postmarketing reports of increased INR and prothrombin time in patients receiving <e1> DRUG1 </e1> , including pantoprazole , and <e2> DRUG2 </e2> concomitantly . 	proton pump inhibitors	warfarin
effect	There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors , including <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> concomitantly . 	pantoprazole	warfarin
advise	Patients treated with <e1> DRUG1 </e1> and <e2> DRUG2 </e2> concomitantly should be monitored for increases in INR and prothrombin time . 	proton pump inhibitors	warfarin
mechanism	Because of profound and long lasting inhibition of gastric acid secretion , <e1> DRUG1 </e1> may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg , <e2> DRUG2 </e2> , ampicillin esters , and iron salts) . 	pantoprazole	ketoconazole
mechanism	Because of profound and long lasting inhibition of gastric acid secretion , <e1> DRUG1 </e1> may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg , ketoconazole , <e2> DRUG2 </e2> esters , and iron salts) . 	pantoprazole	ampicillin
mechanism	Because of profound and long lasting inhibition of gastric acid secretion , <e1> DRUG1 </e1> may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg , ketoconazole , ampicillin esters , and <e2> DRUG2 </e2> salts) . 	pantoprazole	iron
other	Because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg , <e1> DRUG1 </e1> , ampicillin esters , and <e2> DRUG2 </e2> salts) . 	ketoconazole	iron
other	Because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg , ketoconazole , <e1> DRUG1 </e1> esters , and <e2> DRUG2 </e2> salts) . 	ampicillin	iron
other	Laboratory Tests There have been reports of false-positive urine screening tests for <e1> DRUG1 </e1> ( THC ) in patients receiving most <e2> DRUG2 </e2> , including pantoprazole . 	tetrahydrocannabinol	proton pump inhibitors
other	Laboratory Tests There have been reports of false-positive urine screening tests for <e1> DRUG1 </e1> ( THC ) in patients receiving most proton pump inhibitors , including <e2> DRUG2 </e2> . 	tetrahydrocannabinol	pantoprazole
other	Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol ( <e1> DRUG1 </e1> ) in patients receiving most <e2> DRUG2 </e2> , including pantoprazole . 	THC	proton pump inhibitors
other	Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol ( <e1> DRUG1 </e1> ) in patients receiving most proton pump inhibitors , including <e2> DRUG2 </e2> . 	THC	pantoprazole
other	Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol ( THC ) in patients receiving most <e1> DRUG1 </e1> , including <e2> DRUG2 </e2> . 	proton pump inhibitors	pantoprazole
mechanism	A multiple dose drug-drug interaction study demonstrated that <e1> DRUG1 </e1> approximately doubled <e2> DRUG2 </e2> AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	ketoconazole	paricalcitol
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1> DRUG1 </e1> is partially metabolized by CYP3A and <e2> DRUG2 </e2> le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	paricalcitol	ketoconazole
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1> DRUG1 </e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with <e2> DRUG2 </e2> and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	paricalcitol	ketoconazole
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1> DRUG1 </e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e2> DRUG2 </e2> , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	paricalcitol	atazanavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1> DRUG1 </e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , <e2> DRUG2 </e2> , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	paricalcitol	clarithromycin
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1> DRUG1 </e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , <e2> DRUG2 </e2> , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	paricalcitol	indinavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1> DRUG1 </e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , <e2> DRUG2 </e2> , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	paricalcitol	itraconazole
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1> DRUG1 </e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , <e2> DRUG2 </e2> , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	paricalcitol	nefazodone
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1> DRUG1 </e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , <e2> DRUG2 </e2> , ritonavir , saquinavir , telithromycin or voriconazole . 	paricalcitol	nelfinavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1> DRUG1 </e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , <e2> DRUG2 </e2> , saquinavir , telithromycin or voriconazole . 	paricalcitol	ritonavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1> DRUG1 </e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , <e2> DRUG2 </e2> , telithromycin or voriconazole . 	paricalcitol	saquinavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1> DRUG1 </e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , <e2> DRUG2 </e2> or voriconazole . 	paricalcitol	telithromycin
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since <e1> DRUG1 </e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or <e2> DRUG2 </e2> . 	paricalcitol	voriconazole
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1> DRUG1 </e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing <e2> DRUG2 </e2> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	ketoconazole	paricalcitol
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1> DRUG1 </e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e2> DRUG2 </e2> , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	ketoconazole	atazanavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1> DRUG1 </e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , <e2> DRUG2 </e2> , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	ketoconazole	clarithromycin
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1> DRUG1 </e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , <e2> DRUG2 </e2> , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	ketoconazole	indinavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1> DRUG1 </e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , <e2> DRUG2 </e2> , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	ketoconazole	itraconazole
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1> DRUG1 </e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , <e2> DRUG2 </e2> , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	ketoconazole	nefazodone
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1> DRUG1 </e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , <e2> DRUG2 </e2> , ritonavir , saquinavir , telithromycin or voriconazole . 	ketoconazole	nelfinavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1> DRUG1 </e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , <e2> DRUG2 </e2> , saquinavir , telithromycin or voriconazole . 	ketoconazole	ritonavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1> DRUG1 </e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , <e2> DRUG2 </e2> , telithromycin or voriconazole . 	ketoconazole	saquinavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1> DRUG1 </e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , <e2> DRUG2 </e2> or voriconazole . 	ketoconazole	telithromycin
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and <e1> DRUG1 </e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or <e2> DRUG2 </e2> . 	ketoconazole	voriconazole
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing <e1> DRUG1 </e1> with <e2> DRUG2 </e2> and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	paricalcitol	ketoconazole
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing <e1> DRUG1 </e1> with ketoconazole and other strong P450 3A inhibitors including <e2> DRUG2 </e2> , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	paricalcitol	atazanavir
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing <e1> DRUG1 </e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir , <e2> DRUG2 </e2> , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	paricalcitol	clarithromycin
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing <e1> DRUG1 </e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , <e2> DRUG2 </e2> , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	paricalcitol	indinavir
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing <e1> DRUG1 </e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , <e2> DRUG2 </e2> , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	paricalcitol	itraconazole
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing <e1> DRUG1 </e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , <e2> DRUG2 </e2> , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	paricalcitol	nefazodone
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing <e1> DRUG1 </e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , <e2> DRUG2 </e2> , ritonavir , saquinavir , telithromycin or voriconazole . 	paricalcitol	nelfinavir
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing <e1> DRUG1 </e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , <e2> DRUG2 </e2> , saquinavir , telithromycin or voriconazole . 	paricalcitol	ritonavir
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing <e1> DRUG1 </e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , <e2> DRUG2 </e2> , telithromycin or voriconazole . 	paricalcitol	saquinavir
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing <e1> DRUG1 </e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , <e2> DRUG2 </e2> or voriconazole . 	paricalcitol	telithromycin
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing <e1> DRUG1 </e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or <e2> DRUG2 </e2> . 	paricalcitol	voriconazole
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with <e1> DRUG1 </e1> and other strong P450 3A inhibitors including <e2> DRUG2 </e2> , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	ketoconazole	atazanavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with <e1> DRUG1 </e1> and other strong P450 3A inhibitors including atazanavir , <e2> DRUG2 </e2> , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	ketoconazole	clarithromycin
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with <e1> DRUG1 </e1> and other strong P450 3A inhibitors including atazanavir , clarithromycin , <e2> DRUG2 </e2> , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	ketoconazole	indinavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with <e1> DRUG1 </e1> and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , <e2> DRUG2 </e2> , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	ketoconazole	itraconazole
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with <e1> DRUG1 </e1> and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , <e2> DRUG2 </e2> , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	ketoconazole	nefazodone
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with <e1> DRUG1 </e1> and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , <e2> DRUG2 </e2> , ritonavir , saquinavir , telithromycin or voriconazole . 	ketoconazole	nelfinavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with <e1> DRUG1 </e1> and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , <e2> DRUG2 </e2> , saquinavir , telithromycin or voriconazole . 	ketoconazole	ritonavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with <e1> DRUG1 </e1> and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , <e2> DRUG2 </e2> , telithromycin or voriconazole . 	ketoconazole	saquinavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with <e1> DRUG1 </e1> and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , <e2> DRUG2 </e2> or voriconazole . 	ketoconazole	telithromycin
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with <e1> DRUG1 </e1> and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or <e2> DRUG2 </e2> . 	ketoconazole	voriconazole
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1> DRUG1 </e1> , clarithromycin , <e2> DRUG2 </e2> , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	atazanavir	indinavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1> DRUG1 </e1> , clarithromycin , indinavir , <e2> DRUG2 </e2> , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	atazanavir	itraconazole
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1> DRUG1 </e1> , clarithromycin , indinavir , itraconazole , <e2> DRUG2 </e2> , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	atazanavir	nefazodone
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1> DRUG1 </e1> , clarithromycin , indinavir , itraconazole , nefazodone , <e2> DRUG2 </e2> , ritonavir , saquinavir , telithromycin or voriconazole . 	atazanavir	nelfinavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1> DRUG1 </e1> , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , <e2> DRUG2 </e2> , saquinavir , telithromycin or voriconazole . 	atazanavir	ritonavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1> DRUG1 </e1> , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , <e2> DRUG2 </e2> , telithromycin or voriconazole . 	atazanavir	saquinavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1> DRUG1 </e1> , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , <e2> DRUG2 </e2> or voriconazole . 	atazanavir	telithromycin
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1> DRUG1 </e1> , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or <e2> DRUG2 </e2> . 	atazanavir	voriconazole
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , <e1> DRUG1 </e1> , indinavir , <e2> DRUG2 </e2> , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	clarithromycin	itraconazole
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , <e1> DRUG1 </e1> , indinavir , itraconazole , <e2> DRUG2 </e2> , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	clarithromycin	nefazodone
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , <e1> DRUG1 </e1> , indinavir , itraconazole , nefazodone , <e2> DRUG2 </e2> , ritonavir , saquinavir , telithromycin or voriconazole . 	clarithromycin	nelfinavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , <e1> DRUG1 </e1> , indinavir , itraconazole , nefazodone , nelfinavir , <e2> DRUG2 </e2> , saquinavir , telithromycin or voriconazole . 	clarithromycin	ritonavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , <e1> DRUG1 </e1> , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , <e2> DRUG2 </e2> , telithromycin or voriconazole . 	clarithromycin	saquinavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , <e1> DRUG1 </e1> , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , <e2> DRUG2 </e2> or voriconazole . 	clarithromycin	telithromycin
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , <e1> DRUG1 </e1> , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or <e2> DRUG2 </e2> . 	clarithromycin	voriconazole
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , <e1> DRUG1 </e1> , itraconazole , <e2> DRUG2 </e2> , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 	indinavir	nefazodone
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , <e1> DRUG1 </e1> , itraconazole , nefazodone , <e2> DRUG2 </e2> , ritonavir , saquinavir , telithromycin or voriconazole . 	indinavir	nelfinavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , <e1> DRUG1 </e1> , itraconazole , nefazodone , nelfinavir , <e2> DRUG2 </e2> , saquinavir , telithromycin or voriconazole . 	indinavir	ritonavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , <e1> DRUG1 </e1> , itraconazole , nefazodone , nelfinavir , ritonavir , <e2> DRUG2 </e2> , telithromycin or voriconazole . 	indinavir	saquinavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , <e1> DRUG1 </e1> , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , <e2> DRUG2 </e2> or voriconazole . 	indinavir	telithromycin
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , <e1> DRUG1 </e1> , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or <e2> DRUG2 </e2> . 	indinavir	voriconazole
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , <e1> DRUG1 </e1> , nefazodone , <e2> DRUG2 </e2> , ritonavir , saquinavir , telithromycin or voriconazole . 	itraconazole	nelfinavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , <e1> DRUG1 </e1> , nefazodone , nelfinavir , <e2> DRUG2 </e2> , saquinavir , telithromycin or voriconazole . 	itraconazole	ritonavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , <e1> DRUG1 </e1> , nefazodone , nelfinavir , ritonavir , <e2> DRUG2 </e2> , telithromycin or voriconazole . 	itraconazole	saquinavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , <e1> DRUG1 </e1> , nefazodone , nelfinavir , ritonavir , saquinavir , <e2> DRUG2 </e2> or voriconazole . 	itraconazole	telithromycin
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , <e1> DRUG1 </e1> , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or <e2> DRUG2 </e2> . 	itraconazole	voriconazole
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , <e1> DRUG1 </e1> , nelfinavir , <e2> DRUG2 </e2> , saquinavir , telithromycin or voriconazole . 	nefazodone	ritonavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , <e1> DRUG1 </e1> , nelfinavir , ritonavir , <e2> DRUG2 </e2> , telithromycin or voriconazole . 	nefazodone	saquinavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , <e1> DRUG1 </e1> , nelfinavir , ritonavir , saquinavir , <e2> DRUG2 </e2> or voriconazole . 	nefazodone	telithromycin
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , <e1> DRUG1 </e1> , nelfinavir , ritonavir , saquinavir , telithromycin or <e2> DRUG2 </e2> . 	nefazodone	voriconazole
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , <e1> DRUG1 </e1> , ritonavir , <e2> DRUG2 </e2> , telithromycin or voriconazole . 	nelfinavir	saquinavir
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , <e1> DRUG1 </e1> , ritonavir , saquinavir , <e2> DRUG2 </e2> or voriconazole . 	nelfinavir	telithromycin
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , <e1> DRUG1 </e1> , ritonavir , saquinavir , telithromycin or <e2> DRUG2 </e2> . 	nelfinavir	voriconazole
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , <e1> DRUG1 </e1> , saquinavir , <e2> DRUG2 </e2> or voriconazole . 	ritonavir	telithromycin
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , <e1> DRUG1 </e1> , saquinavir , telithromycin or <e2> DRUG2 </e2> . 	ritonavir	voriconazole
other	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , <e1> DRUG1 </e1> , telithromycin or <e2> DRUG2 </e2> . 	saquinavir	voriconazole
mechanism	Drugs that impair intestinal absorption of <e1> DRUG1 </e1> , such as <e2> DRUG2 </e2> , may interfere with the absorption of Zemplar Capsules . 	fat-soluble vitamins	cholestyramine
other	Drugs that impair intestinal absorption of <e1> DRUG1 </e1> , such as cholestyramine , may interfere with the absorption of <e2> DRUG2 </e2> Capsules . 	fat-soluble vitamins	Zemplar
mechanism	Drugs that impair intestinal absorption of fat-soluble vitamins , such as <e1> DRUG1 </e1> , may interfere with the absorption of <e2> DRUG2 </e2> Capsules . 	cholestyramine	Zemplar
advise	patients receiving <e1> DRUG1 </e1> and <e2> DRUG2 </e2> should have more frequent monitoring of neutrophil counts . 	lithium	Neulasta
mechanism	In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving <e1> DRUG1 </e1> , treatment with <e2> DRUG2 </e2> once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC; 	methadone	PEG-Intron
other	In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone , treatment with <e1> DRUG1 </e1> once weekly for 4 weeks was associated with a mean increase of 16% in <e2> DRUG2 </e2> AUC; 	PEG-Intron	methadone
other	Acromegalic patients with diabetes mellitus being treated with <e1> DRUG1 </e1> and/or oral <e2> DRUG2 </e2> agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT . 	insulin	hypoglycemic
advise	Acromegalic patients with diabetes mellitus being treated with <e1> DRUG1 </e1> and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with <e2> DRUG2 </e2> . 	insulin	SOMAVERT
advise	Acromegalic patients with diabetes mellitus being treated with insulin and/or oral <e1> DRUG1 </e1> agents may require dose reductions of these therapeutic agents after the initiation of therapy with <e2> DRUG2 </e2> . 	hypoglycemic	SOMAVERT
mechanism	In clinical studies , patients on <e1> DRUG1 </e1> often needed higher serum <e2> DRUG2 </e2> concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids . 	opioids	pegvisomant
other	In clinical studies , patients on opioids often needed higher serum <e1> DRUG1 </e1> concentrations to achieve appropriate IGF-I suppression compared with patients not receiving <e2> DRUG2 </e2> . 	pegvisomant	opioids
mechanism	Concomitant administration of substances that are also tubularly secreted (e.g. , <e1> DRUG1 </e1> ) could potentially result in delayed clearance of <e2> DRUG2 </e2> . 	probenecid	ALIMTA
other	Although <e1> DRUG1 </e1> (400 mg qid) can be administered with <e2> DRUG2 </e2> in patients with normal renal function (creatinine clearance    80 mL/min) , caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min) . 	ibuprofen	ALIMTA
other	Although <e1> DRUG1 </e1> (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min) , caution should be used when administering ibuprofen concurrently with <e2> DRUG2 </e2> to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min) . 	ibuprofen	ALIMTA
other	Although ibuprofen (400 mg qid) can be administered with <e1> DRUG1 </e1> in patients with normal renal function (creatinine clearance    80 mL/min) , caution should be used when administering <e2> DRUG2 </e2> concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min) . 	ALIMTA	ibuprofen
advise	Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min) , caution should be used when administering <e1> DRUG1 </e1> concurrently with <e2> DRUG2 </e2> to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min) . 	ibuprofen	ALIMTA
advise	Patients with mild to moderate renal insufficiency should avoid taking <e1> DRUG1 </e1> with short elimination half-lives for a period of 2 days before , the day of , and 2 days following administration of <e2> DRUG2 </e2> . 	NSAIDs	ALIMTA
other	In the absence of data regarding potential interaction between <e1> DRUG1 </e1> and <e2> DRUG2 </e2> with longer half-lives , all patients taking these NSAIDs should interrupt dosing for at least 5 days before , the day of , and 2 days following ALIMTA administration . 	ALIMTA	NSAIDs
other	In the absence of data regarding potential interaction between <e1> DRUG1 </e1> and NSAIDs with longer half-lives , all patients taking these <e2> DRUG2 </e2> should interrupt dosing for at least 5 days before , the day of , and 2 days following ALIMTA administration . 	ALIMTA	NSAIDs
other	In the absence of data regarding potential interaction between ALIMTA and <e1> DRUG1 </e1> with longer half-lives , all patients taking these NSAIDs should interrupt dosing for at least 5 days before , the day of , and 2 days following <e2> DRUG2 </e2> administration . 	NSAIDs	ALIMTA
advise	In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives , all patients taking these <e1> DRUG1 </e1> should interrupt dosing for at least 5 days before , the day of , and 2 days following <e2> DRUG2 </e2> administration . 	NSAIDs	ALIMTA
effect	Decreased seizure threshold has been reported in patients receiving <e1> DRUG1 </e1> concomitantly with <e2> DRUG2 </e2> . 	CYLERT	antiepileptic medications
other	Concurrent administration of <e1> DRUG1 </e1> (e.g. , <e2> DRUG2 </e2> , tetracycline ) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth . 	bacteriostatic antibiotics	erythromycin
other	Concurrent administration of <e1> DRUG1 </e1> (e.g. , erythromycin , <e2> DRUG2 </e2> ) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth . 	bacteriostatic antibiotics	tetracycline
effect	Concurrent administration of <e1> DRUG1 </e1> (e.g. , erythromycin , tetracycline ) may diminish the bactericidal effects of <e2> DRUG2 </e2> by slowing the rate of bacterial growth . 	bacteriostatic antibiotics	penicillins
effect	Concurrent administration of bacteriostatic antibiotics (e.g. , <e1> DRUG1 </e1> , tetracycline ) may diminish the bactericidal effects of <e2> DRUG2 </e2> by slowing the rate of bacterial growth . 	erythromycin	penicillins
effect	Concurrent administration of bacteriostatic antibiotics (e.g. , erythromycin , <e1> DRUG1 </e1> ) may diminish the bactericidal effects of <e2> DRUG2 </e2> by slowing the rate of bacterial growth . 	tetracycline	penicillins
mechanism	<e1> DRUG1 </e1> blood levels may be prolonged by concurrent administration of <e2> DRUG2 </e2> which blocks the renal tubular secretion of penicillins . 	Penicillin	probenecid
other	<e1> DRUG1 </e1> blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of <e2> DRUG2 </e2> . 	Penicillin	penicillins
other	Penicillin blood levels may be prolonged by concurrent administration of <e1> DRUG1 </e1> which blocks the renal tubular secretion of <e2> DRUG2 </e2> . 	probenecid	penicillins
other	Usage with <e1> DRUG1 </e1> : Due to the potential for increased CNS depressants effects , alcohol should be used with caution in patients who are currently receiving <e2> DRUG2 </e2> . 	Alcohol	pentazocine
advise	Usage with Alcohol : Due to the potential for increased CNS depressants effects , <e1> DRUG1 </e1> should be used with caution in patients who are currently receiving <e2> DRUG2 </e2> . 	alcohol	pentazocine
effect	Although a causal relationship has not been established , there have been reports of bleeding and/or prolonged prothrombin time in patients treated with <e1> DRUG1 </e1> with and without <e2> DRUG2 </e2> or platelet aggregation inhibitors . 	TRENTAL	anticoagulants
effect	Although a causal relationship has not been established , there have been reports of bleeding and/or prolonged prothrombin time in patients treated with <e1> DRUG1 </e1> with and without anticoagulants or <e2> DRUG2 </e2> . 	TRENTAL	platelet aggregation inhibitors
mechanism	Concomitant administration of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> -containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals . 	TRENTAL	theophylline
other	Concomitant administration of <e1> DRUG1 </e1> and theophylline -containing drugs leads to increased <e2> DRUG2 </e2> levels and theophylline toxicity in some individuals . 	TRENTAL	theophylline
other	Concomitant administration of <e1> DRUG1 </e1> and theophylline -containing drugs leads to increased theophylline levels and <e2> DRUG2 </e2> toxicity in some individuals . 	TRENTAL	theophylline
other	<e1> DRUG1 </e1> has been used concurrently with <e2> DRUG2 </e2> , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 	TRENTAL	antihypertensive drugs
other	<e1> DRUG1 </e1> has been used concurrently with antihypertensive drugs , <e2> DRUG2 </e2> , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 	TRENTAL	beta blockers
other	<e1> DRUG1 </e1> has been used concurrently with antihypertensive drugs , beta blockers , <e2> DRUG2 </e2> , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 	TRENTAL	digitalis
other	<e1> DRUG1 </e1> has been used concurrently with antihypertensive drugs , beta blockers , digitalis , <e2> DRUG2 </e2> , antidiabetic agents , and antiarrhythmics , without observed problems . 	TRENTAL	diuretics
other	<e1> DRUG1 </e1> has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , <e2> DRUG2 </e2> , and antiarrhythmics , without observed problems . 	TRENTAL	antidiabetic agents
other	<e1> DRUG1 </e1> has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and <e2> DRUG2 </e2> , without observed problems . 	TRENTAL	antiarrhythmics
other	TRENTAL has been used concurrently with <e1> DRUG1 </e1> , beta blockers , <e2> DRUG2 </e2> , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 	antihypertensive drugs	digitalis
other	TRENTAL has been used concurrently with <e1> DRUG1 </e1> , beta blockers , digitalis , <e2> DRUG2 </e2> , antidiabetic agents , and antiarrhythmics , without observed problems . 	antihypertensive drugs	diuretics
other	TRENTAL has been used concurrently with <e1> DRUG1 </e1> , beta blockers , digitalis , diuretics , <e2> DRUG2 </e2> , and antiarrhythmics , without observed problems . 	antihypertensive drugs	antidiabetic agents
other	TRENTAL has been used concurrently with <e1> DRUG1 </e1> , beta blockers , digitalis , diuretics , antidiabetic agents , and <e2> DRUG2 </e2> , without observed problems . 	antihypertensive drugs	antiarrhythmics
other	TRENTAL has been used concurrently with antihypertensive drugs , <e1> DRUG1 </e1> , digitalis , <e2> DRUG2 </e2> , antidiabetic agents , and antiarrhythmics , without observed problems . 	beta blockers	diuretics
other	TRENTAL has been used concurrently with antihypertensive drugs , <e1> DRUG1 </e1> , digitalis , diuretics , <e2> DRUG2 </e2> , and antiarrhythmics , without observed problems . 	beta blockers	antidiabetic agents
other	TRENTAL has been used concurrently with antihypertensive drugs , <e1> DRUG1 </e1> , digitalis , diuretics , antidiabetic agents , and <e2> DRUG2 </e2> , without observed problems . 	beta blockers	antiarrhythmics
other	TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , <e1> DRUG1 </e1> , diuretics , <e2> DRUG2 </e2> , and antiarrhythmics , without observed problems . 	digitalis	antidiabetic agents
other	TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , <e1> DRUG1 </e1> , diuretics , antidiabetic agents , and <e2> DRUG2 </e2> , without observed problems . 	digitalis	antiarrhythmics
other	TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , <e1> DRUG1 </e1> , antidiabetic agents , and <e2> DRUG2 </e2> , without observed problems . 	diuretics	antiarrhythmics
other	TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> , without observed problems . 	antidiabetic agents	antiarrhythmics
other	<e1> DRUG1 </e1> , such as the <e2> DRUG2 </e2> ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax (a dopamine agonist ); 	Dopamine antagonists	neuroleptics
other	<e1> DRUG1 </e1> , such as the neuroleptics ( <e2> DRUG2 </e2> , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax (a dopamine agonist ); 	Dopamine antagonists	phenothiazines
other	<e1> DRUG1 </e1> , such as the neuroleptics ( phenothiazines , <e2> DRUG2 </e2> , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax (a dopamine agonist ); 	Dopamine antagonists	butyrophenones
other	<e1> DRUG1 </e1> , such as the neuroleptics ( phenothiazines , butyrophenones , <e2> DRUG2 </e2> ) or metoclopramide , ordinarily should not be administered concurrently with Permax (a dopamine agonist ); 	Dopamine antagonists	thioxanthines
other	<e1> DRUG1 </e1> , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or <e2> DRUG2 </e2> , ordinarily should not be administered concurrently with Permax (a dopamine agonist ); 	Dopamine antagonists	metoclopramide
advise	<e1> DRUG1 </e1> , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with <e2> DRUG2 </e2> (a dopamine agonist ); 	Dopamine antagonists	Permax
other	<e1> DRUG1 </e1> , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax (a <e2> DRUG2 </e2> ); 	Dopamine antagonists	dopamine agonist
other	Dopamine antagonists , such as the <e1> DRUG1 </e1> ( phenothiazines , <e2> DRUG2 </e2> , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax (a dopamine agonist ); 	neuroleptics	butyrophenones
other	Dopamine antagonists , such as the <e1> DRUG1 </e1> ( phenothiazines , butyrophenones , <e2> DRUG2 </e2> ) or metoclopramide , ordinarily should not be administered concurrently with Permax (a dopamine agonist ); 	neuroleptics	thioxanthines
other	Dopamine antagonists , such as the <e1> DRUG1 </e1> ( phenothiazines , butyrophenones , thioxanthines ) or <e2> DRUG2 </e2> , ordinarily should not be administered concurrently with Permax (a dopamine agonist ); 	neuroleptics	metoclopramide
advise	Dopamine antagonists , such as the <e1> DRUG1 </e1> ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with <e2> DRUG2 </e2> (a dopamine agonist ); 	neuroleptics	Permax
other	Dopamine antagonists , such as the <e1> DRUG1 </e1> ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax (a <e2> DRUG2 </e2> ); 	neuroleptics	dopamine agonist
other	Dopamine antagonists , such as the neuroleptics ( <e1> DRUG1 </e1> , butyrophenones , <e2> DRUG2 </e2> ) or metoclopramide , ordinarily should not be administered concurrently with Permax (a dopamine agonist ); 	phenothiazines	thioxanthines
other	Dopamine antagonists , such as the neuroleptics ( <e1> DRUG1 </e1> , butyrophenones , thioxanthines ) or <e2> DRUG2 </e2> , ordinarily should not be administered concurrently with Permax (a dopamine agonist ); 	phenothiazines	metoclopramide
advise	Dopamine antagonists , such as the neuroleptics ( <e1> DRUG1 </e1> , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with <e2> DRUG2 </e2> (a dopamine agonist ); 	phenothiazines	Permax
other	Dopamine antagonists , such as the neuroleptics ( <e1> DRUG1 </e1> , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax (a <e2> DRUG2 </e2> ); 	phenothiazines	dopamine agonist
other	Dopamine antagonists , such as the neuroleptics ( phenothiazines , <e1> DRUG1 </e1> , thioxanthines ) or <e2> DRUG2 </e2> , ordinarily should not be administered concurrently with Permax (a dopamine agonist ); 	butyrophenones	metoclopramide
advise	Dopamine antagonists , such as the neuroleptics ( phenothiazines , <e1> DRUG1 </e1> , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with <e2> DRUG2 </e2> (a dopamine agonist ); 	butyrophenones	Permax
other	Dopamine antagonists , such as the neuroleptics ( phenothiazines , <e1> DRUG1 </e1> , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax (a <e2> DRUG2 </e2> ); 	butyrophenones	dopamine agonist
other	Dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , <e1> DRUG1 </e1> ) or <e2> DRUG2 </e2> , ordinarily should not be administered concurrently with Permax (a dopamine agonist ); 	thioxanthines	metoclopramide
advise	Dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , <e1> DRUG1 </e1> ) or metoclopramide , ordinarily should not be administered concurrently with <e2> DRUG2 </e2> (a dopamine agonist ); 	thioxanthines	Permax
other	Dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , <e1> DRUG1 </e1> ) or metoclopramide , ordinarily should not be administered concurrently with Permax (a <e2> DRUG2 </e2> ); 	thioxanthines	dopamine agonist
advise	Dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or <e1> DRUG1 </e1> , ordinarily should not be administered concurrently with <e2> DRUG2 </e2> (a dopamine agonist ); 	metoclopramide	Permax
other	Dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or <e1> DRUG1 </e1> , ordinarily should not be administered concurrently with Permax (a <e2> DRUG2 </e2> ); 	metoclopramide	dopamine agonist
other	Dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with <e1> DRUG1 </e1> (a <e2> DRUG2 </e2> ); 	Permax	dopamine agonist
other	<e1> DRUG1 </e1> : Patients on diuretics , and especially those started recently , may occasionally experience an excessive reduction of blood pressure after initiation of <e2> DRUG2 </e2> Tablets therapy . 	Diuretics	ACEON
effect	Diuretics : Patients on <e1> DRUG1 </e1> , and especially those started recently , may occasionally experience an excessive reduction of blood pressure after initiation of <e2> DRUG2 </e2> Tablets therapy . 	diuretics	ACEON
effect	The possibility of hypotensive effects can be minimized by either discontinuing the <e1> DRUG1 </e1> or increasing the salt intake prior to initiation of treatment with <e2> DRUG2 </e2> . 	diuretic	perindopril
advise	If <e1> DRUG1 </e1> cannot be interrupted , close medical supervision should be provided with the first dose of <e2> DRUG2 </e2> Tablets , for at least two hours and until blood pressure has stabilized for another hour . 	diuretics	ACEON
other	The rate and extent of <e1> DRUG1 </e1> absorption and elimination are not affected by concomitant <e2> DRUG2 </e2> . 	perindopril	diuretics
other	The bioavailability of <e1> DRUG1 </e1> was reduced by <e2> DRUG2 </e2> , however , and this was associated with a decrease in plasma ACE inhibition . 	perindoprilat	diuretics
other	<e1> DRUG1 </e1> Supplements and <e2> DRUG2 </e2> : ACEON Tablets may increase serum potassium because of its potential to decrease aldosterone production . 	Potassium	Potassium-Sparing Diuretics
other	<e1> DRUG1 </e1> Supplements and Potassium-Sparing Diuretics : <e2> DRUG2 </e2> Tablets may increase serum potassium because of its potential to decrease aldosterone production . 	Potassium	ACEON
other	Potassium Supplements and <e1> DRUG1 </e1> : <e2> DRUG2 </e2> Tablets may increase serum potassium because of its potential to decrease aldosterone production . 	Potassium-Sparing Diuretics	ACEON
other	Use of <e1> DRUG1 </e1> ( spironolactone , <e2> DRUG2 </e2> , triamterene and others) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others) can increase the risk of hyperkalemia . 	potassium-sparing diuretics	amiloride
other	Use of <e1> DRUG1 </e1> ( spironolactone , amiloride , <e2> DRUG2 </e2> and others) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others) can increase the risk of hyperkalemia . 	potassium-sparing diuretics	triamterene
other	Use of <e1> DRUG1 </e1> ( spironolactone , amiloride , triamterene and others) , <e2> DRUG2 </e2> supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others) can increase the risk of hyperkalemia . 	potassium-sparing diuretics	potassium
other	Use of <e1> DRUG1 </e1> ( spironolactone , amiloride , triamterene and others) , potassium supplements or other drugs capable of increasing serum potassium ( <e2> DRUG2 </e2> , heparin , cyclosporine and others) can increase the risk of hyperkalemia . 	potassium-sparing diuretics	indomethacin
other	Use of <e1> DRUG1 </e1> ( spironolactone , amiloride , triamterene and others) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , <e2> DRUG2 </e2> , cyclosporine and others) can increase the risk of hyperkalemia . 	potassium-sparing diuretics	heparin
other	Use of <e1> DRUG1 </e1> ( spironolactone , amiloride , triamterene and others) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , <e2> DRUG2 </e2> and others) can increase the risk of hyperkalemia . 	potassium-sparing diuretics	cyclosporine
other	Use of potassium-sparing diuretics ( <e1> DRUG1 </e1> , amiloride , <e2> DRUG2 </e2> and others) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others) can increase the risk of hyperkalemia . 	spironolactone	triamterene
other	Use of potassium-sparing diuretics ( <e1> DRUG1 </e1> , amiloride , triamterene and others) , <e2> DRUG2 </e2> supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others) can increase the risk of hyperkalemia . 	spironolactone	potassium
other	Use of potassium-sparing diuretics ( <e1> DRUG1 </e1> , amiloride , triamterene and others) , potassium supplements or other drugs capable of increasing serum potassium ( <e2> DRUG2 </e2> , heparin , cyclosporine and others) can increase the risk of hyperkalemia . 	spironolactone	indomethacin
other	Use of potassium-sparing diuretics ( <e1> DRUG1 </e1> , amiloride , triamterene and others) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , <e2> DRUG2 </e2> , cyclosporine and others) can increase the risk of hyperkalemia . 	spironolactone	heparin
other	Use of potassium-sparing diuretics ( <e1> DRUG1 </e1> , amiloride , triamterene and others) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , <e2> DRUG2 </e2> and others) can increase the risk of hyperkalemia . 	spironolactone	cyclosporine
other	Use of potassium-sparing diuretics ( spironolactone , <e1> DRUG1 </e1> , triamterene and others) , <e2> DRUG2 </e2> supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others) can increase the risk of hyperkalemia . 	amiloride	potassium
other	Use of potassium-sparing diuretics ( spironolactone , <e1> DRUG1 </e1> , triamterene and others) , potassium supplements or other drugs capable of increasing serum potassium ( <e2> DRUG2 </e2> , heparin , cyclosporine and others) can increase the risk of hyperkalemia . 	amiloride	indomethacin
other	Use of potassium-sparing diuretics ( spironolactone , <e1> DRUG1 </e1> , triamterene and others) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , <e2> DRUG2 </e2> , cyclosporine and others) can increase the risk of hyperkalemia . 	amiloride	heparin
other	Use of potassium-sparing diuretics ( spironolactone , <e1> DRUG1 </e1> , triamterene and others) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , <e2> DRUG2 </e2> and others) can increase the risk of hyperkalemia . 	amiloride	cyclosporine
other	Use of potassium-sparing diuretics ( spironolactone , amiloride , <e1> DRUG1 </e1> and others) , <e2> DRUG2 </e2> supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others) can increase the risk of hyperkalemia . 	triamterene	potassium
other	Use of potassium-sparing diuretics ( spironolactone , amiloride , <e1> DRUG1 </e1> and others) , potassium supplements or other drugs capable of increasing serum potassium ( <e2> DRUG2 </e2> , heparin , cyclosporine and others) can increase the risk of hyperkalemia . 	triamterene	indomethacin
other	Use of potassium-sparing diuretics ( spironolactone , amiloride , <e1> DRUG1 </e1> and others) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , <e2> DRUG2 </e2> , cyclosporine and others) can increase the risk of hyperkalemia . 	triamterene	heparin
other	Use of potassium-sparing diuretics ( spironolactone , amiloride , <e1> DRUG1 </e1> and others) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , <e2> DRUG2 </e2> and others) can increase the risk of hyperkalemia . 	triamterene	cyclosporine
other	Use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others) , <e1> DRUG1 </e1> supplements or other drugs capable of increasing serum potassium ( <e2> DRUG2 </e2> , heparin , cyclosporine and others) can increase the risk of hyperkalemia . 	potassium	indomethacin
other	Use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others) , <e1> DRUG1 </e1> supplements or other drugs capable of increasing serum potassium ( indomethacin , <e2> DRUG2 </e2> , cyclosporine and others) can increase the risk of hyperkalemia . 	potassium	heparin
other	Use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others) , <e1> DRUG1 </e1> supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , <e2> DRUG2 </e2> and others) can increase the risk of hyperkalemia . 	potassium	cyclosporine
other	Use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others) , potassium supplements or other drugs capable of increasing serum potassium ( <e1> DRUG1 </e1> , heparin , <e2> DRUG2 </e2> and others) can increase the risk of hyperkalemia . 	indomethacin	cyclosporine
other	Use of a <e1> DRUG1 </e1> may further increase the risk of <e2> DRUG2 </e2> toxicity . 	diuretic	lithium
other	<e1> DRUG1 </e1> : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with <e2> DRUG2 </e2> Tablets , but an effect of digoxin on the plasma concentration of perindopril / perindoprilat has not been excluded . 	Digoxin	ACEON
other	Digoxin : A controlled pharmacokinetic study has shown no effect on plasma <e1> DRUG1 </e1> concentrations when coadministered with <e2> DRUG2 </e2> Tablets , but an effect of digoxin on the plasma concentration of perindopril / perindoprilat has not been excluded . 	digoxin	ACEON
mechanism	Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of <e1> DRUG1 </e1> on the plasma concentration of <e2> DRUG2 </e2> / perindoprilat has not been excluded . 	digoxin	perindopril
mechanism	Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of <e1> DRUG1 </e1> on the plasma concentration of perindopril / <e2> DRUG2 </e2> has not been excluded . 	digoxin	perindoprilat
other	Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of <e1> DRUG1 </e1> / <e2> DRUG2 </e2> has not been excluded . 	perindopril	perindoprilat
other	<e1> DRUG1 </e1> : Animal data have suggested the possibility of interaction between <e2> DRUG2 </e2> and gentamicin . 	Gentamicin	perindopril
int	Gentamicin : Animal data have suggested the possibility of interaction between <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	perindopril	gentamicin
other	However , the extent of biotransformation of <e1> DRUG1 </e1> to the active metabolite , <e2> DRUG2 </e2> , is reduced approximately 43% , resulting in a reduction in the plasma ACE inhibition curve of approximately 20% , probably clinically insignificant . 	perindopril	perindoprilat
int	Concomitant use of <e1> DRUG1 </e1> with <e2> DRUG2 </e2> may result in an adverse drug interaction . 	alcohol	phentermine hydrochloride
other	<e1> DRUG1 </e1> , particularly <e2> DRUG2 </e2> , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all . 	Vasopressors	metaraminol
effect	<e1> DRUG1 </e1> , particularly metaraminol , may cause serious cardiac arrhythmias during <e2> DRUG2 </e2> anesthesia and therefore should be used only with great caution or not at all . 	Vasopressors	halothane
effect	Vasopressors , particularly <e1> DRUG1 </e1> , may cause serious cardiac arrhythmias during <e2> DRUG2 </e2> anesthesia and therefore should be used only with great caution or not at all . 	metaraminol	halothane
other	<e1> DRUG1 </e1> : The pressor effect of <e2> DRUG2 </e2> is markedly potentiated in patients receiving monoamine oxidase inhibitors ( MAOI ) . 	MAO Inhibitors	sympathomimetic pressor amines
other	<e1> DRUG1 </e1> : The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving <e2> DRUG2 </e2> ( MAOI ) . 	MAO Inhibitors	monoamine oxidase inhibitors
other	<e1> DRUG1 </e1> : The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( <e2> DRUG2 </e2> ) . 	MAO Inhibitors	MAOI
effect	MAO Inhibitors : The pressor effect of <e1> DRUG1 </e1> is markedly potentiated in patients receiving <e2> DRUG2 </e2> ( MAOI ) . 	sympathomimetic pressor amines	monoamine oxidase inhibitors
effect	MAO Inhibitors : The pressor effect of <e1> DRUG1 </e1> is markedly potentiated in patients receiving monoamine oxidase inhibitors ( <e2> DRUG2 </e2> ) . 	sympathomimetic pressor amines	MAOI
effect	The pressor response of <e1> DRUG1 </e1> may also be potentiated by <e2> DRUG2 </e2> . 	adrenergic agents	tricyclic antidepressants
other	<e1> DRUG1 </e1> , particularly <e2> DRUG2 </e2> , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all . 	Vasopressors	metaraminol
effect	<e1> DRUG1 </e1> , particularly metaraminol , may cause serious cardiac arrhythmias during <e2> DRUG2 </e2> anesthesia and therefore should be used only with great caution or not at all . 	Vasopressors	halothane
effect	Vasopressors , particularly <e1> DRUG1 </e1> , may cause serious cardiac arrhythmias during <e2> DRUG2 </e2> anesthesia and therefore should be used only with great caution or not at all . 	metaraminol	halothane
other	<e1> DRUG1 </e1> - The pressor effect of <e2> DRUG2 </e2> is markedly potentiated in patients receiving monoamine oxidase inhibitors ( MAOI ) . 	MAO Inhibitors	sympathomimetic pressor amines
other	<e1> DRUG1 </e1> - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving <e2> DRUG2 </e2> ( MAOI ) . 	MAO Inhibitors	monoamine oxidase inhibitors
other	<e1> DRUG1 </e1> - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( <e2> DRUG2 </e2> ) . 	MAO Inhibitors	MAOI
effect	MAO Inhibitors - The pressor effect of <e1> DRUG1 </e1> is markedly potentiated in patients receiving <e2> DRUG2 </e2> ( MAOI ) . 	sympathomimetic pressor amines	monoamine oxidase inhibitors
effect	MAO Inhibitors - The pressor effect of <e1> DRUG1 </e1> is markedly potentiated in patients receiving monoamine oxidase inhibitors ( <e2> DRUG2 </e2> ) . 	sympathomimetic pressor amines	MAOI
effect	The pressor response of <e1> DRUG1 </e1> may also be potentiated by <e2> DRUG2 </e2> . 	adrenergic agents	tricyclic antidepressants
advise	<e1> DRUG1 </e1> should be administered with caution to patients taking <e2> DRUG2 </e2> because of the possibility of conduction disturbances . 	Pilocarpine	beta adrenergic antagonists
other	These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g. , <e1> DRUG1 </e1> , inhaled <e2> DRUG2 </e2> ) . 	atropine	ipratropium
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : <e1> DRUG1 </e1> , artificial tears , <e2> DRUG2 </e2> , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 	acetylsalicylic acid	calcium
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : <e1> DRUG1 </e1> , artificial tears , calcium , <e2> DRUG2 </e2> , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 	acetylsalicylic acid	conjugated estrogens
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : <e1> DRUG1 </e1> , artificial tears , calcium , conjugated estrogens , <e2> DRUG2 </e2> , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 	acetylsalicylic acid	hydroxychloroquine sulfate
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : <e1> DRUG1 </e1> , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , <e2> DRUG2 </e2> , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 	acetylsalicylic acid	ibuprofen
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : <e1> DRUG1 </e1> , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , <e2> DRUG2 </e2> , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 	acetylsalicylic acid	levothyroxine sodium
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : <e1> DRUG1 </e1> , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , <e2> DRUG2 </e2> , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 	acetylsalicylic acid	medroxyprogesterone acetate
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : <e1> DRUG1 </e1> , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , <e2> DRUG2 </e2> , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 	acetylsalicylic acid	methotrexate
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : <e1> DRUG1 </e1> , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , <e2> DRUG2 </e2> , naproxen , omeprazole , paracetamol , and prednisone . 	acetylsalicylic acid	multivitamins
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : <e1> DRUG1 </e1> , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , <e2> DRUG2 </e2> , omeprazole , paracetamol , and prednisone . 	acetylsalicylic acid	naproxen
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : <e1> DRUG1 </e1> , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , <e2> DRUG2 </e2> , paracetamol , and prednisone . 	acetylsalicylic acid	omeprazole
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : <e1> DRUG1 </e1> , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , <e2> DRUG2 </e2> , and prednisone . 	acetylsalicylic acid	paracetamol
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : <e1> DRUG1 </e1> , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and <e2> DRUG2 </e2> . 	acetylsalicylic acid	prednisone
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , <e1> DRUG1 </e1> , conjugated estrogens , <e2> DRUG2 </e2> , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 	calcium	hydroxychloroquine sulfate
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , <e1> DRUG1 </e1> , conjugated estrogens , hydroxychloroquine sulfate , <e2> DRUG2 </e2> , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 	calcium	ibuprofen
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , <e1> DRUG1 </e1> , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , <e2> DRUG2 </e2> , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 	calcium	levothyroxine sodium
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , <e1> DRUG1 </e1> , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , <e2> DRUG2 </e2> , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 	calcium	medroxyprogesterone acetate
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , <e1> DRUG1 </e1> , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , <e2> DRUG2 </e2> , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 	calcium	methotrexate
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , <e1> DRUG1 </e1> , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , <e2> DRUG2 </e2> , naproxen , omeprazole , paracetamol , and prednisone . 	calcium	multivitamins
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , <e1> DRUG1 </e1> , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , <e2> DRUG2 </e2> , omeprazole , paracetamol , and prednisone . 	calcium	naproxen
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , <e1> DRUG1 </e1> , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , <e2> DRUG2 </e2> , paracetamol , and prednisone . 	calcium	omeprazole
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , <e1> DRUG1 </e1> , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , <e2> DRUG2 </e2> , and prednisone . 	calcium	paracetamol
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , <e1> DRUG1 </e1> , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and <e2> DRUG2 </e2> . 	calcium	prednisone
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , <e1> DRUG1 </e1> , hydroxychloroquine sulfate , <e2> DRUG2 </e2> , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 	conjugated estrogens	ibuprofen
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , <e1> DRUG1 </e1> , hydroxychloroquine sulfate , ibuprofen , <e2> DRUG2 </e2> , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 	conjugated estrogens	levothyroxine sodium
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , <e1> DRUG1 </e1> , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , <e2> DRUG2 </e2> , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 	conjugated estrogens	medroxyprogesterone acetate
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , <e1> DRUG1 </e1> , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , <e2> DRUG2 </e2> , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 	conjugated estrogens	methotrexate
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , <e1> DRUG1 </e1> , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , <e2> DRUG2 </e2> , naproxen , omeprazole , paracetamol , and prednisone . 	conjugated estrogens	multivitamins
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , <e1> DRUG1 </e1> , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , <e2> DRUG2 </e2> , omeprazole , paracetamol , and prednisone . 	conjugated estrogens	naproxen
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , <e1> DRUG1 </e1> , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , <e2> DRUG2 </e2> , paracetamol , and prednisone . 	conjugated estrogens	omeprazole
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , <e1> DRUG1 </e1> , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , <e2> DRUG2 </e2> , and prednisone . 	conjugated estrogens	paracetamol
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , <e1> DRUG1 </e1> , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and <e2> DRUG2 </e2> . 	conjugated estrogens	prednisone
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , <e1> DRUG1 </e1> , ibuprofen , <e2> DRUG2 </e2> , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 	hydroxychloroquine sulfate	levothyroxine sodium
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , <e1> DRUG1 </e1> , ibuprofen , levothyroxine sodium , <e2> DRUG2 </e2> , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 	hydroxychloroquine sulfate	medroxyprogesterone acetate
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , <e1> DRUG1 </e1> , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , <e2> DRUG2 </e2> , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 	hydroxychloroquine sulfate	methotrexate
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , <e1> DRUG1 </e1> , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , <e2> DRUG2 </e2> , naproxen , omeprazole , paracetamol , and prednisone . 	hydroxychloroquine sulfate	multivitamins
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , <e1> DRUG1 </e1> , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , <e2> DRUG2 </e2> , omeprazole , paracetamol , and prednisone . 	hydroxychloroquine sulfate	naproxen
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , <e1> DRUG1 </e1> , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , <e2> DRUG2 </e2> , paracetamol , and prednisone . 	hydroxychloroquine sulfate	omeprazole
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , <e1> DRUG1 </e1> , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , <e2> DRUG2 </e2> , and prednisone . 	hydroxychloroquine sulfate	paracetamol
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , <e1> DRUG1 </e1> , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and <e2> DRUG2 </e2> . 	hydroxychloroquine sulfate	prednisone
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , <e1> DRUG1 </e1> , levothyroxine sodium , <e2> DRUG2 </e2> , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 	ibuprofen	medroxyprogesterone acetate
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , <e1> DRUG1 </e1> , levothyroxine sodium , medroxyprogesterone acetate , <e2> DRUG2 </e2> , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 	ibuprofen	methotrexate
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , <e1> DRUG1 </e1> , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , <e2> DRUG2 </e2> , naproxen , omeprazole , paracetamol , and prednisone . 	ibuprofen	multivitamins
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , <e1> DRUG1 </e1> , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , <e2> DRUG2 </e2> , omeprazole , paracetamol , and prednisone . 	ibuprofen	naproxen
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , <e1> DRUG1 </e1> , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , <e2> DRUG2 </e2> , paracetamol , and prednisone . 	ibuprofen	omeprazole
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , <e1> DRUG1 </e1> , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , <e2> DRUG2 </e2> , and prednisone . 	ibuprofen	paracetamol
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , <e1> DRUG1 </e1> , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and <e2> DRUG2 </e2> . 	ibuprofen	prednisone
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , <e1> DRUG1 </e1> , medroxyprogesterone acetate , <e2> DRUG2 </e2> , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 	levothyroxine sodium	methotrexate
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , <e1> DRUG1 </e1> , medroxyprogesterone acetate , methotrexate , <e2> DRUG2 </e2> , naproxen , omeprazole , paracetamol , and prednisone . 	levothyroxine sodium	multivitamins
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , <e1> DRUG1 </e1> , medroxyprogesterone acetate , methotrexate , multivitamins , <e2> DRUG2 </e2> , omeprazole , paracetamol , and prednisone . 	levothyroxine sodium	naproxen
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , <e1> DRUG1 </e1> , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , <e2> DRUG2 </e2> , paracetamol , and prednisone . 	levothyroxine sodium	omeprazole
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , <e1> DRUG1 </e1> , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , <e2> DRUG2 </e2> , and prednisone . 	levothyroxine sodium	paracetamol
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , <e1> DRUG1 </e1> , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and <e2> DRUG2 </e2> . 	levothyroxine sodium	prednisone
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , <e1> DRUG1 </e1> , methotrexate , <e2> DRUG2 </e2> , naproxen , omeprazole , paracetamol , and prednisone . 	medroxyprogesterone acetate	multivitamins
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , <e1> DRUG1 </e1> , methotrexate , multivitamins , <e2> DRUG2 </e2> , omeprazole , paracetamol , and prednisone . 	medroxyprogesterone acetate	naproxen
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , <e1> DRUG1 </e1> , methotrexate , multivitamins , naproxen , <e2> DRUG2 </e2> , paracetamol , and prednisone . 	medroxyprogesterone acetate	omeprazole
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , <e1> DRUG1 </e1> , methotrexate , multivitamins , naproxen , omeprazole , <e2> DRUG2 </e2> , and prednisone . 	medroxyprogesterone acetate	paracetamol
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , <e1> DRUG1 </e1> , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and <e2> DRUG2 </e2> . 	medroxyprogesterone acetate	prednisone
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , <e1> DRUG1 </e1> , multivitamins , <e2> DRUG2 </e2> , omeprazole , paracetamol , and prednisone . 	methotrexate	naproxen
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , <e1> DRUG1 </e1> , multivitamins , naproxen , <e2> DRUG2 </e2> , paracetamol , and prednisone . 	methotrexate	omeprazole
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , <e1> DRUG1 </e1> , multivitamins , naproxen , omeprazole , <e2> DRUG2 </e2> , and prednisone . 	methotrexate	paracetamol
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , <e1> DRUG1 </e1> , multivitamins , naproxen , omeprazole , paracetamol , and <e2> DRUG2 </e2> . 	methotrexate	prednisone
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , <e1> DRUG1 </e1> , naproxen , <e2> DRUG2 </e2> , paracetamol , and prednisone . 	multivitamins	omeprazole
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , <e1> DRUG1 </e1> , naproxen , omeprazole , <e2> DRUG2 </e2> , and prednisone . 	multivitamins	paracetamol
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , <e1> DRUG1 </e1> , naproxen , omeprazole , paracetamol , and <e2> DRUG2 </e2> . 	multivitamins	prednisone
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , <e1> DRUG1 </e1> , omeprazole , <e2> DRUG2 </e2> , and prednisone . 	naproxen	paracetamol
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , <e1> DRUG1 </e1> , omeprazole , paracetamol , and <e2> DRUG2 </e2> . 	naproxen	prednisone
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , <e1> DRUG1 </e1> , paracetamol , and <e2> DRUG2 </e2> . 	omeprazole	prednisone
other	While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> . 	paracetamol	prednisone
effect	Catecholamine-depleting drugs (e.g. , <e1> DRUG1 </e1> ) may have an additive effect when given with <e2> DRUG2 </e2> . 	reserpine	beta-blocking agents
other	<e1> DRUG1 </e1> has been used with a variety of <e2> DRUG2 </e2> , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions . 	Pindolol	antihypertensive agents
other	<e1> DRUG1 </e1> has been used with a variety of antihypertensive agents , including <e2> DRUG2 </e2> , hydralazine , and guanethidine without unexpected adverse interactions . 	Pindolol	hydrochlorothiazide
other	<e1> DRUG1 </e1> has been used with a variety of antihypertensive agents , including hydrochlorothiazide , <e2> DRUG2 </e2> , and guanethidine without unexpected adverse interactions . 	Pindolol	hydralazine
other	<e1> DRUG1 </e1> has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and <e2> DRUG2 </e2> without unexpected adverse interactions . 	Pindolol	guanethidine
other	Pindolol has been used with a variety of <e1> DRUG1 </e1> , including <e2> DRUG2 </e2> , hydralazine , and guanethidine without unexpected adverse interactions . 	antihypertensive agents	hydrochlorothiazide
other	Pindolol has been used with a variety of <e1> DRUG1 </e1> , including hydrochlorothiazide , <e2> DRUG2 </e2> , and guanethidine without unexpected adverse interactions . 	antihypertensive agents	hydralazine
other	Pindolol has been used with a variety of <e1> DRUG1 </e1> , including hydrochlorothiazide , hydralazine , and <e2> DRUG2 </e2> without unexpected adverse interactions . 	antihypertensive agents	guanethidine
other	Pindolol has been used with a variety of antihypertensive agents , including <e1> DRUG1 </e1> , hydralazine , and <e2> DRUG2 </e2> without unexpected adverse interactions . 	hydrochlorothiazide	guanethidine
other	Pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> without unexpected adverse interactions . 	hydralazine	guanethidine
mechanism	<e1> DRUG1 </e1> has been shown to increase serum <e2> DRUG2 </e2> levels when both drugs are co-administered . 	Pindolol	thioridazine
advise	Other <e1> DRUG1 </e1> should not be used concomitantly with <e2> DRUG2 </e2> because they may have additive effects . 	short-acting beta adrenergic aerosol bronchodilators	MAXAIR AUTOHALER
other	Although this has not occurred in in vitro studies with <e1> DRUG1 </e1> , interactions with coumarin-type anticoagulants have been reported with <e2> DRUG2 </e2> since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs . 	coumarin-type anticoagulants	FELDENE
other	Although this has not occurred in in vitro studies with <e1> DRUG1 </e1> , interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering <e2> DRUG2 </e2> to patients on coumarin-type anticoagulants and other highly protein-bound drugs . 	coumarin-type anticoagulants	FELDENE
int	Although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with <e1> DRUG1 </e1> have been reported with <e2> DRUG2 </e2> since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs . 	coumarin-type anticoagulants	FELDENE
other	Although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with <e1> DRUG1 </e1> have been reported with FELDENE since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering <e2> DRUG2 </e2> to patients on coumarin-type anticoagulants and other highly protein-bound drugs . 	coumarin-type anticoagulants	FELDENE
other	Although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with coumarin-type anticoagulants have been reported with <e1> DRUG1 </e1> since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on <e2> DRUG2 </e2> and other highly protein-bound drugs . 	FELDENE	coumarin-type anticoagulants
advise	Although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering <e1> DRUG1 </e1> to patients on <e2> DRUG2 </e2> and other highly protein-bound drugs . 	FELDENE	coumarin-type anticoagulants
other	Plasma levels of <e1> DRUG1 </e1> are depressed to approximately 80% of their normal values when <e2> DRUG2 </e2> is administered in conjunction with aspirin (3900 mg/day) , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 	piroxicam	FELDENE
other	Plasma levels of <e1> DRUG1 </e1> are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with <e2> DRUG2 </e2> (3900 mg/day) , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 	piroxicam	aspirin
other	Plasma levels of <e1> DRUG1 </e1> are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day) , but concomitant administration of <e2> DRUG2 </e2> has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 	piroxicam	antacids
mechanism	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when <e1> DRUG1 </e1> is administered in conjunction with <e2> DRUG2 </e2> (3900 mg/day) , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 	FELDENE	aspirin
other	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when <e1> DRUG1 </e1> is administered in conjunction with aspirin (3900 mg/day) , but concomitant administration of <e2> DRUG2 </e2> has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 	FELDENE	antacids
other	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when <e1> DRUG1 </e1> is administered in conjunction with aspirin (3900 mg/day) , but concomitant administration of antacids has no effect on <e2> DRUG2 </e2> plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 	FELDENE	piroxicam
other	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with <e1> DRUG1 </e1> (3900 mg/day) , but concomitant administration of <e2> DRUG2 </e2> has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 	aspirin	antacids
other	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with <e1> DRUG1 </e1> (3900 mg/day) , but concomitant administration of antacids has no effect on <e2> DRUG2 </e2> plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 	aspirin	piroxicam
other	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day) , but concomitant administration of <e1> DRUG1 </e1> has no effect on <e2> DRUG2 </e2> plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 	antacids	piroxicam
other	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day) , but concomitant administration of antacids has no effect on piroxicam plasma levels . <e1> DRUG1 </e1> , including <e2> DRUG2 </e2> , have been reported to increase steady state plasma lithium levels . 	Nonsteroidal anti-inflammatory agents	FELDENE
mechanism	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day) , but concomitant administration of antacids has no effect on piroxicam plasma levels . <e1> DRUG1 </e1> , including FELDENE , have been reported to increase steady state plasma <e2> DRUG2 </e2> levels . 	Nonsteroidal anti-inflammatory agents	lithium
mechanism	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day) , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including <e1> DRUG1 </e1> , have been reported to increase steady state plasma <e2> DRUG2 </e2> levels . 	FELDENE	lithium
advise	It is recommended that plasma <e1> DRUG1 </e1> levels be monitored when initiating , adjusting and discontinuing <e2> DRUG2 </e2> . 	lithium	FELDENE
effect	When <e1> DRUG1 </e1> and <e2> DRUG2 </e2> are used together , the signs of atropinization (flushing , mydriasis , tachycardia , dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone . 	atropine	pralidoxime
other	When atropine and <e1> DRUG1 </e1> are used together , the signs of atropinization (flushing , mydriasis , tachycardia , dryness of the mouth and nose) may occur earlier than might be expected when <e2> DRUG2 </e2> is used alone . 	pralidoxime	atropine
other	This is especially true if the total dose of <e1> DRUG1 </e1> has been large and the administration of <e2> DRUG2 </e2> has been delayed . 	atropine	pralidoxime
other	2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning , although they do not bear directly on the use of <e1> DRUG1 </e1> : since <e2> DRUG2 </e2> are potentiated by the anticholinesterases , they should be used cautiously in the treatment of convulsions; 	pralidoxime	barbiturates
other	2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning , although they do not bear directly on the use of <e1> DRUG1 </e1> : since barbiturates are potentiated by the <e2> DRUG2 </e2> , they should be used cautiously in the treatment of convulsions; 	pralidoxime	anticholinesterases
effect	2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning , although they do not bear directly on the use of pralidoxime : since <e1> DRUG1 </e1> are potentiated by the <e2> DRUG2 </e2> , they should be used cautiously in the treatment of convulsions; 	barbiturates	anticholinesterases
other	<e1> DRUG1 </e1> , theophylline , <e2> DRUG2 </e2> , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 	morphine	aminophylline
other	<e1> DRUG1 </e1> , theophylline , aminophylline , <e2> DRUG2 </e2> , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 	morphine	succinylcholine
other	<e1> DRUG1 </e1> , theophylline , aminophylline , succinylcholine , <e2> DRUG2 </e2> , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 	morphine	reserpine
other	<e1> DRUG1 </e1> , theophylline , aminophylline , succinylcholine , reserpine , and <e2> DRUG2 </e2> should be avoided in patients with organophosphate poisoning . 	morphine	phenothiazine-type tranquilizers
other	morphine , <e1> DRUG1 </e1> , aminophylline , <e2> DRUG2 </e2> , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 	theophylline	succinylcholine
other	morphine , <e1> DRUG1 </e1> , aminophylline , succinylcholine , <e2> DRUG2 </e2> , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 	theophylline	reserpine
other	morphine , <e1> DRUG1 </e1> , aminophylline , succinylcholine , reserpine , and <e2> DRUG2 </e2> should be avoided in patients with organophosphate poisoning . 	theophylline	phenothiazine-type tranquilizers
other	morphine , theophylline , <e1> DRUG1 </e1> , succinylcholine , <e2> DRUG2 </e2> , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 	aminophylline	reserpine
other	morphine , theophylline , <e1> DRUG1 </e1> , succinylcholine , reserpine , and <e2> DRUG2 </e2> should be avoided in patients with organophosphate poisoning . 	aminophylline	phenothiazine-type tranquilizers
other	morphine , theophylline , aminophylline , <e1> DRUG1 </e1> , reserpine , and <e2> DRUG2 </e2> should be avoided in patients with organophosphate poisoning . 	succinylcholine	phenothiazine-type tranquilizers
other	morphine , theophylline , aminophylline , succinylcholine , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> should be avoided in patients with organophosphate poisoning . 	reserpine	phenothiazine-type tranquilizers
other	<e1> DRUG1 </e1> / <e2> DRUG2 </e2> : Carbidopa / Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10) . 	Carbidopa	Levodopa
other	<e1> DRUG1 </e1> / Levodopa : Carbidopa / <e2> DRUG2 </e2> does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10) . 	Carbidopa	Levodopa
other	<e1> DRUG1 </e1> / Levodopa : Carbidopa / Levodopa does not influence the pharmacokinetics of <e2> DRUG2 </e2> in healthy volunteers (N= 10) . 	Carbidopa	pramipexole
other	Carbidopa / <e1> DRUG1 </e1> : <e2> DRUG2 </e2> / Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10) . 	Levodopa	Carbidopa
other	Carbidopa / <e1> DRUG1 </e1> : Carbidopa / Levodopa does not influence the pharmacokinetics of <e2> DRUG2 </e2> in healthy volunteers (N= 10) . 	Levodopa	pramipexole
other	Carbidopa / Levodopa : <e1> DRUG1 </e1> / <e2> DRUG2 </e2> does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10) . 	Carbidopa	Levodopa
other	Carbidopa / Levodopa : <e1> DRUG1 </e1> / Levodopa does not influence the pharmacokinetics of <e2> DRUG2 </e2> in healthy volunteers (N= 10) . 	Carbidopa	pramipexole
other	Carbidopa / Levodopa : Carbidopa / <e1> DRUG1 </e1> does not influence the pharmacokinetics of <e2> DRUG2 </e2> in healthy volunteers (N= 10) . 	Levodopa	pramipexole
other	<e1> DRUG1 </e1> : In healthy volunteers (N= 11) , selegiline did not influence the pharmacokinetics of <e2> DRUG2 </e2> . 	Selegiline	pramipexole
other	Selegiline : In healthy volunteers (N= 11) , <e1> DRUG1 </e1> did not influence the pharmacokinetics of <e2> DRUG2 </e2> . 	selegiline	pramipexole
other	<e1> DRUG1 </e1> : Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of <e2> DRUG2 </e2> (N= 54) . 	Amantadine	pramipexole
other	Amantadine : Population pharmacokinetic analysis suggests that <e1> DRUG1 </e1> is unlikely to alter the oral clearance of <e2> DRUG2 </e2> (N= 54) . 	amantadine	pramipexole
other	<e1> DRUG1 </e1> : Cimetidine , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system , caused a 50% increase in <e2> DRUG2 </e2> AUC and a 40% increase in half-life (N= 12) . 	Cimetidine	pramipexole
mechanism	Cimetidine : <e1> DRUG1 </e1> , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system , caused a 50% increase in <e2> DRUG2 </e2> AUC and a 40% increase in half-life (N= 12) . 	Cimetidine	pramipexole
other	<e1> DRUG1 </e1> : Probenecid , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter , did not noticeably influence <e2> DRUG2 </e2> pharmacokinetics (N= 12) . 	Probenecid	pramipexole
other	Probenecid : <e1> DRUG1 </e1> , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter , did not noticeably influence <e2> DRUG2 </e2> pharmacokinetics (N= 12) . 	Probenecid	pramipexole
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , <e1> DRUG1 </e1> , ranitidine , <e2> DRUG2 </e2> , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	cimetidine	diltiazem
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , <e1> DRUG1 </e1> , ranitidine , diltiazem , <e2> DRUG2 </e2> , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	cimetidine	triamterene
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , <e1> DRUG1 </e1> , ranitidine , diltiazem , triamterene , <e2> DRUG2 </e2> , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	cimetidine	verapamil
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , <e1> DRUG1 </e1> , ranitidine , diltiazem , triamterene , verapamil , <e2> DRUG2 </e2> , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	cimetidine	quinidine
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , <e1> DRUG1 </e1> , ranitidine , diltiazem , triamterene , verapamil , quinidine , and <e2> DRUG2 </e2> ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	cimetidine	quinine
mechanism	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , <e1> DRUG1 </e1> , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of <e2> DRUG2 </e2> by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	cimetidine	pramipexole
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , <e1> DRUG1 </e1> , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , <e2> DRUG2 </e2> , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	cimetidine	cephalosporins
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , <e1> DRUG1 </e1> , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , <e2> DRUG2 </e2> , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	cimetidine	penicillins
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , <e1> DRUG1 </e1> , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , <e2> DRUG2 </e2> , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	cimetidine	indomethacin
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , <e1> DRUG1 </e1> , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , <e2> DRUG2 </e2> , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	cimetidine	hydrochlorothiazide
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , <e1> DRUG1 </e1> , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and <e2> DRUG2 </e2> ) are likely to have little effect on the oral clearance of pramipexole . 	cimetidine	chlorpropamide
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , <e1> DRUG1 </e1> , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e2> DRUG2 </e2> . 	cimetidine	pramipexole
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , <e1> DRUG1 </e1> , diltiazem , <e2> DRUG2 </e2> , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	ranitidine	triamterene
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , <e1> DRUG1 </e1> , diltiazem , triamterene , <e2> DRUG2 </e2> , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	ranitidine	verapamil
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , <e1> DRUG1 </e1> , diltiazem , triamterene , verapamil , <e2> DRUG2 </e2> , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	ranitidine	quinidine
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , <e1> DRUG1 </e1> , diltiazem , triamterene , verapamil , quinidine , and <e2> DRUG2 </e2> ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	ranitidine	quinine
mechanism	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , <e1> DRUG1 </e1> , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of <e2> DRUG2 </e2> by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	ranitidine	pramipexole
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , <e1> DRUG1 </e1> , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , <e2> DRUG2 </e2> , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	ranitidine	cephalosporins
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , <e1> DRUG1 </e1> , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , <e2> DRUG2 </e2> , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	ranitidine	penicillins
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , <e1> DRUG1 </e1> , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , <e2> DRUG2 </e2> , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	ranitidine	indomethacin
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , <e1> DRUG1 </e1> , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , <e2> DRUG2 </e2> , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	ranitidine	hydrochlorothiazide
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , <e1> DRUG1 </e1> , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and <e2> DRUG2 </e2> ) are likely to have little effect on the oral clearance of pramipexole . 	ranitidine	chlorpropamide
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , <e1> DRUG1 </e1> , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e2> DRUG2 </e2> . 	ranitidine	pramipexole
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , <e1> DRUG1 </e1> , triamterene , <e2> DRUG2 </e2> , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	diltiazem	verapamil
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , <e1> DRUG1 </e1> , triamterene , verapamil , <e2> DRUG2 </e2> , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	diltiazem	quinidine
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , <e1> DRUG1 </e1> , triamterene , verapamil , quinidine , and <e2> DRUG2 </e2> ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	diltiazem	quinine
mechanism	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , <e1> DRUG1 </e1> , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of <e2> DRUG2 </e2> by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	diltiazem	pramipexole
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , <e1> DRUG1 </e1> , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , <e2> DRUG2 </e2> , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	diltiazem	cephalosporins
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , <e1> DRUG1 </e1> , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , <e2> DRUG2 </e2> , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	diltiazem	penicillins
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , <e1> DRUG1 </e1> , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , <e2> DRUG2 </e2> , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	diltiazem	indomethacin
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , <e1> DRUG1 </e1> , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , <e2> DRUG2 </e2> , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	diltiazem	hydrochlorothiazide
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , <e1> DRUG1 </e1> , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and <e2> DRUG2 </e2> ) are likely to have little effect on the oral clearance of pramipexole . 	diltiazem	chlorpropamide
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , <e1> DRUG1 </e1> , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e2> DRUG2 </e2> . 	diltiazem	pramipexole
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , <e1> DRUG1 </e1> , verapamil , <e2> DRUG2 </e2> , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	triamterene	quinidine
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , <e1> DRUG1 </e1> , verapamil , quinidine , and <e2> DRUG2 </e2> ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	triamterene	quinine
mechanism	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , <e1> DRUG1 </e1> , verapamil , quinidine , and quinine ) decreases the oral clearance of <e2> DRUG2 </e2> by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	triamterene	pramipexole
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , <e1> DRUG1 </e1> , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , <e2> DRUG2 </e2> , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	triamterene	cephalosporins
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , <e1> DRUG1 </e1> , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , <e2> DRUG2 </e2> , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	triamterene	penicillins
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , <e1> DRUG1 </e1> , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , <e2> DRUG2 </e2> , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	triamterene	indomethacin
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , <e1> DRUG1 </e1> , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , <e2> DRUG2 </e2> , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	triamterene	hydrochlorothiazide
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , <e1> DRUG1 </e1> , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and <e2> DRUG2 </e2> ) are likely to have little effect on the oral clearance of pramipexole . 	triamterene	chlorpropamide
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , <e1> DRUG1 </e1> , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e2> DRUG2 </e2> . 	triamterene	pramipexole
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , <e1> DRUG1 </e1> , quinidine , and <e2> DRUG2 </e2> ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	verapamil	quinine
mechanism	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , <e1> DRUG1 </e1> , quinidine , and quinine ) decreases the oral clearance of <e2> DRUG2 </e2> by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	verapamil	pramipexole
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , <e1> DRUG1 </e1> , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , <e2> DRUG2 </e2> , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	verapamil	cephalosporins
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , <e1> DRUG1 </e1> , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , <e2> DRUG2 </e2> , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	verapamil	penicillins
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , <e1> DRUG1 </e1> , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , <e2> DRUG2 </e2> , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	verapamil	indomethacin
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , <e1> DRUG1 </e1> , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , <e2> DRUG2 </e2> , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	verapamil	hydrochlorothiazide
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , <e1> DRUG1 </e1> , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and <e2> DRUG2 </e2> ) are likely to have little effect on the oral clearance of pramipexole . 	verapamil	chlorpropamide
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , <e1> DRUG1 </e1> , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e2> DRUG2 </e2> . 	verapamil	pramipexole
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	quinidine	quinine
mechanism	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , <e1> DRUG1 </e1> , and quinine ) decreases the oral clearance of <e2> DRUG2 </e2> by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	quinidine	pramipexole
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , <e1> DRUG1 </e1> , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , <e2> DRUG2 </e2> , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	quinidine	cephalosporins
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , <e1> DRUG1 </e1> , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , <e2> DRUG2 </e2> , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	quinidine	penicillins
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , <e1> DRUG1 </e1> , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , <e2> DRUG2 </e2> , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	quinidine	indomethacin
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , <e1> DRUG1 </e1> , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , <e2> DRUG2 </e2> , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	quinidine	hydrochlorothiazide
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , <e1> DRUG1 </e1> , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and <e2> DRUG2 </e2> ) are likely to have little effect on the oral clearance of pramipexole . 	quinidine	chlorpropamide
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , <e1> DRUG1 </e1> , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e2> DRUG2 </e2> . 	quinidine	pramipexole
mechanism	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and <e1> DRUG1 </e1> ) decreases the oral clearance of <e2> DRUG2 </e2> by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	quinine	pramipexole
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and <e1> DRUG1 </e1> ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , <e2> DRUG2 </e2> , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	quinine	cephalosporins
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and <e1> DRUG1 </e1> ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , <e2> DRUG2 </e2> , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	quinine	penicillins
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and <e1> DRUG1 </e1> ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , <e2> DRUG2 </e2> , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	quinine	indomethacin
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and <e1> DRUG1 </e1> ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , <e2> DRUG2 </e2> , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	quinine	hydrochlorothiazide
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and <e1> DRUG1 </e1> ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and <e2> DRUG2 </e2> ) are likely to have little effect on the oral clearance of pramipexole . 	quinine	chlorpropamide
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and <e1> DRUG1 </e1> ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e2> DRUG2 </e2> . 	quinine	pramipexole
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of <e1> DRUG1 </e1> by about 20% , while those secreted by the anionic transport system (e.g. , <e2> DRUG2 </e2> , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	pramipexole	cephalosporins
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of <e1> DRUG1 </e1> by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , <e2> DRUG2 </e2> , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	pramipexole	penicillins
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of <e1> DRUG1 </e1> by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , <e2> DRUG2 </e2> , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	pramipexole	indomethacin
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of <e1> DRUG1 </e1> by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , <e2> DRUG2 </e2> , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	pramipexole	hydrochlorothiazide
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of <e1> DRUG1 </e1> by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and <e2> DRUG2 </e2> ) are likely to have little effect on the oral clearance of pramipexole . 	pramipexole	chlorpropamide
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , <e1> DRUG1 </e1> , penicillins , <e2> DRUG2 </e2> , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	cephalosporins	indomethacin
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , <e1> DRUG1 </e1> , penicillins , indomethacin , <e2> DRUG2 </e2> , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	cephalosporins	hydrochlorothiazide
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , <e1> DRUG1 </e1> , penicillins , indomethacin , hydrochlorothiazide , and <e2> DRUG2 </e2> ) are likely to have little effect on the oral clearance of pramipexole . 	cephalosporins	chlorpropamide
mechanism	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , <e1> DRUG1 </e1> , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e2> DRUG2 </e2> . 	cephalosporins	pramipexole
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , <e1> DRUG1 </e1> , indomethacin , <e2> DRUG2 </e2> , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 	penicillins	hydrochlorothiazide
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , <e1> DRUG1 </e1> , indomethacin , hydrochlorothiazide , and <e2> DRUG2 </e2> ) are likely to have little effect on the oral clearance of pramipexole . 	penicillins	chlorpropamide
mechanism	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , <e1> DRUG1 </e1> , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e2> DRUG2 </e2> . 	penicillins	pramipexole
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , <e1> DRUG1 </e1> , hydrochlorothiazide , and <e2> DRUG2 </e2> ) are likely to have little effect on the oral clearance of pramipexole . 	indomethacin	chlorpropamide
mechanism	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , <e1> DRUG1 </e1> , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e2> DRUG2 </e2> . 	indomethacin	pramipexole
other	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> ) are likely to have little effect on the oral clearance of pramipexole . 	hydrochlorothiazide	chlorpropamide
mechanism	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , <e1> DRUG1 </e1> , and chlorpropamide ) are likely to have little effect on the oral clearance of <e2> DRUG2 </e2> . 	hydrochlorothiazide	pramipexole
mechanism	Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20% , while those secreted by the anionic transport system (e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and <e1> DRUG1 </e1> ) are likely to have little effect on the oral clearance of <e2> DRUG2 </e2> . 	chlorpropamide	pramipexole
other	<e1> DRUG1 </e1> : Since <e2> DRUG2 </e2> is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	Dopamine antagonists	pramipexole
other	<e1> DRUG1 </e1> : Since pramipexole is a <e2> DRUG2 </e2> , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	Dopamine antagonists	dopamine agonist
other	<e1> DRUG1 </e1> : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the <e2> DRUG2 </e2> ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	Dopamine antagonists	neuroleptics
other	<e1> DRUG1 </e1> : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( <e2> DRUG2 </e2> , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	Dopamine antagonists	phenothiazines
other	<e1> DRUG1 </e1> : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , <e2> DRUG2 </e2> , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	Dopamine antagonists	butyrophenones
other	<e1> DRUG1 </e1> : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , <e2> DRUG2 </e2> ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	Dopamine antagonists	thioxanthenes
other	<e1> DRUG1 </e1> : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or <e2> DRUG2 </e2> , may diminish the effectiveness of MIRAPEX . 	Dopamine antagonists	metoclopramide
other	<e1> DRUG1 </e1> : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of <e2> DRUG2 </e2> . 	Dopamine antagonists	MIRAPEX
other	Dopamine antagonists : Since <e1> DRUG1 </e1> is a <e2> DRUG2 </e2> , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	pramipexole	dopamine agonist
other	Dopamine antagonists : Since <e1> DRUG1 </e1> is a dopamine agonist , it is possible that <e2> DRUG2 </e2> , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	pramipexole	dopamine antagonists
other	Dopamine antagonists : Since <e1> DRUG1 </e1> is a dopamine agonist , it is possible that dopamine antagonists , such as the <e2> DRUG2 </e2> ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	pramipexole	neuroleptics
other	Dopamine antagonists : Since <e1> DRUG1 </e1> is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( <e2> DRUG2 </e2> , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	pramipexole	phenothiazines
other	Dopamine antagonists : Since <e1> DRUG1 </e1> is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , <e2> DRUG2 </e2> , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	pramipexole	butyrophenones
other	Dopamine antagonists : Since <e1> DRUG1 </e1> is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , <e2> DRUG2 </e2> ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	pramipexole	thioxanthenes
other	Dopamine antagonists : Since <e1> DRUG1 </e1> is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or <e2> DRUG2 </e2> , may diminish the effectiveness of MIRAPEX . 	pramipexole	metoclopramide
other	Dopamine antagonists : Since <e1> DRUG1 </e1> is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of <e2> DRUG2 </e2> . 	pramipexole	MIRAPEX
other	Dopamine antagonists : Since pramipexole is a <e1> DRUG1 </e1> , it is possible that <e2> DRUG2 </e2> , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	dopamine agonist	dopamine antagonists
other	Dopamine antagonists : Since pramipexole is a <e1> DRUG1 </e1> , it is possible that dopamine antagonists , such as the <e2> DRUG2 </e2> ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	dopamine agonist	neuroleptics
other	Dopamine antagonists : Since pramipexole is a <e1> DRUG1 </e1> , it is possible that dopamine antagonists , such as the neuroleptics ( <e2> DRUG2 </e2> , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	dopamine agonist	phenothiazines
other	Dopamine antagonists : Since pramipexole is a <e1> DRUG1 </e1> , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , <e2> DRUG2 </e2> , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	dopamine agonist	butyrophenones
other	Dopamine antagonists : Since pramipexole is a <e1> DRUG1 </e1> , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , <e2> DRUG2 </e2> ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	dopamine agonist	thioxanthenes
other	Dopamine antagonists : Since pramipexole is a <e1> DRUG1 </e1> , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or <e2> DRUG2 </e2> , may diminish the effectiveness of MIRAPEX . 	dopamine agonist	metoclopramide
other	Dopamine antagonists : Since pramipexole is a <e1> DRUG1 </e1> , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of <e2> DRUG2 </e2> . 	dopamine agonist	MIRAPEX
other	Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that <e1> DRUG1 </e1> , such as the <e2> DRUG2 </e2> ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	dopamine antagonists	neuroleptics
other	Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that <e1> DRUG1 </e1> , such as the neuroleptics ( <e2> DRUG2 </e2> , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	dopamine antagonists	phenothiazines
other	Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that <e1> DRUG1 </e1> , such as the neuroleptics ( phenothiazines , <e2> DRUG2 </e2> , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	dopamine antagonists	butyrophenones
other	Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that <e1> DRUG1 </e1> , such as the neuroleptics ( phenothiazines , butyrophenones , <e2> DRUG2 </e2> ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	dopamine antagonists	thioxanthenes
other	Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that <e1> DRUG1 </e1> , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or <e2> DRUG2 </e2> , may diminish the effectiveness of MIRAPEX . 	dopamine antagonists	metoclopramide
effect	Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that <e1> DRUG1 </e1> , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of <e2> DRUG2 </e2> . 	dopamine antagonists	MIRAPEX
other	Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the <e1> DRUG1 </e1> ( phenothiazines , <e2> DRUG2 </e2> , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	neuroleptics	butyrophenones
other	Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the <e1> DRUG1 </e1> ( phenothiazines , butyrophenones , <e2> DRUG2 </e2> ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	neuroleptics	thioxanthenes
other	Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the <e1> DRUG1 </e1> ( phenothiazines , butyrophenones , thioxanthenes ) or <e2> DRUG2 </e2> , may diminish the effectiveness of MIRAPEX . 	neuroleptics	metoclopramide
effect	Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the <e1> DRUG1 </e1> ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of <e2> DRUG2 </e2> . 	neuroleptics	MIRAPEX
other	Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( <e1> DRUG1 </e1> , butyrophenones , <e2> DRUG2 </e2> ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 	phenothiazines	thioxanthenes
other	Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( <e1> DRUG1 </e1> , butyrophenones , thioxanthenes ) or <e2> DRUG2 </e2> , may diminish the effectiveness of MIRAPEX . 	phenothiazines	metoclopramide
effect	Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( <e1> DRUG1 </e1> , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of <e2> DRUG2 </e2> . 	phenothiazines	MIRAPEX
other	Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , <e1> DRUG1 </e1> , thioxanthenes ) or <e2> DRUG2 </e2> , may diminish the effectiveness of MIRAPEX . 	butyrophenones	metoclopramide
effect	Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , <e1> DRUG1 </e1> , thioxanthenes ) or metoclopramide , may diminish the effectiveness of <e2> DRUG2 </e2> . 	butyrophenones	MIRAPEX
other	Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , <e1> DRUG1 </e1> ) or <e2> DRUG2 </e2> , may diminish the effectiveness of MIRAPEX . 	thioxanthenes	metoclopramide
effect	Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , <e1> DRUG1 </e1> ) or metoclopramide , may diminish the effectiveness of <e2> DRUG2 </e2> . 	thioxanthenes	MIRAPEX
effect	Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or <e1> DRUG1 </e1> , may diminish the effectiveness of <e2> DRUG2 </e2> . 	metoclopramide	MIRAPEX
advise	Due to its effects on gastric emptying , <e1> DRUG1 </e1> therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g. , <e2> DRUG2 </e2> such as atropine ) and agents that slow the intestinal absorption of nutrients (e.g. , alpha glucosidase inhibitors ) . 	SYMLIN	anticholinergic agents
advise	Due to its effects on gastric emptying , <e1> DRUG1 </e1> therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g. , anticholinergic agents such as <e2> DRUG2 </e2> ) and agents that slow the intestinal absorption of nutrients (e.g. , alpha glucosidase inhibitors ) . 	SYMLIN	atropine
advise	Due to its effects on gastric emptying , <e1> DRUG1 </e1> therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g. , anticholinergic agents such as atropine ) and agents that slow the intestinal absorption of nutrients (e.g. , <e2> DRUG2 </e2> ) . 	SYMLIN	alpha glucosidase inhibitors
other	Due to its effects on gastric emptying , SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g. , <e1> DRUG1 </e1> such as atropine ) and agents that slow the intestinal absorption of nutrients (e.g. , <e2> DRUG2 </e2> ) . 	anticholinergic agents	alpha glucosidase inhibitors
other	Due to its effects on gastric emptying , SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g. , anticholinergic agents such as <e1> DRUG1 </e1> ) and agents that slow the intestinal absorption of nutrients (e.g. , <e2> DRUG2 </e2> ) . 	atropine	alpha glucosidase inhibitors
advise	When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as <e1> DRUG1 </e1> ) , the agent should be administered at least 1 hour prior to or 2 hours after <e2> DRUG2 </e2> injection . 	analgesics	SYMLIN
other	In clinical trials , the concomitant use of <e1> DRUG1 </e1> or biguanides did not alter the adverse event profile of <e2> DRUG2 </e2> . 	sulfonylureas	SYMLIN
other	In clinical trials , the concomitant use of sulfonylureas or <e1> DRUG1 </e1> did not alter the adverse event profile of <e2> DRUG2 </e2> . 	biguanides	SYMLIN
other	No formal interaction studies have been performed to assess the effect of <e1> DRUG1 </e1> on the kinetics of oral <e2> DRUG2 </e2> . 	SYMLIN	antidiabetic agents
other	Mixing <e1> DRUG1 </e1> and <e2> DRUG2 </e2> The pharmacokinetic parameters of SYMLIN were altered when mixed with regular , NPH , and 70/30 premixed formulations of recombinant human insulin immediately prior to injection . 	SYMLIN	Insulin
mechanism	Mixing SYMLIN and Insulin The pharmacokinetic parameters of <e1> DRUG1 </e1> were altered when mixed with regular , NPH , and 70/30 premixed formulations of recombinant <e2> DRUG2 </e2> immediately prior to injection . 	SYMLIN	human insulin
other	Thus , <e1> DRUG1 </e1> and <e2> DRUG2 </e2> should not be mixed and must be administered separately . 	SYMLIN	insulin
other	Drugs that induce hepatic enzymes such as <e1> DRUG1 </e1> , phenytoin and <e2> DRUG2 </e2> may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . 	phenobarbital	rifampin
mechanism	Drugs that induce hepatic enzymes such as <e1> DRUG1 </e1> , phenytoin and rifampin may increase the clearance of <e2> DRUG2 </e2> and may require increases in corticosteroid dose to achieve the desired response . 	phenobarbital	corticosteroids
mechanism	Drugs that induce hepatic enzymes such as <e1> DRUG1 </e1> , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in <e2> DRUG2 </e2> dose to achieve the desired response . 	phenobarbital	corticosteroid
other	Drugs that induce hepatic enzymes such as phenobarbital , <e1> DRUG1 </e1> and <e2> DRUG2 </e2> may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . 	phenytoin	rifampin
mechanism	Drugs that induce hepatic enzymes such as phenobarbital , <e1> DRUG1 </e1> and rifampin may increase the clearance of <e2> DRUG2 </e2> and may require increases in corticosteroid dose to achieve the desired response . 	phenytoin	corticosteroids
mechanism	Drugs that induce hepatic enzymes such as phenobarbital , <e1> DRUG1 </e1> and rifampin may increase the clearance of corticosteroids and may require increases in <e2> DRUG2 </e2> dose to achieve the desired response . 	phenytoin	corticosteroid
mechanism	Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and <e1> DRUG1 </e1> may increase the clearance of <e2> DRUG2 </e2> and may require increases in corticosteroid dose to achieve the desired response . 	rifampin	corticosteroids
mechanism	Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and <e1> DRUG1 </e1> may increase the clearance of corticosteroids and may require increases in <e2> DRUG2 </e2> dose to achieve the desired response . 	rifampin	corticosteroid
other	Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of <e1> DRUG1 </e1> and may require increases in <e2> DRUG2 </e2> dose to achieve the desired response . 	corticosteroids	corticosteroid
other	Drugs such as <e1> DRUG1 </e1> and <e2> DRUG2 </e2> may inhibit the metabolism of corticosteroids and thus decrease their clearance . 	troleandomycin	ketoconazole
mechanism	Drugs such as <e1> DRUG1 </e1> and ketoconazole may inhibit the metabolism of <e2> DRUG2 </e2> and thus decrease their clearance . 	troleandomycin	corticosteroids
mechanism	Drugs such as troleandomycin and <e1> DRUG1 </e1> may inhibit the metabolism of <e2> DRUG2 </e2> and thus decrease their clearance . 	ketoconazole	corticosteroids
mechanism	<e1> DRUG1 </e1> may increase the clearance of chronic high dose <e2> DRUG2 </e2> . 	Corticosteroids	aspirin
other	This could lead to decreased <e1> DRUG1 </e1> serum levels or increase the risk of salicylate toxicity when <e2> DRUG2 </e2> is withdrawn . 	salicylate	corticosteroid
effect	This could lead to decreased salicylate serum levels or increase the risk of <e1> DRUG1 </e1> toxicity when <e2> DRUG2 </e2> is withdrawn . 	salicylate	corticosteroid
advise	<e1> DRUG1 </e1> should be used cautiously in conjunction with <e2> DRUG2 </e2> in patients suffering from hypoprothrombinemia . 	Aspirin	corticosteroids
effect	The effect of <e1> DRUG1 </e1> on oral <e2> DRUG2 </e2> is variable . 	corticosteroids	anticoagulants
effect	There are reports of enhanced as well as diminished effects of <e1> DRUG1 </e1> when given concurrently with <e2> DRUG2 </e2> . 	anticoagulants	corticosteroids
other	<e1> DRUG1 </e1> : Concurrent use of <e2> DRUG2 </e2> and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride . 	Anticholinesterases	procaine hydrochloride
other	<e1> DRUG1 </e1> : Concurrent use of procaine hydrochloride and <e2> DRUG2 </e2> may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride . 	Anticholinesterases	anticholinesterase agents
other	<e1> DRUG1 </e1> : Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of <e2> DRUG2 </e2> . 	Anticholinesterases	procaine hydrochloride
effect	Anticholinesterases : Concurrent use of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride . 	procaine hydrochloride	anticholinesterase agents
other	Anticholinesterases : Concurrent use of <e1> DRUG1 </e1> and anticholinesterase agents may result in increased systemic toxicity since <e2> DRUG2 </e2> inhibit the breakdown of procaine hydrochloride . 	procaine hydrochloride	anticholinesterases
other	Anticholinesterases : Concurrent use of procaine hydrochloride and <e1> DRUG1 </e1> may result in increased systemic toxicity since <e2> DRUG2 </e2> inhibit the breakdown of procaine hydrochloride . 	anticholinesterase agents	anticholinesterases
other	Anticholinesterases : Concurrent use of procaine hydrochloride and <e1> DRUG1 </e1> may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of <e2> DRUG2 </e2> . 	anticholinesterase agents	procaine hydrochloride
mechanism	Anticholinesterases : Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since <e1> DRUG1 </e1> inhibit the breakdown of <e2> DRUG2 </e2> . 	anticholinesterases	procaine hydrochloride
other	<e1> DRUG1 </e1> medications : Concurrent use of <e2> DRUG2 </e2> and CNS depressant medications may result in additive depressant effects . 	CNS depressant	procaine hydrochloride
other	<e1> DRUG1 </e1> medications : Concurrent use of procaine hydrochloride and <e2> DRUG2 </e2> may result in additive depressant effects . 	CNS depressant	CNS depressant medications
effect	CNS depressant medications : Concurrent use of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> may result in additive depressant effects . 	procaine hydrochloride	CNS depressant medications
other	<e1> DRUG1 </e1> : Hyaluronidase may increase the diffusion rate of <e2> DRUG2 </e2> , resulting in a decreased time of onset , but an increase in systemic toxicity . 	Hyaluronidase	procaine hydrochloride
mechanism	Hyaluronidase : <e1> DRUG1 </e1> may increase the diffusion rate of <e2> DRUG2 </e2> , resulting in a decreased time of onset , but an increase in systemic toxicity . 	Hyaluronidase	procaine hydrochloride
other	<e1> DRUG1 </e1> (such as <e2> DRUG2 </e2> ) : Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade . 	Neuromuscular blocking agents	suxamethonium chloride
other	<e1> DRUG1 </e1> (such as suxamethonium chloride ) : Concurrent use of <e2> DRUG2 </e2> and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade . 	Neuromuscular blocking agents	procaine hydrochloride
other	Neuromuscular blocking agents (such as <e1> DRUG1 </e1> ) : Concurrent use of <e2> DRUG2 </e2> and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade . 	suxamethonium chloride	procaine hydrochloride
other	Neuromuscular blocking agents (such as <e1> DRUG1 </e1> ) : Concurrent use of procaine hydrochloride and <e2> DRUG2 </e2> may result in prolongation or enhancement of the neuromuscular blockade . 	suxamethonium chloride	neuromuscular blocking agents
effect	Neuromuscular blocking agents (such as suxamethonium chloride ) : Concurrent use of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> may result in prolongation or enhancement of the neuromuscular blockade . 	procaine hydrochloride	neuromuscular blocking agents
other	<e1> DRUG1 </e1> : Concurrent use of <e2> DRUG2 </e2> and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide . 	Sulfonamides	procaine hydrochloride
other	<e1> DRUG1 </e1> : Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the <e2> DRUG2 </e2> . 	Sulfonamides	sulfonamide
effect	Sulfonamides : Concurrent use of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> may result in a reduction of the antibacterial action of the sulfonamide . 	procaine hydrochloride	sulfonamides
other	Sulfonamides : Concurrent use of <e1> DRUG1 </e1> and sulfonamides may result in a reduction of the antibacterial action of the <e2> DRUG2 </e2> . 	procaine hydrochloride	sulfonamide
other	Sulfonamides : Concurrent use of procaine hydrochloride and <e1> DRUG1 </e1> may result in a reduction of the antibacterial action of the <e2> DRUG2 </e2> . 	sulfonamides	sulfonamide
other	<e1> DRUG1 </e1> : Concurrent use of acetazolamide and <e2> DRUG2 </e2> may extend the plasma half-life of procaine . 	Acetazolamide	procaine hydrochloride
other	<e1> DRUG1 </e1> : Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of <e2> DRUG2 </e2> . 	Acetazolamide	procaine
mechanism	Acetazolamide : Concurrent use of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> may extend the plasma half-life of procaine . 	acetazolamide	procaine hydrochloride
other	Acetazolamide : Concurrent use of <e1> DRUG1 </e1> and procaine hydrochloride may extend the plasma half-life of <e2> DRUG2 </e2> . 	acetazolamide	procaine
other	Acetazolamide : Concurrent use of acetazolamide and <e1> DRUG1 </e1> may extend the plasma half-life of <e2> DRUG2 </e2> . 	procaine hydrochloride	procaine
other	To minimize CNS depression and possible potentiation , <e1> DRUG1 </e1> , antihistamines , <e2> DRUG2 </e2> , hypotensive agents or phenothiazines should be used with caution . 	barbiturates	narcotics
other	To minimize CNS depression and possible potentiation , <e1> DRUG1 </e1> , antihistamines , narcotics , <e2> DRUG2 </e2> or phenothiazines should be used with caution . 	barbiturates	hypotensive agents
other	To minimize CNS depression and possible potentiation , <e1> DRUG1 </e1> , antihistamines , narcotics , hypotensive agents or <e2> DRUG2 </e2> should be used with caution . 	barbiturates	phenothiazines
other	To minimize CNS depression and possible potentiation , barbiturates , <e1> DRUG1 </e1> , narcotics , <e2> DRUG2 </e2> or phenothiazines should be used with caution . 	antihistamines	hypotensive agents
other	To minimize CNS depression and possible potentiation , barbiturates , <e1> DRUG1 </e1> , narcotics , hypotensive agents or <e2> DRUG2 </e2> should be used with caution . 	antihistamines	phenothiazines
other	To minimize CNS depression and possible potentiation , barbiturates , antihistamines , <e1> DRUG1 </e1> , hypotensive agents or <e2> DRUG2 </e2> should be used with caution . 	narcotics	phenothiazines
advise	Because <e1> DRUG1 </e1> exhibits some monoamine oxidase inhibitory activity , <e2> DRUG2 </e2> , tricyclic antidepressant drugs (e.g. , amitriptyline HCl , imipramine HCl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 	Matulane	sympathomimetic drugs
advise	Because <e1> DRUG1 </e1> exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , <e2> DRUG2 </e2> drugs (e.g. , amitriptyline HCl , imipramine HCl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 	Matulane	tricyclic antidepressant
advise	Because <e1> DRUG1 </e1> exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs (e.g. , <e2> DRUG2 </e2> , imipramine HCl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 	Matulane	amitriptyline HCl
advise	Because <e1> DRUG1 </e1> exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs (e.g. , amitriptyline HCl , <e2> DRUG2 </e2> ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 	Matulane	imipramine HCl
advise	Because <e1> DRUG1 </e1> exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs (e.g. , amitriptyline HCl , imipramine HCl ) and other drugs and foods with known high <e2> DRUG2 </e2> content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 	Matulane	tyramine
other	Because Matulane exhibits some monoamine oxidase inhibitory activity , <e1> DRUG1 </e1> , tricyclic antidepressant drugs (e.g. , <e2> DRUG2 </e2> , imipramine HCl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 	sympathomimetic drugs	amitriptyline HCl
other	Because Matulane exhibits some monoamine oxidase inhibitory activity , <e1> DRUG1 </e1> , tricyclic antidepressant drugs (e.g. , amitriptyline HCl , <e2> DRUG2 </e2> ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 	sympathomimetic drugs	imipramine HCl
other	Because Matulane exhibits some monoamine oxidase inhibitory activity , <e1> DRUG1 </e1> , tricyclic antidepressant drugs (e.g. , amitriptyline HCl , imipramine HCl ) and other drugs and foods with known high <e2> DRUG2 </e2> content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 	sympathomimetic drugs	tyramine
other	Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , <e1> DRUG1 </e1> drugs (e.g. , <e2> DRUG2 </e2> , imipramine HCl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 	tricyclic antidepressant	amitriptyline HCl
other	Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , <e1> DRUG1 </e1> drugs (e.g. , amitriptyline HCl , <e2> DRUG2 </e2> ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 	tricyclic antidepressant	imipramine HCl
other	Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , <e1> DRUG1 </e1> drugs (e.g. , amitriptyline HCl , imipramine HCl ) and other drugs and foods with known high <e2> DRUG2 </e2> content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 	tricyclic antidepressant	tyramine
other	Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs (e.g. , <e1> DRUG1 </e1> , imipramine HCl ) and other drugs and foods with known high <e2> DRUG2 </e2> content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 	amitriptyline HCl	tyramine
other	Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs (e.g. , amitriptyline HCl , <e1> DRUG1 </e1> ) and other drugs and foods with known high <e2> DRUG2 </e2> content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 	imipramine HCl	tyramine
other	No cross-resistance with other <e1> DRUG1 </e1> , radiotherapy or <e2> DRUG2 </e2> has been demonstrated . 	chemotherapeutic agents	steroids
effect	<e1> DRUG1 </e1> may accentuate the orthostatic hypotension that may occur with <e2> DRUG2 </e2> . 	Thiazide diuretics	phenothiazines
effect	Antihypertensive effects of <e1> DRUG1 </e1> and related compounds may be counteracted when <e2> DRUG2 </e2> are used concomitantly . 	guanethidine	phenothiazines
mechanism	Concomitant administration of <e1> DRUG1 </e1> with <e2> DRUG2 </e2> results in increased plasma levels of both drugs . 	propranolol	phenothiazines
effect	The induction dose requirements of <e1> DRUG1 </e1> Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with <e2> DRUG2 </e2> (eg , morphine , meperidine , and fentanyl , etc.) 	DIPRIVAN	narcotics
effect	The induction dose requirements of <e1> DRUG1 </e1> Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics (eg , <e2> DRUG2 </e2> , meperidine , and fentanyl , etc.) 	DIPRIVAN	morphine
effect	The induction dose requirements of <e1> DRUG1 </e1> Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics (eg , morphine , <e2> DRUG2 </e2> , and fentanyl , etc.) 	DIPRIVAN	meperidine
effect	The induction dose requirements of <e1> DRUG1 </e1> Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics (eg , morphine , meperidine , and <e2> DRUG2 </e2> , etc.) 	DIPRIVAN	fentanyl
other	The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with <e1> DRUG1 </e1> (eg , <e2> DRUG2 </e2> , meperidine , and fentanyl , etc.) 	narcotics	morphine
other	The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with <e1> DRUG1 </e1> (eg , morphine , <e2> DRUG2 </e2> , and fentanyl , etc.) 	narcotics	meperidine
other	The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with <e1> DRUG1 </e1> (eg , morphine , meperidine , and <e2> DRUG2 </e2> , etc.) 	narcotics	fentanyl
other	The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics (eg , <e1> DRUG1 </e1> , meperidine , and <e2> DRUG2 </e2> , etc.) 	morphine	fentanyl
other	The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics (eg , morphine , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> , etc.) 	meperidine	fentanyl
other	and combinations of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> (eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc.) . 	opioids	sedatives
other	and combinations of <e1> DRUG1 </e1> and sedatives (eg , <e2> DRUG2 </e2> , barbiturates , chloral hydrate , droperidol , etc.) . 	opioids	benzodiazepines
other	and combinations of <e1> DRUG1 </e1> and sedatives (eg , benzodiazepines , <e2> DRUG2 </e2> , chloral hydrate , droperidol , etc.) . 	opioids	barbiturates
other	and combinations of <e1> DRUG1 </e1> and sedatives (eg , benzodiazepines , barbiturates , <e2> DRUG2 </e2> , droperidol , etc.) . 	opioids	chloral hydrate
other	and combinations of <e1> DRUG1 </e1> and sedatives (eg , benzodiazepines , barbiturates , chloral hydrate , <e2> DRUG2 </e2> , etc.) . 	opioids	droperidol
other	and combinations of opioids and <e1> DRUG1 </e1> (eg , <e2> DRUG2 </e2> , barbiturates , chloral hydrate , droperidol , etc.) . 	sedatives	benzodiazepines
other	and combinations of opioids and <e1> DRUG1 </e1> (eg , benzodiazepines , <e2> DRUG2 </e2> , chloral hydrate , droperidol , etc.) . 	sedatives	barbiturates
other	and combinations of opioids and <e1> DRUG1 </e1> (eg , benzodiazepines , barbiturates , <e2> DRUG2 </e2> , droperidol , etc.) . 	sedatives	chloral hydrate
other	and combinations of opioids and <e1> DRUG1 </e1> (eg , benzodiazepines , barbiturates , chloral hydrate , <e2> DRUG2 </e2> , etc.) . 	sedatives	droperidol
other	and combinations of opioids and sedatives (eg , <e1> DRUG1 </e1> , barbiturates , <e2> DRUG2 </e2> , droperidol , etc.) . 	benzodiazepines	chloral hydrate
other	and combinations of opioids and sedatives (eg , <e1> DRUG1 </e1> , barbiturates , chloral hydrate , <e2> DRUG2 </e2> , etc.) . 	benzodiazepines	droperidol
other	and combinations of opioids and sedatives (eg , benzodiazepines , <e1> DRUG1 </e1> , chloral hydrate , <e2> DRUG2 </e2> , etc.) . 	barbiturates	droperidol
advise	During maintenance of anesthesia or sedation , the rate of <e1> DRUG1 </e1> Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental <e2> DRUG2 </e2> (eg , nitrous oxide or opioids ) . 	DIPRIVAN	analgesic agents
advise	During maintenance of anesthesia or sedation , the rate of <e1> DRUG1 </e1> Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg , <e2> DRUG2 </e2> or opioids ) . 	DIPRIVAN	nitrous oxide
advise	During maintenance of anesthesia or sedation , the rate of <e1> DRUG1 </e1> Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg , nitrous oxide or <e2> DRUG2 </e2> ) . 	DIPRIVAN	opioids
other	During maintenance of anesthesia or sedation , the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental <e1> DRUG1 </e1> (eg , <e2> DRUG2 </e2> or opioids ) . 	analgesic agents	nitrous oxide
other	During maintenance of anesthesia or sedation , the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental <e1> DRUG1 </e1> (eg , nitrous oxide or <e2> DRUG2 </e2> ) . 	analgesic agents	opioids
other	The concurrent administration of potent inhalational agents (eg , <e1> DRUG1 </e1> , enflurane , and <e2> DRUG2 </e2> ) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated . 	isoflurane	halothane
other	The concurrent administration of potent inhalational agents (eg , <e1> DRUG1 </e1> , enflurane , and halothane ) during maintenance with <e2> DRUG2 </e2> Injectable Emulsion has not been extensively evaluated . 	isoflurane	DIPRIVAN
other	The concurrent administration of potent inhalational agents (eg , isoflurane , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> ) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated . 	enflurane	halothane
other	The concurrent administration of potent inhalational agents (eg , isoflurane , <e1> DRUG1 </e1> , and halothane ) during maintenance with <e2> DRUG2 </e2> Injectable Emulsion has not been extensively evaluated . 	enflurane	DIPRIVAN
other	The concurrent administration of potent inhalational agents (eg , isoflurane , enflurane , and <e1> DRUG1 </e1> ) during maintenance with <e2> DRUG2 </e2> Injectable Emulsion has not been extensively evaluated . 	halothane	DIPRIVAN
other	DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used <e1> DRUG1 </e1> (eg , <e2> DRUG2 </e2> and nondepolarizing muscle relaxants ) . 	neuromuscular blocking agents	succinylcholine
other	DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used <e1> DRUG1 </e1> (eg , succinylcholine and <e2> DRUG2 </e2> ) . 	neuromuscular blocking agents	nondepolarizing muscle relaxants
other	DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used neuromuscular blocking agents (eg , <e1> DRUG1 </e1> and <e2> DRUG2 </e2> ) . 	succinylcholine	nondepolarizing muscle relaxants
other	No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of <e1> DRUG1 </e1> , inhalational agents , <e2> DRUG2 </e2> , and local anesthetic agents ) have been observed . 	muscle relaxants	analgesic agents
other	No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of <e1> DRUG1 </e1> , inhalational agents , analgesic agents , and local <e2> DRUG2 </e2> ) have been observed . 	muscle relaxants	anesthetic agents
other	No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants , inhalational agents , <e1> DRUG1 </e1> , and local <e2> DRUG2 </e2> ) have been observed . 	analgesic agents	anesthetic agents
effect	The CNS-depressant effect of <e1> DRUG1 </e1> is additive with that of other <e2> DRUG2 </e2> , including alcohol . 	propoxyphene	CNS depressants
effect	The CNS-depressant effect of <e1> DRUG1 </e1> is additive with that of other CNS depressants , including <e2> DRUG2 </e2> . 	propoxyphene	alcohol
other	The CNS-depressant effect of propoxyphene is additive with that of other <e1> DRUG1 </e1> , including <e2> DRUG2 </e2> . 	CNS depressants	alcohol
other	Such occurrences have been reported when <e1> DRUG1 </e1> was administered to patients on <e2> DRUG2 </e2> , anticonvulsants , or warfarin -like drugs . 	propoxyphene	antidepressants
other	Such occurrences have been reported when <e1> DRUG1 </e1> was administered to patients on antidepressants , <e2> DRUG2 </e2> , or warfarin -like drugs . 	propoxyphene	anticonvulsants
other	Such occurrences have been reported when <e1> DRUG1 </e1> was administered to patients on antidepressants , anticonvulsants , or <e2> DRUG2 </e2> -like drugs . 	propoxyphene	warfarin
other	Such occurrences have been reported when propoxyphene was administered to patients on <e1> DRUG1 </e1> , anticonvulsants , or <e2> DRUG2 </e2> -like drugs . 	antidepressants	warfarin
other	<e1> DRUG1 </e1> and <e2> DRUG2 </e2> increase the effects of pseudoephedrine . 	MAO inhibitors	beta adrenergic blockers
effect	<e1> DRUG1 </e1> and beta adrenergic blockers increase the effects of <e2> DRUG2 </e2> . 	MAO inhibitors	pseudoephedrine
effect	MAO inhibitors and <e1> DRUG1 </e1> increase the effects of <e2> DRUG2 </e2> . 	beta adrenergic blockers	pseudoephedrine
effect	<e1> DRUG1 </e1> may reduce the antihypertensive effects of <e2> DRUG2 </e2> , mecamylamine , reserpine and veratrum alkaloids . 	Sympathomimetics	methyldopa
effect	<e1> DRUG1 </e1> may reduce the antihypertensive effects of methyldopa , <e2> DRUG2 </e2> , reserpine and veratrum alkaloids . 	Sympathomimetics	mecamylamine
effect	<e1> DRUG1 </e1> may reduce the antihypertensive effects of methyldopa , mecamylamine , <e2> DRUG2 </e2> and veratrum alkaloids . 	Sympathomimetics	reserpine
effect	<e1> DRUG1 </e1> may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and <e2> DRUG2 </e2> . 	Sympathomimetics	veratrum alkaloids
other	Sympathomimetics may reduce the antihypertensive effects of <e1> DRUG1 </e1> , mecamylamine , <e2> DRUG2 </e2> and veratrum alkaloids . 	methyldopa	reserpine
other	Sympathomimetics may reduce the antihypertensive effects of <e1> DRUG1 </e1> , mecamylamine , reserpine and <e2> DRUG2 </e2> . 	methyldopa	veratrum alkaloids
other	Sympathomimetics may reduce the antihypertensive effects of methyldopa , <e1> DRUG1 </e1> , reserpine and <e2> DRUG2 </e2> . 	mecamylamine	veratrum alkaloids
other	Sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	reserpine	veratrum alkaloids
other	<e1> DRUG1 </e1> may be used with <e2> DRUG2 </e2> , quinine and other antimalarials , and with other antibiotics . 	Pyrimethamine	sulfonamides
other	<e1> DRUG1 </e1> may be used with sulfonamides , <e2> DRUG2 </e2> and other antimalarials , and with other antibiotics . 	Pyrimethamine	quinine
other	<e1> DRUG1 </e1> may be used with sulfonamides , quinine and other <e2> DRUG2 </e2> , and with other antibiotics . 	Pyrimethamine	antimalarials
other	<e1> DRUG1 </e1> may be used with sulfonamides , quinine and other antimalarials , and with other <e2> DRUG2 </e2> . 	Pyrimethamine	antibiotics
other	Pyrimethamine may be used with <e1> DRUG1 </e1> , quinine and other <e2> DRUG2 </e2> , and with other antibiotics . 	sulfonamides	antimalarials
other	Pyrimethamine may be used with <e1> DRUG1 </e1> , quinine and other antimalarials , and with other <e2> DRUG2 </e2> . 	sulfonamides	antibiotics
other	Pyrimethamine may be used with sulfonamides , <e1> DRUG1 </e1> and other <e2> DRUG2 </e2> , and with other antibiotics . 	quinine	antimalarials
other	Pyrimethamine may be used with sulfonamides , <e1> DRUG1 </e1> and other antimalarials , and with other <e2> DRUG2 </e2> . 	quinine	antibiotics
other	Pyrimethamine may be used with sulfonamides , quinine and other <e1> DRUG1 </e1> , and with other <e2> DRUG2 </e2> . 	antimalarials	antibiotics
effect	Mild hepatotoxicity has been reported in some patients when <e1> DRUG1 </e1> and <e2> DRUG2 </e2> were administered concomitantly . 	lorazepam	pyrimethamine
other	<e1> DRUG1 </e1> : Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of <e2> DRUG2 </e2> and should not be coadministered with EVISTA . 	Cholestyramine	raloxifene
other	<e1> DRUG1 </e1> : Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with <e2> DRUG2 </e2> . 	Cholestyramine	EVISTA
mechanism	Cholestyramine : <e1> DRUG1 </e1> causes a 60% reduction in the absorption and enterohepatic cycling of <e2> DRUG2 </e2> and should not be coadministered with EVISTA . 	Cholestyramine	raloxifene
advise	Cholestyramine : <e1> DRUG1 </e1> causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with <e2> DRUG2 </e2> . 	Cholestyramine	EVISTA
other	Cholestyramine : Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of <e1> DRUG1 </e1> and should not be coadministered with <e2> DRUG2 </e2> . 	raloxifene	EVISTA
other	<e1> DRUG1 </e1> : The coadministration of <e2> DRUG2 </e2> and warfarin has not been assessed under chronic conditions . 	Warfarin	EVISTA
other	Warfarin : The coadministration of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> has not been assessed under chronic conditions . 	EVISTA	warfarin
advise	If <e1> DRUG1 </e1> is given concurrently with <e2> DRUG2 </e2> , prothrombin time should be monitored . 	EVISTA	warfarin
other	In vitro , <e1> DRUG1 </e1> did not affect the binding of <e2> DRUG2 </e2> , phenytoin , or tamoxifen . 	raloxifene	warfarin
other	In vitro , <e1> DRUG1 </e1> did not affect the binding of warfarin , <e2> DRUG2 </e2> , or tamoxifen . 	raloxifene	phenytoin
other	In vitro , <e1> DRUG1 </e1> did not affect the binding of warfarin , phenytoin , or <e2> DRUG2 </e2> . 	raloxifene	tamoxifen
other	In vitro , raloxifene did not affect the binding of <e1> DRUG1 </e1> , phenytoin , or <e2> DRUG2 </e2> . 	warfarin	tamoxifen
advise	Caution should be used when <e1> DRUG1 </e1> is coadministered with other highly protein-bound drugs , such as <e2> DRUG2 </e2> , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 	EVISTA	clofibrate
advise	Caution should be used when <e1> DRUG1 </e1> is coadministered with other highly protein-bound drugs , such as clofibrate , <e2> DRUG2 </e2> , naproxen , ibuprofen , diazepam , and diazoxide . 	EVISTA	indomethacin
advise	Caution should be used when <e1> DRUG1 </e1> is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , <e2> DRUG2 </e2> , ibuprofen , diazepam , and diazoxide . 	EVISTA	naproxen
advise	Caution should be used when <e1> DRUG1 </e1> is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , <e2> DRUG2 </e2> , diazepam , and diazoxide . 	EVISTA	ibuprofen
advise	Caution should be used when <e1> DRUG1 </e1> is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , <e2> DRUG2 </e2> , and diazoxide . 	EVISTA	diazepam
advise	Caution should be used when <e1> DRUG1 </e1> is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and <e2> DRUG2 </e2> . 	EVISTA	diazoxide
other	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as <e1> DRUG1 </e1> , indomethacin , <e2> DRUG2 </e2> , ibuprofen , diazepam , and diazoxide . 	clofibrate	naproxen
other	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as <e1> DRUG1 </e1> , indomethacin , naproxen , <e2> DRUG2 </e2> , diazepam , and diazoxide . 	clofibrate	ibuprofen
other	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as <e1> DRUG1 </e1> , indomethacin , naproxen , ibuprofen , <e2> DRUG2 </e2> , and diazoxide . 	clofibrate	diazepam
other	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as <e1> DRUG1 </e1> , indomethacin , naproxen , ibuprofen , diazepam , and <e2> DRUG2 </e2> . 	clofibrate	diazoxide
other	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , <e1> DRUG1 </e1> , naproxen , <e2> DRUG2 </e2> , diazepam , and diazoxide . 	indomethacin	ibuprofen
other	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , <e1> DRUG1 </e1> , naproxen , ibuprofen , <e2> DRUG2 </e2> , and diazoxide . 	indomethacin	diazepam
other	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , <e1> DRUG1 </e1> , naproxen , ibuprofen , diazepam , and <e2> DRUG2 </e2> . 	indomethacin	diazoxide
other	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , <e1> DRUG1 </e1> , ibuprofen , <e2> DRUG2 </e2> , and diazoxide . 	naproxen	diazepam
other	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , <e1> DRUG1 </e1> , ibuprofen , diazepam , and <e2> DRUG2 </e2> . 	naproxen	diazoxide
other	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , <e1> DRUG1 </e1> , diazepam , and <e2> DRUG2 </e2> . 	ibuprofen	diazoxide
other	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> . 	diazepam	diazoxide
mechanism	Coadministration of <e1> DRUG1 </e1> with <e2> DRUG2 </e2> resulted in increased plasma ranitidine concentrations (57%) , increased plasma bismuth trough concentrations (48%) , and increased 14- hydroxy- clarithromycin plasma concentrations (31%) . 	TRITEC	clarithromycin
other	Coadministration of <e1> DRUG1 </e1> with clarithromycin resulted in increased plasma <e2> DRUG2 </e2> concentrations (57%) , increased plasma bismuth trough concentrations (48%) , and increased 14- hydroxy- clarithromycin plasma concentrations (31%) . 	TRITEC	ranitidine
other	Coadministration of <e1> DRUG1 </e1> with clarithromycin resulted in increased plasma ranitidine concentrations (57%) , increased plasma bismuth trough concentrations (48%) , and increased <e2> DRUG2 </e2> plasma concentrations (31%) . 	TRITEC	14- hydroxy- clarithromycin
other	Coadministration of TRITEC with <e1> DRUG1 </e1> resulted in increased plasma <e2> DRUG2 </e2> concentrations (57%) , increased plasma bismuth trough concentrations (48%) , and increased 14- hydroxy- clarithromycin plasma concentrations (31%) . 	clarithromycin	ranitidine
other	Coadministration of TRITEC with <e1> DRUG1 </e1> resulted in increased plasma ranitidine concentrations (57%) , increased plasma bismuth trough concentrations (48%) , and increased <e2> DRUG2 </e2> plasma concentrations (31%) . 	clarithromycin	14- hydroxy- clarithromycin
other	Coadministration of TRITEC with clarithromycin resulted in increased plasma <e1> DRUG1 </e1> concentrations (57%) , increased plasma bismuth trough concentrations (48%) , and increased <e2> DRUG2 </e2> plasma concentrations (31%) . 	ranitidine	14- hydroxy- clarithromycin
other	Coadministration with <e1> DRUG1 </e1> results in a slight decrease in the rate of <e2> DRUG2 </e2> absorption that is clinically unimportant . 	aspirin	salicylate
mechanism	Coadministration with a high dose of <e1> DRUG1 </e1> (170 mEq) results in a 28% decrease in plasma concentrations of <e2> DRUG2 </e2> and may decrease plasma concentrations of bismuth from TRITEC . 	antacid	ranitidine
mechanism	Coadministration with a high dose of <e1> DRUG1 </e1> (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from <e2> DRUG2 </e2> . 	antacid	TRITEC
other	Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of <e1> DRUG1 </e1> and may decrease plasma concentrations of bismuth from <e2> DRUG2 </e2> . 	ranitidine	TRITEC
other	For information on drug interactions associated with <e1> DRUG1 </e1> , refer to the <e2> DRUG2 </e2> package insert . 	ranitidine	ZANTAC
other	Co-administration of oral <e1> DRUG1 </e1> 200 mg twice daily increased <e2> DRUG2 </e2> geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment , 1% on the abraded skin of healthy adult males . 	ketoconazole	retapamulin
mechanism	Co-administration of oral <e1> DRUG1 </e1> 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of <e2> DRUG2 </e2> ointment , 1% on the abraded skin of healthy adult males . 	ketoconazole	retapamulin
other	Due to low systemic exposure to <e1> DRUG1 </e1> following topical application in patients , dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors , such as <e2> DRUG2 </e2> . 	retapamulin	ketoconazole
other	Due to low systemic exposure to retapamulin following topical application in patients , dosage adjustments for <e1> DRUG1 </e1> are unnecessary when co-administered with CYP3A4 inhibitors , such as <e2> DRUG2 </e2> . 	retapamulin	ketoconazole
other	In addition to bleeding associated with <e1> DRUG1 </e1> and <e2> DRUG2 </e2> , drugs that alter platelet function (such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after Retavase therapy . 	heparin	vitamin K antagonists
other	In addition to bleeding associated with <e1> DRUG1 </e1> and vitamin K antagonists , drugs that alter platelet function (such as <e2> DRUG2 </e2> , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after Retavase therapy . 	heparin	aspirin
other	In addition to bleeding associated with <e1> DRUG1 </e1> and vitamin K antagonists , drugs that alter platelet function (such as aspirin , <e2> DRUG2 </e2> , and abciximab ) may increase the risk of bleeding if administered prior to or after Retavase therapy . 	heparin	dipyridamole
other	In addition to bleeding associated with <e1> DRUG1 </e1> and vitamin K antagonists , drugs that alter platelet function (such as aspirin , dipyridamole , and <e2> DRUG2 </e2> ) may increase the risk of bleeding if administered prior to or after Retavase therapy . 	heparin	abciximab
effect	In addition to bleeding associated with <e1> DRUG1 </e1> and vitamin K antagonists , drugs that alter platelet function (such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after <e2> DRUG2 </e2> therapy . 	heparin	Retavase
other	In addition to bleeding associated with heparin and <e1> DRUG1 </e1> , drugs that alter platelet function (such as <e2> DRUG2 </e2> , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after Retavase therapy . 	vitamin K antagonists	aspirin
other	In addition to bleeding associated with heparin and <e1> DRUG1 </e1> , drugs that alter platelet function (such as aspirin , <e2> DRUG2 </e2> , and abciximab ) may increase the risk of bleeding if administered prior to or after Retavase therapy . 	vitamin K antagonists	dipyridamole
other	In addition to bleeding associated with heparin and <e1> DRUG1 </e1> , drugs that alter platelet function (such as aspirin , dipyridamole , and <e2> DRUG2 </e2> ) may increase the risk of bleeding if administered prior to or after Retavase therapy . 	vitamin K antagonists	abciximab
effect	In addition to bleeding associated with heparin and <e1> DRUG1 </e1> , drugs that alter platelet function (such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after <e2> DRUG2 </e2> therapy . 	vitamin K antagonists	Retavase
other	In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function (such as <e1> DRUG1 </e1> , dipyridamole , and <e2> DRUG2 </e2> ) may increase the risk of bleeding if administered prior to or after Retavase therapy . 	aspirin	abciximab
effect	In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function (such as <e1> DRUG1 </e1> , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after <e2> DRUG2 </e2> therapy . 	aspirin	Retavase
other	In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function (such as aspirin , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> ) may increase the risk of bleeding if administered prior to or after Retavase therapy . 	dipyridamole	abciximab
effect	In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function (such as aspirin , <e1> DRUG1 </e1> , and abciximab ) may increase the risk of bleeding if administered prior to or after <e2> DRUG2 </e2> therapy . 	dipyridamole	Retavase
effect	In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function (such as aspirin , dipyridamole , and <e1> DRUG1 </e1> ) may increase the risk of bleeding if administered prior to or after <e2> DRUG2 </e2> therapy . 	abciximab	Retavase
other	Interactions for <e1> DRUG1 </e1> ( Riboflavin ) : <e2> DRUG2 </e2> - impairs the intestinal absorption of riboflavin 	Vitamin B2	Alcohol
other	Interactions for <e1> DRUG1 </e1> ( Riboflavin ) : Alcohol - impairs the intestinal absorption of <e2> DRUG2 </e2> 	Vitamin B2	riboflavin
other	Interactions for Vitamin B2 ( <e1> DRUG1 </e1> ) : <e2> DRUG2 </e2> - impairs the intestinal absorption of riboflavin 	Riboflavin	Alcohol
mechanism	Interactions for Vitamin B2 ( Riboflavin ) : <e1> DRUG1 </e1> - impairs the intestinal absorption of <e2> DRUG2 </e2> 	Alcohol	riboflavin
mechanism	<e1> DRUG1 </e1> - concurrent use decreases gastrointestinal absorption of <e2> DRUG2 </e2> ; 	Probenecid	riboflavin
effect	requirements for <e1> DRUG1 </e1> may be increased in patients receiving <e2> DRUG2 </e2> . 	riboflavin	probenecid
other	<e1> DRUG1 </e1> : The effects of chronic cimetidine use on the metabolism of <e2> DRUG2 </e2> are not known . 	Cimetidine	rimantadine
other	Cimetidine : The effects of chronic <e1> DRUG1 </e1> use on the metabolism of <e2> DRUG2 </e2> are not known . 	cimetidine	rimantadine
mechanism	When a single 100 mg dose of <e1> DRUG1 </e1> was administered one hour after the initiation of <e2> DRUG2 </e2> (300 mg four times a day) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ) . 	rimantadine HCl	Cimetidine
other	When a single 100 mg dose of <e1> DRUG1 </e1> was administered one hour after the initiation of Cimetidine (300 mg four times a day) , the apparent total <e2> DRUG2 </e2> clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ) . 	rimantadine HCl	rimantadine
other	When a single 100 mg dose of <e1> DRUG1 </e1> was administered one hour after the initiation of Cimetidine (300 mg four times a day) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total <e2> DRUG2 </e2> clearance in the same subjects in the absence of cimetidine ) . 	rimantadine HCl	rimantadine
other	When a single 100 mg dose of <e1> DRUG1 </e1> was administered one hour after the initiation of Cimetidine (300 mg four times a day) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of <e2> DRUG2 </e2> ) . 	rimantadine HCl	cimetidine
other	When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of <e1> DRUG1 </e1> (300 mg four times a day) , the apparent total <e2> DRUG2 </e2> clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ) . 	Cimetidine	rimantadine
other	When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of <e1> DRUG1 </e1> (300 mg four times a day) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total <e2> DRUG2 </e2> clearance in the same subjects in the absence of cimetidine ) . 	Cimetidine	rimantadine
other	When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day) , the apparent total <e1> DRUG1 </e1> clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of <e2> DRUG2 </e2> ) . 	rimantadine	cimetidine
other	When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total <e1> DRUG1 </e1> clearance in the same subjects in the absence of <e2> DRUG2 </e2> ) . 	rimantadine	cimetidine
other	<e1> DRUG1 </e1> : <e2> DRUG2 </e2> , 100 mg , was given twice daily for 13 days to 12 healthy volunteers . 	Acetaminophen	Rimantadine HCl
mechanism	Coadministration with <e1> DRUG1 </e1> reduced the peak concentration and AUC values for <e2> DRUG2 </e2> by approximately 11% . 	acetaminophen	rimantadine
other	<e1> DRUG1 </e1> : <e2> DRUG2 </e2> , 100 mg , was given twice daily fro 13 days to 12 healthy volunteers . 	Aspirin	Rimantadine HCl
mechanism	Peak plasma concentrations and AUC of <e1> DRUG1 </e1> were reduced approximately 10% in the presence of <e2> DRUG2 </e2> . 	rimantadine	aspirin
other	Drug-Drug Interactions Effect of <e1> DRUG1 </e1> ( rivastigmine tartrate ) on the Metabolism of Other Drugs : <e2> DRUG2 </e2> is primarily metabolized through hydrolysis by esterases . 	Exelon	Rivastigmine
other	Drug-Drug Interactions Effect of Exelon ( <e1> DRUG1 </e1> ) on the Metabolism of Other Drugs : <e2> DRUG2 </e2> is primarily metabolized through hydrolysis by esterases . 	rivastigmine tartrate	Rivastigmine
other	No pharmacokinetic interaction was observed between <e1> DRUG1 </e1> and <e2> DRUG2 </e2> , warfarin , diazepam , or fluoxetine in studies in healthy volunteers . 	rivastigmine	digoxin
other	No pharmacokinetic interaction was observed between <e1> DRUG1 </e1> and digoxin , <e2> DRUG2 </e2> , diazepam , or fluoxetine in studies in healthy volunteers . 	rivastigmine	warfarin
other	No pharmacokinetic interaction was observed between <e1> DRUG1 </e1> and digoxin , warfarin , <e2> DRUG2 </e2> , or fluoxetine in studies in healthy volunteers . 	rivastigmine	diazepam
other	No pharmacokinetic interaction was observed between <e1> DRUG1 </e1> and digoxin , warfarin , diazepam , or <e2> DRUG2 </e2> in studies in healthy volunteers . 	rivastigmine	fluoxetine
other	No pharmacokinetic interaction was observed between rivastigmine and <e1> DRUG1 </e1> , warfarin , <e2> DRUG2 </e2> , or fluoxetine in studies in healthy volunteers . 	digoxin	diazepam
other	No pharmacokinetic interaction was observed between rivastigmine and <e1> DRUG1 </e1> , warfarin , diazepam , or <e2> DRUG2 </e2> in studies in healthy volunteers . 	digoxin	fluoxetine
other	No pharmacokinetic interaction was observed between rivastigmine and digoxin , <e1> DRUG1 </e1> , diazepam , or <e2> DRUG2 </e2> in studies in healthy volunteers . 	warfarin	fluoxetine
other	The elevation of prothrombin time induced by <e1> DRUG1 </e1> is not affected by administration of <e2> DRUG2 </e2> . 	warfarin	Exelon
other	Effect of Other Drugs on the Metabolism of <e1> DRUG1 </e1> : Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of <e2> DRUG2 </e2> . 	Exelon	rivastigmine
other	Single dose pharmacokinetic studies demonstrated that the metabolism of <e1> DRUG1 </e1> is not significantly affected by concurrent administration of <e2> DRUG2 </e2> , warfarin , diazepam , or fluoxetine . 	rivastigmine	digoxin
other	Single dose pharmacokinetic studies demonstrated that the metabolism of <e1> DRUG1 </e1> is not significantly affected by concurrent administration of digoxin , <e2> DRUG2 </e2> , diazepam , or fluoxetine . 	rivastigmine	warfarin
other	Single dose pharmacokinetic studies demonstrated that the metabolism of <e1> DRUG1 </e1> is not significantly affected by concurrent administration of digoxin , warfarin , <e2> DRUG2 </e2> , or fluoxetine . 	rivastigmine	diazepam
other	Single dose pharmacokinetic studies demonstrated that the metabolism of <e1> DRUG1 </e1> is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or <e2> DRUG2 </e2> . 	rivastigmine	fluoxetine
other	Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of <e1> DRUG1 </e1> , warfarin , <e2> DRUG2 </e2> , or fluoxetine . 	digoxin	diazepam
other	Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of <e1> DRUG1 </e1> , warfarin , diazepam , or <e2> DRUG2 </e2> . 	digoxin	fluoxetine
other	Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , <e1> DRUG1 </e1> , diazepam , or <e2> DRUG2 </e2> . 	warfarin	fluoxetine
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1> DRUG1 </e1> were not influenced by commonly prescribed medications such as <e2> DRUG2 </e2> (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	rivastigmine	antacids
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1> DRUG1 </e1> were not influenced by commonly prescribed medications such as antacids (n=77) , <e2> DRUG2 </e2> (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	rivastigmine	antihypertensives
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1> DRUG1 </e1> were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , <e2> DRUG2 </e2> (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	rivastigmine	calcium channel blockers
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1> DRUG1 </e1> were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , <e2> DRUG2 </e2> (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	rivastigmine	antidiabetics
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1> DRUG1 </e1> were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , <e2> DRUG2 </e2> (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	rivastigmine	nonsteroidal anti-inflammatory drugs
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1> DRUG1 </e1> were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , <e2> DRUG2 </e2> (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	rivastigmine	estrogens
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1> DRUG1 </e1> were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , <e2> DRUG2 </e2> (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	rivastigmine	salicylate analgesics
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1> DRUG1 </e1> were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , <e2> DRUG2 </e2> (n=35) , and antihistamines (n=15) . 	rivastigmine	antianginals
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1> DRUG1 </e1> were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and <e2> DRUG2 </e2> (n=15) . 	rivastigmine	antihistamines
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1> DRUG1 </e1> (n=77) , <e2> DRUG2 </e2> (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	antacids	antihypertensives
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1> DRUG1 </e1> (n=77) , antihypertensives (n=72) , <e2> DRUG2 </e2> (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	antacids	calcium channel blockers
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1> DRUG1 </e1> (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , <e2> DRUG2 </e2> (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	antacids	antidiabetics
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1> DRUG1 </e1> (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , <e2> DRUG2 </e2> (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	antacids	nonsteroidal anti-inflammatory drugs
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1> DRUG1 </e1> (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , <e2> DRUG2 </e2> (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	antacids	estrogens
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1> DRUG1 </e1> (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , <e2> DRUG2 </e2> (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	antacids	salicylate analgesics
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1> DRUG1 </e1> (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , <e2> DRUG2 </e2> (n=35) , and antihistamines (n=15) . 	antacids	antianginals
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1> DRUG1 </e1> (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and <e2> DRUG2 </e2> (n=15) . 	antacids	antihistamines
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , <e1> DRUG1 </e1> (n=72) , <e2> DRUG2 </e2> (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	antihypertensives	calcium channel blockers
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , <e1> DRUG1 </e1> (n=72) , calcium channel blockers (n=75) , <e2> DRUG2 </e2> (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	antihypertensives	antidiabetics
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , <e1> DRUG1 </e1> (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , <e2> DRUG2 </e2> (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	antihypertensives	nonsteroidal anti-inflammatory drugs
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , <e1> DRUG1 </e1> (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , <e2> DRUG2 </e2> (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	antihypertensives	estrogens
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , <e1> DRUG1 </e1> (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , <e2> DRUG2 </e2> (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	antihypertensives	salicylate analgesics
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , <e1> DRUG1 </e1> (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , <e2> DRUG2 </e2> (n=35) , and antihistamines (n=15) . 	antihypertensives	antianginals
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , <e1> DRUG1 </e1> (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and <e2> DRUG2 </e2> (n=15) . 	antihypertensives	antihistamines
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , <e1> DRUG1 </e1> (n=75) , <e2> DRUG2 </e2> (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	calcium channel blockers	antidiabetics
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , <e1> DRUG1 </e1> (n=75) , antidiabetics (n=21) , <e2> DRUG2 </e2> (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	calcium channel blockers	nonsteroidal anti-inflammatory drugs
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , <e1> DRUG1 </e1> (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , <e2> DRUG2 </e2> (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	calcium channel blockers	estrogens
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , <e1> DRUG1 </e1> (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , <e2> DRUG2 </e2> (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	calcium channel blockers	salicylate analgesics
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , <e1> DRUG1 </e1> (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , <e2> DRUG2 </e2> (n=35) , and antihistamines (n=15) . 	calcium channel blockers	antianginals
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , <e1> DRUG1 </e1> (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and <e2> DRUG2 </e2> (n=15) . 	calcium channel blockers	antihistamines
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , <e1> DRUG1 </e1> (n=21) , <e2> DRUG2 </e2> (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	antidiabetics	nonsteroidal anti-inflammatory drugs
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , <e1> DRUG1 </e1> (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , <e2> DRUG2 </e2> (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	antidiabetics	estrogens
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , <e1> DRUG1 </e1> (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , <e2> DRUG2 </e2> (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	antidiabetics	salicylate analgesics
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , <e1> DRUG1 </e1> (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , <e2> DRUG2 </e2> (n=35) , and antihistamines (n=15) . 	antidiabetics	antianginals
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , <e1> DRUG1 </e1> (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and <e2> DRUG2 </e2> (n=15) . 	antidiabetics	antihistamines
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , <e1> DRUG1 </e1> (n=79) , <e2> DRUG2 </e2> (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	nonsteroidal anti-inflammatory drugs	estrogens
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , <e1> DRUG1 </e1> (n=79) , estrogens (n=70) , <e2> DRUG2 </e2> (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	nonsteroidal anti-inflammatory drugs	salicylate analgesics
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , <e1> DRUG1 </e1> (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , <e2> DRUG2 </e2> (n=35) , and antihistamines (n=15) . 	nonsteroidal anti-inflammatory drugs	antianginals
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , <e1> DRUG1 </e1> (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and <e2> DRUG2 </e2> (n=15) . 	nonsteroidal anti-inflammatory drugs	antihistamines
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , <e1> DRUG1 </e1> (n=70) , <e2> DRUG2 </e2> (n=177) , antianginals (n=35) , and antihistamines (n=15) . 	estrogens	salicylate analgesics
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , <e1> DRUG1 </e1> (n=70) , salicylate analgesics (n=177) , <e2> DRUG2 </e2> (n=35) , and antihistamines (n=15) . 	estrogens	antianginals
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , <e1> DRUG1 </e1> (n=70) , salicylate analgesics (n=177) , antianginals (n=35) , and <e2> DRUG2 </e2> (n=15) . 	estrogens	antihistamines
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , <e1> DRUG1 </e1> (n=177) , <e2> DRUG2 </e2> (n=35) , and antihistamines (n=15) . 	salicylate analgesics	antianginals
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , <e1> DRUG1 </e1> (n=177) , antianginals (n=35) , and <e2> DRUG2 </e2> (n=15) . 	salicylate analgesics	antihistamines
other	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77) , antihypertensives (n=72) , calcium channel blockers (n=75) , antidiabetics (n=21) , nonsteroidal anti-inflammatory drugs (n=79) , estrogens (n=70) , salicylate analgesics (n=177) , <e1> DRUG1 </e1> (n=35) , and <e2> DRUG2 </e2> (n=15) . 	antianginals	antihistamines
other	Use with <e1> DRUG1 </e1> : Because of their mechanism of action , <e2> DRUG2 </e2> have the potential to interfere with the activity of anticholinergic medications . 	Anticholinergics	cholinesterase inhibitors
other	Use with <e1> DRUG1 </e1> : Because of their mechanism of action , cholinesterase inhibitors have the potential to interfere with the activity of <e2> DRUG2 </e2> . 	Anticholinergics	anticholinergic medications
int	Use with Anticholinergics : Because of their mechanism of action , <e1> DRUG1 </e1> have the potential to interfere with the activity of <e2> DRUG2 </e2> . 	cholinesterase inhibitors	anticholinergic medications
other	Use with <e1> DRUG1 </e1> and Other <e2> DRUG2 </e2> : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 	Cholinomimetics	Cholinesterase Inhibitors
other	Use with <e1> DRUG1 </e1> and Other Cholinesterase Inhibitors : A synergistic effect may be expected when <e2> DRUG2 </e2> are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 	Cholinomimetics	cholinesterase inhibitors
other	Use with <e1> DRUG1 </e1> and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with <e2> DRUG2 </e2> , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 	Cholinomimetics	succinylcholine
other	Use with <e1> DRUG1 </e1> and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar <e2> DRUG2 </e2> or cholinergic agonists such as bethanechol . 	Cholinomimetics	neuromuscular blocking agents
other	Use with <e1> DRUG1 </e1> and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or <e2> DRUG2 </e2> such as bethanechol . 	Cholinomimetics	cholinergic agonists
other	Use with <e1> DRUG1 </e1> and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as <e2> DRUG2 </e2> . 	Cholinomimetics	bethanechol
other	Use with Cholinomimetics and Other <e1> DRUG1 </e1> : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with <e2> DRUG2 </e2> , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 	Cholinesterase Inhibitors	succinylcholine
other	Use with Cholinomimetics and Other <e1> DRUG1 </e1> : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar <e2> DRUG2 </e2> or cholinergic agonists such as bethanechol . 	Cholinesterase Inhibitors	neuromuscular blocking agents
other	Use with Cholinomimetics and Other <e1> DRUG1 </e1> : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or <e2> DRUG2 </e2> such as bethanechol . 	Cholinesterase Inhibitors	cholinergic agonists
other	Use with Cholinomimetics and Other <e1> DRUG1 </e1> : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as <e2> DRUG2 </e2> . 	Cholinesterase Inhibitors	bethanechol
effect	Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when <e1> DRUG1 </e1> are given concurrently with <e2> DRUG2 </e2> , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 	cholinesterase inhibitors	succinylcholine
effect	Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when <e1> DRUG1 </e1> are given concurrently with succinylcholine , similar <e2> DRUG2 </e2> or cholinergic agonists such as bethanechol . 	cholinesterase inhibitors	neuromuscular blocking agents
effect	Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when <e1> DRUG1 </e1> are given concurrently with succinylcholine , similar neuromuscular blocking agents or <e2> DRUG2 </e2> such as bethanechol . 	cholinesterase inhibitors	cholinergic agonists
effect	Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when <e1> DRUG1 </e1> are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as <e2> DRUG2 </e2> . 	cholinesterase inhibitors	bethanechol
other	Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with <e1> DRUG1 </e1> , similar <e2> DRUG2 </e2> or cholinergic agonists such as bethanechol . 	succinylcholine	neuromuscular blocking agents
other	Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with <e1> DRUG1 </e1> , similar neuromuscular blocking agents or <e2> DRUG2 </e2> such as bethanechol . 	succinylcholine	cholinergic agonists
other	Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with <e1> DRUG1 </e1> , similar neuromuscular blocking agents or cholinergic agonists such as <e2> DRUG2 </e2> . 	succinylcholine	bethanechol
other	Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar <e1> DRUG1 </e1> or cholinergic agonists such as <e2> DRUG2 </e2> . 	neuromuscular blocking agents	bethanechol
other	Drug Interactions : The use of ZEMURON ( <e1> DRUG1 </e1> ) Injection before <e2> DRUG2 </e2> , for the purpose of attenuating some of the side effects of succinylcholine , has not been studied . 	rocuronium bromide	succinylcholine
other	Drug Interactions : The use of ZEMURON ( <e1> DRUG1 </e1> ) Injection before succinylcholine , for the purpose of attenuating some of the side effects of <e2> DRUG2 </e2> , has not been studied . 	rocuronium bromide	succinylcholine
advise	If <e1> DRUG1 </e1> is administered following administration of <e2> DRUG2 </e2> , it should not be given until recovery from succinylcholine has been observed . 	ZEMURON	succinylcholine
other	If <e1> DRUG1 </e1> is administered following administration of succinylcholine , it should not be given until recovery from <e2> DRUG2 </e2> has been observed . 	ZEMURON	succinylcholine
other	The median duration of action of <e1> DRUG1 </e1> 0.6 mg/kg administered after a 1 mg/kg dose of <e2> DRUG2 </e2> when T 1 returned to 75% of control was 36 minutes (range 14-57 , n=12) vs . 	ZEMURON	succinylcholine
other	There are no controlled studies documenting the use of <e1> DRUG1 </e1> before or after other <e2> DRUG2 </e2> . 	ZEMURON	nondepolarizing muscle relaxants
advise	<e1> DRUG1 </e1> should be used with caution in patients receiving other local <e2> DRUG2 </e2> or agents structurally related to amide-type local anesthetics , since the toxic effects of these drugs are additive . 	Ropivacaine	anesthetics
other	<e1> DRUG1 </e1> should be used with caution in patients receiving other local anesthetics or agents structurally related to <e2> DRUG2 </e2> , since the toxic effects of these drugs are additive . 	Ropivacaine	amide-type local anesthetics
other	Ropivacaine should be used with caution in patients receiving other local <e1> DRUG1 </e1> or agents structurally related to <e2> DRUG2 </e2> , since the toxic effects of these drugs are additive . 	anesthetics	amide-type local anesthetics
mechanism	In vivo , the plasma clearance of <e1> DRUG1 </e1> was reduced by 70% during coadministration of <e2> DRUG2 </e2> (25 mg bid for 2 days) , a selective and potent CYP1A2 inhibitor . 	ropivacaine	fluvoxamine
int	Thus strong inhibitors of cytochrome P4501A2 , such as <e1> DRUG1 </e1> , given concomitantly during administration of <e2> DRUG2 </e2> , can interact with Ropivacaine leading to increased ropivacaine plasma levels . 	fluvoxamine	Ropivacaine
other	Thus strong inhibitors of cytochrome P4501A2 , such as <e1> DRUG1 </e1> , given concomitantly during administration of Ropivacaine , can interact with <e2> DRUG2 </e2> leading to increased ropivacaine plasma levels . 	fluvoxamine	Ropivacaine
other	Thus strong inhibitors of cytochrome P4501A2 , such as <e1> DRUG1 </e1> , given concomitantly during administration of Ropivacaine , can interact with Ropivacaine leading to increased <e2> DRUG2 </e2> plasma levels . 	fluvoxamine	ropivacaine
other	Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as <e1> DRUG1 </e1> and <e2> DRUG2 </e2> may also occur . 	theophylline	imipramine
other	Coadministration of a selective and potent inhibitor of CYP3A4 , <e1> DRUG1 </e1> (100 mg bid for 2 days with <e2> DRUG2 </e2> infusion administered 1 hour after ketoconazole ) caused a 15% reduction in in-vivo plasma clearance of ropivacaine . 	ketoconazole	ropivacaine
mechanism	Coadministration of a selective and potent inhibitor of CYP3A4 , <e1> DRUG1 </e1> (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole ) caused a 15% reduction in in-vivo plasma clearance of <e2> DRUG2 </e2> . 	ketoconazole	ropivacaine
other	Coadministration of a selective and potent inhibitor of CYP3A4 , ketoconazole (100 mg bid for 2 days with <e1> DRUG1 </e1> infusion administered 1 hour after <e2> DRUG2 </e2> ) caused a 15% reduction in in-vivo plasma clearance of ropivacaine . 	ropivacaine	ketoconazole
other	Coadministration of a selective and potent inhibitor of CYP3A4 , ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after <e1> DRUG1 </e1> ) caused a 15% reduction in in-vivo plasma clearance of <e2> DRUG2 </e2> . 	ketoconazole	ropivacaine
mechanism	An inhibitor of CYP2C8 (such as <e1> DRUG1 </e1> ) may increase the AUC of <e2> DRUG2 </e2> and an inducer of CYP2C8 (such as rifampin ) may decrease the AUC of rosiglitazone . 	gemfibrozil	rosiglitazone
other	An inhibitor of CYP2C8 (such as <e1> DRUG1 </e1> ) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as <e2> DRUG2 </e2> ) may decrease the AUC of rosiglitazone . 	gemfibrozil	rifampin
other	An inhibitor of CYP2C8 (such as <e1> DRUG1 </e1> ) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin ) may decrease the AUC of <e2> DRUG2 </e2> . 	gemfibrozil	rosiglitazone
other	An inhibitor of CYP2C8 (such as gemfibrozil ) may increase the AUC of <e1> DRUG1 </e1> and an inducer of CYP2C8 (such as <e2> DRUG2 </e2> ) may decrease the AUC of rosiglitazone . 	rosiglitazone	rifampin
mechanism	An inhibitor of CYP2C8 (such as gemfibrozil ) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as <e1> DRUG1 </e1> ) may decrease the AUC of <e2> DRUG2 </e2> . 	rifampin	rosiglitazone
other	Concomitant administrations not recommended :  - <e1> DRUG1 </e1> and <e2> DRUG2 </e2> : Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter . 	Terfenadine	astemizole
other	Concomitant administrations not recommended :  - <e1> DRUG1 </e1> and astemizole : Certain <e2> DRUG2 </e2> interact with terfenadine and astemizole leading to increased serum concentrations of the latter . 	Terfenadine	macrolides
other	Concomitant administrations not recommended :  - <e1> DRUG1 </e1> and astemizole : Certain macrolides interact with terfenadine and <e2> DRUG2 </e2> leading to increased serum concentrations of the latter . 	Terfenadine	astemizole
other	Concomitant administrations not recommended :  - Terfenadine and <e1> DRUG1 </e1> : Certain <e2> DRUG2 </e2> interact with terfenadine and astemizole leading to increased serum concentrations of the latter . 	astemizole	macrolides
other	Concomitant administrations not recommended :  - Terfenadine and <e1> DRUG1 </e1> : Certain macrolides interact with <e2> DRUG2 </e2> and astemizole leading to increased serum concentrations of the latter . 	astemizole	terfenadine
int	Concomitant administrations not recommended :  - Terfenadine and astemizole : Certain <e1> DRUG1 </e1> interact with <e2> DRUG2 </e2> and astemizole leading to increased serum concentrations of the latter . 	macrolides	terfenadine
int	Concomitant administrations not recommended :  - Terfenadine and astemizole : Certain <e1> DRUG1 </e1> interact with terfenadine and <e2> DRUG2 </e2> leading to increased serum concentrations of the latter . 	macrolides	astemizole
other	Concomitant administrations not recommended :  - Terfenadine and astemizole : Certain macrolides interact with <e1> DRUG1 </e1> and <e2> DRUG2 </e2> leading to increased serum concentrations of the latter . 	terfenadine	astemizole
other	Although such a reaction has not been demonstrated with <e1> DRUG1 </e1> , concomitant administration of roxithromycin with <e2> DRUG2 </e2> or astemizole is not recommended . 	roxithromycin	terfenadine
other	Although such a reaction has not been demonstrated with <e1> DRUG1 </e1> , concomitant administration of roxithromycin with terfenadine or <e2> DRUG2 </e2> is not recommended . 	roxithromycin	astemizole
advise	Although such a reaction has not been demonstrated with roxithromycin , concomitant administration of <e1> DRUG1 </e1> with <e2> DRUG2 </e2> or astemizole is not recommended . 	roxithromycin	terfenadine
advise	Although such a reaction has not been demonstrated with roxithromycin , concomitant administration of <e1> DRUG1 </e1> with terfenadine or <e2> DRUG2 </e2> is not recommended . 	roxithromycin	astemizole
other	- <e1> DRUG1 </e1> , pimozide : Other drugs such as cisapride or <e2> DRUG2 </e2> , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials . 	Cisapride	pimozide
other	- <e1> DRUG1 </e1> , pimozide : Other drugs such as cisapride or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some <e2> DRUG2 </e2> . 	Cisapride	macrolide antibacterials
other	- Cisapride , <e1> DRUG1 </e1> : Other drugs such as <e2> DRUG2 </e2> or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials . 	pimozide	cisapride
mechanism	- Cisapride , <e1> DRUG1 </e1> : Other drugs such as cisapride or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some <e2> DRUG2 </e2> . 	pimozide	macrolide antibacterials
mechanism	- Cisapride , pimozide : Other drugs such as <e1> DRUG1 </e1> or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some <e2> DRUG2 </e2> . 	cisapride	macrolide antibacterials
other	- Cisapride , pimozide : Other drugs such as cisapride or <e1> DRUG1 </e1> , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some <e2> DRUG2 </e2> . 	pimozide	macrolide antibacterials
effect	however , in patients with Paget's Disease prior <e1> DRUG1 </e1> use appears to reduce the anti-resorptive response to <e2> DRUG2 </e2> nasal spray . 	diphosphonate	Calcitonin (salmon)
other	<e1> DRUG1 </e1> AND OTHER <e2> DRUG2 </e2> WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS . 	ASPIRIN	SALICYLATE DRUGS
effect	<e1> DRUG1 </e1> AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO <e2> DRUG2 </e2> AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS . 	ASPIRIN	DISALCID
other	<e1> DRUG1 </e1> AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF <e2> DRUG2 </e2> TO TOXIC LEVELS . 	ASPIRIN	SALICYLIC ACID
effect	ASPIRIN AND OTHER <e1> DRUG1 </e1> WILL BE ADDITIVE TO <e2> DRUG2 </e2> AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS . 	SALICYLATE DRUGS	DISALCID
other	ASPIRIN AND OTHER <e1> DRUG1 </e1> WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF <e2> DRUG2 </e2> TO TOXIC LEVELS . 	SALICYLATE DRUGS	SALICYLIC ACID
other	ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO <e1> DRUG1 </e1> AND MAY INCREASE PLASMA CONCENTRATIONS OF <e2> DRUG2 </e2> TO TOXIC LEVELS . 	DISALCID	SALICYLIC ACID
effect	<e1> DRUG1 </e1> given concomitantly with <e2> DRUG2 </e2> may predispose to systemic bleeding . 	Salicylates	anticoagulant drugs
effect	<e1> DRUG1 </e1> may enhance the hypoglycemic effect of oral <e2> DRUG2 </e2> of the sulfonylurea class . 	Salicylates	antidiabetic drugs
mechanism	<e1> DRUG1 </e1> competes with a number of drugs for protein binding sites , notably <e2> DRUG2 </e2> , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 	Salicylate	penicillin
mechanism	<e1> DRUG1 </e1> competes with a number of drugs for protein binding sites , notably penicillin , <e2> DRUG2 </e2> , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 	Salicylate	thiopental
mechanism	<e1> DRUG1 </e1> competes with a number of drugs for protein binding sites , notably penicillin , thiopental , <e2> DRUG2 </e2> , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 	Salicylate	thyroxine
mechanism	<e1> DRUG1 </e1> competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , <e2> DRUG2 </e2> , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 	Salicylate	triiodothyronine
mechanism	<e1> DRUG1 </e1> competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , <e2> DRUG2 </e2> , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 	Salicylate	phenytoin
mechanism	<e1> DRUG1 </e1> competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , <e2> DRUG2 </e2> , naproxen , warfarin , methotrexate , and possibly corticosteroids . 	Salicylate	sulfinpyrazone
mechanism	<e1> DRUG1 </e1> competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , <e2> DRUG2 </e2> , warfarin , methotrexate , and possibly corticosteroids . 	Salicylate	naproxen
mechanism	<e1> DRUG1 </e1> competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , <e2> DRUG2 </e2> , methotrexate , and possibly corticosteroids . 	Salicylate	warfarin
mechanism	<e1> DRUG1 </e1> competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , <e2> DRUG2 </e2> , and possibly corticosteroids . 	Salicylate	methotrexate
mechanism	<e1> DRUG1 </e1> competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly <e2> DRUG2 </e2> . 	Salicylate	corticosteroids
other	Salicylate competes with a number of drugs for protein binding sites , notably <e1> DRUG1 </e1> , thiopental , <e2> DRUG2 </e2> , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 	penicillin	thyroxine
other	Salicylate competes with a number of drugs for protein binding sites , notably <e1> DRUG1 </e1> , thiopental , thyroxine , <e2> DRUG2 </e2> , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 	penicillin	triiodothyronine
other	Salicylate competes with a number of drugs for protein binding sites , notably <e1> DRUG1 </e1> , thiopental , thyroxine , triiodothyronine , <e2> DRUG2 </e2> , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 	penicillin	phenytoin
other	Salicylate competes with a number of drugs for protein binding sites , notably <e1> DRUG1 </e1> , thiopental , thyroxine , triiodothyronine , phenytoin , <e2> DRUG2 </e2> , naproxen , warfarin , methotrexate , and possibly corticosteroids . 	penicillin	sulfinpyrazone
other	Salicylate competes with a number of drugs for protein binding sites , notably <e1> DRUG1 </e1> , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , <e2> DRUG2 </e2> , warfarin , methotrexate , and possibly corticosteroids . 	penicillin	naproxen
other	Salicylate competes with a number of drugs for protein binding sites , notably <e1> DRUG1 </e1> , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , <e2> DRUG2 </e2> , methotrexate , and possibly corticosteroids . 	penicillin	warfarin
other	Salicylate competes with a number of drugs for protein binding sites , notably <e1> DRUG1 </e1> , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , <e2> DRUG2 </e2> , and possibly corticosteroids . 	penicillin	methotrexate
other	Salicylate competes with a number of drugs for protein binding sites , notably <e1> DRUG1 </e1> , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly <e2> DRUG2 </e2> . 	penicillin	corticosteroids
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , <e1> DRUG1 </e1> , thyroxine , <e2> DRUG2 </e2> , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 	thiopental	triiodothyronine
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , <e1> DRUG1 </e1> , thyroxine , triiodothyronine , <e2> DRUG2 </e2> , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 	thiopental	phenytoin
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , <e1> DRUG1 </e1> , thyroxine , triiodothyronine , phenytoin , <e2> DRUG2 </e2> , naproxen , warfarin , methotrexate , and possibly corticosteroids . 	thiopental	sulfinpyrazone
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , <e1> DRUG1 </e1> , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , <e2> DRUG2 </e2> , warfarin , methotrexate , and possibly corticosteroids . 	thiopental	naproxen
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , <e1> DRUG1 </e1> , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , <e2> DRUG2 </e2> , methotrexate , and possibly corticosteroids . 	thiopental	warfarin
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , <e1> DRUG1 </e1> , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , <e2> DRUG2 </e2> , and possibly corticosteroids . 	thiopental	methotrexate
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , <e1> DRUG1 </e1> , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly <e2> DRUG2 </e2> . 	thiopental	corticosteroids
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , <e1> DRUG1 </e1> , triiodothyronine , <e2> DRUG2 </e2> , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 	thyroxine	phenytoin
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , <e1> DRUG1 </e1> , triiodothyronine , phenytoin , <e2> DRUG2 </e2> , naproxen , warfarin , methotrexate , and possibly corticosteroids . 	thyroxine	sulfinpyrazone
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , <e1> DRUG1 </e1> , triiodothyronine , phenytoin , sulfinpyrazone , <e2> DRUG2 </e2> , warfarin , methotrexate , and possibly corticosteroids . 	thyroxine	naproxen
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , <e1> DRUG1 </e1> , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , <e2> DRUG2 </e2> , methotrexate , and possibly corticosteroids . 	thyroxine	warfarin
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , <e1> DRUG1 </e1> , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , <e2> DRUG2 </e2> , and possibly corticosteroids . 	thyroxine	methotrexate
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , <e1> DRUG1 </e1> , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly <e2> DRUG2 </e2> . 	thyroxine	corticosteroids
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , <e1> DRUG1 </e1> , phenytoin , <e2> DRUG2 </e2> , naproxen , warfarin , methotrexate , and possibly corticosteroids . 	triiodothyronine	sulfinpyrazone
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , <e1> DRUG1 </e1> , phenytoin , sulfinpyrazone , <e2> DRUG2 </e2> , warfarin , methotrexate , and possibly corticosteroids . 	triiodothyronine	naproxen
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , <e1> DRUG1 </e1> , phenytoin , sulfinpyrazone , naproxen , <e2> DRUG2 </e2> , methotrexate , and possibly corticosteroids . 	triiodothyronine	warfarin
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , <e1> DRUG1 </e1> , phenytoin , sulfinpyrazone , naproxen , warfarin , <e2> DRUG2 </e2> , and possibly corticosteroids . 	triiodothyronine	methotrexate
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , <e1> DRUG1 </e1> , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly <e2> DRUG2 </e2> . 	triiodothyronine	corticosteroids
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , <e1> DRUG1 </e1> , sulfinpyrazone , <e2> DRUG2 </e2> , warfarin , methotrexate , and possibly corticosteroids . 	phenytoin	naproxen
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , <e1> DRUG1 </e1> , sulfinpyrazone , naproxen , <e2> DRUG2 </e2> , methotrexate , and possibly corticosteroids . 	phenytoin	warfarin
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , <e1> DRUG1 </e1> , sulfinpyrazone , naproxen , warfarin , <e2> DRUG2 </e2> , and possibly corticosteroids . 	phenytoin	methotrexate
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , <e1> DRUG1 </e1> , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly <e2> DRUG2 </e2> . 	phenytoin	corticosteroids
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , <e1> DRUG1 </e1> , naproxen , <e2> DRUG2 </e2> , methotrexate , and possibly corticosteroids . 	sulfinpyrazone	warfarin
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , <e1> DRUG1 </e1> , naproxen , warfarin , <e2> DRUG2 </e2> , and possibly corticosteroids . 	sulfinpyrazone	methotrexate
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , <e1> DRUG1 </e1> , naproxen , warfarin , methotrexate , and possibly <e2> DRUG2 </e2> . 	sulfinpyrazone	corticosteroids
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , <e1> DRUG1 </e1> , warfarin , <e2> DRUG2 </e2> , and possibly corticosteroids . 	naproxen	methotrexate
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , <e1> DRUG1 </e1> , warfarin , methotrexate , and possibly <e2> DRUG2 </e2> . 	naproxen	corticosteroids
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , <e1> DRUG1 </e1> , methotrexate , and possibly <e2> DRUG2 </e2> . 	warfarin	corticosteroids
other	Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , <e1> DRUG1 </e1> , and possibly <e2> DRUG2 </e2> . 	methotrexate	corticosteroids
effect	Drugs which may potentiate the myeloproliferative effects of <e1> DRUG1 </e1> , such as <e2> DRUG2 </e2> and corticosteroids , should be used with caution . 	Leukine	lithium
effect	Drugs which may potentiate the myeloproliferative effects of <e1> DRUG1 </e1> , such as lithium and <e2> DRUG2 </e2> , should be used with caution . 	Leukine	corticosteroids
other	Drugs which may potentiate the myeloproliferative effects of Leukine , such as <e1> DRUG1 </e1> and <e2> DRUG2 </e2> , should be used with caution . 	lithium	corticosteroids
advise	<e1> DRUG1 </e1> should be used with care in patients taking other drugs that are capable of causing CNS effects such as <e2> DRUG2 </e2> , tranquilizers , or alcohol . 	Scopolamine	sedatives
advise	<e1> DRUG1 </e1> should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives , <e2> DRUG2 </e2> , or alcohol . 	Scopolamine	tranquilizers
advise	<e1> DRUG1 </e1> should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives , tranquilizers , or <e2> DRUG2 </e2> . 	Scopolamine	alcohol
other	Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as <e1> DRUG1 </e1> , tranquilizers , or <e2> DRUG2 </e2> . 	sedatives	alcohol
other	e.g. , other <e1> DRUG1 </e1> , antihistamines (including <e2> DRUG2 </e2> ) , tricyclic antidepressants , and muscle relaxants . 	belladonna alkaloids	meclizine
other	e.g. , other <e1> DRUG1 </e1> , antihistamines (including meclizine ) , <e2> DRUG2 </e2> , and muscle relaxants . 	belladonna alkaloids	tricyclic antidepressants
other	e.g. , other <e1> DRUG1 </e1> , antihistamines (including meclizine ) , tricyclic antidepressants , and <e2> DRUG2 </e2> . 	belladonna alkaloids	muscle relaxants
other	e.g. , other belladonna alkaloids , <e1> DRUG1 </e1> (including <e2> DRUG2 </e2> ) , tricyclic antidepressants , and muscle relaxants . 	antihistamines	meclizine
other	e.g. , other belladonna alkaloids , <e1> DRUG1 </e1> (including meclizine ) , <e2> DRUG2 </e2> , and muscle relaxants . 	antihistamines	tricyclic antidepressants
other	e.g. , other belladonna alkaloids , <e1> DRUG1 </e1> (including meclizine ) , tricyclic antidepressants , and <e2> DRUG2 </e2> . 	antihistamines	muscle relaxants
other	e.g. , other belladonna alkaloids , antihistamines (including <e1> DRUG1 </e1> ) , <e2> DRUG2 </e2> , and muscle relaxants . 	meclizine	tricyclic antidepressants
other	e.g. , other belladonna alkaloids , antihistamines (including <e1> DRUG1 </e1> ) , tricyclic antidepressants , and <e2> DRUG2 </e2> . 	meclizine	muscle relaxants
other	e.g. , other belladonna alkaloids , antihistamines (including meclizine ) , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> . 	tricyclic antidepressants	muscle relaxants
int	<e1> DRUG1 </e1> may decrease the effectiveness of oral <e2> DRUG2 </e2> , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 	Barbiturates	contraceptives
int	<e1> DRUG1 </e1> may decrease the effectiveness of oral contraceptives , certain <e2> DRUG2 </e2> , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 	Barbiturates	antibiotics
int	<e1> DRUG1 </e1> may decrease the effectiveness of oral contraceptives , certain antibiotics , <e2> DRUG2 </e2> , theophylline , corticosteroids , anticoagulants , and beta blockers . 	Barbiturates	quinidine
int	<e1> DRUG1 </e1> may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , <e2> DRUG2 </e2> , corticosteroids , anticoagulants , and beta blockers . 	Barbiturates	theophylline
int	<e1> DRUG1 </e1> may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , <e2> DRUG2 </e2> , anticoagulants , and beta blockers . 	Barbiturates	corticosteroids
int	<e1> DRUG1 </e1> may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , <e2> DRUG2 </e2> , and beta blockers . 	Barbiturates	anticoagulants
int	<e1> DRUG1 </e1> may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and <e2> DRUG2 </e2> . 	Barbiturates	beta blockers
other	Barbiturates may decrease the effectiveness of oral <e1> DRUG1 </e1> , certain <e2> DRUG2 </e2> , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 	contraceptives	antibiotics
other	Barbiturates may decrease the effectiveness of oral <e1> DRUG1 </e1> , certain antibiotics , <e2> DRUG2 </e2> , theophylline , corticosteroids , anticoagulants , and beta blockers . 	contraceptives	quinidine
other	Barbiturates may decrease the effectiveness of oral <e1> DRUG1 </e1> , certain antibiotics , quinidine , <e2> DRUG2 </e2> , corticosteroids , anticoagulants , and beta blockers . 	contraceptives	theophylline
other	Barbiturates may decrease the effectiveness of oral <e1> DRUG1 </e1> , certain antibiotics , quinidine , theophylline , <e2> DRUG2 </e2> , anticoagulants , and beta blockers . 	contraceptives	corticosteroids
other	Barbiturates may decrease the effectiveness of oral <e1> DRUG1 </e1> , certain antibiotics , quinidine , theophylline , corticosteroids , <e2> DRUG2 </e2> , and beta blockers . 	contraceptives	anticoagulants
other	Barbiturates may decrease the effectiveness of oral <e1> DRUG1 </e1> , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and <e2> DRUG2 </e2> . 	contraceptives	beta blockers
other	Barbiturates may decrease the effectiveness of oral contraceptives , certain <e1> DRUG1 </e1> , quinidine , <e2> DRUG2 </e2> , corticosteroids , anticoagulants , and beta blockers . 	antibiotics	theophylline
other	Barbiturates may decrease the effectiveness of oral contraceptives , certain <e1> DRUG1 </e1> , quinidine , theophylline , <e2> DRUG2 </e2> , anticoagulants , and beta blockers . 	antibiotics	corticosteroids
other	Barbiturates may decrease the effectiveness of oral contraceptives , certain <e1> DRUG1 </e1> , quinidine , theophylline , corticosteroids , <e2> DRUG2 </e2> , and beta blockers . 	antibiotics	anticoagulants
other	Barbiturates may decrease the effectiveness of oral contraceptives , certain <e1> DRUG1 </e1> , quinidine , theophylline , corticosteroids , anticoagulants , and <e2> DRUG2 </e2> . 	antibiotics	beta blockers
other	Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , <e1> DRUG1 </e1> , theophylline , <e2> DRUG2 </e2> , anticoagulants , and beta blockers . 	quinidine	corticosteroids
other	Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , <e1> DRUG1 </e1> , theophylline , corticosteroids , <e2> DRUG2 </e2> , and beta blockers . 	quinidine	anticoagulants
other	Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , <e1> DRUG1 </e1> , theophylline , corticosteroids , anticoagulants , and <e2> DRUG2 </e2> . 	quinidine	beta blockers
other	Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , <e1> DRUG1 </e1> , corticosteroids , <e2> DRUG2 </e2> , and beta blockers . 	theophylline	anticoagulants
other	Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , <e1> DRUG1 </e1> , corticosteroids , anticoagulants , and <e2> DRUG2 </e2> . 	theophylline	beta blockers
other	Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , <e1> DRUG1 </e1> , anticoagulants , and <e2> DRUG2 </e2> . 	corticosteroids	beta blockers
other	Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> . 	anticoagulants	beta blockers
effect	The occurrence of stupor , muscular rigidity , severe agitation , and elevated temperature has been reported in some patients receiving the combination of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	selegiline	meperidine
int	This is typical of the interaction of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	meperidine	MAOIs
effect	Severe toxicity has also been reported in patients receiving the combination of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> and selective serotonin reuptake inhibitors and ELDEPRYL . 	tricyclic antidepressants	ELDEPRYL
other	Severe toxicity has also been reported in patients receiving the combination of <e1> DRUG1 </e1> and ELDEPRYL and <e2> DRUG2 </e2> and ELDEPRYL . 	tricyclic antidepressants	selective serotonin reuptake inhibitors
other	Severe toxicity has also been reported in patients receiving the combination of <e1> DRUG1 </e1> and ELDEPRYL and selective serotonin reuptake inhibitors and <e2> DRUG2 </e2> . 	tricyclic antidepressants	ELDEPRYL
other	Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and <e1> DRUG1 </e1> and <e2> DRUG2 </e2> and ELDEPRYL . 	ELDEPRYL	selective serotonin reuptake inhibitors
effect	Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	selective serotonin reuptake inhibitors	ELDEPRYL
effect	One case of hypertensive crisis has been reported in a patient taking the recommended doses of <e1> DRUG1 </e1> and a <e2> DRUG2 </e2> ( ephedrine ) . 	selegiline	sympathomimetic medication
effect	One case of hypertensive crisis has been reported in a patient taking the recommended doses of <e1> DRUG1 </e1> and a sympathomimetic medication ( <e2> DRUG2 </e2> ) . 	selegiline	ephedrine
other	<e1> DRUG1 </e1> : There was a slight increase in the area under the curve (AUC , 11%) and mean peak drug concentration (Cmax , 18%) of digoxin with the co-administration of 100 mg <e2> DRUG2 </e2> for 10 days . 	Digoxin	sitagliptin
mechanism	Digoxin : There was a slight increase in the area under the curve (AUC , 11%) and mean peak drug concentration (Cmax , 18%) of <e1> DRUG1 </e1> with the co-administration of 100 mg <e2> DRUG2 </e2> for 10 days . 	digoxin	sitagliptin
other	<e1> DRUG1 </e1> and <e2> DRUG2 </e2> are incompatible with sodium bicarbonate solution . 	norepinephrine	dobutamine
int	<e1> DRUG1 </e1> and dobutamine are incompatible with <e2> DRUG2 </e2> solution . 	norepinephrine	sodium bicarbonate
int	norepinephrine and <e1> DRUG1 </e1> are incompatible with <e2> DRUG2 </e2> solution . 	dobutamine	sodium bicarbonate
other	The addition of <e1> DRUG1 </e1> to parenteral solutions containing <e2> DRUG2 </e2> should be avoided , except where compatibility has been previously established . 	sodium bicarbonate	calcium
advise	Do not exceed a 5 mg daily dose of <e1> DRUG1 </e1> when administered with therapeutic doses of <e2> DRUG2 </e2> or other potent CYP3A4 inhibitors . 	VESIcare	ketoconazole
other	Patients with Congenital or Acquired QT Prolongation In a study of the effect of <e1> DRUG1 </e1> on the QT interval in 76 healthy women , the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose) , and the effect of solifenacin 30 mg did not appear as large as that of the positive control <e2> DRUG2 </e2> at its therapeutic dose . 	solifenacin	moxifloxacin
other	Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women , the QT prolonging effect appeared less with <e1> DRUG1 </e1> 10 mg than with 30 mg (three times the maximum recommended dose) , and the effect of solifenacin 30 mg did not appear as large as that of the positive control <e2> DRUG2 </e2> at its therapeutic dose . 	solifenacin	moxifloxacin
other	Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women , the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose) , and the effect of <e1> DRUG1 </e1> 30 mg did not appear as large as that of the positive control <e2> DRUG2 </e2> at its therapeutic dose . 	solifenacin	moxifloxacin
mechanism	Limited published data indicate that <e1> DRUG1 </e1> treatment increases cytochrome P450 (CP450) mediated <e2> DRUG2 </e2> clearance in man . 	GH	antipyrine
mechanism	These data suggest that <e1> DRUG1 </e1> administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g. , <e2> DRUG2 </e2> , sex steroids , anticonvulsants , cyclosporin ) . 	GH	corticosteroids
mechanism	These data suggest that <e1> DRUG1 </e1> administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g. , corticosteroids , <e2> DRUG2 </e2> , anticonvulsants , cyclosporin ) . 	GH	sex steroids
mechanism	These data suggest that <e1> DRUG1 </e1> administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g. , corticosteroids , sex steroids , <e2> DRUG2 </e2> , cyclosporin ) . 	GH	anticonvulsants
mechanism	These data suggest that <e1> DRUG1 </e1> administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g. , corticosteroids , sex steroids , anticonvulsants , <e2> DRUG2 </e2> ) . 	GH	cyclosporin
other	These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g. , <e1> DRUG1 </e1> , sex steroids , <e2> DRUG2 </e2> , cyclosporin ) . 	corticosteroids	anticonvulsants
other	These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g. , <e1> DRUG1 </e1> , sex steroids , anticonvulsants , <e2> DRUG2 </e2> ) . 	corticosteroids	cyclosporin
other	These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g. , corticosteroids , <e1> DRUG1 </e1> , anticonvulsants , <e2> DRUG2 </e2> ) . 	sex steroids	cyclosporin
advise	Caution is recommended when administering <e1> DRUG1 </e1> with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g . <e2> DRUG2 </e2> ) . 	NEXAVAR	irinotecan
mechanism	Concomitant treatment with <e1> DRUG1 </e1> resulted in a 21% increase in the AUC of <e2> DRUG2 </e2> . 	NEXAVAR	doxorubicin
advise	Caution is recommended when administering <e1> DRUG1 </e1> with <e2> DRUG2 </e2> . 	doxorubicin	NEXAVAR
effect	<e1> DRUG1 </e1> competitively inhibits the intracellular phosphorylation of <e2> DRUG2 </e2> . 	Zidovudine	stavudine
advise	Therefore , use of <e1> DRUG1 </e1> in combination with <e2> DRUG2 </e2> should be avoided . 	zidovudine	ZERIT
effect	In vitro data indicate that the phosphorylation of <e1> DRUG1 </e1> is also inhibited at relevant concentrations by <e2> DRUG2 </e2> and ribavirin . 	stavudine	doxorubicin
effect	In vitro data indicate that the phosphorylation of <e1> DRUG1 </e1> is also inhibited at relevant concentrations by doxorubicin and <e2> DRUG2 </e2> . 	stavudine	ribavirin
other	In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	doxorubicin	ribavirin
other	Use of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . 	Anticoagulants	Antiplatelet Agents
effect	Use of Anticoagulants and Antiplatelet Agents -- <e1> DRUG1 </e1> , Streptokinase , alone or in combination with <e2> DRUG2 </e2> and anticoagulants , may cause bleeding complications . 	Streptase	antiplatelet agents
effect	Use of Anticoagulants and Antiplatelet Agents -- <e1> DRUG1 </e1> , Streptokinase , alone or in combination with antiplatelet agents and <e2> DRUG2 </e2> , may cause bleeding complications . 	Streptase	anticoagulants
effect	Use of Anticoagulants and Antiplatelet Agents -- Streptase , <e1> DRUG1 </e1> , alone or in combination with <e2> DRUG2 </e2> and anticoagulants , may cause bleeding complications . 	Streptokinase	antiplatelet agents
effect	Use of Anticoagulants and Antiplatelet Agents -- Streptase , <e1> DRUG1 </e1> , alone or in combination with antiplatelet agents and <e2> DRUG2 </e2> , may cause bleeding complications . 	Streptokinase	anticoagulants
other	Use of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with <e1> DRUG1 </e1> and <e2> DRUG2 </e2> , may cause bleeding complications . 	antiplatelet agents	anticoagulants
other	In the treatment of acute MI , <e1> DRUG1 </e1> , when not otherwise contraindicated , should be administered with <e2> DRUG2 </e2> ( see below ) . 	aspirin	Streptokinase
effect	The addition of <e1> DRUG1 </e1> to <e2> DRUG2 </e2> causes a minimal increase in the risk of minor bleeding (3.9% vs . 3.1%) , but does not appear to increase the incidence of major bleeding (see 	aspirin	Streptokinase
mechanism	<e1> DRUG1 </e1> has been reported to prolong the elimination half-life of <e2> DRUG2 </e2> and may lead to severe bone marrow suppression; 	Streptozocin	doxorubicin
advise	a reduction of the <e1> DRUG1 </e1> dosage should be considered in patients receiving <e2> DRUG2 </e2> concurrently . 	doxorubicin	ZANOSAR
effect	The concurrent use of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> has been reported in one case to result in reduced streptozocin cytotoxicity . 	streptozocin	phenytoin
other	The concurrent use of streptozocin and <e1> DRUG1 </e1> has been reported in one case to result in reduced <e2> DRUG2 </e2> cytotoxicity . 	phenytoin	streptozocin
other	<e1> DRUG1 </e1> is not known to interact with other drugs including <e2> DRUG2 </e2> supplements; 	CHEMET	iron
advise	Concomitant administration of <e1> DRUG1 </e1> with other chelation therapy , such as <e2> DRUG2 </e2> is not recommended . 	CHEMET	CaNa 2 EDTA
effect	<e1> DRUG1 </e1> may increase the effects of <e2> DRUG2 </e2> , tolbutamide , and uricosurics . 	Sulfamethizole	barbiturates
effect	<e1> DRUG1 </e1> may increase the effects of barbiturates , <e2> DRUG2 </e2> , and uricosurics . 	Sulfamethizole	tolbutamide
effect	<e1> DRUG1 </e1> may increase the effects of barbiturates , tolbutamide , and <e2> DRUG2 </e2> . 	Sulfamethizole	uricosurics
other	Sulfamethizole may increase the effects of <e1> DRUG1 </e1> , tolbutamide , and <e2> DRUG2 </e2> . 	barbiturates	uricosurics
other	Sulfamethizole may increase the effects of barbiturates , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> . 	tolbutamide	uricosurics
other	It may also interact with <e1> DRUG1 </e1> (increased thrombocytopenia) , <e2> DRUG2 </e2> (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	thiazides	cyclosporine
other	It may also interact with <e1> DRUG1 </e1> (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , <e2> DRUG2 </e2> (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	thiazides	sulfonylurea agents
other	It may also interact with <e1> DRUG1 </e1> (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , <e2> DRUG2 </e2> (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	thiazides	warfarin
other	It may also interact with <e1> DRUG1 </e1> (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , <e2> DRUG2 </e2> (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	thiazides	methotrexate
other	It may also interact with <e1> DRUG1 </e1> (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of <e2> DRUG2 </e2> ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	thiazides	methotrexate
other	It may also interact with <e1> DRUG1 </e1> (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , <e2> DRUG2 </e2> (decreased hepatic clearance of phenytoin ) . 	thiazides	phenytoin
other	It may also interact with <e1> DRUG1 </e1> (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of <e2> DRUG2 </e2> ) . 	thiazides	phenytoin
other	It may also interact with thiazides (increased thrombocytopenia) , <e1> DRUG1 </e1> (increased nephrotoxicity) , <e2> DRUG2 </e2> (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	cyclosporine	sulfonylurea agents
other	It may also interact with thiazides (increased thrombocytopenia) , <e1> DRUG1 </e1> (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , <e2> DRUG2 </e2> (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	cyclosporine	warfarin
other	It may also interact with thiazides (increased thrombocytopenia) , <e1> DRUG1 </e1> (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , <e2> DRUG2 </e2> (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	cyclosporine	methotrexate
other	It may also interact with thiazides (increased thrombocytopenia) , <e1> DRUG1 </e1> (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of <e2> DRUG2 </e2> ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	cyclosporine	methotrexate
other	It may also interact with thiazides (increased thrombocytopenia) , <e1> DRUG1 </e1> (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , <e2> DRUG2 </e2> (decreased hepatic clearance of phenytoin ) . 	cyclosporine	phenytoin
other	It may also interact with thiazides (increased thrombocytopenia) , <e1> DRUG1 </e1> (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of <e2> DRUG2 </e2> ) . 	cyclosporine	phenytoin
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , <e1> DRUG1 </e1> (increased hypoglycemic response) , <e2> DRUG2 </e2> (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	sulfonylurea agents	warfarin
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , <e1> DRUG1 </e1> (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , <e2> DRUG2 </e2> (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	sulfonylurea agents	methotrexate
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , <e1> DRUG1 </e1> (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of <e2> DRUG2 </e2> ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	sulfonylurea agents	methotrexate
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , <e1> DRUG1 </e1> (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , <e2> DRUG2 </e2> (decreased hepatic clearance of phenytoin ) . 	sulfonylurea agents	phenytoin
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , <e1> DRUG1 </e1> (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of <e2> DRUG2 </e2> ) . 	sulfonylurea agents	phenytoin
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , <e1> DRUG1 </e1> (increased anticoagulant effect) , <e2> DRUG2 </e2> (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	warfarin	methotrexate
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , <e1> DRUG1 </e1> (increased anticoagulant effect) , methotrexate (decreased renal excretion of <e2> DRUG2 </e2> ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	warfarin	methotrexate
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , <e1> DRUG1 </e1> (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , <e2> DRUG2 </e2> (decreased hepatic clearance of phenytoin ) . 	warfarin	phenytoin
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , <e1> DRUG1 </e1> (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of <e2> DRUG2 </e2> ) . 	warfarin	phenytoin
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , <e1> DRUG1 </e1> (decreased renal excretion of methotrexate ) , <e2> DRUG2 </e2> (decreased hepatic clearance of phenytoin ) . 	methotrexate	phenytoin
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , <e1> DRUG1 </e1> (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of <e2> DRUG2 </e2> ) . 	methotrexate	phenytoin
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of <e1> DRUG1 </e1> ) , <e2> DRUG2 </e2> (decreased hepatic clearance of phenytoin ) . 	methotrexate	phenytoin
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of <e1> DRUG1 </e1> ) , phenytoin (decreased hepatic clearance of <e2> DRUG2 </e2> ) . 	methotrexate	phenytoin
other	In elderly patients concurrently receiving certain <e1> DRUG1 </e1> , primarily <e2> DRUG2 </e2> , an increased incidence of thrombopenia with purpura has been reported . 	diuretics	thiazides
other	It has been reported that <e1> DRUG1 </e1> may prolong the prothrombin time in patients who are receiving the <e2> DRUG2 </e2> warfarin . 	sulfamethoxazole	anticoagulant
effect	It has been reported that <e1> DRUG1 </e1> may prolong the prothrombin time in patients who are receiving the anticoagulant <e2> DRUG2 </e2> . 	sulfamethoxazole	warfarin
mechanism	<e1> DRUG1 </e1> may inhibit the hepatic metabolism of <e2> DRUG2 </e2> . 	Sulfamethoxazole	phenytoin
mechanism	At a 1.6-g dose , <e1> DRUG1 </e1> produced a slight but significant increase in the half-life of <e2> DRUG2 </e2> but did not produce a corresponding decrease in the metabolic clearance rate . 	sulfamethoxazole	phenytoin
mechanism	<e1> DRUG1 </e1> can also displace <e2> DRUG2 </e2> from plasma protein-binding sites , thus increasing free methotrexate concentrations . 	Sulfonamides	methotrexate
other	<e1> DRUG1 </e1> can also displace methotrexate from plasma protein-binding sites , thus increasing free <e2> DRUG2 </e2> concentrations . 	Sulfonamides	methotrexate
other	Reduced absorption of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> have been reported when those agents were administered concomitantly with sulfasalazine . 	folic acid	digoxin
mechanism	Reduced absorption of <e1> DRUG1 </e1> and digoxin have been reported when those agents were administered concomitantly with <e2> DRUG2 </e2> . 	folic acid	sulfasalazine
mechanism	Reduced absorption of folic acid and <e1> DRUG1 </e1> have been reported when those agents were administered concomitantly with <e2> DRUG2 </e2> . 	digoxin	sulfasalazine
other	When daily doses of <e1> DRUG1 </e1> 2 g and weekly doses of <e2> DRUG2 </e2> 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study , the pharmacokinetic disposition of the drugs was not altered . 	sulfasalazine	methotrexate
other	Daily doses of <e1> DRUG1 </e1> 2 g (maximum 3 g) and weekly doses of <e2> DRUG2 </e2> 7.5 mg (maximum 15 mg) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies . 	sulfasalazine	methotrexate
effect	<e1> DRUG1 </e1> may increase the effects of <e2> DRUG2 </e2> , tolbutamide , and uricosurics . 	Sulfoxone	barbiturates
effect	<e1> DRUG1 </e1> may increase the effects of barbiturates , <e2> DRUG2 </e2> , and uricosurics . 	Sulfoxone	tolbutamide
effect	<e1> DRUG1 </e1> may increase the effects of barbiturates , tolbutamide , and <e2> DRUG2 </e2> . 	Sulfoxone	uricosurics
other	Sulfoxone may increase the effects of <e1> DRUG1 </e1> , tolbutamide , and <e2> DRUG2 </e2> . 	barbiturates	uricosurics
other	Sulfoxone may increase the effects of barbiturates , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> . 	tolbutamide	uricosurics
other	It may also interact with <e1> DRUG1 </e1> (increased thrombocytopenia) , <e2> DRUG2 </e2> (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	thiazides	cyclosporine
other	It may also interact with <e1> DRUG1 </e1> (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , <e2> DRUG2 </e2> (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	thiazides	sulfonylurea agents
other	It may also interact with <e1> DRUG1 </e1> (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , <e2> DRUG2 </e2> (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	thiazides	warfarin
other	It may also interact with <e1> DRUG1 </e1> (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , <e2> DRUG2 </e2> (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	thiazides	methotrexate
other	It may also interact with <e1> DRUG1 </e1> (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of <e2> DRUG2 </e2> ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	thiazides	methotrexate
other	It may also interact with <e1> DRUG1 </e1> (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , <e2> DRUG2 </e2> (decreased hepatic clearance of phenytoin ) . 	thiazides	phenytoin
other	It may also interact with <e1> DRUG1 </e1> (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of <e2> DRUG2 </e2> ) . 	thiazides	phenytoin
other	It may also interact with thiazides (increased thrombocytopenia) , <e1> DRUG1 </e1> (increased nephrotoxicity) , <e2> DRUG2 </e2> (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	cyclosporine	sulfonylurea agents
other	It may also interact with thiazides (increased thrombocytopenia) , <e1> DRUG1 </e1> (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , <e2> DRUG2 </e2> (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	cyclosporine	warfarin
other	It may also interact with thiazides (increased thrombocytopenia) , <e1> DRUG1 </e1> (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , <e2> DRUG2 </e2> (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	cyclosporine	methotrexate
other	It may also interact with thiazides (increased thrombocytopenia) , <e1> DRUG1 </e1> (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of <e2> DRUG2 </e2> ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	cyclosporine	methotrexate
other	It may also interact with thiazides (increased thrombocytopenia) , <e1> DRUG1 </e1> (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , <e2> DRUG2 </e2> (decreased hepatic clearance of phenytoin ) . 	cyclosporine	phenytoin
other	It may also interact with thiazides (increased thrombocytopenia) , <e1> DRUG1 </e1> (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of <e2> DRUG2 </e2> ) . 	cyclosporine	phenytoin
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , <e1> DRUG1 </e1> (increased hypoglycemic response) , <e2> DRUG2 </e2> (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	sulfonylurea agents	warfarin
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , <e1> DRUG1 </e1> (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , <e2> DRUG2 </e2> (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	sulfonylurea agents	methotrexate
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , <e1> DRUG1 </e1> (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of <e2> DRUG2 </e2> ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	sulfonylurea agents	methotrexate
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , <e1> DRUG1 </e1> (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , <e2> DRUG2 </e2> (decreased hepatic clearance of phenytoin ) . 	sulfonylurea agents	phenytoin
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , <e1> DRUG1 </e1> (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of <e2> DRUG2 </e2> ) . 	sulfonylurea agents	phenytoin
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , <e1> DRUG1 </e1> (increased anticoagulant effect) , <e2> DRUG2 </e2> (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	warfarin	methotrexate
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , <e1> DRUG1 </e1> (increased anticoagulant effect) , methotrexate (decreased renal excretion of <e2> DRUG2 </e2> ) , phenytoin (decreased hepatic clearance of phenytoin ) . 	warfarin	methotrexate
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , <e1> DRUG1 </e1> (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , <e2> DRUG2 </e2> (decreased hepatic clearance of phenytoin ) . 	warfarin	phenytoin
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , <e1> DRUG1 </e1> (increased anticoagulant effect) , methotrexate (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of <e2> DRUG2 </e2> ) . 	warfarin	phenytoin
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , <e1> DRUG1 </e1> (decreased renal excretion of methotrexate ) , <e2> DRUG2 </e2> (decreased hepatic clearance of phenytoin ) . 	methotrexate	phenytoin
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , <e1> DRUG1 </e1> (decreased renal excretion of methotrexate ) , phenytoin (decreased hepatic clearance of <e2> DRUG2 </e2> ) . 	methotrexate	phenytoin
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of <e1> DRUG1 </e1> ) , <e2> DRUG2 </e2> (decreased hepatic clearance of phenytoin ) . 	methotrexate	phenytoin
other	It may also interact with thiazides (increased thrombocytopenia) , cyclosporine (increased nephrotoxicity) , sulfonylurea agents (increased hypoglycemic response) , warfarin (increased anticoagulant effect) , methotrexate (decreased renal excretion of <e1> DRUG1 </e1> ) , phenytoin (decreased hepatic clearance of <e2> DRUG2 </e2> ) . 	methotrexate	phenytoin
other	Because there is a theoretical basis that these effects may be additive , use of <e1> DRUG1 </e1> -containing or <e2> DRUG2 </e2> (like dihydroergotamine or methysergide ) and sumatriptan within 24 hours of each other should be avoided . 	ergotamine	ergot-type medications
other	Because there is a theoretical basis that these effects may be additive , use of <e1> DRUG1 </e1> -containing or ergot-type medications (like <e2> DRUG2 </e2> or methysergide ) and sumatriptan within 24 hours of each other should be avoided . 	ergotamine	dihydroergotamine
other	Because there is a theoretical basis that these effects may be additive , use of <e1> DRUG1 </e1> -containing or ergot-type medications (like dihydroergotamine or <e2> DRUG2 </e2> ) and sumatriptan within 24 hours of each other should be avoided . 	ergotamine	methysergide
advise	Because there is a theoretical basis that these effects may be additive , use of <e1> DRUG1 </e1> -containing or ergot-type medications (like dihydroergotamine or methysergide ) and <e2> DRUG2 </e2> within 24 hours of each other should be avoided . 	ergotamine	sumatriptan
other	Because there is a theoretical basis that these effects may be additive , use of ergotamine -containing or <e1> DRUG1 </e1> (like <e2> DRUG2 </e2> or methysergide ) and sumatriptan within 24 hours of each other should be avoided . 	ergot-type medications	dihydroergotamine
other	Because there is a theoretical basis that these effects may be additive , use of ergotamine -containing or <e1> DRUG1 </e1> (like dihydroergotamine or <e2> DRUG2 </e2> ) and sumatriptan within 24 hours of each other should be avoided . 	ergot-type medications	methysergide
advise	Because there is a theoretical basis that these effects may be additive , use of ergotamine -containing or <e1> DRUG1 </e1> (like dihydroergotamine or methysergide ) and <e2> DRUG2 </e2> within 24 hours of each other should be avoided . 	ergot-type medications	sumatriptan
advise	Because there is a theoretical basis that these effects may be additive , use of ergotamine -containing or ergot-type medications (like <e1> DRUG1 </e1> or methysergide ) and <e2> DRUG2 </e2> within 24 hours of each other should be avoided . 	dihydroergotamine	sumatriptan
advise	Because there is a theoretical basis that these effects may be additive , use of ergotamine -containing or ergot-type medications (like dihydroergotamine or <e1> DRUG1 </e1> ) and <e2> DRUG2 </e2> within 24 hours of each other should be avoided . 	methysergide	sumatriptan
mechanism	<e1> DRUG1 </e1> reduce <e2> DRUG2 </e2> clearance , significantly increasing systemic exposure . 	MAO-A inhibitors	sumatriptan
advise	Therefore , the use of <e1> DRUG1 </e1> tablets in patients receiving <e2> DRUG2 </e2> is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) (e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 	sumatriptan succinate	MAO-A inhibitors
other	Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . <e1> DRUG1 </e1> ( SSRIs ) (e.g. , <e2> DRUG2 </e2> , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 	Selective serotonin reuptake inhibitors	fluoxetine
other	Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . <e1> DRUG1 </e1> ( SSRIs ) (e.g. , fluoxetine , <e2> DRUG2 </e2> , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 	Selective serotonin reuptake inhibitors	fluvoxamine
other	Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . <e1> DRUG1 </e1> ( SSRIs ) (e.g. , fluoxetine , fluvoxamine , <e2> DRUG2 </e2> , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 	Selective serotonin reuptake inhibitors	paroxetine
other	Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . <e1> DRUG1 </e1> ( SSRIs ) (e.g. , fluoxetine , fluvoxamine , paroxetine , <e2> DRUG2 </e2> ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 	Selective serotonin reuptake inhibitors	sertraline
effect	Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . <e1> DRUG1 </e1> ( SSRIs ) (e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with <e2> DRUG2 </e2> . 	Selective serotonin reuptake inhibitors	sumatriptan
other	Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( <e1> DRUG1 </e1> ) (e.g. , <e2> DRUG2 </e2> , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 	SSRIs	fluoxetine
other	Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( <e1> DRUG1 </e1> ) (e.g. , fluoxetine , <e2> DRUG2 </e2> , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 	SSRIs	fluvoxamine
other	Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( <e1> DRUG1 </e1> ) (e.g. , fluoxetine , fluvoxamine , <e2> DRUG2 </e2> , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 	SSRIs	paroxetine
other	Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( <e1> DRUG1 </e1> ) (e.g. , fluoxetine , fluvoxamine , paroxetine , <e2> DRUG2 </e2> ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 	SSRIs	sertraline
effect	Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( <e1> DRUG1 </e1> ) (e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with <e2> DRUG2 </e2> . 	SSRIs	sumatriptan
other	Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) (e.g. , <e1> DRUG1 </e1> , fluvoxamine , <e2> DRUG2 </e2> , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 	fluoxetine	paroxetine
other	Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) (e.g. , <e1> DRUG1 </e1> , fluvoxamine , paroxetine , <e2> DRUG2 </e2> ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 	fluoxetine	sertraline
effect	Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) (e.g. , <e1> DRUG1 </e1> , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with <e2> DRUG2 </e2> . 	fluoxetine	sumatriptan
other	Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) (e.g. , fluoxetine , <e1> DRUG1 </e1> , paroxetine , <e2> DRUG2 </e2> ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 	fluvoxamine	sertraline
effect	Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) (e.g. , fluoxetine , <e1> DRUG1 </e1> , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with <e2> DRUG2 </e2> . 	fluvoxamine	sumatriptan
effect	Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) (e.g. , fluoxetine , fluvoxamine , <e1> DRUG1 </e1> , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with <e2> DRUG2 </e2> . 	paroxetine	sumatriptan
effect	Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) (e.g. , fluoxetine , fluvoxamine , paroxetine , <e1> DRUG1 </e1> ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with <e2> DRUG2 </e2> . 	sertraline	sumatriptan
advise	If concomitant treatment with <e1> DRUG1 </e1> and an <e2> DRUG2 </e2> is clinically warranted , appropriate observation of the patient is advised . 	sumatriptan	SSRI
mechanism	Co-administration of <e1> DRUG1 </e1> with strong inhibitors of the CYP3A4 family (e.g. , <e2> DRUG2 </e2> , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	SUTENT	ketoconazole
mechanism	Co-administration of <e1> DRUG1 </e1> with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , <e2> DRUG2 </e2> , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	SUTENT	itraconazole
mechanism	Co-administration of <e1> DRUG1 </e1> with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , <e2> DRUG2 </e2> , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	SUTENT	clarithromycin
mechanism	Co-administration of <e1> DRUG1 </e1> with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , <e2> DRUG2 </e2> , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	SUTENT	atazanavir
mechanism	Co-administration of <e1> DRUG1 </e1> with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , <e2> DRUG2 </e2> , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	SUTENT	indinavir
mechanism	Co-administration of <e1> DRUG1 </e1> with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , <e2> DRUG2 </e2> , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	SUTENT	nefazodone
mechanism	Co-administration of <e1> DRUG1 </e1> with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , <e2> DRUG2 </e2> , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	SUTENT	nelfinavir
mechanism	Co-administration of <e1> DRUG1 </e1> with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , <e2> DRUG2 </e2> , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	SUTENT	ritonavir
mechanism	Co-administration of <e1> DRUG1 </e1> with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , <e2> DRUG2 </e2> , telithromycin , voriconizole ) may increases sunitinib concentrations . 	SUTENT	saquinavir
mechanism	Co-administration of <e1> DRUG1 </e1> with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , <e2> DRUG2 </e2> , voriconizole ) may increases sunitinib concentrations . 	SUTENT	telithromycin
mechanism	Co-administration of <e1> DRUG1 </e1> with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , <e2> DRUG2 </e2> ) may increases sunitinib concentrations . 	SUTENT	voriconizole
other	Co-administration of <e1> DRUG1 </e1> with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases <e2> DRUG2 </e2> concentrations . 	SUTENT	sunitinib
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , <e1> DRUG1 </e1> , itraconazole , <e2> DRUG2 </e2> , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	ketoconazole	clarithromycin
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , <e1> DRUG1 </e1> , itraconazole , clarithromycin , <e2> DRUG2 </e2> , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	ketoconazole	atazanavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , <e1> DRUG1 </e1> , itraconazole , clarithromycin , atazanavir , <e2> DRUG2 </e2> , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	ketoconazole	indinavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , <e1> DRUG1 </e1> , itraconazole , clarithromycin , atazanavir , indinavir , <e2> DRUG2 </e2> , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	ketoconazole	nefazodone
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , <e1> DRUG1 </e1> , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , <e2> DRUG2 </e2> , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	ketoconazole	nelfinavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , <e1> DRUG1 </e1> , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , <e2> DRUG2 </e2> , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	ketoconazole	ritonavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , <e1> DRUG1 </e1> , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , <e2> DRUG2 </e2> , telithromycin , voriconizole ) may increases sunitinib concentrations . 	ketoconazole	saquinavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , <e1> DRUG1 </e1> , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , <e2> DRUG2 </e2> , voriconizole ) may increases sunitinib concentrations . 	ketoconazole	telithromycin
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , <e1> DRUG1 </e1> , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , <e2> DRUG2 </e2> ) may increases sunitinib concentrations . 	ketoconazole	voriconizole
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , <e1> DRUG1 </e1> , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases <e2> DRUG2 </e2> concentrations . 	ketoconazole	sunitinib
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , <e1> DRUG1 </e1> , clarithromycin , <e2> DRUG2 </e2> , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	itraconazole	atazanavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , <e1> DRUG1 </e1> , clarithromycin , atazanavir , <e2> DRUG2 </e2> , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	itraconazole	indinavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , <e1> DRUG1 </e1> , clarithromycin , atazanavir , indinavir , <e2> DRUG2 </e2> , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	itraconazole	nefazodone
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , <e1> DRUG1 </e1> , clarithromycin , atazanavir , indinavir , nefazodone , <e2> DRUG2 </e2> , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	itraconazole	nelfinavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , <e1> DRUG1 </e1> , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , <e2> DRUG2 </e2> , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	itraconazole	ritonavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , <e1> DRUG1 </e1> , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , <e2> DRUG2 </e2> , telithromycin , voriconizole ) may increases sunitinib concentrations . 	itraconazole	saquinavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , <e1> DRUG1 </e1> , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , <e2> DRUG2 </e2> , voriconizole ) may increases sunitinib concentrations . 	itraconazole	telithromycin
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , <e1> DRUG1 </e1> , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , <e2> DRUG2 </e2> ) may increases sunitinib concentrations . 	itraconazole	voriconizole
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , <e1> DRUG1 </e1> , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases <e2> DRUG2 </e2> concentrations . 	itraconazole	sunitinib
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , <e1> DRUG1 </e1> , atazanavir , <e2> DRUG2 </e2> , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	clarithromycin	indinavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , <e1> DRUG1 </e1> , atazanavir , indinavir , <e2> DRUG2 </e2> , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	clarithromycin	nefazodone
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , <e1> DRUG1 </e1> , atazanavir , indinavir , nefazodone , <e2> DRUG2 </e2> , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	clarithromycin	nelfinavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , <e1> DRUG1 </e1> , atazanavir , indinavir , nefazodone , nelfinavir , <e2> DRUG2 </e2> , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	clarithromycin	ritonavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , <e1> DRUG1 </e1> , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , <e2> DRUG2 </e2> , telithromycin , voriconizole ) may increases sunitinib concentrations . 	clarithromycin	saquinavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , <e1> DRUG1 </e1> , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , <e2> DRUG2 </e2> , voriconizole ) may increases sunitinib concentrations . 	clarithromycin	telithromycin
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , <e1> DRUG1 </e1> , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , <e2> DRUG2 </e2> ) may increases sunitinib concentrations . 	clarithromycin	voriconizole
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , <e1> DRUG1 </e1> , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases <e2> DRUG2 </e2> concentrations . 	clarithromycin	sunitinib
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , <e1> DRUG1 </e1> , indinavir , <e2> DRUG2 </e2> , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	atazanavir	nefazodone
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , <e1> DRUG1 </e1> , indinavir , nefazodone , <e2> DRUG2 </e2> , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	atazanavir	nelfinavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , <e1> DRUG1 </e1> , indinavir , nefazodone , nelfinavir , <e2> DRUG2 </e2> , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	atazanavir	ritonavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , <e1> DRUG1 </e1> , indinavir , nefazodone , nelfinavir , ritonavir , <e2> DRUG2 </e2> , telithromycin , voriconizole ) may increases sunitinib concentrations . 	atazanavir	saquinavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , <e1> DRUG1 </e1> , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , <e2> DRUG2 </e2> , voriconizole ) may increases sunitinib concentrations . 	atazanavir	telithromycin
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , <e1> DRUG1 </e1> , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , <e2> DRUG2 </e2> ) may increases sunitinib concentrations . 	atazanavir	voriconizole
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , <e1> DRUG1 </e1> , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases <e2> DRUG2 </e2> concentrations . 	atazanavir	sunitinib
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , <e1> DRUG1 </e1> , nefazodone , <e2> DRUG2 </e2> , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	indinavir	nelfinavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , <e1> DRUG1 </e1> , nefazodone , nelfinavir , <e2> DRUG2 </e2> , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	indinavir	ritonavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , <e1> DRUG1 </e1> , nefazodone , nelfinavir , ritonavir , <e2> DRUG2 </e2> , telithromycin , voriconizole ) may increases sunitinib concentrations . 	indinavir	saquinavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , <e1> DRUG1 </e1> , nefazodone , nelfinavir , ritonavir , saquinavir , <e2> DRUG2 </e2> , voriconizole ) may increases sunitinib concentrations . 	indinavir	telithromycin
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , <e1> DRUG1 </e1> , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , <e2> DRUG2 </e2> ) may increases sunitinib concentrations . 	indinavir	voriconizole
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , <e1> DRUG1 </e1> , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases <e2> DRUG2 </e2> concentrations . 	indinavir	sunitinib
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , <e1> DRUG1 </e1> , nelfinavir , <e2> DRUG2 </e2> , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 	nefazodone	ritonavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , <e1> DRUG1 </e1> , nelfinavir , ritonavir , <e2> DRUG2 </e2> , telithromycin , voriconizole ) may increases sunitinib concentrations . 	nefazodone	saquinavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , <e1> DRUG1 </e1> , nelfinavir , ritonavir , saquinavir , <e2> DRUG2 </e2> , voriconizole ) may increases sunitinib concentrations . 	nefazodone	telithromycin
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , <e1> DRUG1 </e1> , nelfinavir , ritonavir , saquinavir , telithromycin , <e2> DRUG2 </e2> ) may increases sunitinib concentrations . 	nefazodone	voriconizole
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , <e1> DRUG1 </e1> , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases <e2> DRUG2 </e2> concentrations . 	nefazodone	sunitinib
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , <e1> DRUG1 </e1> , ritonavir , <e2> DRUG2 </e2> , telithromycin , voriconizole ) may increases sunitinib concentrations . 	nelfinavir	saquinavir
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , <e1> DRUG1 </e1> , ritonavir , saquinavir , <e2> DRUG2 </e2> , voriconizole ) may increases sunitinib concentrations . 	nelfinavir	telithromycin
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , <e1> DRUG1 </e1> , ritonavir , saquinavir , telithromycin , <e2> DRUG2 </e2> ) may increases sunitinib concentrations . 	nelfinavir	voriconizole
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , <e1> DRUG1 </e1> , ritonavir , saquinavir , telithromycin , voriconizole ) may increases <e2> DRUG2 </e2> concentrations . 	nelfinavir	sunitinib
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , <e1> DRUG1 </e1> , saquinavir , <e2> DRUG2 </e2> , voriconizole ) may increases sunitinib concentrations . 	ritonavir	telithromycin
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , <e1> DRUG1 </e1> , saquinavir , telithromycin , <e2> DRUG2 </e2> ) may increases sunitinib concentrations . 	ritonavir	voriconizole
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , <e1> DRUG1 </e1> , saquinavir , telithromycin , voriconizole ) may increases <e2> DRUG2 </e2> concentrations . 	ritonavir	sunitinib
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , <e1> DRUG1 </e1> , telithromycin , <e2> DRUG2 </e2> ) may increases sunitinib concentrations . 	saquinavir	voriconizole
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , <e1> DRUG1 </e1> , telithromycin , voriconizole ) may increases <e2> DRUG2 </e2> concentrations . 	saquinavir	sunitinib
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , <e1> DRUG1 </e1> , voriconizole ) may increases <e2> DRUG2 </e2> concentrations . 	telithromycin	sunitinib
other	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , <e1> DRUG1 </e1> ) may increases <e2> DRUG2 </e2> concentrations . 	voriconizole	sunitinib
mechanism	Co-administration of <e1> DRUG1 </e1> with inducers of the CYP3A4 family (e.g. , <e2> DRUG2 </e2> , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St . Johns Wort) may decrease sunitinib concentrations . 	SUTENT	dexamethasone
mechanism	Co-administration of <e1> DRUG1 </e1> with inducers of the CYP3A4 family (e.g. , dexamethasone , <e2> DRUG2 </e2> , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St . Johns Wort) may decrease sunitinib concentrations . 	SUTENT	phenytoin
mechanism	Co-administration of <e1> DRUG1 </e1> with inducers of the CYP3A4 family (e.g. , dexamethasone , phenytoin , <e2> DRUG2 </e2> , rifampin , rifabutin , rifapentin , phenobarbital , St . Johns Wort) may decrease sunitinib concentrations . 	SUTENT	carbamazepine
mechanism	Co-administration of <e1> DRUG1 </e1> with inducers of the CYP3A4 family (e.g. , dexamethasone , phenytoin , carbamazepine , <e2> DRUG2 </e2> , rifabutin , rifapentin , phenobarbital , St . Johns Wort) may decrease sunitinib concentrations . 	SUTENT	rifampin
mechanism	Co-administration of <e1> DRUG1 </e1> with inducers of the CYP3A4 family (e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , <e2> DRUG2 </e2> , rifapentin , phenobarbital , St . Johns Wort) may decrease sunitinib concentrations . 	SUTENT	rifabutin
mechanism	Co-administration of <e1> DRUG1 </e1> with inducers of the CYP3A4 family (e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , <e2> DRUG2 </e2> , phenobarbital , St . Johns Wort) may decrease sunitinib concentrations . 	SUTENT	rifapentin
mechanism	Co-administration of <e1> DRUG1 </e1> with inducers of the CYP3A4 family (e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , <e2> DRUG2 </e2> , St . Johns Wort) may decrease sunitinib concentrations . 	SUTENT	phenobarbital
other	Co-administration of <e1> DRUG1 </e1> with inducers of the CYP3A4 family (e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St . Johns Wort) may decrease <e2> DRUG2 </e2> concentrations . 	SUTENT	sunitinib
other	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g. , <e1> DRUG1 </e1> , phenytoin , <e2> DRUG2 </e2> , rifampin , rifabutin , rifapentin , phenobarbital , St . Johns Wort) may decrease sunitinib concentrations . 	dexamethasone	carbamazepine
other	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g. , <e1> DRUG1 </e1> , phenytoin , carbamazepine , <e2> DRUG2 </e2> , rifabutin , rifapentin , phenobarbital , St . Johns Wort) may decrease sunitinib concentrations . 	dexamethasone	rifampin
other	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g. , <e1> DRUG1 </e1> , phenytoin , carbamazepine , rifampin , <e2> DRUG2 </e2> , rifapentin , phenobarbital , St . Johns Wort) may decrease sunitinib concentrations . 	dexamethasone	rifabutin
other	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g. , <e1> DRUG1 </e1> , phenytoin , carbamazepine , rifampin , rifabutin , <e2> DRUG2 </e2> , phenobarbital , St . Johns Wort) may decrease sunitinib concentrations . 	dexamethasone	rifapentin
other	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g. , <e1> DRUG1 </e1> , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , <e2> DRUG2 </e2> , St . Johns Wort) may decrease sunitinib concentrations . 	dexamethasone	phenobarbital
other	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g. , <e1> DRUG1 </e1> , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St . Johns Wort) may decrease <e2> DRUG2 </e2> concentrations . 	dexamethasone	sunitinib
other	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g. , dexamethasone , <e1> DRUG1 </e1> , carbamazepine , <e2> DRUG2 </e2> , rifabutin , rifapentin , phenobarbital , St . Johns Wort) may decrease sunitinib concentrations . 	phenytoin	rifampin
other	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g. , dexamethasone , <e1> DRUG1 </e1> , carbamazepine , rifampin , <e2> DRUG2 </e2> , rifapentin , phenobarbital , St . Johns Wort) may decrease sunitinib concentrations . 	phenytoin	rifabutin
other	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g. , dexamethasone , <e1> DRUG1 </e1> , carbamazepine , rifampin , rifabutin , <e2> DRUG2 </e2> , phenobarbital , St . Johns Wort) may decrease sunitinib concentrations . 	phenytoin	rifapentin
other	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g. , dexamethasone , <e1> DRUG1 </e1> , carbamazepine , rifampin , rifabutin , rifapentin , <e2> DRUG2 </e2> , St . Johns Wort) may decrease sunitinib concentrations . 	phenytoin	phenobarbital
other	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g. , dexamethasone , <e1> DRUG1 </e1> , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St . Johns Wort) may decrease <e2> DRUG2 </e2> concentrations . 	phenytoin	sunitinib
other	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g. , dexamethasone , phenytoin , <e1> DRUG1 </e1> , rifampin , <e2> DRUG2 </e2> , rifapentin , phenobarbital , St . Johns Wort) may decrease sunitinib concentrations . 	carbamazepine	rifabutin
other	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g. , dexamethasone , phenytoin , <e1> DRUG1 </e1> , rifampin , rifabutin , <e2> DRUG2 </e2> , phenobarbital , St . Johns Wort) may decrease sunitinib concentrations . 	carbamazepine	rifapentin
other	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g. , dexamethasone , phenytoin , <e1> DRUG1 </e1> , rifampin , rifabutin , rifapentin , <e2> DRUG2 </e2> , St . Johns Wort) may decrease sunitinib concentrations . 	carbamazepine	phenobarbital
other	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g. , dexamethasone , phenytoin , <e1> DRUG1 </e1> , rifampin , rifabutin , rifapentin , phenobarbital , St . Johns Wort) may decrease <e2> DRUG2 </e2> concentrations . 	carbamazepine	sunitinib
other	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g. , dexamethasone , phenytoin , carbamazepine , <e1> DRUG1 </e1> , rifabutin , <e2> DRUG2 </e2> , phenobarbital , St . Johns Wort) may decrease sunitinib concentrations . 	rifampin	rifapentin
other	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g. , dexamethasone , phenytoin , carbamazepine , <e1> DRUG1 </e1> , rifabutin , rifapentin , <e2> DRUG2 </e2> , St . Johns Wort) may decrease sunitinib concentrations . 	rifampin	phenobarbital
other	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g. , dexamethasone , phenytoin , carbamazepine , <e1> DRUG1 </e1> , rifabutin , rifapentin , phenobarbital , St . Johns Wort) may decrease <e2> DRUG2 </e2> concentrations . 	rifampin	sunitinib
other	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , <e1> DRUG1 </e1> , rifapentin , <e2> DRUG2 </e2> , St . Johns Wort) may decrease sunitinib concentrations . 	rifabutin	phenobarbital
other	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , <e1> DRUG1 </e1> , rifapentin , phenobarbital , St . Johns Wort) may decrease <e2> DRUG2 </e2> concentrations . 	rifabutin	sunitinib
other	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , <e1> DRUG1 </e1> , phenobarbital , St . Johns Wort) may decrease <e2> DRUG2 </e2> concentrations . 	rifapentin	sunitinib
other	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , <e1> DRUG1 </e1> , St . Johns Wort) may decrease <e2> DRUG2 </e2> concentrations . 	phenobarbital	sunitinib
other	Other eye drops or medications such as <e1> DRUG1 </e1> ( Miochol ) and <e2> DRUG2 </e2> ( Carboptic , Isopto Carbachol ) may decrease the effects of suprofen ophthalmic . 	acetylcholine chloride	carbachol
other	Other eye drops or medications such as <e1> DRUG1 </e1> ( Miochol ) and carbachol ( <e2> DRUG2 </e2> , Isopto Carbachol ) may decrease the effects of suprofen ophthalmic . 	acetylcholine chloride	Carboptic
other	Other eye drops or medications such as <e1> DRUG1 </e1> ( Miochol ) and carbachol ( Carboptic , <e2> DRUG2 </e2> ) may decrease the effects of suprofen ophthalmic . 	acetylcholine chloride	Isopto Carbachol
effect	Other eye drops or medications such as <e1> DRUG1 </e1> ( Miochol ) and carbachol ( Carboptic , Isopto Carbachol ) may decrease the effects of <e2> DRUG2 </e2> ophthalmic . 	acetylcholine chloride	suprofen
other	Other eye drops or medications such as acetylcholine chloride ( <e1> DRUG1 </e1> ) and <e2> DRUG2 </e2> ( Carboptic , Isopto Carbachol ) may decrease the effects of suprofen ophthalmic . 	Miochol	carbachol
other	Other eye drops or medications such as acetylcholine chloride ( <e1> DRUG1 </e1> ) and carbachol ( <e2> DRUG2 </e2> , Isopto Carbachol ) may decrease the effects of suprofen ophthalmic . 	Miochol	Carboptic
other	Other eye drops or medications such as acetylcholine chloride ( <e1> DRUG1 </e1> ) and carbachol ( Carboptic , <e2> DRUG2 </e2> ) may decrease the effects of suprofen ophthalmic . 	Miochol	Isopto Carbachol
effect	Other eye drops or medications such as acetylcholine chloride ( <e1> DRUG1 </e1> ) and carbachol ( Carboptic , Isopto Carbachol ) may decrease the effects of <e2> DRUG2 </e2> ophthalmic . 	Miochol	suprofen
other	Other eye drops or medications such as acetylcholine chloride ( Miochol ) and <e1> DRUG1 </e1> ( Carboptic , <e2> DRUG2 </e2> ) may decrease the effects of suprofen ophthalmic . 	carbachol	Isopto Carbachol
effect	Other eye drops or medications such as acetylcholine chloride ( Miochol ) and <e1> DRUG1 </e1> ( Carboptic , Isopto Carbachol ) may decrease the effects of <e2> DRUG2 </e2> ophthalmic . 	carbachol	suprofen
effect	Other eye drops or medications such as acetylcholine chloride ( Miochol ) and carbachol ( <e1> DRUG1 </e1> , Isopto Carbachol ) may decrease the effects of <e2> DRUG2 </e2> ophthalmic . 	Carboptic	suprofen
effect	Other eye drops or medications such as acetylcholine chloride ( Miochol ) and carbachol ( Carboptic , <e1> DRUG1 </e1> ) may decrease the effects of <e2> DRUG2 </e2> ophthalmic . 	Isopto Carbachol	suprofen
other	Drug-Drug Interactions : The pharmacokinetic and pharmacodynamic interactions between <e1> DRUG1 </e1> capsules and other <e2> DRUG2 </e2> have not been determined . 	FLOMAX	alpha-adrenergic blocking agents
advise	However , interactions may be expected and <e1> DRUG1 </e1> capsules should NOT be used in combination with other <e2> DRUG2 </e2> . 	FLOMAX	alpha-adrenergic blocking agents
other	The pharmacokinetic interaction between <e1> DRUG1 </e1> and <e2> DRUG2 </e2> capsules was investigated . 	cimetidine	FLOMAX
advise	Therefore , <e1> DRUG1 </e1> capsules should be used with caution in combination with <e2> DRUG2 </e2> , particularly at doses higher than 0.4 mg . 	FLOMAX	cimetidine
other	Results from limited in vitro and in vivo drug-drug interaction studies between <e1> DRUG1 </e1> and <e2> DRUG2 </e2> are inconclusive . 	tamsulosin HCI	warfarin
advise	Therefore , caution should be exercised with concomitant administration of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> capsules . 	warfarin	FLOMAX
mechanism	Administration of <e1> DRUG1 </e1> decreases oral clearance of <e2> DRUG2 </e2> by about 5% . 	valproic acid	temozolomide
other	Patients studied in clinical trials of <e1> DRUG1 </e1> were routinely treated with <e2> DRUG2 </e2> and aspirin . 	TNKase	heparin
other	Patients studied in clinical trials of <e1> DRUG1 </e1> were routinely treated with heparin and <e2> DRUG2 </e2> . 	TNKase	aspirin
other	Patients studied in clinical trials of TNKase were routinely treated with <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	heparin	aspirin
other	<e1> DRUG1 </e1> (such as <e2> DRUG2 </e2> and vitamin K antagonists ) and drugs that alter platelet function (such as acetylsalicylic acid , dipyridamole , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 	Anticoagulants	heparin
other	<e1> DRUG1 </e1> (such as heparin and <e2> DRUG2 </e2> ) and drugs that alter platelet function (such as acetylsalicylic acid , dipyridamole , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 	Anticoagulants	vitamin K antagonists
other	<e1> DRUG1 </e1> (such as heparin and vitamin K antagonists ) and drugs that alter platelet function (such as <e2> DRUG2 </e2> , dipyridamole , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 	Anticoagulants	acetylsalicylic acid
other	<e1> DRUG1 </e1> (such as heparin and vitamin K antagonists ) and drugs that alter platelet function (such as acetylsalicylic acid , <e2> DRUG2 </e2> , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 	Anticoagulants	dipyridamole
effect	<e1> DRUG1 </e1> (such as heparin and vitamin K antagonists ) and drugs that alter platelet function (such as acetylsalicylic acid , dipyridamole , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to , during , or after <e2> DRUG2 </e2> therapy . 	Anticoagulants	TNKase
other	Anticoagulants (such as <e1> DRUG1 </e1> and <e2> DRUG2 </e2> ) and drugs that alter platelet function (such as acetylsalicylic acid , dipyridamole , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 	heparin	vitamin K antagonists
other	Anticoagulants (such as <e1> DRUG1 </e1> and vitamin K antagonists ) and drugs that alter platelet function (such as <e2> DRUG2 </e2> , dipyridamole , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 	heparin	acetylsalicylic acid
other	Anticoagulants (such as <e1> DRUG1 </e1> and vitamin K antagonists ) and drugs that alter platelet function (such as acetylsalicylic acid , <e2> DRUG2 </e2> , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 	heparin	dipyridamole
effect	Anticoagulants (such as <e1> DRUG1 </e1> and vitamin K antagonists ) and drugs that alter platelet function (such as acetylsalicylic acid , dipyridamole , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to , during , or after <e2> DRUG2 </e2> therapy . 	heparin	TNKase
other	Anticoagulants (such as heparin and <e1> DRUG1 </e1> ) and drugs that alter platelet function (such as <e2> DRUG2 </e2> , dipyridamole , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 	vitamin K antagonists	acetylsalicylic acid
other	Anticoagulants (such as heparin and <e1> DRUG1 </e1> ) and drugs that alter platelet function (such as acetylsalicylic acid , <e2> DRUG2 </e2> , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 	vitamin K antagonists	dipyridamole
effect	Anticoagulants (such as heparin and <e1> DRUG1 </e1> ) and drugs that alter platelet function (such as acetylsalicylic acid , dipyridamole , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to , during , or after <e2> DRUG2 </e2> therapy . 	vitamin K antagonists	TNKase
effect	Anticoagulants (such as heparin and vitamin K antagonists ) and drugs that alter platelet function (such as <e1> DRUG1 </e1> , dipyridamole , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to , during , or after <e2> DRUG2 </e2> therapy . 	acetylsalicylic acid	TNKase
effect	Anticoagulants (such as heparin and vitamin K antagonists ) and drugs that alter platelet function (such as acetylsalicylic acid , <e1> DRUG1 </e1> , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to , during , or after <e2> DRUG2 </e2> therapy . 	dipyridamole	TNKase
other	In a study in which 34 different drugs were tested , therapeutically relevant concentrations of <e1> DRUG1 </e1> , sodium salicylate and <e2> DRUG2 </e2> displaced protein-bound teniposide in fresh human serum to a small but significant extent . 	tolbutamide	sulfamethizole
mechanism	In a study in which 34 different drugs were tested , therapeutically relevant concentrations of <e1> DRUG1 </e1> , sodium salicylate and sulfamethizole displaced protein-bound <e2> DRUG2 </e2> in fresh human serum to a small but significant extent . 	tolbutamide	teniposide
other	In a study in which 34 different drugs were tested , therapeutically relevant concentrations of tolbutamide , <e1> DRUG1 </e1> and <e2> DRUG2 </e2> displaced protein-bound teniposide in fresh human serum to a small but significant extent . 	sodium salicylate	sulfamethizole
mechanism	In a study in which 34 different drugs were tested , therapeutically relevant concentrations of tolbutamide , <e1> DRUG1 </e1> and sulfamethizole displaced protein-bound <e2> DRUG2 </e2> in fresh human serum to a small but significant extent . 	sodium salicylate	teniposide
mechanism	In a study in which 34 different drugs were tested , therapeutically relevant concentrations of tolbutamide , sodium salicylate and <e1> DRUG1 </e1> displaced protein-bound <e2> DRUG2 </e2> in fresh human serum to a small but significant extent . 	sulfamethizole	teniposide
other	There was no change in the plasma kinetics of <e1> DRUG1 </e1> when coadministered with <e2> DRUG2 </e2> . 	teniposide	methotrexate
mechanism	An increase in intracellular levels of <e1> DRUG1 </e1> was observed in vitro in the presence of <e2> DRUG2 </e2> . 	methotrexate	teniposide
other	In vitro studies with human liver microsomes showed that <e1> DRUG1 </e1> does not inhibit the metabolism of <e2> DRUG2 </e2> , ethinylestradiol , ethoxycoumarin , and cyclosporine . 	terbinafine	tolbutamide
other	In vitro studies with human liver microsomes showed that <e1> DRUG1 </e1> does not inhibit the metabolism of tolbutamide , <e2> DRUG2 </e2> , ethoxycoumarin , and cyclosporine . 	terbinafine	ethinylestradiol
other	In vitro studies with human liver microsomes showed that <e1> DRUG1 </e1> does not inhibit the metabolism of tolbutamide , ethinylestradiol , <e2> DRUG2 </e2> , and cyclosporine . 	terbinafine	ethoxycoumarin
other	In vitro studies with human liver microsomes showed that <e1> DRUG1 </e1> does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and <e2> DRUG2 </e2> . 	terbinafine	cyclosporine
other	In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of <e1> DRUG1 </e1> , ethinylestradiol , <e2> DRUG2 </e2> , and cyclosporine . 	tolbutamide	ethoxycoumarin
other	In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of <e1> DRUG1 </e1> , ethinylestradiol , ethoxycoumarin , and <e2> DRUG2 </e2> . 	tolbutamide	cyclosporine
other	In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , <e1> DRUG1 </e1> , ethoxycoumarin , and <e2> DRUG2 </e2> . 	ethinylestradiol	cyclosporine
other	In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> . 	ethoxycoumarin	cyclosporine
other	This may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as <e1> DRUG1 </e1> ,    -blockers , <e2> DRUG2 </e2> ( SSRIs ) , and monoamine oxidase inhibitors (MAO-Is) Type B , if they have a narrow therapeutic window . 	tricyclic antidepressants	selective serotonin reuptake inhibitors
other	This may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as <e1> DRUG1 </e1> ,    -blockers , selective serotonin reuptake inhibitors ( <e2> DRUG2 </e2> ) , and monoamine oxidase inhibitors (MAO-Is) Type B , if they have a narrow therapeutic window . 	tricyclic antidepressants	SSRIs
other	This may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as <e1> DRUG1 </e1> ,    -blockers , selective serotonin reuptake inhibitors ( SSRIs ) , and <e2> DRUG2 </e2> , if they have a narrow therapeutic window . 	tricyclic antidepressants	monoamine oxidase inhibitors (MAO-Is) Type B
other	This may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as tricyclic antidepressants ,    -blockers , <e1> DRUG1 </e1> ( SSRIs ) , and <e2> DRUG2 </e2> , if they have a narrow therapeutic window . 	selective serotonin reuptake inhibitors	monoamine oxidase inhibitors (MAO-Is) Type B
other	This may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as tricyclic antidepressants ,    -blockers , selective serotonin reuptake inhibitors ( <e1> DRUG1 </e1> ) , and <e2> DRUG2 </e2> , if they have a narrow therapeutic window . 	SSRIs	monoamine oxidase inhibitors (MAO-Is) Type B
other	In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that <e1> DRUG1 </e1> does not affect the clearance of <e2> DRUG2 </e2> or digoxin . 	terbinafine	antipyrine
other	In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that <e1> DRUG1 </e1> does not affect the clearance of antipyrine or <e2> DRUG2 </e2> . 	terbinafine	digoxin
mechanism	<e1> DRUG1 </e1> decreases the clearance of <e2> DRUG2 </e2> by 19% . 	Terbinafine	caffeine
mechanism	<e1> DRUG1 </e1> increases the clearance of <e2> DRUG2 </e2> by 15% . 	Terbinafine	cyclosporine
effect	There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral <e1> DRUG1 </e1> and <e2> DRUG2 </e2> , however , a causal relationship between LAMISIL Tablets and these changes has not been established . 	terbinafine	warfarin
other	There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral <e1> DRUG1 </e1> and warfarin , however , a causal relationship between <e2> DRUG2 </e2> Tablets and these changes has not been established . 	terbinafine	LAMISIL
other	There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and <e1> DRUG1 </e1> , however , a causal relationship between <e2> DRUG2 </e2> Tablets and these changes has not been established . 	warfarin	LAMISIL
mechanism	<e1> DRUG1 </e1> clearance is increased 100% by <e2> DRUG2 </e2> , a CyP450 enzyme inducer , and decreased 33% by cimetidine , a CyP450 enzyme inhibitor . 	Terbinafine	rifampin
mechanism	<e1> DRUG1 </e1> clearance is increased 100% by rifampin , a CyP450 enzyme inducer , and decreased 33% by <e2> DRUG2 </e2> , a CyP450 enzyme inhibitor . 	Terbinafine	cimetidine
other	Terbinafine clearance is increased 100% by <e1> DRUG1 </e1> , a CyP450 enzyme inducer , and decreased 33% by <e2> DRUG2 </e2> , a CyP450 enzyme inhibitor . 	rifampin	cimetidine
other	<e1> DRUG1 </e1> clearance is unaffected by <e2> DRUG2 </e2> . 	Terbinafine	cyclosporine
other	There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral <e1> DRUG1 </e1> , hormone replacement therapies , <e2> DRUG2 </e2> , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 	contraceptives	hypoglycemics
other	There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral <e1> DRUG1 </e1> , hormone replacement therapies , hypoglycemics , <e2> DRUG2 </e2> , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 	contraceptives	theophyllines
other	There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral <e1> DRUG1 </e1> , hormone replacement therapies , hypoglycemics , theophyllines , <e2> DRUG2 </e2> , thiazide diuretics , beta blockers , and calcium channel blockers . 	contraceptives	phenytoins
other	There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral <e1> DRUG1 </e1> , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , <e2> DRUG2 </e2> , beta blockers , and calcium channel blockers . 	contraceptives	thiazide diuretics
other	There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral <e1> DRUG1 </e1> , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , <e2> DRUG2 </e2> , and calcium channel blockers . 	contraceptives	beta blockers
other	There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral <e1> DRUG1 </e1> , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and <e2> DRUG2 </e2> . 	contraceptives	calcium channel blockers
other	There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , <e1> DRUG1 </e1> , theophyllines , <e2> DRUG2 </e2> , thiazide diuretics , beta blockers , and calcium channel blockers . 	hypoglycemics	phenytoins
other	There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , <e1> DRUG1 </e1> , theophyllines , phenytoins , <e2> DRUG2 </e2> , beta blockers , and calcium channel blockers . 	hypoglycemics	thiazide diuretics
other	There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , <e1> DRUG1 </e1> , theophyllines , phenytoins , thiazide diuretics , <e2> DRUG2 </e2> , and calcium channel blockers . 	hypoglycemics	beta blockers
other	There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , <e1> DRUG1 </e1> , theophyllines , phenytoins , thiazide diuretics , beta blockers , and <e2> DRUG2 </e2> . 	hypoglycemics	calcium channel blockers
other	There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , <e1> DRUG1 </e1> , phenytoins , <e2> DRUG2 </e2> , beta blockers , and calcium channel blockers . 	theophyllines	thiazide diuretics
other	There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , <e1> DRUG1 </e1> , phenytoins , thiazide diuretics , <e2> DRUG2 </e2> , and calcium channel blockers . 	theophyllines	beta blockers
other	There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , <e1> DRUG1 </e1> , phenytoins , thiazide diuretics , beta blockers , and <e2> DRUG2 </e2> . 	theophyllines	calcium channel blockers
other	There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , <e1> DRUG1 </e1> , thiazide diuretics , <e2> DRUG2 </e2> , and calcium channel blockers . 	phenytoins	beta blockers
other	There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , <e1> DRUG1 </e1> , thiazide diuretics , beta blockers , and <e2> DRUG2 </e2> . 	phenytoins	calcium channel blockers
other	There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , <e1> DRUG1 </e1> , beta blockers , and <e2> DRUG2 </e2> . 	thiazide diuretics	calcium channel blockers
other	There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> . 	beta blockers	calcium channel blockers
other	<e1> DRUG1 </e1> : Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of <e2> DRUG2 </e2> demonstrate QT interval prolongation and rare serious cardiac events , e.g . 	Ketoconazole	terfenadine
effect	Ketoconazole : Spontaneous adverse reaction reports of patients taking concomitant <e1> DRUG1 </e1> with recommended doses of <e2> DRUG2 </e2> demonstrate QT interval prolongation and rare serious cardiac events , e.g . 	ketoconazole	terfenadine
mechanism	Pharmacokinetic data indicate that <e1> DRUG1 </e1> markedly inhibits the metabolism of <e2> DRUG2 </e2> , resulting in elevated plasma terfenadine levels . 	ketoconazole	terfenadine
other	Pharmacokinetic data indicate that <e1> DRUG1 </e1> markedly inhibits the metabolism of terfenadine , resulting in elevated plasma <e2> DRUG2 </e2> levels . 	ketoconazole	terfenadine
advise	Concomitant administration of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> is contraindicated . 	ketoconazole	terfenadine
other	<e1> DRUG1 </e1> : Torsades de pointes and elevated parent <e2> DRUG2 </e2> levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources . 	Itraconazole	terfenadine
other	<e1> DRUG1 </e1> : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of <e2> DRUG2 </e2> and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources . 	Itraconazole	terfenadine
other	Itraconazole : Torsades de pointes and elevated parent <e1> DRUG1 </e1> levels have been reported during concomitant use of terfenadine and <e2> DRUG2 </e2> in clinical trials of itraconazole and from foreign post-marketing sources . 	terfenadine	itraconazole
other	Itraconazole : Torsades de pointes and elevated parent <e1> DRUG1 </e1> levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of <e2> DRUG2 </e2> and from foreign post-marketing sources . 	terfenadine	itraconazole
mechanism	Itraconazole : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> in clinical trials of itraconazole and from foreign post-marketing sources . 	terfenadine	itraconazole
other	Itraconazole : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of <e1> DRUG1 </e1> and itraconazole in clinical trials of <e2> DRUG2 </e2> and from foreign post-marketing sources . 	terfenadine	itraconazole
advise	Concomitant administration of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> is contraindicated . 	itraconazole	terfenadine
other	Due to the chemical similarity of other <e1> DRUG1 </e1> (including <e2> DRUG2 </e2> , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 	azole-type antifungal agents	fluconazole
other	Due to the chemical similarity of other <e1> DRUG1 </e1> (including fluconazole , <e2> DRUG2 </e2> , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 	azole-type antifungal agents	metronidazole
other	Due to the chemical similarity of other <e1> DRUG1 </e1> (including fluconazole , metronidazole , and <e2> DRUG2 </e2> ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 	azole-type antifungal agents	miconazole
other	Due to the chemical similarity of other <e1> DRUG1 </e1> (including fluconazole , metronidazole , and miconazole ) to <e2> DRUG2 </e2> , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 	azole-type antifungal agents	ketoconazole
other	Due to the chemical similarity of other <e1> DRUG1 </e1> (including fluconazole , metronidazole , and miconazole ) to ketoconazole , and <e2> DRUG2 </e2> , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 	azole-type antifungal agents	itraconazole
advise	Due to the chemical similarity of other <e1> DRUG1 </e1> (including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with <e2> DRUG2 </e2> is not recommended pending full examination of potential interactions . 	azole-type antifungal agents	terfenadine
other	Due to the chemical similarity of other azole-type antifungal agents (including <e1> DRUG1 </e1> , metronidazole , and <e2> DRUG2 </e2> ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 	fluconazole	miconazole
other	Due to the chemical similarity of other azole-type antifungal agents (including <e1> DRUG1 </e1> , metronidazole , and miconazole ) to <e2> DRUG2 </e2> , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 	fluconazole	ketoconazole
other	Due to the chemical similarity of other azole-type antifungal agents (including <e1> DRUG1 </e1> , metronidazole , and miconazole ) to ketoconazole , and <e2> DRUG2 </e2> , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 	fluconazole	itraconazole
advise	Due to the chemical similarity of other azole-type antifungal agents (including <e1> DRUG1 </e1> , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with <e2> DRUG2 </e2> is not recommended pending full examination of potential interactions . 	fluconazole	terfenadine
other	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 	metronidazole	miconazole
other	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole , <e1> DRUG1 </e1> , and miconazole ) to <e2> DRUG2 </e2> , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 	metronidazole	ketoconazole
other	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole , <e1> DRUG1 </e1> , and miconazole ) to ketoconazole , and <e2> DRUG2 </e2> , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 	metronidazole	itraconazole
advise	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole , <e1> DRUG1 </e1> , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with <e2> DRUG2 </e2> is not recommended pending full examination of potential interactions . 	metronidazole	terfenadine
other	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole , metronidazole , and <e1> DRUG1 </e1> ) to <e2> DRUG2 </e2> , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 	miconazole	ketoconazole
other	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole , metronidazole , and <e1> DRUG1 </e1> ) to ketoconazole , and <e2> DRUG2 </e2> , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 	miconazole	itraconazole
advise	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole , metronidazole , and <e1> DRUG1 </e1> ) to ketoconazole , and itraconazole , concomitant use of these products with <e2> DRUG2 </e2> is not recommended pending full examination of potential interactions . 	miconazole	terfenadine
other	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole , metronidazole , and miconazole ) to <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 	ketoconazole	itraconazole
other	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole , metronidazole , and miconazole ) to <e1> DRUG1 </e1> , and itraconazole , concomitant use of these products with <e2> DRUG2 </e2> is not recommended pending full examination of potential interactions . 	ketoconazole	terfenadine
other	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole , metronidazole , and miconazole ) to ketoconazole , and <e1> DRUG1 </e1> , concomitant use of these products with <e2> DRUG2 </e2> is not recommended pending full examination of potential interactions . 	itraconazole	terfenadine
other	<e1> DRUG1 </e1> : Clinical drug interaction studies indicate that <e2> DRUG2 </e2> and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 	Macrolides	erythromycin
other	<e1> DRUG1 </e1> : Clinical drug interaction studies indicate that erythromycin and <e2> DRUG2 </e2> can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 	Macrolides	clarithromycin
other	<e1> DRUG1 </e1> : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on <e2> DRUG2 </e2> metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 	Macrolides	terfenadine
other	<e1> DRUG1 </e1> : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of <e2> DRUG2 </e2> , but to a lesser extent . 	Macrolides	ketoconazole
other	Macrolides : Clinical drug interaction studies indicate that <e1> DRUG1 </e1> and <e2> DRUG2 </e2> can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 	erythromycin	clarithromycin
mechanism	Macrolides : Clinical drug interaction studies indicate that <e1> DRUG1 </e1> and clarithromycin can exert an effect on <e2> DRUG2 </e2> metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 	erythromycin	terfenadine
other	Macrolides : Clinical drug interaction studies indicate that <e1> DRUG1 </e1> and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of <e2> DRUG2 </e2> , but to a lesser extent . 	erythromycin	ketoconazole
mechanism	Macrolides : Clinical drug interaction studies indicate that erythromycin and <e1> DRUG1 </e1> can exert an effect on <e2> DRUG2 </e2> metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 	clarithromycin	terfenadine
other	Macrolides : Clinical drug interaction studies indicate that erythromycin and <e1> DRUG1 </e1> can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of <e2> DRUG2 </e2> , but to a lesser extent . 	clarithromycin	ketoconazole
other	Macrolides : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on <e1> DRUG1 </e1> metabolism by a mechanism which may be similar to that of <e2> DRUG2 </e2> , but to a lesser extent . 	terfenadine	ketoconazole
advise	Concomitant administration of <e1> DRUG1 </e1> with <e2> DRUG2 </e2> , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 	terfenadine	clarithromycin
advise	Concomitant administration of <e1> DRUG1 </e1> with clarithromycin , <e2> DRUG2 </e2> , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 	terfenadine	erythromycin
advise	Concomitant administration of <e1> DRUG1 </e1> with clarithromycin , erythromycin , or <e2> DRUG2 </e2> is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 	terfenadine	troleandomycin
other	Concomitant administration of <e1> DRUG1 </e1> with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other <e2> DRUG2 </e2> , including azithromycin , is not recommended . 	terfenadine	macrolide antibiotics
other	Concomitant administration of <e1> DRUG1 </e1> with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including <e2> DRUG2 </e2> , is not recommended . 	terfenadine	azithromycin
other	Concomitant administration of terfenadine with <e1> DRUG1 </e1> , erythromycin , or <e2> DRUG2 </e2> is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 	clarithromycin	troleandomycin
other	Concomitant administration of terfenadine with <e1> DRUG1 </e1> , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of <e2> DRUG2 </e2> with other macrolide antibiotics , including azithromycin , is not recommended . 	clarithromycin	terfenadine
other	Concomitant administration of terfenadine with <e1> DRUG1 </e1> , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other <e2> DRUG2 </e2> , including azithromycin , is not recommended . 	clarithromycin	macrolide antibiotics
other	Concomitant administration of terfenadine with <e1> DRUG1 </e1> , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including <e2> DRUG2 </e2> , is not recommended . 	clarithromycin	azithromycin
other	Concomitant administration of terfenadine with clarithromycin , <e1> DRUG1 </e1> , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of <e2> DRUG2 </e2> with other macrolide antibiotics , including azithromycin , is not recommended . 	erythromycin	terfenadine
other	Concomitant administration of terfenadine with clarithromycin , <e1> DRUG1 </e1> , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other <e2> DRUG2 </e2> , including azithromycin , is not recommended . 	erythromycin	macrolide antibiotics
other	Concomitant administration of terfenadine with clarithromycin , <e1> DRUG1 </e1> , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including <e2> DRUG2 </e2> , is not recommended . 	erythromycin	azithromycin
other	Concomitant administration of terfenadine with clarithromycin , erythromycin , or <e1> DRUG1 </e1> is contraindicated : Pending full characterization of potential interactions , concomitant administration of <e2> DRUG2 </e2> with other macrolide antibiotics , including azithromycin , is not recommended . 	troleandomycin	terfenadine
other	Concomitant administration of terfenadine with clarithromycin , erythromycin , or <e1> DRUG1 </e1> is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other <e2> DRUG2 </e2> , including azithromycin , is not recommended . 	troleandomycin	macrolide antibiotics
other	Concomitant administration of terfenadine with clarithromycin , erythromycin , or <e1> DRUG1 </e1> is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including <e2> DRUG2 </e2> , is not recommended . 	troleandomycin	azithromycin
advise	Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of <e1> DRUG1 </e1> with other <e2> DRUG2 </e2> , including azithromycin , is not recommended . 	terfenadine	macrolide antibiotics
advise	Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of <e1> DRUG1 </e1> with other macrolide antibiotics , including <e2> DRUG2 </e2> , is not recommended . 	terfenadine	azithromycin
other	Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other <e1> DRUG1 </e1> , including <e2> DRUG2 </e2> , is not recommended . 	macrolide antibiotics	azithromycin
other	Studies to evaluate potential interactions of <e1> DRUG1 </e1> with <e2> DRUG2 </e2> are in progress . 	terfenadine	azithromycin
effect	When administered concurrently , <e1> DRUG1 </e1> may increase the effects of oral <e2> DRUG2 </e2> ; 	testolactone	anticoagulants
effect	<e1> DRUG1 </e1> has been reported to enhance the sedative activity of <e2> DRUG2 </e2> , alcohol , chlorpromazine , and reserpine . 	Thalidomide	barbiturates
other	<e1> DRUG1 </e1> has been reported to enhance the sedative activity of barbiturates , <e2> DRUG2 </e2> , chlorpromazine , and reserpine . 	Thalidomide	alcohol
other	<e1> DRUG1 </e1> has been reported to enhance the sedative activity of barbiturates , alcohol , <e2> DRUG2 </e2> , and reserpine . 	Thalidomide	chlorpromazine
other	<e1> DRUG1 </e1> has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and <e2> DRUG2 </e2> . 	Thalidomide	reserpine
other	Thalidomide has been reported to enhance the sedative activity of <e1> DRUG1 </e1> , alcohol , <e2> DRUG2 </e2> , and reserpine . 	barbiturates	chlorpromazine
other	Thalidomide has been reported to enhance the sedative activity of <e1> DRUG1 </e1> , alcohol , chlorpromazine , and <e2> DRUG2 </e2> . 	barbiturates	reserpine
other	Thalidomide has been reported to enhance the sedative activity of barbiturates , <e1> DRUG1 </e1> , chlorpromazine , and <e2> DRUG2 </e2> . 	alcohol	reserpine
other	Thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> . 	chlorpromazine	reserpine
other	Oral <e1> DRUG1 </e1> : In 10 healthy women , the pharmacokinetic profiles of <e2> DRUG2 </e2> and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied . 	Contraceptives	norethindrone
other	Oral <e1> DRUG1 </e1> : In 10 healthy women , the pharmacokinetic profiles of norethindrone and <e2> DRUG2 </e2> following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied . 	Contraceptives	ethinyl estradiol
other	Oral <e1> DRUG1 </e1> : In 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of <e2> DRUG2 </e2> and 75    g of ethinyl estradiol were studied . 	Contraceptives	norethindrone acetate
other	Oral <e1> DRUG1 </e1> : In 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of <e2> DRUG2 </e2> were studied . 	Contraceptives	ethinyl estradiol
other	Oral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied . 	norethindrone	ethinyl estradiol
other	Oral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of <e1> DRUG1 </e1> and ethinyl estradiol following administration of a single dose containing 1.0 mg of <e2> DRUG2 </e2> and 75    g of ethinyl estradiol were studied . 	norethindrone	norethindrone acetate
other	Oral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of <e1> DRUG1 </e1> and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of <e2> DRUG2 </e2> were studied . 	norethindrone	ethinyl estradiol
other	Oral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of norethindrone and <e1> DRUG1 </e1> following administration of a single dose containing 1.0 mg of <e2> DRUG2 </e2> and 75    g of ethinyl estradiol were studied . 	ethinyl estradiol	norethindrone acetate
other	Oral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of <e1> DRUG1 </e1> and 75    g of <e2> DRUG2 </e2> were studied . 	norethindrone acetate	ethinyl estradiol
other	Important Non- <e1> DRUG1 </e1> Drug Interactions Drugs That Interfere with <e2> DRUG2 </e2> : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 	Thalidomide	Hormonal Contraceptives
other	Important Non- <e1> DRUG1 </e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of <e2> DRUG2 </e2> , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 	Thalidomide	HIV-protease inhibitors
other	Important Non- <e1> DRUG1 </e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , <e2> DRUG2 </e2> , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 	Thalidomide	griseofulvin
other	Important Non- <e1> DRUG1 </e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , <e2> DRUG2 </e2> , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 	Thalidomide	modafinil
other	Important Non- <e1> DRUG1 </e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , <e2> DRUG2 </e2> , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 	Thalidomide	penicillins
other	Important Non- <e1> DRUG1 </e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , <e2> DRUG2 </e2> , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 	Thalidomide	rifampin
other	Important Non- <e1> DRUG1 </e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , <e2> DRUG2 </e2> , phenytoin , carbamazepine , or certain herbal supplements such as St . 	Thalidomide	rifabutin
other	Important Non- <e1> DRUG1 </e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , <e2> DRUG2 </e2> , carbamazepine , or certain herbal supplements such as St . 	Thalidomide	phenytoin
other	Important Non- <e1> DRUG1 </e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , <e2> DRUG2 </e2> , or certain herbal supplements such as St . 	Thalidomide	carbamazepine
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with <e1> DRUG1 </e1> : Concomitant use of <e2> DRUG2 </e2> , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 	Hormonal Contraceptives	HIV-protease inhibitors
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with <e1> DRUG1 </e1> : Concomitant use of HIV-protease inhibitors , <e2> DRUG2 </e2> , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 	Hormonal Contraceptives	griseofulvin
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with <e1> DRUG1 </e1> : Concomitant use of HIV-protease inhibitors , griseofulvin , <e2> DRUG2 </e2> , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 	Hormonal Contraceptives	modafinil
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with <e1> DRUG1 </e1> : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , <e2> DRUG2 </e2> , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 	Hormonal Contraceptives	penicillins
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with <e1> DRUG1 </e1> : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , <e2> DRUG2 </e2> , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 	Hormonal Contraceptives	rifampin
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with <e1> DRUG1 </e1> : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , <e2> DRUG2 </e2> , phenytoin , carbamazepine , or certain herbal supplements such as St . 	Hormonal Contraceptives	rifabutin
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with <e1> DRUG1 </e1> : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , <e2> DRUG2 </e2> , carbamazepine , or certain herbal supplements such as St . 	Hormonal Contraceptives	phenytoin
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with <e1> DRUG1 </e1> : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , <e2> DRUG2 </e2> , or certain herbal supplements such as St . 	Hormonal Contraceptives	carbamazepine
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of <e1> DRUG1 </e1> , griseofulvin , <e2> DRUG2 </e2> , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 	HIV-protease inhibitors	modafinil
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of <e1> DRUG1 </e1> , griseofulvin , modafinil , <e2> DRUG2 </e2> , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 	HIV-protease inhibitors	penicillins
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of <e1> DRUG1 </e1> , griseofulvin , modafinil , penicillins , <e2> DRUG2 </e2> , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 	HIV-protease inhibitors	rifampin
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of <e1> DRUG1 </e1> , griseofulvin , modafinil , penicillins , rifampin , <e2> DRUG2 </e2> , phenytoin , carbamazepine , or certain herbal supplements such as St . 	HIV-protease inhibitors	rifabutin
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of <e1> DRUG1 </e1> , griseofulvin , modafinil , penicillins , rifampin , rifabutin , <e2> DRUG2 </e2> , carbamazepine , or certain herbal supplements such as St . 	HIV-protease inhibitors	phenytoin
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of <e1> DRUG1 </e1> , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , <e2> DRUG2 </e2> , or certain herbal supplements such as St . 	HIV-protease inhibitors	carbamazepine
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , <e1> DRUG1 </e1> , modafinil , <e2> DRUG2 </e2> , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 	griseofulvin	penicillins
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , <e1> DRUG1 </e1> , modafinil , penicillins , <e2> DRUG2 </e2> , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 	griseofulvin	rifampin
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , <e1> DRUG1 </e1> , modafinil , penicillins , rifampin , <e2> DRUG2 </e2> , phenytoin , carbamazepine , or certain herbal supplements such as St . 	griseofulvin	rifabutin
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , <e1> DRUG1 </e1> , modafinil , penicillins , rifampin , rifabutin , <e2> DRUG2 </e2> , carbamazepine , or certain herbal supplements such as St . 	griseofulvin	phenytoin
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , <e1> DRUG1 </e1> , modafinil , penicillins , rifampin , rifabutin , phenytoin , <e2> DRUG2 </e2> , or certain herbal supplements such as St . 	griseofulvin	carbamazepine
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , <e1> DRUG1 </e1> , penicillins , <e2> DRUG2 </e2> , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 	modafinil	rifampin
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , <e1> DRUG1 </e1> , penicillins , rifampin , <e2> DRUG2 </e2> , phenytoin , carbamazepine , or certain herbal supplements such as St . 	modafinil	rifabutin
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , <e1> DRUG1 </e1> , penicillins , rifampin , rifabutin , <e2> DRUG2 </e2> , carbamazepine , or certain herbal supplements such as St . 	modafinil	phenytoin
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , <e1> DRUG1 </e1> , penicillins , rifampin , rifabutin , phenytoin , <e2> DRUG2 </e2> , or certain herbal supplements such as St . 	modafinil	carbamazepine
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , <e1> DRUG1 </e1> , rifampin , <e2> DRUG2 </e2> , phenytoin , carbamazepine , or certain herbal supplements such as St . 	penicillins	rifabutin
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , <e1> DRUG1 </e1> , rifampin , rifabutin , <e2> DRUG2 </e2> , carbamazepine , or certain herbal supplements such as St . 	penicillins	phenytoin
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , <e1> DRUG1 </e1> , rifampin , rifabutin , phenytoin , <e2> DRUG2 </e2> , or certain herbal supplements such as St . 	penicillins	carbamazepine
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , <e1> DRUG1 </e1> , rifabutin , <e2> DRUG2 </e2> , carbamazepine , or certain herbal supplements such as St . 	rifampin	phenytoin
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , <e1> DRUG1 </e1> , rifabutin , phenytoin , <e2> DRUG2 </e2> , or certain herbal supplements such as St . 	rifampin	carbamazepine
other	Important Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , <e1> DRUG1 </e1> , phenytoin , <e2> DRUG2 </e2> , or certain herbal supplements such as St . 	rifabutin	carbamazepine
effect	<e1> DRUG1 </e1> with <e2> DRUG2 </e2> may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies . 	John's Wort	hormonal contraceptive agents
mechanism	<e1> DRUG1 </e1> may compete with other drugs , such as <e2> DRUG2 </e2> , for sites of metabolism in the liver , thus elevating the serum levels of such compounds to potentially toxic levels . 	Thiabendazole	theophylline
advise	Therefore , when concomitant use of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> is anticipated , it may be necessary to monitor blood levels and/or reduce the dosage of such compounds . 	thiabendazole	xanthine derivatives
int	Interactions for <e1> DRUG1 </e1> ( Thiamine ) : <e2> DRUG2 </e2> , Oral Contraceptives , Stavudine , Tricyclic Antidepressants 	Vitamin B1	Loop Diuretics
int	Interactions for <e1> DRUG1 </e1> ( Thiamine ) : Loop Diuretics , Oral <e2> DRUG2 </e2> , Stavudine , Tricyclic Antidepressants 	Vitamin B1	Contraceptives
int	Interactions for <e1> DRUG1 </e1> ( Thiamine ) : Loop Diuretics , Oral Contraceptives , <e2> DRUG2 </e2> , Tricyclic Antidepressants 	Vitamin B1	Stavudine
int	Interactions for <e1> DRUG1 </e1> ( Thiamine ) : Loop Diuretics , Oral Contraceptives , Stavudine , <e2> DRUG2 </e2> 	Vitamin B1	Tricyclic Antidepressants
int	Interactions for Vitamin B1 ( <e1> DRUG1 </e1> ) : <e2> DRUG2 </e2> , Oral Contraceptives , Stavudine , Tricyclic Antidepressants 	Thiamine	Loop Diuretics
int	Interactions for Vitamin B1 ( <e1> DRUG1 </e1> ) : Loop Diuretics , Oral <e2> DRUG2 </e2> , Stavudine , Tricyclic Antidepressants 	Thiamine	Contraceptives
int	Interactions for Vitamin B1 ( <e1> DRUG1 </e1> ) : Loop Diuretics , Oral Contraceptives , <e2> DRUG2 </e2> , Tricyclic Antidepressants 	Thiamine	Stavudine
int	Interactions for Vitamin B1 ( <e1> DRUG1 </e1> ) : Loop Diuretics , Oral Contraceptives , Stavudine , <e2> DRUG2 </e2> 	Thiamine	Tricyclic Antidepressants
other	Interactions for Vitamin B1 ( Thiamine ) : <e1> DRUG1 </e1> , Oral <e2> DRUG2 </e2> , Stavudine , Tricyclic Antidepressants 	Loop Diuretics	Contraceptives
other	Interactions for Vitamin B1 ( Thiamine ) : <e1> DRUG1 </e1> , Oral Contraceptives , <e2> DRUG2 </e2> , Tricyclic Antidepressants 	Loop Diuretics	Stavudine
other	Interactions for Vitamin B1 ( Thiamine ) : <e1> DRUG1 </e1> , Oral Contraceptives , Stavudine , <e2> DRUG2 </e2> 	Loop Diuretics	Tricyclic Antidepressants
other	Interactions for Vitamin B1 ( Thiamine ) : Loop Diuretics , Oral <e1> DRUG1 </e1> , Stavudine , <e2> DRUG2 </e2> 	Contraceptives	Tricyclic Antidepressants
effect	<e1> DRUG1 </e1> are capable of potentiating <e2> DRUG2 </e2> (e.g. , barbiturates , anesthetics , opiates , alcohol , etc.) 	Phenothiazines	CNS depressants
effect	<e1> DRUG1 </e1> are capable of potentiating CNS depressants (e.g. , <e2> DRUG2 </e2> , anesthetics , opiates , alcohol , etc.) 	Phenothiazines	barbiturates
effect	<e1> DRUG1 </e1> are capable of potentiating CNS depressants (e.g. , barbiturates , <e2> DRUG2 </e2> , opiates , alcohol , etc.) 	Phenothiazines	anesthetics
effect	<e1> DRUG1 </e1> are capable of potentiating CNS depressants (e.g. , barbiturates , anesthetics , <e2> DRUG2 </e2> , alcohol , etc.) 	Phenothiazines	opiates
effect	<e1> DRUG1 </e1> are capable of potentiating CNS depressants (e.g. , barbiturates , anesthetics , opiates , <e2> DRUG2 </e2> , etc.) 	Phenothiazines	alcohol
other	Phenothiazines are capable of potentiating <e1> DRUG1 </e1> (e.g. , <e2> DRUG2 </e2> , anesthetics , opiates , alcohol , etc.) 	CNS depressants	barbiturates
other	Phenothiazines are capable of potentiating <e1> DRUG1 </e1> (e.g. , barbiturates , <e2> DRUG2 </e2> , opiates , alcohol , etc.) 	CNS depressants	anesthetics
other	Phenothiazines are capable of potentiating <e1> DRUG1 </e1> (e.g. , barbiturates , anesthetics , <e2> DRUG2 </e2> , alcohol , etc.) 	CNS depressants	opiates
other	Phenothiazines are capable of potentiating <e1> DRUG1 </e1> (e.g. , barbiturates , anesthetics , opiates , <e2> DRUG2 </e2> , etc.) 	CNS depressants	alcohol
other	Phenothiazines are capable of potentiating CNS depressants (e.g. , <e1> DRUG1 </e1> , anesthetics , <e2> DRUG2 </e2> , alcohol , etc.) 	barbiturates	opiates
other	Phenothiazines are capable of potentiating CNS depressants (e.g. , <e1> DRUG1 </e1> , anesthetics , opiates , <e2> DRUG2 </e2> , etc.) 	barbiturates	alcohol
other	Phenothiazines are capable of potentiating CNS depressants (e.g. , barbiturates , <e1> DRUG1 </e1> , opiates , <e2> DRUG2 </e2> , etc.) 	anesthetics	alcohol
other	as well as <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	atropine	phosphorous insecticides
effect	There is usually complete cross-resistance between <e1> DRUG1 </e1> ( mercaptopurine ) and <e2> DRUG2 </e2> brand Thioguanine . 	PURINETHOL	TABLOID
effect	There is usually complete cross-resistance between <e1> DRUG1 </e1> ( mercaptopurine ) and TABLOID brand <e2> DRUG2 </e2> . 	PURINETHOL	Thioguanine
effect	There is usually complete cross-resistance between PURINETHOL ( <e1> DRUG1 </e1> ) and <e2> DRUG2 </e2> brand Thioguanine . 	mercaptopurine	TABLOID
effect	There is usually complete cross-resistance between PURINETHOL ( <e1> DRUG1 </e1> ) and TABLOID brand <e2> DRUG2 </e2> . 	mercaptopurine	Thioguanine
other	There is usually complete cross-resistance between PURINETHOL ( mercaptopurine ) and <e1> DRUG1 </e1> brand <e2> DRUG2 </e2> . 	TABLOID	Thioguanine
other	As there is in vitro evidence that <e1> DRUG1 </e1> (e.g. , <e2> DRUG2 </e2> , mesalazine , or sulphasalazine ) inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy . 	aminosalicylate derivatives	olsalazine
other	As there is in vitro evidence that <e1> DRUG1 </e1> (e.g. , olsalazine , <e2> DRUG2 </e2> , or sulphasalazine ) inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy . 	aminosalicylate derivatives	mesalazine
other	As there is in vitro evidence that <e1> DRUG1 </e1> (e.g. , olsalazine , mesalazine , or <e2> DRUG2 </e2> ) inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy . 	aminosalicylate derivatives	sulphasalazine
mechanism	As there is in vitro evidence that <e1> DRUG1 </e1> (e.g. , olsalazine , mesalazine , or sulphasalazine ) inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent <e2> DRUG2 </e2> therapy . 	aminosalicylate derivatives	thioguanine
other	As there is in vitro evidence that aminosalicylate derivatives (e.g. , <e1> DRUG1 </e1> , mesalazine , or <e2> DRUG2 </e2> ) inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy . 	olsalazine	sulphasalazine
mechanism	As there is in vitro evidence that aminosalicylate derivatives (e.g. , <e1> DRUG1 </e1> , mesalazine , or sulphasalazine ) inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent <e2> DRUG2 </e2> therapy . 	olsalazine	thioguanine
mechanism	As there is in vitro evidence that aminosalicylate derivatives (e.g. , olsalazine , <e1> DRUG1 </e1> , or sulphasalazine ) inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent <e2> DRUG2 </e2> therapy . 	mesalazine	thioguanine
mechanism	As there is in vitro evidence that aminosalicylate derivatives (e.g. , olsalazine , mesalazine , or <e1> DRUG1 </e1> ) inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent <e2> DRUG2 </e2> therapy . 	sulphasalazine	thioguanine
advise	Caution should be exercised when administering <e1> DRUG1 </e1> therapy in combination with other <e2> DRUG2 </e2> . 	ZADAXIN	immunomodulating drugs
advise	Prothrombin time or other suitable anticoagulation test should be monitored if <e1> DRUG1 </e1> is administered with <e2> DRUG2 </e2> . 	tigecycline	warfarin
effect	Concurrent use of <e1> DRUG1 </e1> with oral <e2> DRUG2 </e2> may render oral contraceptives less effective . 	antibacterial drugs	contraceptives
other	Concurrent use of <e1> DRUG1 </e1> with oral contraceptives may render oral <e2> DRUG2 </e2> less effective . 	antibacterial drugs	contraceptives
mechanism	The bioavailability of <e1> DRUG1 </e1> is decreased 80% by <e2> DRUG2 </e2> , when calcium and SKELID are administered at the same time , and 60% by some aluminum - or magnesium -containing antacids , when administered 1 hour before SKELID . 	SKELID	calcium
other	The bioavailability of <e1> DRUG1 </e1> is decreased 80% by calcium , when <e2> DRUG2 </e2> and SKELID are administered at the same time , and 60% by some aluminum - or magnesium -containing antacids , when administered 1 hour before SKELID . 	SKELID	calcium
other	The bioavailability of <e1> DRUG1 </e1> is decreased 80% by calcium , when calcium and SKELID are administered at the same time , and 60% by some <e2> DRUG2 </e2> - or magnesium -containing antacids , when administered 1 hour before SKELID . 	SKELID	aluminum
other	The bioavailability of <e1> DRUG1 </e1> is decreased 80% by calcium , when calcium and SKELID are administered at the same time , and 60% by some aluminum - or <e2> DRUG2 </e2> -containing antacids , when administered 1 hour before SKELID . 	SKELID	magnesium
other	The bioavailability of <e1> DRUG1 </e1> is decreased 80% by calcium , when calcium and SKELID are administered at the same time , and 60% by some aluminum - or magnesium -containing <e2> DRUG2 </e2> , when administered 1 hour before SKELID . 	SKELID	antacids
other	The bioavailability of SKELID is decreased 80% by <e1> DRUG1 </e1> , when calcium and <e2> DRUG2 </e2> are administered at the same time , and 60% by some aluminum - or magnesium -containing antacids , when administered 1 hour before SKELID . 	calcium	SKELID
other	The bioavailability of SKELID is decreased 80% by <e1> DRUG1 </e1> , when calcium and SKELID are administered at the same time , and 60% by some <e2> DRUG2 </e2> - or magnesium -containing antacids , when administered 1 hour before SKELID . 	calcium	aluminum
other	The bioavailability of SKELID is decreased 80% by <e1> DRUG1 </e1> , when calcium and SKELID are administered at the same time , and 60% by some aluminum - or <e2> DRUG2 </e2> -containing antacids , when administered 1 hour before SKELID . 	calcium	magnesium
other	The bioavailability of SKELID is decreased 80% by <e1> DRUG1 </e1> , when calcium and SKELID are administered at the same time , and 60% by some aluminum - or magnesium -containing <e2> DRUG2 </e2> , when administered 1 hour before SKELID . 	calcium	antacids
other	The bioavailability of SKELID is decreased 80% by <e1> DRUG1 </e1> , when calcium and SKELID are administered at the same time , and 60% by some aluminum - or magnesium -containing antacids , when administered 1 hour before <e2> DRUG2 </e2> . 	calcium	SKELID
other	The bioavailability of SKELID is decreased 80% by calcium , when <e1> DRUG1 </e1> and <e2> DRUG2 </e2> are administered at the same time , and 60% by some aluminum - or magnesium -containing antacids , when administered 1 hour before SKELID . 	calcium	SKELID
other	The bioavailability of SKELID is decreased 80% by calcium , when <e1> DRUG1 </e1> and SKELID are administered at the same time , and 60% by some <e2> DRUG2 </e2> - or magnesium -containing antacids , when administered 1 hour before SKELID . 	calcium	aluminum
other	The bioavailability of SKELID is decreased 80% by calcium , when <e1> DRUG1 </e1> and SKELID are administered at the same time , and 60% by some aluminum - or <e2> DRUG2 </e2> -containing antacids , when administered 1 hour before SKELID . 	calcium	magnesium
other	The bioavailability of SKELID is decreased 80% by calcium , when <e1> DRUG1 </e1> and SKELID are administered at the same time , and 60% by some aluminum - or magnesium -containing <e2> DRUG2 </e2> , when administered 1 hour before SKELID . 	calcium	antacids
other	The bioavailability of SKELID is decreased 80% by calcium , when <e1> DRUG1 </e1> and SKELID are administered at the same time , and 60% by some aluminum - or magnesium -containing antacids , when administered 1 hour before <e2> DRUG2 </e2> . 	calcium	SKELID
other	The bioavailability of SKELID is decreased 80% by calcium , when calcium and <e1> DRUG1 </e1> are administered at the same time , and 60% by some <e2> DRUG2 </e2> - or magnesium -containing antacids , when administered 1 hour before SKELID . 	SKELID	aluminum
other	The bioavailability of SKELID is decreased 80% by calcium , when calcium and <e1> DRUG1 </e1> are administered at the same time , and 60% by some aluminum - or <e2> DRUG2 </e2> -containing antacids , when administered 1 hour before SKELID . 	SKELID	magnesium
other	The bioavailability of SKELID is decreased 80% by calcium , when calcium and <e1> DRUG1 </e1> are administered at the same time , and 60% by some aluminum - or magnesium -containing <e2> DRUG2 </e2> , when administered 1 hour before SKELID . 	SKELID	antacids
other	The bioavailability of SKELID is decreased 80% by calcium , when calcium and SKELID are administered at the same time , and 60% by some <e1> DRUG1 </e1> - or <e2> DRUG2 </e2> -containing antacids , when administered 1 hour before SKELID . 	aluminum	magnesium
other	The bioavailability of SKELID is decreased 80% by calcium , when calcium and SKELID are administered at the same time , and 60% by some <e1> DRUG1 </e1> - or magnesium -containing <e2> DRUG2 </e2> , when administered 1 hour before SKELID . 	aluminum	antacids
mechanism	The bioavailability of SKELID is decreased 80% by calcium , when calcium and SKELID are administered at the same time , and 60% by some <e1> DRUG1 </e1> - or magnesium -containing antacids , when administered 1 hour before <e2> DRUG2 </e2> . 	aluminum	SKELID
other	The bioavailability of SKELID is decreased 80% by calcium , when calcium and SKELID are administered at the same time , and 60% by some aluminum - or <e1> DRUG1 </e1> -containing <e2> DRUG2 </e2> , when administered 1 hour before SKELID . 	magnesium	antacids
mechanism	The bioavailability of SKELID is decreased 80% by calcium , when calcium and SKELID are administered at the same time , and 60% by some aluminum - or <e1> DRUG1 </e1> -containing antacids , when administered 1 hour before <e2> DRUG2 </e2> . 	magnesium	SKELID
other	The bioavailability of SKELID is decreased 80% by calcium , when calcium and SKELID are administered at the same time , and 60% by some aluminum - or magnesium -containing <e1> DRUG1 </e1> , when administered 1 hour before <e2> DRUG2 </e2> . 	antacids	SKELID
mechanism	<e1> DRUG1 </e1> may decrease bioavailability of <e2> DRUG2 </e2> by up to 50% when taken 2 hours after SKELID . 	Aspirin	SKELID
other	<e1> DRUG1 </e1> may decrease bioavailability of SKELID by up to 50% when taken 2 hours after <e2> DRUG2 </e2> . 	Aspirin	SKELID
mechanism	The bioavailability of <e1> DRUG1 </e1> is increased 2-4 fold by <e2> DRUG2 </e2> but is not significantly altered by coadministration of diclofenac . 	SKELID	indomethacin
other	The bioavailability of <e1> DRUG1 </e1> is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of <e2> DRUG2 </e2> . 	SKELID	diclofenac
other	The bioavailability of SKELID is increased 2-4 fold by <e1> DRUG1 </e1> but is not significantly altered by coadministration of <e2> DRUG2 </e2> . 	indomethacin	diclofenac
other	The pharmacokinetic parameters of <e1> DRUG1 </e1> are not significantly modified by <e2> DRUG2 </e2> coadministration . 	digoxin	SKELID
other	In vitro studies show that <e1> DRUG1 </e1> does not displace <e2> DRUG2 </e2> from its binding site on protein . 	tiludronate	warfarin
other	These include <e1> DRUG1 </e1> , methylxanthines , and oral and inhaled <e2> DRUG2 </e2> . 	sympathomimetic bronchodilators	steroids
other	These include sympathomimetic bronchodilators , <e1> DRUG1 </e1> , and oral and inhaled <e2> DRUG2 </e2> . 	methylxanthines	steroids
advise	However , the co   administration of <e1> DRUG1 </e1> with other <e2> DRUG2 </e2> containing drugs (e.g. , ipratropium ) has not been studied and is therefore not recommended . 	SPIRIVA	anticholinergic
advise	However , the co   administration of <e1> DRUG1 </e1> with other anticholinergic containing drugs (e.g. , <e2> DRUG2 </e2> ) has not been studied and is therefore not recommended . 	SPIRIVA	ipratropium
other	However , the co   administration of SPIRIVA with other <e1> DRUG1 </e1> containing drugs (e.g. , <e2> DRUG2 </e2> ) has not been studied and is therefore not recommended . 	anticholinergic	ipratropium
other	<e1> DRUG1 </e1> has been studied on a background of <e2> DRUG2 </e2> and heparin . 	AGGRASTAT	aspirin
other	<e1> DRUG1 </e1> has been studied on a background of aspirin and <e2> DRUG2 </e2> . 	AGGRASTAT	heparin
other	AGGRASTAT has been studied on a background of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	aspirin	heparin
effect	The use of <e1> DRUG1 </e1> , in combination with <e2> DRUG2 </e2> and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone (see 	AGGRASTAT	heparin
effect	The use of <e1> DRUG1 </e1> , in combination with heparin and <e2> DRUG2 </e2> , has been associated with an increase in bleeding compared to heparin and aspirin alone (see 	AGGRASTAT	aspirin
other	The use of <e1> DRUG1 </e1> , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to <e2> DRUG2 </e2> and aspirin alone (see 	AGGRASTAT	heparin
other	The use of <e1> DRUG1 </e1> , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and <e2> DRUG2 </e2> alone (see 	AGGRASTAT	aspirin
other	The use of AGGRASTAT , in combination with <e1> DRUG1 </e1> and <e2> DRUG2 </e2> , has been associated with an increase in bleeding compared to heparin and aspirin alone (see 	heparin	aspirin
other	The use of AGGRASTAT , in combination with <e1> DRUG1 </e1> and aspirin , has been associated with an increase in bleeding compared to heparin and <e2> DRUG2 </e2> alone (see 	heparin	aspirin
other	The use of AGGRASTAT , in combination with heparin and <e1> DRUG1 </e1> , has been associated with an increase in bleeding compared to <e2> DRUG2 </e2> and aspirin alone (see 	aspirin	heparin
other	The use of AGGRASTAT , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to <e1> DRUG1 </e1> and <e2> DRUG2 </e2> alone (see 	heparin	aspirin
other	In clinical studies of <e1> DRUG1 </e1> , patients taking TOBI concomitantly with <e2> DRUG2 </e2> ( PULMOZYME , Genentech) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 	TOBI	dornase alfa
other	In clinical studies of <e1> DRUG1 </e1> , patients taking TOBI concomitantly with dornase alfa ( <e2> DRUG2 </e2> , Genentech) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 	TOBI	PULMOZYME
other	In clinical studies of <e1> DRUG1 </e1> , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech) , <e2> DRUG2 </e2> , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 	TOBI	(beta)-agonists
other	In clinical studies of <e1> DRUG1 </e1> , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech) , (beta)-agonists , inhaled <e2> DRUG2 </e2> , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 	TOBI	corticosteroids
other	In clinical studies of <e1> DRUG1 </e1> , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech) , (beta)-agonists , inhaled corticosteroids , other <e2> DRUG2 </e2> , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 	TOBI	anti-pseudomonal antibiotics
other	In clinical studies of <e1> DRUG1 </e1> , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral <e2> DRUG2 </e2> demonstrated adverse experience profiles similar to the study population as a whole . 	TOBI	aminoglycosides
effect	In clinical studies of TOBI , patients taking <e1> DRUG1 </e1> concomitantly with <e2> DRUG2 </e2> ( PULMOZYME , Genentech) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 	TOBI	dornase alfa
effect	In clinical studies of TOBI , patients taking <e1> DRUG1 </e1> concomitantly with dornase alfa ( <e2> DRUG2 </e2> , Genentech) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 	TOBI	PULMOZYME
effect	In clinical studies of TOBI , patients taking <e1> DRUG1 </e1> concomitantly with dornase alfa ( PULMOZYME , Genentech) , <e2> DRUG2 </e2> , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 	TOBI	(beta)-agonists
effect	In clinical studies of TOBI , patients taking <e1> DRUG1 </e1> concomitantly with dornase alfa ( PULMOZYME , Genentech) , (beta)-agonists , inhaled <e2> DRUG2 </e2> , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 	TOBI	corticosteroids
effect	In clinical studies of TOBI , patients taking <e1> DRUG1 </e1> concomitantly with dornase alfa ( PULMOZYME , Genentech) , (beta)-agonists , inhaled corticosteroids , other <e2> DRUG2 </e2> , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 	TOBI	anti-pseudomonal antibiotics
effect	In clinical studies of TOBI , patients taking <e1> DRUG1 </e1> concomitantly with dornase alfa ( PULMOZYME , Genentech) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral <e2> DRUG2 </e2> demonstrated adverse experience profiles similar to the study population as a whole . 	TOBI	aminoglycosides
other	In clinical studies of TOBI , patients taking TOBI concomitantly with <e1> DRUG1 </e1> ( PULMOZYME , Genentech) , <e2> DRUG2 </e2> , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 	dornase alfa	(beta)-agonists
other	In clinical studies of TOBI , patients taking TOBI concomitantly with <e1> DRUG1 </e1> ( PULMOZYME , Genentech) , (beta)-agonists , inhaled <e2> DRUG2 </e2> , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 	dornase alfa	corticosteroids
other	In clinical studies of TOBI , patients taking TOBI concomitantly with <e1> DRUG1 </e1> ( PULMOZYME , Genentech) , (beta)-agonists , inhaled corticosteroids , other <e2> DRUG2 </e2> , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 	dornase alfa	anti-pseudomonal antibiotics
other	In clinical studies of TOBI , patients taking TOBI concomitantly with <e1> DRUG1 </e1> ( PULMOZYME , Genentech) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral <e2> DRUG2 </e2> demonstrated adverse experience profiles similar to the study population as a whole . 	dornase alfa	aminoglycosides
other	In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( <e1> DRUG1 </e1> , Genentech) , <e2> DRUG2 </e2> , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 	PULMOZYME	(beta)-agonists
other	In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( <e1> DRUG1 </e1> , Genentech) , (beta)-agonists , inhaled <e2> DRUG2 </e2> , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 	PULMOZYME	corticosteroids
other	In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( <e1> DRUG1 </e1> , Genentech) , (beta)-agonists , inhaled corticosteroids , other <e2> DRUG2 </e2> , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 	PULMOZYME	anti-pseudomonal antibiotics
other	In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( <e1> DRUG1 </e1> , Genentech) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral <e2> DRUG2 </e2> demonstrated adverse experience profiles similar to the study population as a whole . 	PULMOZYME	aminoglycosides
other	In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech) , <e1> DRUG1 </e1> , inhaled <e2> DRUG2 </e2> , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 	(beta)-agonists	corticosteroids
other	In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech) , <e1> DRUG1 </e1> , inhaled corticosteroids , other <e2> DRUG2 </e2> , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 	(beta)-agonists	anti-pseudomonal antibiotics
other	In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech) , <e1> DRUG1 </e1> , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral <e2> DRUG2 </e2> demonstrated adverse experience profiles similar to the study population as a whole . 	(beta)-agonists	aminoglycosides
other	In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech) , (beta)-agonists , inhaled <e1> DRUG1 </e1> , other <e2> DRUG2 </e2> , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 	corticosteroids	anti-pseudomonal antibiotics
other	In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech) , (beta)-agonists , inhaled <e1> DRUG1 </e1> , other anti-pseudomonal antibiotics , or parenteral <e2> DRUG2 </e2> demonstrated adverse experience profiles similar to the study population as a whole . 	corticosteroids	aminoglycosides
other	In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech) , (beta)-agonists , inhaled corticosteroids , other <e1> DRUG1 </e1> , or parenteral <e2> DRUG2 </e2> demonstrated adverse experience profiles similar to the study population as a whole . 	anti-pseudomonal antibiotics	aminoglycosides
effect	Some <e1> DRUG1 </e1> can enhance <e2> DRUG2 </e2> toxicity by altering antibiotic concentrations in serum and tissue . 	diuretics	aminoglycoside
other	Some <e1> DRUG1 </e1> can enhance aminoglycoside toxicity by altering <e2> DRUG2 </e2> concentrations in serum and tissue . 	diuretics	antibiotic
other	Some diuretics can enhance <e1> DRUG1 </e1> toxicity by altering <e2> DRUG2 </e2> concentrations in serum and tissue . 	aminoglycoside	antibiotic
advise	<e1> DRUG1 </e1> should not be administered concomitantly with <e2> DRUG2 </e2> , furosemide , urea , or mannitol . 	TOBI	ethacrynic acid
advise	<e1> DRUG1 </e1> should not be administered concomitantly with ethacrynic acid , <e2> DRUG2 </e2> , urea , or mannitol . 	TOBI	furosemide
advise	<e1> DRUG1 </e1> should not be administered concomitantly with ethacrynic acid , furosemide , <e2> DRUG2 </e2> , or mannitol . 	TOBI	urea
advise	<e1> DRUG1 </e1> should not be administered concomitantly with ethacrynic acid , furosemide , urea , or <e2> DRUG2 </e2> . 	TOBI	mannitol
other	TOBI should not be administered concomitantly with <e1> DRUG1 </e1> , furosemide , <e2> DRUG2 </e2> , or mannitol . 	ethacrynic acid	urea
other	TOBI should not be administered concomitantly with <e1> DRUG1 </e1> , furosemide , urea , or <e2> DRUG2 </e2> . 	ethacrynic acid	mannitol
other	TOBI should not be administered concomitantly with ethacrynic acid , <e1> DRUG1 </e1> , urea , or <e2> DRUG2 </e2> . 	furosemide	mannitol
other	The in vitro binding of <e1> DRUG1 </e1> to human plasma proteins is unaffected by <e2> DRUG2 </e2> , and tolmetin does not alter the prothrombin time of normal volunteers . 	warfarin	tolmetin
other	The in vitro binding of <e1> DRUG1 </e1> to human plasma proteins is unaffected by tolmetin , and <e2> DRUG2 </e2> does not alter the prothrombin time of normal volunteers . 	warfarin	tolmetin
effect	However , increased prothrombin time and bleeding have been reported in patients on concomitant <e1> DRUG1 </e1> and <e2> DRUG2 </e2> therapy . 	TOLECTIN	warfarin
advise	Therefore , caution should be exercised when administering <e1> DRUG1 </e1> to patients on <e2> DRUG2 </e2> . 	TOLECTIN	anticoagulants
other	In adult diabetic patients under treatment with either <e1> DRUG1 </e1> or insulin there is no change in the clinical effects of either <e2> DRUG2 </e2> or the hypoglycemic agents . 	sulfonylureas	TOLECTIN
other	In adult diabetic patients under treatment with either <e1> DRUG1 </e1> or insulin there is no change in the clinical effects of either TOLECTIN or the <e2> DRUG2 </e2> . 	sulfonylureas	hypoglycemic agents
other	In adult diabetic patients under treatment with either sulfonylureas or <e1> DRUG1 </e1> there is no change in the clinical effects of either <e2> DRUG2 </e2> or the hypoglycemic agents . 	insulin	TOLECTIN
other	In adult diabetic patients under treatment with either sulfonylureas or <e1> DRUG1 </e1> there is no change in the clinical effects of either TOLECTIN or the <e2> DRUG2 </e2> . 	insulin	hypoglycemic agents
other	In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either <e1> DRUG1 </e1> or the <e2> DRUG2 </e2> . 	TOLECTIN	hypoglycemic agents
advise	Caution should be used if <e1> DRUG1 </e1> is administered concomitantly with <e2> DRUG2 </e2> . 	TOLECTIN	methotrexate
other	<e1> DRUG1 </e1> and other <e2> DRUG2 </e2> have been reported to reduce the tubular secretion of methotrexate in an animal model , possibly enhancing the toxicity of methotrexate . 	TOLECTIN	nonsteroidal anti-inflammatory drugs
mechanism	<e1> DRUG1 </e1> and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of <e2> DRUG2 </e2> in an animal model , possibly enhancing the toxicity of methotrexate . 	TOLECTIN	methotrexate
other	<e1> DRUG1 </e1> and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model , possibly enhancing the toxicity of <e2> DRUG2 </e2> . 	TOLECTIN	methotrexate
mechanism	TOLECTIN and other <e1> DRUG1 </e1> have been reported to reduce the tubular secretion of <e2> DRUG2 </e2> in an animal model , possibly enhancing the toxicity of methotrexate . 	nonsteroidal anti-inflammatory drugs	methotrexate
other	TOLECTIN and other <e1> DRUG1 </e1> have been reported to reduce the tubular secretion of methotrexate in an animal model , possibly enhancing the toxicity of <e2> DRUG2 </e2> . 	nonsteroidal anti-inflammatory drugs	methotrexate
mechanism	CYP3A4 Inhibitors : <e1> DRUG1 </e1> , an inhibitor of the drug metabolizing enzyme CYP3A4 , significantly increased plasma concentrations of <e2> DRUG2 </e2> when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY , Variability in Metabolism and Drug-Drug Interactions) . 	Ketoconazole	tolterodine
other	For patients receiving <e1> DRUG1 </e1> or other potent CYP3A4 inhibitors such as other <e2> DRUG2 </e2> (eg , itraconazole , miconazole ) or macrolide antibiotics (eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	ketoconazole	azole antifungals
other	For patients receiving <e1> DRUG1 </e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg , <e2> DRUG2 </e2> , miconazole ) or macrolide antibiotics (eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	ketoconazole	itraconazole
other	For patients receiving <e1> DRUG1 </e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , <e2> DRUG2 </e2> ) or macrolide antibiotics (eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	ketoconazole	miconazole
other	For patients receiving <e1> DRUG1 </e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , miconazole ) or <e2> DRUG2 </e2> (eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	ketoconazole	macrolide antibiotics
other	For patients receiving <e1> DRUG1 </e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , miconazole ) or macrolide antibiotics (eg , <e2> DRUG2 </e2> , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	ketoconazole	erythromycin
other	For patients receiving <e1> DRUG1 </e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , miconazole ) or macrolide antibiotics (eg , erythromycin , <e2> DRUG2 </e2> ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	ketoconazole	clarithromycin
other	For patients receiving <e1> DRUG1 </e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , miconazole ) or macrolide antibiotics (eg , erythromycin , clarithromycin ) or <e2> DRUG2 </e2> or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	ketoconazole	cyclosporine
other	For patients receiving <e1> DRUG1 </e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , miconazole ) or macrolide antibiotics (eg , erythromycin , clarithromycin ) or cyclosporine or <e2> DRUG2 </e2> , the recommended dose of DETROL LA is 2 mg daily . 	ketoconazole	vinblastine
advise	For patients receiving <e1> DRUG1 </e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , miconazole ) or macrolide antibiotics (eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of <e2> DRUG2 </e2> is 2 mg daily . 	ketoconazole	DETROL LA
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1> DRUG1 </e1> (eg , <e2> DRUG2 </e2> , miconazole ) or macrolide antibiotics (eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	azole antifungals	itraconazole
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1> DRUG1 </e1> (eg , itraconazole , <e2> DRUG2 </e2> ) or macrolide antibiotics (eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	azole antifungals	miconazole
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1> DRUG1 </e1> (eg , itraconazole , miconazole ) or <e2> DRUG2 </e2> (eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	azole antifungals	macrolide antibiotics
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1> DRUG1 </e1> (eg , itraconazole , miconazole ) or macrolide antibiotics (eg , <e2> DRUG2 </e2> , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	azole antifungals	erythromycin
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1> DRUG1 </e1> (eg , itraconazole , miconazole ) or macrolide antibiotics (eg , erythromycin , <e2> DRUG2 </e2> ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	azole antifungals	clarithromycin
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1> DRUG1 </e1> (eg , itraconazole , miconazole ) or macrolide antibiotics (eg , erythromycin , clarithromycin ) or <e2> DRUG2 </e2> or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	azole antifungals	cyclosporine
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1> DRUG1 </e1> (eg , itraconazole , miconazole ) or macrolide antibiotics (eg , erythromycin , clarithromycin ) or cyclosporine or <e2> DRUG2 </e2> , the recommended dose of DETROL LA is 2 mg daily . 	azole antifungals	vinblastine
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1> DRUG1 </e1> (eg , itraconazole , miconazole ) or macrolide antibiotics (eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of <e2> DRUG2 </e2> is 2 mg daily . 	azole antifungals	DETROL LA
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , <e1> DRUG1 </e1> , miconazole ) or <e2> DRUG2 </e2> (eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	itraconazole	macrolide antibiotics
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , <e1> DRUG1 </e1> , miconazole ) or macrolide antibiotics (eg , <e2> DRUG2 </e2> , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	itraconazole	erythromycin
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , <e1> DRUG1 </e1> , miconazole ) or macrolide antibiotics (eg , erythromycin , <e2> DRUG2 </e2> ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	itraconazole	clarithromycin
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , <e1> DRUG1 </e1> , miconazole ) or macrolide antibiotics (eg , erythromycin , clarithromycin ) or <e2> DRUG2 </e2> or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	itraconazole	cyclosporine
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , <e1> DRUG1 </e1> , miconazole ) or macrolide antibiotics (eg , erythromycin , clarithromycin ) or cyclosporine or <e2> DRUG2 </e2> , the recommended dose of DETROL LA is 2 mg daily . 	itraconazole	vinblastine
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , <e1> DRUG1 </e1> , miconazole ) or macrolide antibiotics (eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of <e2> DRUG2 </e2> is 2 mg daily . 	itraconazole	DETROL LA
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , <e1> DRUG1 </e1> ) or <e2> DRUG2 </e2> (eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	miconazole	macrolide antibiotics
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , <e1> DRUG1 </e1> ) or macrolide antibiotics (eg , <e2> DRUG2 </e2> , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	miconazole	erythromycin
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , <e1> DRUG1 </e1> ) or macrolide antibiotics (eg , erythromycin , <e2> DRUG2 </e2> ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	miconazole	clarithromycin
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , <e1> DRUG1 </e1> ) or macrolide antibiotics (eg , erythromycin , clarithromycin ) or <e2> DRUG2 </e2> or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	miconazole	cyclosporine
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , <e1> DRUG1 </e1> ) or macrolide antibiotics (eg , erythromycin , clarithromycin ) or cyclosporine or <e2> DRUG2 </e2> , the recommended dose of DETROL LA is 2 mg daily . 	miconazole	vinblastine
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , <e1> DRUG1 </e1> ) or macrolide antibiotics (eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of <e2> DRUG2 </e2> is 2 mg daily . 	miconazole	DETROL LA
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , miconazole ) or <e1> DRUG1 </e1> (eg , <e2> DRUG2 </e2> , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	macrolide antibiotics	erythromycin
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , miconazole ) or <e1> DRUG1 </e1> (eg , erythromycin , <e2> DRUG2 </e2> ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	macrolide antibiotics	clarithromycin
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , miconazole ) or <e1> DRUG1 </e1> (eg , erythromycin , clarithromycin ) or <e2> DRUG2 </e2> or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	macrolide antibiotics	cyclosporine
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , miconazole ) or <e1> DRUG1 </e1> (eg , erythromycin , clarithromycin ) or cyclosporine or <e2> DRUG2 </e2> , the recommended dose of DETROL LA is 2 mg daily . 	macrolide antibiotics	vinblastine
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , miconazole ) or <e1> DRUG1 </e1> (eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of <e2> DRUG2 </e2> is 2 mg daily . 	macrolide antibiotics	DETROL LA
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , miconazole ) or macrolide antibiotics (eg , <e1> DRUG1 </e1> , clarithromycin ) or <e2> DRUG2 </e2> or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	erythromycin	cyclosporine
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , miconazole ) or macrolide antibiotics (eg , <e1> DRUG1 </e1> , clarithromycin ) or cyclosporine or <e2> DRUG2 </e2> , the recommended dose of DETROL LA is 2 mg daily . 	erythromycin	vinblastine
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , miconazole ) or macrolide antibiotics (eg , <e1> DRUG1 </e1> , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of <e2> DRUG2 </e2> is 2 mg daily . 	erythromycin	DETROL LA
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , miconazole ) or macrolide antibiotics (eg , erythromycin , <e1> DRUG1 </e1> ) or <e2> DRUG2 </e2> or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 	clarithromycin	cyclosporine
other	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , miconazole ) or macrolide antibiotics (eg , erythromycin , <e1> DRUG1 </e1> ) or cyclosporine or <e2> DRUG2 </e2> , the recommended dose of DETROL LA is 2 mg daily . 	clarithromycin	vinblastine
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , miconazole ) or macrolide antibiotics (eg , erythromycin , <e1> DRUG1 </e1> ) or cyclosporine or vinblastine , the recommended dose of <e2> DRUG2 </e2> is 2 mg daily . 	clarithromycin	DETROL LA
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , miconazole ) or macrolide antibiotics (eg , erythromycin , clarithromycin ) or <e1> DRUG1 </e1> or vinblastine , the recommended dose of <e2> DRUG2 </e2> is 2 mg daily . 	cyclosporine	DETROL LA
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg , itraconazole , miconazole ) or macrolide antibiotics (eg , erythromycin , clarithromycin ) or cyclosporine or <e1> DRUG1 </e1> , the recommended dose of <e2> DRUG2 </e2> is 2 mg daily . 	vinblastine	DETROL LA
mechanism	Administration of <e1> DRUG1 </e1> in combination with <e2> DRUG2 </e2> resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies . 	paclitaxel	HERCEPTIN
other	Administration of <e1> DRUG1 </e1> in combination with HERCEPTIN resulted in a two-fold decrease in <e2> DRUG2 </e2> clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies . 	paclitaxel	HERCEPTIN
other	Administration of <e1> DRUG1 </e1> in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in <e2> DRUG2 </e2> serum levels in clinical studies . 	paclitaxel	HERCEPTIN
int	<e1> DRUG1 </e1> may interact with <e2> DRUG2 </e2> or mitotane (causing too great a decrease in adrenal function) . 	Trilostane	aminoglutethimide
int	<e1> DRUG1 </e1> may interact with aminoglutethimide or <e2> DRUG2 </e2> (causing too great a decrease in adrenal function) . 	Trilostane	mitotane
mechanism	<e1> DRUG1 </e1> may inhibit the hepatic metabolism of <e2> DRUG2 </e2> . 	Trimethoprim	phenytoin
mechanism	<e1> DRUG1 </e1> , given at a common clinical dosage , increased the <e2> DRUG2 </e2> half-life by 51% and decreased the phenytoin metabolic clearance rate by 30% . 	Trimethoprim	phenytoin
mechanism	<e1> DRUG1 </e1> , given at a common clinical dosage , increased the phenytoin half-life by 51% and decreased the <e2> DRUG2 </e2> metabolic clearance rate by 30% . 	Trimethoprim	phenytoin
effect	Agents that might be coadministered with <e1> DRUG1 </e1> in AIDS patients for other indications that could elicit this activity include <e2> DRUG2 </e2> , rifampin , rifabutin , ketoconazole , and fluconazole . 	trimetrexate	erythromycin
effect	Agents that might be coadministered with <e1> DRUG1 </e1> in AIDS patients for other indications that could elicit this activity include erythromycin , <e2> DRUG2 </e2> , rifabutin , ketoconazole , and fluconazole . 	trimetrexate	rifampin
effect	Agents that might be coadministered with <e1> DRUG1 </e1> in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , <e2> DRUG2 </e2> , ketoconazole , and fluconazole . 	trimetrexate	rifabutin
effect	Agents that might be coadministered with <e1> DRUG1 </e1> in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , <e2> DRUG2 </e2> , and fluconazole . 	trimetrexate	ketoconazole
effect	Agents that might be coadministered with <e1> DRUG1 </e1> in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and <e2> DRUG2 </e2> . 	trimetrexate	fluconazole
other	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include <e1> DRUG1 </e1> , rifampin , <e2> DRUG2 </e2> , ketoconazole , and fluconazole . 	erythromycin	rifabutin
other	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include <e1> DRUG1 </e1> , rifampin , rifabutin , <e2> DRUG2 </e2> , and fluconazole . 	erythromycin	ketoconazole
other	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include <e1> DRUG1 </e1> , rifampin , rifabutin , ketoconazole , and <e2> DRUG2 </e2> . 	erythromycin	fluconazole
other	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , <e1> DRUG1 </e1> , rifabutin , <e2> DRUG2 </e2> , and fluconazole . 	rifampin	ketoconazole
other	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , <e1> DRUG1 </e1> , rifabutin , ketoconazole , and <e2> DRUG2 </e2> . 	rifampin	fluconazole
other	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , <e1> DRUG1 </e1> , ketoconazole , and <e2> DRUG2 </e2> . 	rifabutin	fluconazole
other	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> . 	ketoconazole	fluconazole
mechanism	In vitro perfusion of isolated rat liver has shown that <e1> DRUG1 </e1> caused a significant reduction in <e2> DRUG2 </e2> metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites . 	cimetidine	trimetrexate
other	In vitro perfusion of isolated rat liver has shown that <e1> DRUG1 </e1> caused a significant reduction in trimetrexate metabolism and that <e2> DRUG2 </e2> altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites . 	cimetidine	acetaminophen
other	In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in <e1> DRUG1 </e1> metabolism and that <e2> DRUG2 </e2> altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites . 	trimetrexate	acetaminophen
other	Based on an in vitro rat liver model , nitrogen substituted <e1> DRUG1 </e1> ( clotrimazole , <e2> DRUG2 </e2> , miconazole ) were potent , non-competitive inhibitors of trimetrexate metabolism . 	imidazole drugs	ketoconazole
other	Based on an in vitro rat liver model , nitrogen substituted <e1> DRUG1 </e1> ( clotrimazole , ketoconazole , <e2> DRUG2 </e2> ) were potent , non-competitive inhibitors of trimetrexate metabolism . 	imidazole drugs	miconazole
mechanism	Based on an in vitro rat liver model , nitrogen substituted <e1> DRUG1 </e1> ( clotrimazole , ketoconazole , miconazole ) were potent , non-competitive inhibitors of <e2> DRUG2 </e2> metabolism . 	imidazole drugs	trimetrexate
other	Based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( <e1> DRUG1 </e1> , ketoconazole , <e2> DRUG2 </e2> ) were potent , non-competitive inhibitors of trimetrexate metabolism . 	clotrimazole	miconazole
mechanism	Based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( <e1> DRUG1 </e1> , ketoconazole , miconazole ) were potent , non-competitive inhibitors of <e2> DRUG2 </e2> metabolism . 	clotrimazole	trimetrexate
mechanism	Based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( clotrimazole , <e1> DRUG1 </e1> , miconazole ) were potent , non-competitive inhibitors of <e2> DRUG2 </e2> metabolism . 	ketoconazole	trimetrexate
mechanism	Based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( clotrimazole , ketoconazole , <e1> DRUG1 </e1> ) were potent , non-competitive inhibitors of <e2> DRUG2 </e2> metabolism . 	miconazole	trimetrexate
effect	<e1> DRUG1 </e1> may enhance the sedative effects of <e2> DRUG2 </e2> including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 	Triprolidine	central nervous system depressants
effect	<e1> DRUG1 </e1> may enhance the sedative effects of central nervous system depressants including <e2> DRUG2 </e2> , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 	Triprolidine	alcohol
effect	<e1> DRUG1 </e1> may enhance the sedative effects of central nervous system depressants including alcohol , <e2> DRUG2 </e2> , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 	Triprolidine	barbiturates
effect	<e1> DRUG1 </e1> may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , <e2> DRUG2 </e2> , narcotic analgesics , sedatives , and tranquillisers . 	Triprolidine	hypnotics
effect	<e1> DRUG1 </e1> may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , <e2> DRUG2 </e2> , sedatives , and tranquillisers . 	Triprolidine	narcotic analgesics
effect	<e1> DRUG1 </e1> may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , <e2> DRUG2 </e2> , and tranquillisers . 	Triprolidine	sedatives
effect	<e1> DRUG1 </e1> may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and <e2> DRUG2 </e2> . 	Triprolidine	tranquillisers
other	Triprolidine may enhance the sedative effects of <e1> DRUG1 </e1> including <e2> DRUG2 </e2> , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 	central nervous system depressants	alcohol
other	Triprolidine may enhance the sedative effects of <e1> DRUG1 </e1> including alcohol , <e2> DRUG2 </e2> , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 	central nervous system depressants	barbiturates
other	Triprolidine may enhance the sedative effects of <e1> DRUG1 </e1> including alcohol , barbiturates , <e2> DRUG2 </e2> , narcotic analgesics , sedatives , and tranquillisers . 	central nervous system depressants	hypnotics
other	Triprolidine may enhance the sedative effects of <e1> DRUG1 </e1> including alcohol , barbiturates , hypnotics , <e2> DRUG2 </e2> , sedatives , and tranquillisers . 	central nervous system depressants	narcotic analgesics
other	Triprolidine may enhance the sedative effects of <e1> DRUG1 </e1> including alcohol , barbiturates , hypnotics , narcotic analgesics , <e2> DRUG2 </e2> , and tranquillisers . 	central nervous system depressants	sedatives
other	Triprolidine may enhance the sedative effects of <e1> DRUG1 </e1> including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and <e2> DRUG2 </e2> . 	central nervous system depressants	tranquillisers
other	Triprolidine may enhance the sedative effects of central nervous system depressants including <e1> DRUG1 </e1> , barbiturates , <e2> DRUG2 </e2> , narcotic analgesics , sedatives , and tranquillisers . 	alcohol	hypnotics
other	Triprolidine may enhance the sedative effects of central nervous system depressants including <e1> DRUG1 </e1> , barbiturates , hypnotics , <e2> DRUG2 </e2> , sedatives , and tranquillisers . 	alcohol	narcotic analgesics
other	Triprolidine may enhance the sedative effects of central nervous system depressants including <e1> DRUG1 </e1> , barbiturates , hypnotics , narcotic analgesics , <e2> DRUG2 </e2> , and tranquillisers . 	alcohol	sedatives
other	Triprolidine may enhance the sedative effects of central nervous system depressants including <e1> DRUG1 </e1> , barbiturates , hypnotics , narcotic analgesics , sedatives , and <e2> DRUG2 </e2> . 	alcohol	tranquillisers
other	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , <e1> DRUG1 </e1> , hypnotics , <e2> DRUG2 </e2> , sedatives , and tranquillisers . 	barbiturates	narcotic analgesics
other	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , <e1> DRUG1 </e1> , hypnotics , narcotic analgesics , <e2> DRUG2 </e2> , and tranquillisers . 	barbiturates	sedatives
other	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , <e1> DRUG1 </e1> , hypnotics , narcotic analgesics , sedatives , and <e2> DRUG2 </e2> . 	barbiturates	tranquillisers
other	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , <e1> DRUG1 </e1> , narcotic analgesics , <e2> DRUG2 </e2> , and tranquillisers . 	hypnotics	sedatives
other	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , <e1> DRUG1 </e1> , narcotic analgesics , sedatives , and <e2> DRUG2 </e2> . 	hypnotics	tranquillisers
other	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , <e1> DRUG1 </e1> , sedatives , and <e2> DRUG2 </e2> . 	narcotic analgesics	tranquillisers
other	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , <e1> DRUG1 </e1> , and <e2> DRUG2 </e2> . 	sedatives	tranquillisers
other	The effects of <e1> DRUG1 </e1> , such as <e2> DRUG2 </e2> and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine . 	anticholinergic drugs	atropine
other	The effects of <e1> DRUG1 </e1> , such as atropine and <e2> DRUG2 </e2> may be enhanced by the concomitant administration of triprolidine . 	anticholinergic drugs	tricyclic antidepressants
effect	The effects of <e1> DRUG1 </e1> , such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of <e2> DRUG2 </e2> . 	anticholinergic drugs	triprolidine
other	The effects of anticholinergic drugs , such as <e1> DRUG1 </e1> and <e2> DRUG2 </e2> may be enhanced by the concomitant administration of triprolidine . 	atropine	tricyclic antidepressants
effect	The effects of anticholinergic drugs , such as <e1> DRUG1 </e1> and tricyclic antidepressants may be enhanced by the concomitant administration of <e2> DRUG2 </e2> . 	atropine	triprolidine
effect	The effects of anticholinergic drugs , such as atropine and <e1> DRUG1 </e1> may be enhanced by the concomitant administration of <e2> DRUG2 </e2> . 	tricyclic antidepressants	triprolidine
effect	The concomitant use of <e1> DRUG1 </e1> with other <e2> DRUG2 </e2> that produce dry mouth , constipation , and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects . 	Sanctura	anticholinergic agents
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with <e1> DRUG1 </e1> have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . <e2> DRUG2 </e2> , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) . 	Sanctura	digoxin
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with <e1> DRUG1 </e1> have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , <e2> DRUG2 </e2> , pancuronium , morphine , vancomycin , metformin and tenofovir ) . 	Sanctura	procainamide
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with <e1> DRUG1 </e1> have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , procainamide , <e2> DRUG2 </e2> , morphine , vancomycin , metformin and tenofovir ) . 	Sanctura	pancuronium
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with <e1> DRUG1 </e1> have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , procainamide , pancuronium , <e2> DRUG2 </e2> , vancomycin , metformin and tenofovir ) . 	Sanctura	morphine
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with <e1> DRUG1 </e1> have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , procainamide , pancuronium , morphine , <e2> DRUG2 </e2> , metformin and tenofovir ) . 	Sanctura	vancomycin
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with <e1> DRUG1 </e1> have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , procainamide , pancuronium , morphine , vancomycin , <e2> DRUG2 </e2> and tenofovir ) . 	Sanctura	metformin
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with <e1> DRUG1 </e1> have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and <e2> DRUG2 </e2> ) . 	Sanctura	tenofovir
mechanism	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , <e1> DRUG1 </e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . <e2> DRUG2 </e2> , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) . 	Sanctura	digoxin
mechanism	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , <e1> DRUG1 </e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , <e2> DRUG2 </e2> , pancuronium , morphine , vancomycin , metformin and tenofovir ) . 	Sanctura	procainamide
mechanism	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , <e1> DRUG1 </e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , procainamide , <e2> DRUG2 </e2> , morphine , vancomycin , metformin and tenofovir ) . 	Sanctura	pancuronium
mechanism	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , <e1> DRUG1 </e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , procainamide , pancuronium , <e2> DRUG2 </e2> , vancomycin , metformin and tenofovir ) . 	Sanctura	morphine
mechanism	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , <e1> DRUG1 </e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , procainamide , pancuronium , morphine , <e2> DRUG2 </e2> , metformin and tenofovir ) . 	Sanctura	vancomycin
mechanism	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , <e1> DRUG1 </e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , procainamide , pancuronium , morphine , vancomycin , <e2> DRUG2 </e2> and tenofovir ) . 	Sanctura	metformin
mechanism	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , <e1> DRUG1 </e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and <e2> DRUG2 </e2> ) . 	Sanctura	tenofovir
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . <e1> DRUG1 </e1> , procainamide , <e2> DRUG2 </e2> , morphine , vancomycin , metformin and tenofovir ) . 	digoxin	pancuronium
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . <e1> DRUG1 </e1> , procainamide , pancuronium , <e2> DRUG2 </e2> , vancomycin , metformin and tenofovir ) . 	digoxin	morphine
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . <e1> DRUG1 </e1> , procainamide , pancuronium , morphine , <e2> DRUG2 </e2> , metformin and tenofovir ) . 	digoxin	vancomycin
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . <e1> DRUG1 </e1> , procainamide , pancuronium , morphine , vancomycin , <e2> DRUG2 </e2> and tenofovir ) . 	digoxin	metformin
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . <e1> DRUG1 </e1> , procainamide , pancuronium , morphine , vancomycin , metformin and <e2> DRUG2 </e2> ) . 	digoxin	tenofovir
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , <e1> DRUG1 </e1> , pancuronium , <e2> DRUG2 </e2> , vancomycin , metformin and tenofovir ) . 	procainamide	morphine
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , <e1> DRUG1 </e1> , pancuronium , morphine , <e2> DRUG2 </e2> , metformin and tenofovir ) . 	procainamide	vancomycin
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , <e1> DRUG1 </e1> , pancuronium , morphine , vancomycin , <e2> DRUG2 </e2> and tenofovir ) . 	procainamide	metformin
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , <e1> DRUG1 </e1> , pancuronium , morphine , vancomycin , metformin and <e2> DRUG2 </e2> ) . 	procainamide	tenofovir
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , procainamide , <e1> DRUG1 </e1> , morphine , <e2> DRUG2 </e2> , metformin and tenofovir ) . 	pancuronium	vancomycin
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , procainamide , <e1> DRUG1 </e1> , morphine , vancomycin , <e2> DRUG2 </e2> and tenofovir ) . 	pancuronium	metformin
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , procainamide , <e1> DRUG1 </e1> , morphine , vancomycin , metformin and <e2> DRUG2 </e2> ) . 	pancuronium	tenofovir
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , procainamide , pancuronium , <e1> DRUG1 </e1> , vancomycin , <e2> DRUG2 </e2> and tenofovir ) . 	morphine	metformin
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , procainamide , pancuronium , <e1> DRUG1 </e1> , vancomycin , metformin and <e2> DRUG2 </e2> ) . 	morphine	tenofovir
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , procainamide , pancuronium , morphine , <e1> DRUG1 </e1> , metformin and <e2> DRUG2 </e2> ) . 	vancomycin	tenofovir
other	Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g . digoxin , procainamide , pancuronium , morphine , vancomycin , <e1> DRUG1 </e1> and <e2> DRUG2 </e2> ) . 	metformin	tenofovir
effect	Concomitant administration of <e1> DRUG1 </e1> and <e2> DRUG2 </e2> has been associated with erythema and histamine-like flushing and anaphylactoid reactions . 	vancomycin	anesthetic agents
other	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as <e1> DRUG1 </e1> , aminoglycosides , <e2> DRUG2 </e2> , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 	amphotericin B	bacitracin
other	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as <e1> DRUG1 </e1> , aminoglycosides , bacitracin , <e2> DRUG2 </e2> , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 	amphotericin B	polymyxin B
other	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as <e1> DRUG1 </e1> , aminoglycosides , bacitracin , polymyxin B , <e2> DRUG2 </e2> , viomycin , or cisplatin , when indicated , requires careful monitoring . 	amphotericin B	colistin
other	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as <e1> DRUG1 </e1> , aminoglycosides , bacitracin , polymyxin B , colistin , <e2> DRUG2 </e2> , or cisplatin , when indicated , requires careful monitoring . 	amphotericin B	viomycin
other	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as <e1> DRUG1 </e1> , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or <e2> DRUG2 </e2> , when indicated , requires careful monitoring . 	amphotericin B	cisplatin
other	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , <e1> DRUG1 </e1> , bacitracin , <e2> DRUG2 </e2> , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 	aminoglycosides	polymyxin B
other	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , <e1> DRUG1 </e1> , bacitracin , polymyxin B , <e2> DRUG2 </e2> , viomycin , or cisplatin , when indicated , requires careful monitoring . 	aminoglycosides	colistin
other	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , <e1> DRUG1 </e1> , bacitracin , polymyxin B , colistin , <e2> DRUG2 </e2> , or cisplatin , when indicated , requires careful monitoring . 	aminoglycosides	viomycin
other	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , <e1> DRUG1 </e1> , bacitracin , polymyxin B , colistin , viomycin , or <e2> DRUG2 </e2> , when indicated , requires careful monitoring . 	aminoglycosides	cisplatin
other	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , <e1> DRUG1 </e1> , polymyxin B , <e2> DRUG2 </e2> , viomycin , or cisplatin , when indicated , requires careful monitoring . 	bacitracin	colistin
other	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , <e1> DRUG1 </e1> , polymyxin B , colistin , <e2> DRUG2 </e2> , or cisplatin , when indicated , requires careful monitoring . 	bacitracin	viomycin
other	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , <e1> DRUG1 </e1> , polymyxin B , colistin , viomycin , or <e2> DRUG2 </e2> , when indicated , requires careful monitoring . 	bacitracin	cisplatin
other	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , <e1> DRUG1 </e1> , colistin , <e2> DRUG2 </e2> , or cisplatin , when indicated , requires careful monitoring . 	polymyxin B	viomycin
other	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , <e1> DRUG1 </e1> , colistin , viomycin , or <e2> DRUG2 </e2> , when indicated , requires careful monitoring . 	polymyxin B	cisplatin
other	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , <e1> DRUG1 </e1> , viomycin , or <e2> DRUG2 </e2> , when indicated , requires careful monitoring . 	colistin	cisplatin
mechanism	A study published in 2002 found that <e1> DRUG1 </e1> causes a statistically significant increase in plasma clearance of <e2> DRUG2 </e2> . 	vigabatrin	carbamazepine
mechanism	In 1984 , Drs Rimmer and Richens at the University of Wales reported that administering <e1> DRUG1 </e1> with <e2> DRUG2 </e2> lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy . 	vigabatrin	phenytoin
other	In 1984 , Drs Rimmer and Richens at the University of Wales reported that administering <e1> DRUG1 </e1> with phenytoin lowered the serum <e2> DRUG2 </e2> concentration in patients with treatment-resistant epilepsy . 	vigabatrin	phenytoin
int	<e1> DRUG1 </e1> can interact with the drugs of the following categories :  - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - <e2> DRUG2 </e2> : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient's response to the vaccine 	Vindesine	Phenytoin
int	<e1> DRUG1 </e1> can interact with the drugs of the following categories :  - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - <e2> DRUG2 </e2> : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient's response to the vaccine 	Vindesine	Live virus vaccines
other	<e1> DRUG1 </e1> can interact with the drugs of the following categories :  - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the <e2> DRUG2 </e2> virus , may increase the side effects of the vaccination , and decrease patient's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient's response to the vaccine 	Vindesine	vaccine
int	<e1> DRUG1 </e1> can interact with the drugs of the following categories :  - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient's response to the vaccine - <e2> DRUG2 </e2> : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient's response to the vaccine 	Vindesine	Mitomycin-C
int	<e1> DRUG1 </e1> can interact with the drugs of the following categories :  - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - <e2> DRUG2 </e2> : may decrease patient's response to the vaccine 	Vindesine	Killed virus vaccines
other	<e1> DRUG1 </e1> can interact with the drugs of the following categories :  - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient's response to the <e2> DRUG2 </e2> 	Vindesine	vaccine
other	Vindesine can interact with the drugs of the following categories :  - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - <e1> DRUG1 </e1> : can increase seizure activity - <e2> DRUG2 </e2> : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient's response to the vaccine 	Phenytoin	Live virus vaccines
other	Vindesine can interact with the drugs of the following categories :  - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - <e1> DRUG1 </e1> : can increase seizure activity - Live virus vaccines : may potentiate the replication of the <e2> DRUG2 </e2> virus , may increase the side effects of the vaccination , and decrease patient's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient's response to the vaccine 	Phenytoin	vaccine
other	Vindesine can interact with the drugs of the following categories :  - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - <e1> DRUG1 </e1> : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient's response to the vaccine - <e2> DRUG2 </e2> : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient's response to the vaccine 	Phenytoin	Mitomycin-C
other	Vindesine can interact with the drugs of the following categories :  - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - <e1> DRUG1 </e1> : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - <e2> DRUG2 </e2> : may decrease patient's response to the vaccine 	Phenytoin	Killed virus vaccines
other	Vindesine can interact with the drugs of the following categories :  - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - <e1> DRUG1 </e1> : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient's response to the <e2> DRUG2 </e2> 	Phenytoin	vaccine
other	Vindesine can interact with the drugs of the following categories :  - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - <e1> DRUG1 </e1> : may potentiate the replication of the <e2> DRUG2 </e2> virus , may increase the side effects of the vaccination , and decrease patient's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient's response to the vaccine 	Live virus vaccines	vaccine
other	Vindesine can interact with the drugs of the following categories :  - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - <e1> DRUG1 </e1> : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient's response to the vaccine - <e2> DRUG2 </e2> : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient's response to the vaccine 	Live virus vaccines	Mitomycin-C
other	Vindesine can interact with the drugs of the following categories :  - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - <e1> DRUG1 </e1> : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - <e2> DRUG2 </e2> : may decrease patient's response to the vaccine 	Live virus vaccines	Killed virus vaccines
other	Vindesine can interact with the drugs of the following categories :  - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - <e1> DRUG1 </e1> : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient's response to the <e2> DRUG2 </e2> 	Live virus vaccines	vaccine
other	Vindesine can interact with the drugs of the following categories :  - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the <e1> DRUG1 </e1> virus , may increase the side effects of the vaccination , and decrease patient's response to the vaccine - <e2> DRUG2 </e2> : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient's response to the vaccine 	vaccine	Mitomycin-C
other	Vindesine can interact with the drugs of the following categories :  - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the <e1> DRUG1 </e1> virus , may increase the side effects of the vaccination , and decrease patient's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - <e2> DRUG2 </e2> : may decrease patient's response to the vaccine 	vaccine	Killed virus vaccines
other	Vindesine can interact with the drugs of the following categories :  - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient's response to the vaccine - <e1> DRUG1 </e1> : may cause shortness of breath and bronchospasm - <e2> DRUG2 </e2> : may decrease patient's response to the vaccine 	Mitomycin-C	Killed virus vaccines
other	Vindesine can interact with the drugs of the following categories :  - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient's response to the vaccine - <e1> DRUG1 </e1> : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient's response to the <e2> DRUG2 </e2> 	Mitomycin-C	vaccine
other	Vindesine can interact with the drugs of the following categories :  - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - <e1> DRUG1 </e1> : may decrease patient's response to the <e2> DRUG2 </e2> 	Killed virus vaccines	vaccine
mechanism	Drug Interactions : Women on oral <e1> DRUG1 </e1> have shown a significant increase in plasma <e2> DRUG2 </e2> levels . 	contraceptives	vitamin A
mechanism	Limited evidence suggests that <e1> DRUG1 </e1> may influence the intensity and duration of action of <e2> DRUG2 </e2> . 	ascorbic acid	bishydroxycoumarin
effect	Coumarin-Derivative Anticoagulants : Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving <e1> DRUG1 </e1> concomitantly with <e2> DRUG2 </e2> . 	ZOLINZA	coumarin-derivative anticoagulants
advise	Physicians should carefully monitor PT and INR in patients concurrently administered <e1> DRUG1 </e1> and <e2> DRUG2 </e2> . 	ZOLINZA	coumarin derivatives
effect	Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of <e1> DRUG1 </e1> and other <e2> DRUG2 </e2> (e.g. , valproic acid ) . 	ZOLINZA	HDAC inhibitors
effect	Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of <e1> DRUG1 </e1> and other HDAC inhibitors (e.g. , <e2> DRUG2 </e2> ) . 	ZOLINZA	valproic acid
other	Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other <e1> DRUG1 </e1> (e.g. , <e2> DRUG2 </e2> ) . 	HDAC inhibitors	valproic acid
